purpos
studi
investig
pace
modal
vvi
vvir
vdd
close
approxim
intrins
sinu
rate
dog
third
degre
av
block
rang
typic
daili
activ
secondari
aim
studi
determin
echocardiograph
paramet
differ
pace
modal
hypothes
vdd
would
close
track
intrins
sinu
rate
activ
echocardiograph
dimens
would
differ
av
asynchron
vvi
vvir
av
synchron
vdd
pace
modal
dog
prospect
recruit
follow
implant
st
jude
dualchamb
pacemak
system
dog
evid
sinu
node
dysfunct
clinic
import
arrhythmia
exclud
dog
program
vdd
studi
entri
averag
lowest
highest
heart
rate
vdd
pace
determin
averag
heart
rate
program
base
rate
vvi
vvir
highest
heart
rate
program
upper
track
rate
vvir
threshold
slope
fast
reaction
recoveri
time
rest
function
use
pace
modal
program
lowest
heart
rate
vdd
pace
lowest
heart
rate
lower
rate
limit
rest
rate
program
slower
dog
randomli
assign
vvi
vvir
initi
vdd
interrog
echocardiographi
doppler
tdi
ambulatori
ecg
record
hour
owner
instruct
record
time
durat
specif
activ
urinationdefec
eat
sleep
walk
play
three
month
echocardiographi
repeat
dog
cross
vvi
vvir
pace
ambulatori
ecg
monitor
repeat
three
addit
month
echocardiographi
repeat
pace
modal
program
vdd
ambulatori
ecg
monitor
repeat
atrial
rate
ventricular
rate
atrialtoventricular
ratio
determin
activ
initi
hour
acclimat
period
ongo
studi
current
dog
enrol
dog
complet
vvi
phase
dog
complet
vvir
phase
dog
complet
vvi
vvir
phase
dog
complet
vvi
vvir
vdd
phase
atrial
rate
atrialtoventricular
ratio
vvi
vvir
vdd
activ
follow
urinationdefec
ae
ae
ae
ae
eat
ae
ae
ae
ae
sleep
ae
ae
ae
ae
walk
ae
ae
ae
ae
play
ae
ae
ae
ae
echocardiograph
data
avail
dog
vdd
dog
vvir
dog
vvi
left
ventricl
appear
larger
diastol
systol
vvi
lvadao
ae
edvao
ae
lvasao
ae
esvao
ae
vvir
lvadao
ae
edvao
ae
lva
ao
ae
esvao
ae
vdd
pace
lvadao
ae
edvao
ae
lvasao
ae
esvao
ae
studi
ongo
final
conclus
made
although
synchron
vdd
pace
appear
close
approxim
sinu
rate
slower
atrial
rate
asynchron
vvi
vvir
pace
dog
complet
studi
within
next
two
month
time
final
conclus
made
clopidogrel
consid
mainstay
therapi
prevent
cardiogen
thromboemboli
cat
shown
superior
aspirin
clopidogrel
prodrug
requir
hepat
bioactiv
cytochrom
format
clopidogrel
activ
metabolit
cam
unstabl
challeng
quantit
bioactiv
cam
bind
adpreceptor
platelet
inhibit
platelet
aggreg
recent
method
stabil
cam
human
plasma
develop
ad
bmap
blood
tube
stabil
derivat
cam
camd
quantit
use
highperform
liquid
chromatographi
tandem
mass
spectrometri
hplcmsm
aim
valid
hplcmsm
detect
clopidogrel
camd
metabolit
felin
plasma
hypothes
hplcmsm
accur
precis
quantit
cam
first
step
determin
cat
consist
metabol
clopidogrel
signific
interindividu
variat
exist
human
genet
polymorph
hepat
cytochrom
furthermor
accur
precis
method
measur
plasma
concentr
cam
allow
safer
use
clopidogrel
potenti
establish
therapeut
index
evalu
whether
coadministr
drug
like
omeprazol
inhibit
cam
format
cat
fda
guidelin
assess
accuraci
precis
follow
vitro
stabil
clopidogrel
camd
clopidogrel
acid
citrat
edta
felin
plasma
evalu
room
temperatur
hour
day
linear
regress
perform
point
standard
curv
clopidogrel
camd
ngml
clopidogrel
acid
evalu
clinic
applic
two
healthi
cat
given
clopidogrel
plavix
clinic
use
dose
mg
oral
daili
blood
taken
prior
clopidogrel
administr
minut
hour
hour
hour
hour
post
clopidogrel
administr
blood
sampl
collect
asept
ml
cryotub
contain
ul
mm
bmap
ul
mm
edta
centrifug
supernat
transfer
new
cryotub
store
sampl
analyz
use
hplcmsm
duplic
standard
curv
vitro
sampl
stabl
temperatur
minimum
hour
differ
appreci
stabil
clopidogrel
metabolit
edta
citrat
plasma
standard
curv
show
linear
clopidogrel
camd
clopidogrel
acid
r
assay
measur
clopidogrel
camd
clopidogrel
acid
accuraci
precis
within
run
plasma
concentr
clopidogrel
camd
clopidogrel
acid
readili
detect
plasma
healthi
cat
receiv
clopidogrel
first
simultan
quantit
clopidogrel
camd
clopidogrel
acid
felin
plasma
hplcmsm
accur
precis
method
simultan
quantit
clopidogrel
metabolit
felin
plasma
vitro
healthi
cat
receiv
oral
clopidogrel
airway
diseas
purpos
studi
review
outcom
dog
bronchial
stent
place
due
bronchial
collaps
hypothes
moder
sever
mmvd
presenc
pulmonari
hypertens
would
neg
effect
lifespan
stent
placement
medic
record
small
breed
dog
bronchial
stent
placement
chronic
cough
secondari
bronchial
collaps
review
hierarch
multipl
linear
regress
analysi
conduct
predict
lifespan
bronchial
stent
placement
base
age
time
stent
placement
sever
mmvd
presenc
pulmonari
hypertens
eighteen
dog
bronchial
stent
place
period
year
age
time
stent
placement
rang
year
year
age
ae
breed
repres
includ
cavali
king
charl
spaniel
beagl
chihuahua
pomeranian
toy
poodl
yorkshir
terrier
maltes
coton
de
tulear
shih
tzu
male
femal
twelv
dog
evid
moder
sever
mmvd
evid
pulmonari
hypertens
six
dog
chf
prior
stent
placement
dog
chf
stent
placement
syncop
report
dog
prior
stent
placement
dog
stent
placement
averag
lifespan
stent
placement
ae
day
three
dog
current
aliv
poststent
placement
day
hierarch
multipl
linear
regress
calcul
predict
lifespan
placement
bronchial
stent
base
age
time
stent
placement
presenc
pulmonari
hypertens
sever
mmvd
stage
one
age
time
stent
placement
significantli
predict
lifespan
placement
bronchial
stent
b
p
lifespan
decreas
day
addit
month
age
time
stent
placement
presenc
pulmonari
hypertens
significantli
predict
lifespan
b
p
sever
mmvd
contribut
significantli
model
stage
two
b
p
result
studi
indic
sever
mmvd
presenc
pulmonari
hypertens
neg
affect
lifespan
bronchial
stent
placement
moder
sever
mmvd
presenc
pulmonari
hypertens
view
exclus
criteria
assess
candid
possibl
bronchial
stent
prospect
studi
conduct
investig
clinic
benefit
bronchial
stent
dog
sever
bronchial
collaps
dog
natur
acquir
tricuspid
regurgit
tr
studi
prospect
dog
degen
valv
diseas
target
variabl
acquir
studi
period
dog
later
recumb
stand
walk
test
sedat
mgkg
butorphanol
im
two
differ
observ
heart
rate
hr
tr
flow
veloc
trfv
pvr
estim
right
atrial
pressur
stroke
volum
cardiac
output
variabl
quantifi
statist
method
includ
repeatedmeasur
anova
mix
model
analysi
p
consid
signific
thirtytwo
dog
small
breed
vari
trfv
ms
pvr
wu
studi
signific
effect
observ
p
respir
p
imag
qualiti
p
outcom
variabl
wherea
imag
posit
dog
lie
versu
stand
caus
differ
p
sedat
significantli
increas
mean
trfv
p
ae
ms
ae
ms
increas
observ
dog
wherea
effect
ae
ms
p
hr
declin
sedat
mean
reduct
ae
bpm
p
increas
mean
increas
ae
bpm
p
correl
tvfv
pvr
influenc
trfv
pvr
data
document
relev
variabl
de
estim
ph
deserv
clinic
consider
surviv
time
cat
congest
heart
failur
chf
variabl
predictor
outcom
would
use
help
guid
treatment
patient
assess
peopl
chf
chang
ntprobnp
concentr
initi
treatment
andor
target
ntprobnp
concentr
absolut
level
provid
valuabl
inform
use
help
guid
treatment
chang
ntprobnp
concentr
cat
chf
treatment
associ
surviv
report
therefor
purpos
studi
measur
chang
ntprobnp
cat
chf
treatment
determin
whether
serial
ntprobnp
measur
provid
prognost
inform
popul
clientown
cat
present
new
onset
chf
secondari
cardiomyopathi
elig
enrol
blood
collect
ntprobnp
analysi
within
hour
admiss
day
discharg
reevalu
day
later
thirtytwo
cat
enrol
male
femal
neuter
median
age
year
rang
year
thirtyon
cat
surviv
discharg
cat
surviv
day
reevalu
median
ntprobnp
concentr
admiss
hospit
discharg
pmoll
rang
pmoll
pmoll
rang
pmoll
respect
median
ntprobnp
concentr
reevalu
pmoll
rang
pmoll
median
ntprobnp
concentr
decreas
significantli
admiss
discharg
p
admiss
reevalu
p
discharg
reevalu
p
median
surviv
time
day
rang
day
cat
still
aliv
time
analysi
cat
receiv
pimobendan
significantli
greater
decreas
ntprobnp
concentr
pmoll
rang
pmoll
admiss
discharg
compar
cat
receiv
pimobendan
pmoll
rang
pmoll
p
cat
whose
owner
difficulti
administ
medic
n
shorter
surviv
time
median
day
rang
day
compar
owner
report
difficulti
n
median
day
rang
day
howev
statist
signific
p
associ
pimobendan
larger
decreas
ntprobnp
concentr
warrant
addit
research
larger
studi
need
determin
whether
ntprobnp
use
help
guid
treatment
cat
chf
pulmonari
annulu
thicken
leaflet
addit
anomal
coronari
arteri
anatomi
commonli
describ
report
imping
right
ventricular
outflow
tract
rvot
english
bulldog
boxer
dog
ps
aim
studi
investig
stenot
lesion
morpholog
coronari
arteri
anatomi
french
bulldog
comparison
english
bulldog
assess
similar
andor
differ
breed
medic
record
review
french
english
bulldog
present
oregon
state
univers
heart
murmur
evalu
imag
prior
balloon
valvuloplasti
bvp
dog
includ
sever
ps
pressur
gradient
mmhg
estim
via
echocardiographi
confirm
coronari
arteri
anatomi
either
angiographi
comput
tomographi
ct
echocardiograph
angiograph
ct
imag
review
pulmon
annulu
pa
aortic
annulu
ao
pa
ao
ratio
valvular
anatomi
coronari
anatomi
assess
imag
modal
three
observ
cs
ks
dd
averag
tricuspid
regurgit
tr
assess
echocardiograph
angiograph
studi
breed
median
mean
compar
mannwhitney
u
test
unpair
ttest
indic
dog
ct
angiograph
studi
valu
compar
pair
ttest
twentysix
dog
review
dog
english
bulldog
exclud
due
lack
definit
coronari
arteri
anatomi
imag
includ
dog
english
male
french
bulldog
femal
male
mean
weight
ae
kg
english
ae
kg
french
bulldog
p
ct
angiograph
imag
perform
english
french
bulldog
respect
coronari
arteri
anomali
definit
identifi
english
bulldog
french
bulldog
median
pa
ao
annulu
ratio
statist
differ
english
rang
french
bulldog
rang
p
addit
differ
found
ct
angiograph
measur
pa
ao
ratio
p
mean
pa
annulu
index
bodi
weight
power
differ
english
ae
french
bulldog
ae
p
tr
note
french
bulldog
mild
moder
sever
english
bulldog
tr
mild
moder
sever
anomal
develop
coronari
arteri
observ
french
bulldog
evalu
studi
wherea
coronari
anomali
identifi
english
bulldog
rvot
obstruct
mark
thicken
pulmon
valv
leaflet
markedli
reduc
leaflet
mobil
observ
french
bulldog
annular
hypoplasia
present
modest
breed
dog
anomali
curvatur
degre
encroach
left
coronari
arteri
rvot
markedli
variabl
combin
valvular
supravalvular
obstruct
identifi
english
bulldog
normal
coronari
anatomi
peopl
obes
independ
risk
factor
develop
obes
relat
cardiac
dysfunct
orcd
character
systol
dysfunct
diastol
dysfunct
andor
vascular
endotheli
dysfunct
compon
metabol
syndrom
includ
dyslipidemia
elev
inflammatori
marker
insulin
resist
believ
play
import
role
pathophysiolog
orcd
obes
reach
epidem
proport
dog
estim
approxim
dog
overweight
obes
unit
state
recent
studi
perform
dog
suggest
metabol
syndrom
also
exist
obes
dog
warrant
investig
risk
orcd
hypothes
obes
dog
cardiac
dysfunct
elev
inflammatori
marker
alter
insulin
sensit
dyslipidemia
consist
metabol
syndrom
compar
nonobes
dog
aim
studi
first
assess
presenc
cardiac
dysfunct
obes
dog
compar
dog
ideal
bodi
composit
second
compar
metabol
paramet
includ
lipid
analysi
inflammatori
marker
obes
versu
normal
dog
healthi
dog
weigh
less
pound
ideal
bodi
condit
n
obes
bodi
condit
n
enrol
dog
normal
physic
exam
thorac
auscult
evid
system
ill
routin
laboratori
diagnost
bodi
composit
use
valid
point
scale
systol
arteri
doppler
blood
pressur
electrocardiogram
echocardiogram
mmode
bmode
doppler
strain
imag
obtain
final
metabol
paramet
includ
lipid
profil
cholesterol
triglycerid
hdl
ldl
insulin
adiponectin
canin
inflammatori
marker
elisa
panel
gmcsf
tnfalpha
infgamma
tnfgamma
crp
kclike
evalu
pair
test
perform
compar
studi
group
pvalu
less
consid
statist
signific
compar
dog
ideal
bodi
condit
score
obes
dog
significantli
increas
septal
wall
thick
increas
systol
function
measur
significantli
reduc
diastol
function
measur
obes
dog
significantli
increas
insulin
insulin
glucos
ratio
cholesterol
triglycerid
hdl
level
remain
metabol
paramet
includ
adiponectin
significantli
differ
group
kclike
inflammatori
marker
significantli
higher
obes
group
mean
blood
pressur
higher
obes
patient
differ
statist
signific
number
obes
dog
n
confirm
system
hypertens
subsequ
examin
conclus
obes
dog
alter
cardiac
structur
function
well
dyslipidaemia
alter
insulin
sensit
elev
inflammatori
marker
find
warrant
addit
studi
investig
inflamm
dyslipidaemia
possibl
system
hypertens
potenti
etiolog
alter
cardiac
function
earli
stage
heart
diseas
character
reduct
energi
reserv
impair
myocardi
contractil
relax
howev
alter
difficult
measur
exist
clinic
imag
modal
echocardiographi
recent
advanc
phosphor
p
magnet
reson
spectroscopi
mr
enabl
chang
energi
reserv
measur
noninvas
creatin
kinas
ck
reaction
primari
energi
reservoir
heart
ck
reaction
revers
convert
adenosin
diphosph
adp
phosphocreatin
pcr
atp
creatin
heart
failur
flux
ck
reaction
decreas
creatin
concentr
cr
ck
activ
decreas
unlik
atp
gener
de
novo
synthesi
pathway
myocyt
cr
produc
excit
tissu
therefor
heart
failur
decreas
cr
occur
earlier
faster
decreas
atp
studi
pcratp
ratio
use
marker
cardiac
energet
hypothesi
chang
cardiac
energet
reserv
measur
mr
preced
global
mri
echocardiograph
biochem
marker
volum
overload
heart
failur
hypothesi
evalu
canin
model
preclin
isol
mitral
regurgit
mr
via
chordal
ruptur
group
dog
minim
dog
sever
mr
induct
one
group
dog
evalu
baselin
data
collect
week
induct
second
group
dog
evalu
baselin
week
induct
parallel
time
point
cardiac
evalu
thorac
radiograph
echocardiographi
mr
standard
mri
collect
addit
peripher
blood
sampl
collect
microrna
biomark
evalu
ntprobnp
baselin
endpoint
cardiac
catheter
record
cardiac
output
right
left
ventricular
function
vascular
resist
conclus
studi
myocardi
function
assess
measur
isol
myocyt
morpholog
size
myocyt
contractil
ca
flux
left
ventricl
mitral
valv
tissu
collect
molecular
studi
mrna
mirna
util
tesla
mri
scanner
p
magnet
reson
spectra
collect
ungat
free
breath
threedimension
chemic
shift
imag
sequenc
dog
three
cc
voxel
septal
wall
near
midventricl
select
analysi
pcratp
ratio
comput
without
satur
blood
correct
voxel
averag
although
rang
sever
mr
group
dog
asymptomat
untreat
stage
observ
period
data
collect
time
point
use
dog
control
echocardiograph
evalu
endpoint
lvdd
increas
diamet
week
dog
week
dog
left
atria
dimens
increas
week
dog
week
dog
fraction
shorten
increas
week
dog
week
dog
compar
baselin
lvd
dimens
increas
wk
week
dog
week
dog
endpoint
catheter
forward
lv
stoke
volum
decreas
week
dog
week
dog
dog
normal
pcratp
ratio
without
satur
blood
correct
determin
baselin
normal
dog
mean
sem
unload
lv
week
pcratp
ratio
increas
dog
time
dysfunct
remodel
mr
dog
pcratp
ratio
decreas
myocyt
energi
reserv
deplet
especi
dog
systol
dysfunct
pcratp
ratio
would
appear
measur
cardiac
energet
earli
remodel
phase
volum
overload
mr
allow
linear
measur
dog
time
determin
diseas
progress
mr
may
provid
use
tool
evalu
drug
therapi
cardiac
energet
mr
dog
corin
express
cardiomyocyt
convert
pronatriuret
peptid
matur
form
play
key
role
fluid
homeostasi
cardiac
remodel
mice
human
fail
heart
myocardi
corin
protein
level
report
increas
howev
without
concomit
increas
corin
activ
find
partli
explain
clear
paradox
congest
heart
failur
chf
natriuret
peptid
elev
yet
bodi
fluid
retain
ultim
result
chf
interestingli
cavali
king
charl
spaniel
loci
associ
develop
myxomat
mitral
valv
diseas
mmvd
identifi
corin
one
loci
latest
dog
assembl
rais
question
whether
defici
myocardi
corin
express
activ
could
mechan
explain
progress
heart
diseas
chf
dog
well
purpos
studi
therefor
character
immunohistochem
express
corin
myocardi
tissu
normal
dog
dog
sever
mmvd
two
group
dog
varieti
breed
recruit
includ
control
dog
euthan
sever
noncardiac
diseas
age
rang
year
dog
sever
mmvd
euthan
refractori
chf
age
rang
year
sampl
collect
right
atrium
ra
right
ventricl
rv
left
atrium
la
left
ventricl
lv
interventricular
septum
iv
immunohistochem
stain
tissu
polyclon
rabbit
antihuman
antibodi
corin
carri
comput
quantif
use
compar
stain
densiti
two
group
cardiac
region
posit
transmembran
intracellular
immunostain
corin
wide
observ
part
myocardium
group
corin
express
upor
downregul
cardiac
chamber
dog
sever
mmvd
figur
differ
seen
chamber
within
group
result
indic
corin
express
might
ratelimit
step
dog
chf
due
mmvd
lack
increas
corin
express
activ
postul
possibl
import
pathophysiolog
mechan
respons
natriuret
peptid
paradox
dog
chf
warrant
investig
figur
quantit
corin
express
myocardi
tissu
control
dog
dog
congest
heart
failur
secondari
myxomat
mitral
valv
diseas
aim
studi
determin
feasibl
repeat
measur
anatom
regurgit
orific
area
aroa
use
realtim
transthorac
echocardiographi
dog
affect
mmvd
determin
aroa
obtain
use
relat
sever
mmvd
assess
echocardiograph
score
system
mrss
american
colleg
veterinari
medicin
acvim
stage
system
dataset
mitral
valv
acquir
privat
own
dog
diagnos
mmvd
aroa
trace
measur
use
dedic
softwar
dog
classifi
mild
moder
sever
accord
echocardiograph
mrss
acvim
stage
c
techniqu
feasibl
dataset
measur
interand
intraoper
repeat
assess
differ
aroa
dog
differ
mrss
acvim
stage
investig
aroa
measur
dog
interand
intraoper
coeffici
variat
respect
aroa
significantli
greater
dog
sever
mrss
compar
dog
mild
mrss
p
differ
aroa
dog
mild
versu
moder
moder
versu
sever
mrss
p
p
respect
differ
aroa
dog
differ
acvim
clinic
stage
p
conclus
obtain
aroa
use
feasibl
offer
addit
noninvas
techniqu
stratifi
mr
sever
dog
mmvd
rel
low
repeat
suggest
standard
techniqu
desir
diagnost
prognost
util
aroa
deserv
investig
threedimension
saddl
shape
mitral
valv
annulu
first
report
levin
colleagu
previou
studi
show
annulu
height
commissur
width
ratio
ahcwr
index
paramet
saddleshap
mitral
annulu
preserv
across
mammalian
speci
suggest
natur
conserv
saddleshap
annulu
mechan
benefit
menciotti
et
al
describ
transthorac
echocardiographi
tte
normal
dog
ahcwr
ae
report
transesophag
echocardiographi
tee
studi
dog
myxomat
mitral
valv
diseas
mmvd
studi
aim
evalu
mitral
valv
annulu
morpholog
use
tee
dog
mmvd
tee
perform
dog
weight
kg
mitral
valv
repair
surgeri
geometri
mitral
valv
apparatu
measur
dedic
quantif
softwar
classif
mmvd
dog
use
studi
basi
acvim
stage
tee
measur
compar
group
dog
twentysix
dog
includ
studi
dog
exclud
studi
due
uninterrupt
echocardiograph
imag
thu
total
dog
evalu
studi
studi
group
includ
dog
acvim
stage
dog
stage
c
dog
stage
characterist
group
summar
ahcwr
decreas
diseas
progress
stage
ae
stage
c
ae
stage
ae
figur
stage
dog
show
significantli
lower
valu
p
compar
stage
dog
nonplanar
angl
measur
tend
increas
valu
sever
mmvd
worsen
howev
signific
differ
group
ae
c
ae
ae
figur
signific
differ
group
annular
circumfer
annular
area
valu
conclus
mitral
valv
dog
mmvd
lose
saddl
shape
mitral
valv
diseas
progress
result
studi
suggest
sever
mmdv
worsen
mechan
stress
would
place
mitral
valv
could
increas
progress
mitral
regurgit
best
knowledg
first
report
morpholog
chang
mitral
valv
annulu
accord
diseas
sever
dog
mmvd
oxid
stress
associ
cardiovascular
diseas
suggest
contribut
cardiac
remodel
human
patient
mitral
regurgit
previou
studi
evalu
relationship
oxid
stress
myxomat
mitral
valv
diseas
mmvd
dog
object
studi
determin
plasma
concentr
certain
marker
oxid
stress
investig
associ
mmvd
sever
select
clinic
variabl
diseas
progress
dog
differ
sever
mmvd
studi
includ
privatelyown
dog
healthi
control
beagl
cavali
king
charl
spaniel
ckc
differ
sever
mmvd
dog
differ
breed
clinic
sign
congest
heart
failur
due
mmvd
marker
oxid
stress
includ
malondialdehyd
mda
oxid
lowdens
lipoprotein
oxldl
vitamin
e
atocopherol
ctocopherol
measur
plasma
influenc
progress
mmvd
determin
plasma
oxldl
concentr
significantli
lower
control
beagl
compar
ckc
p
femal
significantli
lower
oxldl
plasma
concentr
compar
male
p
plasma
vitamin
e
concentr
associ
bodi
condit
score
bc
atocopherol
p
ctocopherol
p
marker
oxid
stress
mda
oxldl
vitamin
e
posit
associ
serum
cholesterol
p
none
marker
associ
sever
progress
mmvd
effect
bc
disappear
adjust
serum
cholesterol
concentr
conclus
beagl
femal
dog
appear
lower
plasma
concentr
oxldl
result
confirm
role
oxid
stress
dog
mmvd
accur
measur
stroke
volum
cardiac
output
co
import
applic
clinic
research
arena
invas
measur
co
thermodilut
td
remain
gold
standard
method
date
compar
studi
evalu
echocardiograph
co
dog
use
noninvas
imag
modal
direct
comparison
noninvas
co
estim
use
multidetector
comput
tomographi
mdct
td
dog
aim
studi
evalu
accuraci
co
estim
noninvas
method
mdct
echocardiographi
compar
invas
measur
co
obtain
td
six
intact
hound
cross
dog
weigh
kg
anesthet
use
standard
protocol
spontan
ventil
dog
underw
mdct
echocardiographi
td
dog
random
order
mdct
echocardiographi
td
perform
last
co
use
td
measur
triplic
variat
minim
chang
heart
rate
imag
method
co
calcul
volumetr
measur
sv
multipli
averag
heart
rate
echocardiograph
left
ventricular
lv
enddiastol
volum
edv
endsystol
volum
esv
measur
right
long
axi
imag
teichholz
right
long
axi
left
apic
imag
singl
plane
simpson
method
disk
mod
averag
consecut
beat
realtim
echocardiograph
lv
volum
measur
use
function
analysi
softwar
right
long
axi
left
apic
imag
plane
mdct
edv
esv
measur
use
specif
lv
function
analysi
softwar
ecggat
studi
excel
correl
found
co
valu
measur
td
mod
r
left
apic
window
well
mod
r
r
right
long
axi
window
less
robust
correl
found
valu
obtain
left
apic
window
r
td
mdctderiv
co
also
strongli
correl
r
td
co
estim
teichholz
formula
r
signific
correl
td
blandaltman
analysi
show
system
underestim
co
valu
deriv
echocardiograph
mdct
measur
bia
co
obtain
right
long
axi
window
lmin
confid
interv
ci
lmin
left
apic
window
lmin
ci
lmin
bia
co
valu
obtain
mdct
lmin
ci
lmin
result
suggest
certain
echocardiograph
techniqu
avail
co
measur
compar
invas
measur
co
specif
mod
use
right
long
axi
left
apic
view
right
long
axi
view
excel
agreement
td
excel
correl
method
indic
close
relationship
select
techniqu
although
interchang
co
underestim
noninvas
techniqu
studi
compar
td
differ
td
noninvas
measur
may
due
error
method
patient
stroke
volum
variabl
heart
rate
fluctuat
inaccuraci
td
one
major
limit
studi
small
number
patient
allow
preliminari
conclus
larger
prospect
studi
need
delin
benefit
constraint
method
myxomat
mitral
valv
diseas
mmvd
common
heart
diseas
dog
angiotensin
convert
enzym
ace
inhibitor
frequent
recommend
manag
dog
mmvd
asymptomat
cardiac
enlarg
howev
benefit
ace
inhibit
dog
onset
congest
heart
failur
chf
controversi
differ
studi
show
conflict
result
variabl
respons
ace
inhibitor
therapi
also
observ
human
be
heart
diseas
case
attribut
polymorph
ace
gene
previous
demonstr
polymorph
canin
ace
gene
although
clinic
signific
find
unknown
hypothes
dog
mmvd
cardiac
enlarg
ace
gene
polymorph
would
less
respons
ace
inhibit
enalapril
measur
plasma
ace
activ
dog
without
polymorph
evalu
dog
prechf
mmvd
vertebr
heart
score
present
ncsu
cvm
last
month
dog
genotyp
ace
polymorph
serum
sampl
collect
analyz
ace
activ
measur
radioimmunoassay
dog
prescrib
enalapril
mgkg
oral
twice
day
revalu
day
second
measur
ace
activ
test
use
compar
ace
activ
wildtyp
normal
canin
sequenc
dna
variant
group
baselin
therapi
pair
test
use
compar
genotyp
ace
activ
therapi
thirtyon
dog
evalu
genotyp
includ
homozyg
dna
variant
homozyg
wild
type
median
baselin
ace
activ
significantli
lower
dog
homozyg
dna
variant
ul
dog
wildtyp
sequenc
ul
p
twentyseven
dog
return
reevalu
day
genotyp
show
signific
suppress
ace
activ
enalapril
p
dna
variant
dog
p
wildtyp
dog
median
post
therapi
ace
activ
differ
two
genotyp
dna
variant
ul
wildtyp
dog
ul
p
conclud
dog
homozyg
ace
variant
lower
baselin
level
ace
activ
still
demonstr
ace
inhibit
respons
enalapril
studi
warrant
evalu
clinic
import
find
cavali
king
charl
spaniel
one
commonli
report
breed
dog
affect
myxomat
mitral
valv
diseas
mmvd
angiotensin
convert
enzym
ace
inhibitor
frequent
recommend
manag
dog
mmvd
howev
benefit
ace
inhibit
mmvd
congest
heart
failur
develop
controversi
differ
studi
show
conflict
result
variabl
respons
ace
inhibitor
therapi
also
observ
human
be
heart
diseas
attribut
polymorph
ace
gene
previous
demonstr
polymorph
canin
ace
gene
small
breed
dog
hypothes
polymorph
would
common
ckc
dog
would
impact
ace
activ
collect
dna
plasma
sampl
ckc
mmvd
dog
genotyp
known
ace
polymorph
plasma
sampl
collect
analyz
ace
activ
measur
radioimmunoassay
test
use
compar
ace
activ
wildtyp
control
sequenc
dna
variant
group
sixtytwo
dog
evalu
genotyp
dog
homozyg
dna
variant
heterozyg
homozyg
wild
type
normal
canin
sequenc
sampl
dog
submit
ace
analysi
includ
homozyg
wild
type
homozyg
variant
median
baselin
ace
activ
significantli
lower
dog
homozyg
dna
variant
ul
dog
wildtyp
sequenc
ul
p
conclud
ace
polymorph
appear
common
ckc
dog
homozyg
ace
variant
lower
baselin
level
ace
activ
studi
warrant
evalu
clinic
import
find
preval
dirofilaria
immiti
antigen
clientown
pet
dog
serum
heat
treatment
laura
nafe
susan
littl
paul
demar
ryan
baumwart
nalani
yamada
eileen
johnson
oklahoma
state
univers
stillwat
ok
usa
pet
dog
routin
screen
heartworm
diseas
compon
annual
well
evalu
recent
evid
suggest
antigenantibodi
complex
canin
serum
may
preclud
accur
diagnosi
heartworm
diseas
commerci
avail
dirofilaria
immiti
antigen
assay
object
studi
determin
whether
normal
dog
present
oklahoma
state
veterinari
teach
hospit
commun
practic
servic
annual
veterinari
care
warrant
heat
treatment
serum
confirm
neg
heartworm
antigen
test
snap
idexx
serum
edta
sampl
collect
clientown
pet
dog
decemb
octob
dog
rang
age
month
year
median
yr
includ
male
femal
complet
survey
result
avail
dog
reveal
dog
receiv
heartworm
prevent
regularli
past
year
edta
sampl
evalu
microfilaria
serum
sampl
immiti
antigen
heat
treatment
use
commerici
assay
dirochek
zoeti
four
dog
test
posit
immiti
antigen
snap
test
idexx
microfilarem
dirochek
antigen
test
dog
posit
heat
treatment
dog
posit
heat
treatment
dog
neg
heat
treatment
despit
microfilarem
one
dog
receiv
heartworm
prevent
heartgard
merial
regularli
dose
miss
heat
treatment
appear
improv
detect
immiti
antigen
asymptomat
pet
dog
undergo
routin
heartworm
diseas
test
snap
test
idexx
mechan
behind
increas
concentr
cardiac
biomark
azotem
dog
warrant
correct
interpret
test
result
aim
studi
investig
associ
measur
glomerular
filtrat
rate
gfr
plasma
concentr
ctni
ntprobnp
stabl
canin
ckd
patient
fifti
clientown
dog
prospect
includ
studi
twentyseven
dog
diagnosi
ckd
structur
andor
function
abnorm
one
kidney
persist
least
month
without
sign
signific
diseas
twentythre
healthi
dog
includ
control
dog
investig
physic
examin
repeat
blood
pressur
measur
complet
urinalysi
full
hematolog
biochemistri
panel
echocardiograph
examin
ultrasound
examin
entir
urinari
tract
scintigraph
examin
estim
kidney
glomerular
filtrat
rate
gfr
plasma
dog
store
assay
batch
median
age
includ
dog
year
rang
year
median
bodyweight
kg
rang
kg
differ
age
weight
healthi
ckd
dog
among
dog
ckd
decreas
gfr
gfr
within
normal
rang
dog
ckd
gfr
normal
rang
evid
kidney
diseas
persist
renal
proteinuria
morpholog
abnorm
univari
analys
perform
evalu
associ
dog
characterist
ctni
ntprobnp
respect
age
r
p
bodi
weight
bw
r
p
creatinin
r
p
systol
blood
pressur
sbp
r
p
associ
ctni
concentr
creatinin
r
p
gfr
r
p
albumin
r
p
erythrocyt
volum
fraction
evf
r
p
associ
ntprobnp
concentr
variabl
associ
ctni
ntprobnp
concentr
respect
pvalu
includ
multipl
regress
analysi
except
creatinin
covari
gfr
age
bw
sbp
variabl
remain
final
model
ctni
adjust
rsquar
p
gfr
bw
serum
albumin
concentr
variabl
remain
final
model
ntprobnp
adjust
rsquar
p
conclus
plasma
concentr
ctni
dog
stabl
ckd
influenc
decreas
gfr
plasma
concentr
ntprobnp
stabl
canin
ckd
patient
hand
appear
influenc
gfr
studi
shown
normal
healthi
adult
dog
may
occasion
ventricular
prematur
complex
vpc
frequent
sequenti
vpc
holter
monitor
may
indic
cardiac
clinic
diseas
pose
problem
cardiac
evalu
puppi
veterinarian
lack
inform
inhibit
abil
screen
puppi
indic
cardiac
diseas
especi
import
breed
tend
inherit
cardiac
arrhythmia
german
shepherd
puppi
purpos
studi
establish
normal
ambulatori
ecg
valu
use
holter
monitor
puppi
effort
enhanc
abil
screen
puppi
cardiac
diseas
primari
object
determin
minimum
averag
maximum
heart
rate
incid
arrhythmia
healthi
puppi
secondari
object
evalu
correl
holter
heart
rate
age
weight
breed
hypothes
healthi
puppi
less
arrhythmia
higher
holter
minimum
averag
maximum
heart
rate
healthi
adult
dog
elig
puppi
healthi
age
week
histori
physic
exam
thorough
auscult
perform
echocardiogram
perform
puppi
heart
murmur
auscult
puppi
physiolog
heart
murmur
includ
studi
puppi
structur
heart
diseas
exclud
hour
holter
monitor
place
puppi
includ
studi
holter
placement
follow
establish
method
wsu
veterinari
holter
servic
total
puppi
repres
breed
includ
studi
minimum
averag
maximum
holter
heart
rate
higher
puppi
compar
healthi
adult
dog
number
supraventricular
complex
seen
puppi
less
healthi
adult
dog
rang
ventricular
complex
puppi
higher
healthi
adult
dog
minimum
averag
holter
heart
rate
decreas
increas
age
maximum
holter
heart
rate
correl
age
correl
minimum
averag
maximum
holter
heart
rate
weight
appreci
statist
signific
differ
maximum
holter
heart
rate
differ
breed
classif
size
small
versu
medium
versu
larg
versu
giant
breed
correl
minimum
averag
holter
heart
rate
breed
classif
identifi
healthi
puppi
studi
first
studi
evalu
normal
ambulatori
electrocardiograph
valu
healthi
puppi
inform
use
potenti
screen
puppi
earlier
age
cardiac
diseas
number
ventricular
arrhythmia
consid
normal
healthi
adult
dog
thought
vari
dog
breed
whether
breed
variat
true
puppi
unknown
normal
baselin
establish
puppi
studi
conduct
evalu
breed
variat
patient
underw
lu
txr
within
hour
lu
imag
score
presenc
bline
site
hemithorax
individu
lu
site
score
posit
bline
observ
within
singl
intercost
space
site
txr
score
presenc
alveolarinterstiti
infiltr
site
hemithorax
analog
lu
individu
txr
site
score
posit
infiltr
present
least
site
medic
record
evalu
final
diagnosi
agreement
distribut
posit
site
lu
txr
compar
use
cohen
kappa
coeffici
pattern
distribut
ai
among
differ
final
diagnos
compar
use
fisher
exact
test
consid
sitebysit
agreement
distribut
ai
lu
txr
poor
fair
howev
consid
larger
spatial
quadrant
agreement
lu
txr
good
distribut
ai
differ
significantli
base
final
diagnosi
cardiogen
noncardiogen
caus
dyspnea
dog
mitral
valv
diseas
like
caudal
distribut
ai
p
dog
dilat
cardiomyopathi
like
diffus
ai
p
patient
airway
diseas
like
absenc
ai
site
p
patient
pneumonia
like
unilater
ai
p
lu
use
detect
ai
appar
txr
agreement
two
modal
improv
consid
larger
spatial
quadrant
rather
smaller
focal
site
distribut
ai
differ
base
final
diagnosi
suggest
patternbas
lu
approach
may
prove
diagnost
use
circul
plasma
mirna
novel
molecular
biomerk
congest
heart
failur
seungwoo
jung
ami
bohan
auburn
univers
auburn
al
usa
congest
heart
failur
chf
carri
poor
prognosi
dog
myxomat
mitral
valv
diseas
mmvd
earli
identif
dog
predispos
develop
chf
critic
improv
long
term
surviv
outcom
aim
studi
character
plasma
molecular
profil
dog
chf
secondari
mmvd
develop
novel
molecular
biomark
via
liquid
biopsi
microrna
mirna
small
noncod
rna
known
regul
express
level
target
gene
involv
human
chf
regulatori
network
mirna
dog
mmvd
need
establish
enhanc
understand
chf
pathogenesi
hypothesi
test
studi
plasma
mirna
may
differenti
express
dog
chf
secondari
mmvd
minimum
seven
dog
group
normal
versu
chf
need
demonstr
statist
power
probabl
type
one
error
p
base
previou
public
blood
collect
edta
tube
normal
geriatr
dog
free
heart
murmur
absent
histori
chf
dog
chf
secondari
mmvd
confirm
clinic
sign
chest
xray
echocardiographi
plasma
sampl
subject
isol
mirna
mirneasi
plasma
kit
qiagen
subsequ
reversetranscript
reaction
miscript
ii
rt
kit
qiagen
valid
canin
primer
candid
mirna
spikein
control
employ
quantifi
rel
express
level
mirna
normal
chf
dog
via
real
time
pcr
miscript
sybr
green
pcr
kit
qiagen
canin
specif
mirna
success
isol
plasma
amplifi
plasma
p
p
p
differenti
express
chf
dog
statist
signific
compar
normal
dog
mirna
known
involv
extracellular
matrix
remodel
regul
fibrot
gene
tgfb
smad
result
suggest
alter
interact
mirna
express
profil
downstream
target
gene
may
play
role
cardiac
progress
chf
dog
mmvd
investig
remain
warrant
determin
diagnost
potenti
molecular
biomark
earli
detect
chf
dog
mmvd
order
assess
signal
concurr
diseas
process
dog
diagnos
aortic
thrombot
diseas
retrospect
review
perform
record
avail
veterinari
medic
databas
dog
examin
inform
age
sex
breed
weight
concurr
diseas
process
dog
report
review
five
control
dog
without
diagnosi
select
case
diagnos
dog
includ
vmdb
odd
dog
differ
significantli
sex
p
age
p
weight
p
compar
mix
breed
dog
shetland
sheepdog
significantli
higher
odd
p
diagnos
proteinlos
nephropathi
commonli
report
diseas
occur
concurr
dog
signal
data
includ
age
sex
weight
significantli
differ
dog
diagnos
compar
dog
diagnos
dog
commonli
diagnos
concurr
pln
contrari
previou
report
cardiac
diseas
common
concurr
diagnosi
dog
includ
studi
function
right
ventricl
rv
gain
increas
recognit
past
year
pulmonari
hypertens
ph
patient
led
reconceptu
rv
part
right
ventricular
pulmon
circul
unit
acknowledg
rv
function
major
determin
prognosi
pulmonari
arteri
hypertens
mind
sought
investig
rv
systol
function
dog
postcapillari
ph
ascrib
mitral
valv
diseas
mvd
twenti
nine
dog
ph
kg
year
dog
without
ph
kg
year
recruit
prospect
crosssect
observ
studi
ph
group
subdivid
mild
ph
n
moder
pa
n
sever
ph
n
sever
breed
repres
anim
underw
complet
echocardiogram
includ
measur
rv
fraction
area
chang
rv
fac
tricuspid
annular
plane
systol
excurs
taps
rv
freewal
longitudin
systol
veloc
tricuspid
annular
rv
fraction
shorten
rv
fs
improv
statist
analysi
normal
data
accord
anim
size
bodi
weightindex
taps
taps
bwindex
creat
standard
echocardiograph
indic
congest
lv
function
includ
earlytol
lv
fill
veloc
ratio
ea
isovolum
relax
time
ivrt
etoivrt
ratio
eivrt
left
atriumtoaorta
ratio
laao
lv
fraction
shorten
lv
fs
record
well
data
normal
distribut
mannwhitney
test
show
differ
p
exist
rv
fac
rv
fs
taps
taps
bwindex
tricuspid
annular
dog
ph
without
ph
also
analysi
subdivid
ph
group
show
statist
differ
three
degre
ph
spearman
correl
coeffici
rv
systol
data
lv
indic
congest
function
show
signific
posit
correl
taps
eivrt
r
p
taps
laao
r
p
taps
bwindex
lv
fs
r
p
final
signific
posit
correl
document
rv
fac
rv
fs
r
p
well
taps
tricuspid
annular
r
p
anim
sever
ph
recruit
studi
absenc
associ
sever
ph
identif
rv
systol
impair
need
investig
nevertheless
observ
downward
trend
rv
fs
taps
taps
bwindex
tricuspid
annular
along
aggrav
ph
studi
found
correl
congest
lv
function
paramet
may
prove
use
monitor
rv
function
dog
sever
mvd
overt
sign
postcapillari
ph
sinc
major
ph
case
mild
like
reactiv
ph
may
explain
rv
function
either
group
behav
similarli
also
clear
whether
rv
remodel
impair
would
stronger
precapillari
ph
dog
includ
investig
decreas
heart
rate
variabl
hrv
found
dog
congest
heart
failur
chf
previou
studi
acknowledg
use
hrv
indic
prognost
indic
patient
mitral
valv
diseas
mvd
vasovag
tonu
index
vvti
unconvent
time
domain
indic
hrv
mainli
influenc
cardiac
parasympathet
tone
crosssect
observ
studi
sought
investig
vvti
dog
mvd
electrocardiograph
record
dog
year
kg
previous
classifi
acvim
stage
control
b
c
dog
group
use
calcul
vvti
consecut
rr
interv
measur
ecg
record
index
obtain
formula
vvti
ln
var
ln
natur
logarithm
var
varianc
bad
qualiti
ecg
trace
record
dog
nonsinu
rhythm
anim
undergo
antiarrhythm
treatment
includ
investig
also
record
bwindex
lv
diastol
systol
wall
stress
index
diastol
systol
fraction
shorten
left
atriumtoaorta
ratio
mitral
e
wave
mitral
ea
isovolumetr
relax
time
etoivrt
ratio
data
underw
shapirowilk
test
check
normal
distribut
anova
follow
tukey
test
use
compar
vvti
group
pearson
test
use
search
linear
correl
vvti
echocardiograph
data
mean
valu
lower
upper
ci
mean
vvti
dog
stage
b
c
respect
signific
differ
found
group
p
mean
vvti
significantli
higher
control
anim
compar
dog
stage
b
mvd
p
come
relationship
vvti
cardiac
rhythm
signific
differ
exist
anim
sinu
rhythm
sr
sinu
arrhythmia
sa
sinu
tachycardia
st
p
lowest
vvti
document
dog
st
ci
higher
found
anim
present
sr
ci
signific
neg
correl
found
vvti
laao
r
p
well
vvti
heart
rate
r
p
although
correl
exist
bodi
weight
vvti
age
vvti
attain
signific
neg
correl
r
p
neg
correl
vvti
heart
rate
like
ascrib
role
play
parasympathet
tone
vvti
therefor
produc
higher
valu
slower
rate
irregular
rhythm
present
even
though
uncontrol
condit
ecg
record
includ
stress
agit
may
increas
hr
lower
vvti
found
anim
exhibit
sinu
tachycardia
may
suggest
sustain
sympathet
activ
although
investig
warrant
confid
interv
studi
point
vvti
potenti
prognost
indic
chf
wherea
vvti
like
suggest
reduc
risk
congest
support
correl
vvti
laao
well
differ
mean
control
dog
stage
stage
b
mvd
anim
poodl
dachshund
besid
mongrel
dog
predomin
femal
dog
common
clinic
manifest
observ
syncop
presyncop
dyspnea
exercis
intoler
twelv
percent
dog
asymptomat
frequent
electrocardiograph
chang
found
sinu
arrest
junction
escap
rhythm
supraventricular
tachycardia
sinu
arrhytmia
fortyseven
percent
dog
present
tachycardiabradycardia
syndrom
anim
receiv
pacemak
implant
given
high
percentag
anim
unabl
go
chirurgicalanesthet
procedur
presenc
asymptomat
anim
dog
receiv
pacemak
implant
live
month
mean
valu
wherea
one
treat
conserv
live
month
mean
valu
valu
show
benefit
patient
receiv
pacemak
implant
hinder
high
percentag
comorbid
older
anim
besid
small
number
patient
enrol
retrospect
studi
kensuk
nakamura
tatsuyuki
osuga
tomoya
morita
keitaro
morishita
noboru
sasaki
hiroshi
ohta
mitsuyoshi
takiguchi
hokkaido
univers
sapporo
japan
echocardiograph
assess
sever
tricuspid
regurgit
tr
less
reliabl
compar
mitral
regurgit
due
complic
geometri
function
right
ventricl
spectral
doppler
hepat
vein
sdhv
emerg
use
examin
evalu
sever
tr
human
hepat
vein
blood
flow
waveform
multiphas
typic
consist
four
peak
small
retrograd
awav
occur
pwave
electrocardiograph
creat
retrograd
blood
flow
atrial
contract
larg
anterograd
swave
occur
immedi
qrx
complex
creat
blood
flow
toward
heart
ventricular
systol
small
retrograd
vwave
occur
ventricular
systol
larg
anterograd
dwave
occur
twave
creat
ventricular
diastol
object
present
studi
investig
correl
presenc
ascit
find
sdhv
dog
tr
clinic
cohort
studi
includ
twentyseven
clientown
dog
tr
dog
divid
two
group
base
presenc
ascit
physic
examin
sdhv
echocardiograph
variabl
compar
group
assess
compar
accuraci
identifi
patient
ascit
receiv
oper
characterist
roc
curv
use
peak
veloc
vwave
dwave
dog
ascit
n
significantli
higher
dog
without
ascit
n
highest
accuraci
obtain
vwave
area
roc
curv
auc
follow
dwave
auc
late
diastol
veloc
septal
mitral
annulu
auc
tr
peak
veloc
signific
differ
two
group
conclus
vwave
dwave
obtain
sdhv
strong
correl
presenc
ascit
dog
tr
event
monitor
use
diagnost
tool
evalu
patient
episod
cardiac
event
ideal
event
monitor
use
veterinari
practic
would
noninvas
afford
accur
reusabl
devic
becom
increas
difficult
obtain
studi
aim
prospect
evalu
feasibl
use
medtron
reveal
linqtm
human
implant
cardiac
monitor
icm
cutan
event
monitor
day
clinic
healthi
canin
kg
rang
kg
year
rang
year
old
two
canin
report
collaps
episod
kg
year
old
studi
consist
develop
method
secur
lowprofil
devic
without
caus
discomfort
locat
gener
strongest
signal
adjust
auto
activ
paramet
activ
devic
manual
assess
record
accuraci
reveal
linqtm
wireless
cardiac
devic
obtain
via
donat
follow
explant
human
patient
batteri
life
assess
prior
use
canin
patient
use
medtron
programm
appropri
softwar
load
area
left
later
thorax
clip
alcohol
use
remov
oil
adhes
electroconduct
gel
pad
appli
underneath
devic
place
within
intercost
space
parallel
rib
slowli
move
grid
pattern
find
consist
electrocardiogram
ecg
programm
screen
devic
secur
thorax
use
tegadermtm
film
gauz
tape
around
thorax
inch
white
tape
vetraptm
patient
fit
holter
monitor
vest
reduc
likelihood
devic
tamper
consumpt
bandag
materi
devic
devic
program
patient
inform
preprogram
manufactur
heart
rate
paramet
patient
wore
icm
day
owner
ask
activ
monitor
manual
total
record
differ
activ
keep
diari
accuraci
assess
base
qualiti
ecg
trace
consist
abil
measur
heart
rate
visual
entir
pqrst
wave
presenc
record
manual
activ
two
dog
fit
hour
holter
monitor
control
sixteen
patient
two
unabl
fit
devic
due
weak
signal
one
client
termin
studi
day
devic
move
place
stop
record
one
dog
remain
twelv
dog
least
interpret
trace
manual
activ
record
autoactiv
record
trigger
preset
paramet
good
qualiti
set
autoactiv
record
review
paramet
adjust
defin
outer
rang
normal
record
rhythm
reclassifi
cours
studi
patient
heart
rate
exceed
bpm
beat
reach
bpm
consecut
beat
fewer
autoactiv
occur
per
dog
paus
paramet
set
second
second
one
symptomat
patient
three
episod
wear
devic
howev
indic
rhythm
abnorm
manual
activ
record
symptomat
patient
episod
wear
monitor
devic
incorrectli
log
atrial
fibril
episod
time
period
ecg
icm
suffici
qualiti
identifi
p
wave
control
holter
record
clearli
show
sinu
arrhythmia
present
devic
still
record
time
remov
one
dog
five
dog
selflimit
mild
skin
irrit
remov
devic
medtron
reveal
linqtm
icm
viabl
option
cutan
cardiac
monitor
dog
day
veterinari
paramet
autoactiv
devic
program
upper
lower
limit
autoactiv
paramet
reduc
number
incorrectli
label
record
record
review
veterinarian
familiar
normal
cardiac
rhythm
subaort
stenosi
sa
common
congenit
cardiac
defect
identifi
dog
difficult
diagnos
sever
form
diseas
treatment
decis
consid
intervent
therapi
remain
challeng
suggest
sa
breed
may
relat
abnorm
steep
aortosept
angl
aosa
qualiti
may
limit
efficaci
balloon
method
abnorm
steep
aosa
contribut
sa
remedi
balloon
possibl
magnitud
aosa
may
serv
use
criterion
determin
dog
respond
better
balloon
valvuloplasti
therefor
better
candid
procedur
studi
investig
relationship
measur
aosa
respons
combin
cut
high
pressur
balloon
valvuloplasti
cbhpbv
dog
sever
sa
retrospect
evalu
angiograph
echocardiograph
video
loop
clientown
dog
variou
breed
affect
sever
sa
pg
mean
mmhg
rang
mmhg
underw
cbhpbv
evalu
baselin
time
point
immedi
prior
procedur
two
boardcertifi
veterinari
cardiologist
novic
evalu
video
loop
identifi
still
frame
imag
use
measur
aosa
evalu
blind
evalu
select
imag
subsequ
measur
aosa
evalu
blind
initi
pg
patient
outcom
follow
procedur
percentag
decreas
pg
hour
month
month
balloon
calcul
correl
measur
aosa
recheck
imag
plane
interobserv
variabl
analysi
suggest
signific
mean
differ
novic
observ
compar
cardiologist
angl
type
signific
differ
observ
cardiologist
left
apic
echocardiograph
p
aosa
measur
signific
differ
observ
angiograph
p
right
side
long
axi
lvot
echocardiograph
aosa
p
measur
measur
aosa
combin
combin
p
base
right
side
long
axi
lvot
echocardiograph
aosa
measur
made
cardiologist
greater
mean
differ
pg
reduct
ratio
observ
angl
angl
hour
significantli
greater
p
mean
differ
pg
ratio
observ
se
ae
compar
mean
se
ae
differ
persist
month
se
ae
se
ae
month
se
ae
se
ae
find
studi
suggest
dog
sever
sa
aosa
measur
right
side
long
axi
lvot
echocardiograph
imag
respond
cbhpbv
better
dog
aosa
differ
respons
procedur
two
set
dog
suggest
magnitud
aosa
play
role
sa
treatment
possibl
measur
aosa
may
help
screen
process
determin
prognosi
follow
cbhpbv
howev
investig
effect
lvot
pg
reduct
surviv
time
qualiti
life
warrant
order
determin
aosa
truli
suitabl
criterion
select
candid
cbhpbv
cardiomyopathi
includ
hypertroph
restrict
common
acquir
cardiac
diseas
cat
mani
affect
cat
develop
pulmonari
edema
secondari
leftsid
congest
heart
failur
lchf
altern
cat
primarili
leftsid
cardiomyopathi
develop
pleural
effus
without
presenc
pulmonari
edema
well
known
well
understood
cat
leftsid
chf
develop
pulmonari
edema
pleural
effus
develop
pulmonari
hypertens
could
lead
rightsid
heart
failur
potenti
caus
pleural
effus
cat
predomin
leftsid
cardiac
diseas
aim
studi
evalu
echocardiograph
evid
pulmonari
hypertens
cat
lchf
pleural
effus
comparison
cat
pulmonari
edema
pulmonari
diseas
healthi
cat
medic
record
echocardiograph
studi
review
measur
cat
categor
four
group
lchf
cat
pleural
effus
without
pulmonari
edema
lchf
cat
pulmonari
edema
cat
pulmonari
diseas
without
evid
cardiomyopathi
healthi
cat
puls
wave
doppler
record
pulmon
outflow
use
measur
acceler
time
eject
time
et
et
ratio
maximum
veloc
pulmon
valv
pa
vmax
main
pulmonari
arteri
diamet
mpa
aortic
diamet
ao
mpa
ao
ratio
left
atrial
diamet
la
la
ao
ratio
measur
right
parastern
short
axi
imag
right
atrial
ra
maximum
diamet
left
atrial
maxim
diamet
la
long
ra
la
long
ratio
ra
ao
ratio
measur
right
parastern
long
axi
imag
studi
review
presenc
tricuspid
regurgit
tr
maximum
tr
veloc
tr
vmax
measur
avail
group
compar
oneway
anova
kruskal
walli
test
appropri
ninetythre
cat
includ
studi
cat
lchf
pleural
effus
cat
lchf
pulmonari
edema
cat
pulmonari
diseas
without
evid
cardiomyopathi
healthi
cat
median
ra
ao
pleural
effus
group
rang
significantli
larger
p
group
mean
ra
la
ratio
pleural
effus
ae
pulmonari
diseas
ae
group
differ
pulmonari
edema
ae
healthi
ae
group
p
though
differ
comparison
puls
wave
doppler
measur
pulmon
outflow
reveal
signific
differ
et
et
pa
vmax
group
tr
vmax
measur
pleural
effus
cat
median
ms
rang
healthi
cat
ms
result
studi
indic
cat
develop
pleural
effus
significantli
right
atrial
enlarg
addit
left
atrial
enlarg
cat
develop
pulmonari
edema
echocardiograph
evid
pulmonari
hypertens
found
four
group
cat
potenti
caus
right
atrial
enlarg
cat
pleural
effus
includ
concurr
rightsid
cardiac
diseas
pulmonari
hypertens
detect
echocardiograph
paramet
addit
studi
determin
degre
ra
enlarg
associ
develop
pleural
effus
could
use
predict
chf
manifest
cat
cardiomyopathi
human
postop
dysrhythmia
import
complic
cardiac
surgeri
major
caus
increas
mortal
lengthen
hospit
veterinari
field
howev
littl
knowledg
rhythmic
disturb
complic
cardiac
surgeri
aim
studi
character
postop
arrhythmia
determin
periop
predispos
factor
arrhythmia
dog
openheart
surgeri
cardiopulmonari
bypass
cpb
prospect
observ
studi
consecut
dog
undergo
mitral
valv
repair
surgeri
incid
type
postop
arrhythmia
determin
continu
monitor
electrocardiogram
first
day
hospit
occasion
prematur
atrial
ventricular
beat
consid
insignific
serolog
bloodga
paramet
measur
serial
time
point
cpb
normal
compar
two
group
nonarrhythm
arrhythm
episod
patient
show
normal
sinu
rhythm
surgeri
patient
total
episod
arrhythmia
cardiac
surgeri
ventricular
arrhythmia
frequent
identifi
supraventricular
nodal
arrhythmia
conduct
block
account
respect
patient
arrhythm
episod
recov
normal
sinu
rhythm
within
first
day
surgeri
patient
persist
arrhythmia
discharg
case
perman
pacemak
implant
although
intraven
bolu
inject
lidocain
mgkg
appli
dog
polymorph
ventricular
tachycardia
last
day
improv
found
hospit
death
caus
postop
arrhythmia
death
hospit
respiratori
failur
embol
event
furthermor
arrhythm
group
show
longer
durat
cpb
ae
minut
p
aortic
crossclamp
time
ae
minut
p
lower
glucos
level
normal
cpb
durat
ae
mgdlcpb
time
p
compar
nonarrhythm
group
cpb
time
ae
minut
crossclamp
time
ae
minut
normal
glucos
level
ae
mgdlcpb
time
also
logist
regress
model
probabl
postop
arrhythmia
reveal
signific
effect
aortic
crossclamp
time
normal
glucos
level
adjust
r
p
incid
cardiac
arrhythmia
quit
high
openheart
surgeri
cpb
dog
howev
clinic
signific
complic
cardiac
surgeri
may
minim
addit
hypoglycem
myocardi
ischem
environ
cpb
may
predispos
postop
cardiac
dysrhythmia
discassoci
cervic
spondylomyelopathi
dacsm
common
condit
doberman
pinscher
dp
similar
pathogenesi
cervic
spondylot
myelopathi
human
hcsm
patient
hcsm
kinemat
mri
kmri
use
evalu
cervic
vertebr
column
flexion
extens
purpos
studi
evalu
kmri
dp
dacsm
use
novel
posit
devic
allow
control
flexion
extens
cervic
vertebr
column
hypothes
kmri
would
caus
worsen
compress
lesion
develop
new
compress
especi
extens
nine
clientown
dp
neurolog
examin
consist
cervic
myelopathi
prospect
evalu
dog
underw
standard
mri
neutral
posit
use
magnet
follow
standard
mri
patient
place
right
later
recumb
posit
devic
addit
mri
sequenc
obtain
cervic
vertebr
column
posit
flexion
extens
morpholog
morphometr
assess
perform
use
neutral
traction
flexion
extens
imag
morpholog
analysi
includ
modifi
spinal
cord
compress
score
previous
publish
direct
spinal
cord
compress
signal
intens
chang
within
spinal
cord
worst
site
spinal
cord
compress
morphometr
assess
includ
spinal
cord
height
intervertebr
disc
width
spinal
cord
width
spinal
cord
area
vertebr
canal
height
fischer
exact
test
use
evalu
morpholog
data
mixedeffect
linear
regress
use
analys
morphometr
data
interobserv
intraobserv
analys
perform
due
space
constraint
part
result
present
neutral
posit
total
compress
note
patient
compress
patient
compress
patient
compress
flexion
total
compress
note
patient
compress
patient
compress
patient
compress
patient
compress
extens
total
compress
note
patient
compress
patient
compress
patient
compress
patient
compress
neutral
major
lesion
mild
locat
ventral
extens
associ
worsen
compress
site
presenc
sever
compress
also
associ
multipl
direct
compress
ventral
dorsal
compress
site
extens
morphometr
result
reveal
decreas
spinal
cord
height
midsagitt
imag
neutral
extens
p
flexion
extens
p
studi
support
use
kmri
evalu
dynam
compon
dacsm
result
suggest
extens
use
demonstr
worsen
multipl
compress
also
abl
detect
new
compress
visual
neutral
posit
space
sampl
perfect
applic
optim
contrast
use
differ
flip
angl
evolut
threedimension
magnet
reson
imag
sequenc
current
dimension
spin
echo
imag
gold
standard
diagnost
imag
thoracolumbar
intervertebr
disk
diseas
space
potenti
advantag
standard
mri
singl
acquisit
faster
technic
easier
modal
higher
resolut
potenti
reconstruct
imag
set
plane
section
purpos
studi
determin
agreement
space
standard
spin
echo
imag
sequenc
presenc
hansen
type
intervertebr
disk
diseas
thoracolumbar
spine
dog
determin
space
viabl
imag
sequenc
canin
patient
hypothesi
mri
sequenc
space
abl
posit
identifi
hansen
type
intervertebr
disk
diseas
equal
accuraci
standard
spin
echo
imag
doubl
blind
control
studi
dog
acut
onset
compress
myelopathi
secondari
hansen
type
intervertebr
disk
diseas
patient
standard
preanesthet
screen
underw
magnet
reson
imag
spine
use
siemen
scanner
imag
obtain
least
follow
sequenc
standard
sagitt
transvers
stir
dorsal
space
dog
underw
decompress
hemilaminectomi
base
imag
find
mri
sequenc
random
three
blind
individu
interpret
mr
imag
total
three
time
evalu
differ
skill
level
includ
one
ecvn
diplom
one
acvr
diplom
third
year
neurolog
resid
standard
space
sequenc
individu
evalu
site
side
degre
compress
well
surgic
recommend
subject
confid
imag
find
dog
met
inclus
criteria
statist
signific
agreement
site
side
pvalu
standard
spin
echo
imag
space
complet
agreement
three
research
concern
site
side
disk
herniat
compar
standard
standard
spin
echo
imag
space
dog
partial
agreement
dog
compress
length
ratio
clr
estim
two
method
similar
variabl
due
evalu
variabl
differ
two
system
similar
intern
intrarat
variabl
two
system
degre
compress
measur
standard
mildmediumsever
rate
protocol
show
significantli
posit
associ
two
method
although
strong
two
method
clr
measur
mri
sequenc
space
abl
posit
identifi
hansen
type
intervertebr
disk
diseas
canin
thoracolumbar
spine
confirm
via
surgeri
equal
accuraci
standard
imag
dog
confirm
ivdh
either
histopatholog
diagnosi
pmm
high
clinic
suspicion
acut
paraplegia
loss
nocicept
loss
patellar
reflex
cranial
advanc
cutan
trunci
muscl
reflex
inconsist
locat
disc
herniat
identifi
medic
record
search
fortyeight
case
identifi
confirm
via
histopatholog
suspect
base
clinic
sign
imag
major
dog
chondrodystroph
includ
dachshund
onset
pmm
sign
rang
present
first
evalu
n
day
present
develop
sign
within
day
progress
sign
onset
euthanasia
exclud
case
euthan
present
rang
day
euthan
within
hour
system
sign
depress
anorexia
abnorm
temperatur
diffus
pain
document
dog
focal
disc
herniat
present
dog
dog
extens
herniat
summari
major
dog
develop
pmm
within
day
present
progress
euthanasia
within
anoth
day
howev
onset
delay
day
present
progress
death
take
long
week
nonspecif
system
sign
commonli
report
benzimidazol
anthelmint
drug
report
antiprolif
effect
sever
cancer
vitro
vivo
reduc
offtarget
toxic
compar
microtubuledisrupt
drug
addit
small
lipophil
drug
readili
cross
bloodbrain
barrier
purpos
studi
evalu
vitro
chemosensit
canin
glioblastoma
cell
mebendazol
mbz
fenbendazol
fbz
cell
expos
drug
hour
cell
viabil
evalu
use
mtt
assay
halfmaxim
inhibitori
concentr
ic
mbz
fbz
calcul
use
fourparamet
variabl
slope
curv
fit
nonlinear
regress
analysi
ic
compar
two
drug
western
blot
use
compar
ratio
polymer
depolymer
tubulin
drugtreat
cell
untreat
control
immunocytochemistri
perform
treat
untreat
cell
visual
effect
treatment
tubulin
mean
ic
mbz
fbz
ae
ae
respect
treatment
mbz
fbz
result
increas
depolymer
tubulin
compar
untreat
control
immunocytochem
studi
show
disrupt
tubulin
evid
apoptot
bodi
hour
treatment
vitro
data
suggest
mbz
fbz
may
good
candid
treatment
canin
glioblastoma
vivo
studi
requir
cerebrospin
fluid
csf
flow
subarachnoid
space
imped
development
anomali
subarachnoid
space
ie
diverticula
acquir
adhes
older
anim
development
lesion
occur
type
dog
clinic
sign
typic
present
anim
less
one
year
old
acquir
lesion
appear
common
middleag
older
small
dog
notabl
pug
clinic
sign
includ
progress
propriocept
ataxia
later
stage
fecal
urinari
incontin
tradit
surgic
treatment
acquir
subarachnoid
adhes
constrict
myelopathi
associ
unreli
outcom
report
surgic
procedur
outcom
use
subarachnoidsubarachnoid
shunt
mean
bridg
area
adhes
nine
dog
treat
techniqu
iowa
state
univers
novemb
august
spinal
cord
expos
via
routin
dorsal
laminectomi
case
thoracolumbar
spinal
cord
via
laminotomi
one
durotomi
made
lesion
site
use
hypoderm
needl
bevel
expand
later
disrupt
adhes
pia
mater
arachnoid
mater
shunt
tube
consist
ventricular
cathet
ventriculoperiton
shunt
kit
red
rubber
cathet
appropri
diamet
trim
span
lesion
plu
mm
either
side
adhes
secur
within
subarachnoid
space
use
nonabsorb
polypropylen
prolen
sutur
dura
close
shunt
one
patient
development
subarachnoid
diverticulum
patient
laminotomi
remain
acquir
adhes
constrict
myelopathi
document
surgeri
four
patient
show
improv
clinic
sign
three
show
complet
recoveri
one
patient
shown
complet
recoveri
group
young
patient
development
subarachnoid
diverticulum
continu
improv
month
postop
one
patient
mix
success
improv
fecal
control
deterior
gait
although
subsequ
gradual
improv
three
patient
show
major
improv
surgeri
one
show
mild
improv
surgeri
acut
progress
paraparesi
month
prompt
euthanasia
caus
acut
paraparesi
ascertain
lack
post
mortem
examin
two
case
show
unchang
clinic
sign
month
post
oper
last
remain
case
improv
immedi
postop
lost
longterm
followup
obstruct
csf
flow
subarachnoid
space
associ
sever
lifethreaten
fecal
incontin
common
reason
euthanasia
neurolog
deficit
result
suggest
subarachnoidsubarachnoid
shunt
effect
surgic
techniqu
amelior
prevent
progress
associ
clinic
sign
meningioma
glioma
common
intracrani
neoplasm
dog
definit
diagnosi
often
problemat
due
cost
invas
intracrani
biopsi
biomark
serum
urin
andor
csf
provid
adjunct
diagnost
data
conjunct
standard
techniqu
magnet
reson
imag
cycloogygenas
pathway
identifi
key
player
cancer
progress
sever
pathway
product
includ
thromboxan
txa
express
varieti
human
cancer
includ
glioma
purpos
pilot
studi
determin
level
b
stabl
hydrolysi
product
txa
dog
varieti
neurolog
nonneurolog
diseas
use
enzym
immunoassay
urin
serum
csf
sampl
store
immedi
follow
collect
day
prior
storag
reliabl
detect
urin
serum
csf
storag
day
significantli
affect
urin
txb
level
concurr
corticosteroid
nonsteroid
antiinflammatori
medic
appar
affect
level
within
studi
group
whole
overlap
urin
level
seen
clinic
normal
neurolog
anim
group
although
highest
valu
seen
anim
intracrani
neoplasia
overlap
neurolog
diseas
group
present
assay
feasibl
howev
addit
analysi
larg
studi
popul
necessari
determin
whether
threshold
urin
level
may
use
diagnost
biomark
canin
degen
myelopathi
dm
adultonset
neurodegen
disord
clinic
progress
homogen
within
across
breed
thu
four
distinct
diseas
stage
identifi
kanazono
et
al
coat
wining
dm
share
similar
form
amyotroph
later
sclerosi
al
includ
underli
mutat
superoxid
microglia
play
central
role
al
progress
rodent
model
microglia
behavior
complex
express
pattern
classic
molecul
variabl
throughout
diseas
speci
studi
mechan
underli
microgli
phenotyp
determin
within
al
known
fractalkin
neuron
produc
chemokin
shown
suppress
mutant
microglialmedi
neurotox
vitro
thu
fractalkin
possibl
contributor
microgli
phenotyp
determin
al
increas
spinal
cord
microglia
document
endstag
dmaffect
dog
howev
respons
phenotyp
throughout
diseas
progress
unknown
goal
studi
quantifi
phenotyp
microgli
cell
close
proxim
lumbar
spinal
cord
motor
neuron
dmaffect
dog
diseas
stage
compar
find
agematch
neurolog
normal
dog
correl
microgli
phenotyp
fractalkin
protein
level
lumbar
spinal
cord
throughout
diseas
progress
spinal
cord
tissu
collect
postmortem
clientown
dog
donat
univers
missouri
research
purpos
lumbar
spinal
cord
microglia
analys
conduct
immunofluoresc
confoc
microscopi
identifi
microglia
close
proxim
motor
neuron
mn
concentr
circl
increas
radii
lm
appli
mn
dmaffect
dog
diseas
stage
stage
n
stage
n
late
dm
n
agematch
control
dog
n
cell
posit
immunoreact
microglia
microglia
quantifi
doubleblind
manner
data
analyz
via
kruskalw
anova
rank
posthoc
dunn
method
fractalkin
total
protein
quantifi
via
western
blot
analysi
lumbar
spinal
cord
dmaffect
dog
stage
n
stage
n
late
dm
n
agematch
control
dog
n
rel
optic
densiti
normal
control
dog
data
analyz
via
anova
posthoc
holmsidak
method
progress
increas
total
microglia
close
associ
lumbar
motor
neuron
observ
dmaffect
dog
ae
stage
ae
late
dm
ae
p
compar
agematch
control
ae
p
total
microglia
increas
stage
ae
late
dmaffect
dog
ae
compar
agematch
control
ae
p
differ
observ
total
microglia
throughout
diseas
progress
lumbar
spinal
cord
fractalkin
protein
increas
stage
ae
late
dmaffect
dog
ae
compar
agematch
control
ae
p
data
suggest
microglia
progress
recruit
motor
neuron
diseas
progress
increas
lumbar
spinal
cord
fractalkin
correl
progress
microglia
dmaffect
dog
canin
degen
myelopathi
dm
adultonset
neurodegen
disord
four
defin
diseas
stage
dm
initi
manifest
spastic
upper
motor
neuron
paraparesi
gener
propriocept
ataxia
stage
progress
neurodegener
result
nonambulatori
paraparesisparaplegia
stage
thorac
limb
paresi
stage
endstag
diseas
culmin
flaccid
tetraplegia
widespread
muscl
atrophi
sign
brainstem
dysfunct
stage
clinic
spectrum
dm
homogen
within
across
breed
phosphoryl
neurofila
heavi
pnfh
major
structur
protein
myelin
motor
axon
shown
promis
prognost
biomark
diseas
nervou
system
amyotroph
later
sclerosi
al
goal
studi
quantifi
concentr
pnfh
csf
dmaffect
dog
throughout
diseas
progress
compar
find
agematch
neurolog
normal
dog
without
mutat
compar
csf
concentr
pnfh
dmaffect
dog
chronic
spinal
cord
diseas
mimic
dm
use
enzymelink
immunosorb
assay
elisa
measur
pnfh
concentr
csf
age
control
dog
n
dmaffect
dog
stage
stage
n
stage
n
stage
n
stage
n
data
analyz
use
kruskalw
anova
rank
posthoc
dunn
method
addit
csf
pnfh
concentr
compar
dmaffect
dog
n
dog
chronic
spinal
cord
diseas
n
data
analyz
student
test
evalu
diagnost
perform
receiv
oper
characterist
curv
gener
csf
concentr
pnfh
increas
dmaffect
dog
diseas
stage
compar
age
control
dog
p
pnfh
concentr
differ
dm
diseas
stage
p
dmaffect
dog
increas
csf
pnfh
compar
dog
chronic
spinal
diseas
p
use
cutoff
concentr
ngml
sensit
specif
diagnosi
dm
respect
area
receiv
oper
characterist
curv
preliminari
find
suggest
pnfh
csf
sensit
specif
diseas
marker
dm
data
warrant
studi
pnfh
csf
serum
diagnosi
diseas
longitudin
monitor
therapeut
efficaci
dm
juvenil
onset
seizur
defin
seizur
start
prior
month
age
studi
aim
studi
identifi
common
etiolog
describ
outcom
dead
aliv
cat
juvenil
onset
seizur
inclus
criteria
confirm
suspect
seizur
month
age
complet
medic
record
includ
final
diagnosi
diagnosi
reclassifi
cat
accord
ila
guidelin
fifteen
cat
met
inclus
criteria
median
age
onset
week
rang
week
six
cat
diagnos
structur
epilepsi
cat
diagnos
unknown
epilepsi
cat
diagnos
reactiv
seizur
gener
seizur
document
cat
cat
focal
seizur
cat
focal
gener
seizur
six
cat
cluster
seizur
statu
epilepticu
document
cat
overal
cat
aliv
cat
dead
cat
lost
follow
follow
month
diagnosi
three
cat
die
euthan
secondari
seizur
underli
diagnosi
cat
die
euthan
unrel
seizur
seizur
diagnosi
cat
die
due
unknown
caus
primari
genet
epilepsi
common
caus
seizur
dog
reportedli
affect
popul
sever
investig
regard
serum
concentr
trace
nutrient
includ
copper
selenium
zinc
manganes
iron
human
epilept
anim
model
howev
research
natur
avail
dog
primari
genet
epilepsi
prospect
pilot
studi
design
compar
serum
concentr
sever
trace
nutrient
nonepilept
dog
compar
dog
epilepsi
blood
sampl
collect
healthi
control
dog
dog
primari
genet
epilepsi
serum
evalu
concentr
copper
selenium
zinc
cobalt
manganes
molybdenum
iron
use
induct
coupl
plasma
mass
spectroscopi
mann
u
whitney
test
use
compar
normal
epilept
dog
serum
level
trace
nutrient
significantli
higher
level
copper
p
selenium
p
manganes
p
found
epilept
dog
compar
normal
dog
signific
differ
found
level
zinc
p
cobalt
p
molybdenum
p
iron
p
result
suggest
differ
concentr
trace
nutrient
epilept
dog
compar
normal
dog
warrant
investig
previou
studi
identifi
associ
modifi
glasgow
coma
scale
mgc
hyperglycemia
surviv
veterinari
patient
head
trauma
lactat
product
anaerob
glycolysi
hyperlactatemia
classic
associ
decreas
tissu
perfus
studi
dog
variou
diseas
includ
trauma
show
higher
initi
lactat
concentr
dog
associ
increas
risk
mortal
main
aim
studi
determin
elev
serum
lactat
follow
head
trauma
dog
cat
associ
mortal
whether
degre
hyperlactatemia
correspond
clinic
outcom
medic
record
dog
cat
diagnos
head
trauma
vetcot
trauma
registri
search
electron
medic
record
veterinari
teach
hospit
examin
case
includ
diagnosi
head
trauma
made
blood
lactat
concentr
measur
day
present
anim
head
trauma
includ
studi
inform
signal
vital
paramet
diagnost
test
treatment
outcom
record
base
inform
medic
record
mgc
assign
patient
univari
logist
regress
use
evalu
associ
surviv
signal
examin
paramet
laboratori
test
administr
treatment
total
anim
dog
cat
met
inclus
criteria
studi
evid
hyperlactatemia
p
hyperglycemia
p
associ
mortal
mgc
score
initi
evalu
variabl
significantli
associ
outcom
p
dog
cat
head
trauma
may
elev
serum
lactat
level
degre
hyperlactatemia
associ
sever
head
trauma
outcom
recent
experi
laboratori
rodent
suggest
constitu
fecal
microbiom
influenc
activ
immun
system
specif
shown
gnotobiot
rat
resist
develop
experiment
autoimmun
enceph
eae
immunemedi
diseas
cn
mimic
aspect
multipl
sclerosi
human
meningoencephalomyel
unknown
origin
muo
dog
experi
shown
restor
normal
microbiom
abrog
resist
eae
studi
investig
whether
similar
suscept
muo
might
exist
dog
specif
microbiom
constitu
previou
publish
work
speci
suggest
faecalibacterium
spp
specif
f
prausnitzii
may
modul
immun
system
reduc
risk
inflammatori
immunemedi
diseas
therefor
studi
test
hypothesi
rel
defici
faecalibacterium
spp
especi
f
prausnitzii
would
associ
develop
muo
obtain
fecal
sampl
dog
diagnos
muo
control
mani
match
breed
age
gender
dog
treat
antibiot
within
previou
week
exclud
fecal
microbiom
character
use
rrna
sequenc
illumina
qpcr
assay
target
faecalibacterium
spp
abund
compar
affect
dog
control
analysi
entir
sampl
popul
signific
reduct
log
dnagram
fece
faecalibacterium
spp
affect
dog
compar
control
median
versu
mannwhitney
test
p
howev
affect
dog
compar
match
control
median
popul
faecalibacterium
spp
smaller
affect
dog
versu
wilcoxon
sign
rank
p
moreov
pair
affect
dog
smaller
popul
faecalibacterium
spp
unaffect
dog
similarli
although
popul
proport
f
prausnitzii
smaller
affect
dog
control
versu
comparison
use
mannwhitney
test
reveal
p
examin
pair
data
reveal
lower
median
proport
affect
dog
versu
wilcoxon
pair
rank
p
studi
suggest
albeit
limit
evid
suggest
abund
faecalibacterium
spp
may
influenc
suscept
individu
dog
develop
muo
one
possibl
explan
result
wellrecogn
breed
suscept
muo
may
mediat
least
partial
effect
gut
microbiom
examin
one
highli
specif
hypothesi
regard
gut
microbiota
diseas
analysi
extens
fecal
microbiom
result
avail
studi
may
gener
hypothes
test
futur
studi
jourdan
brune
anni
chenallen
washington
state
univers
pullman
wa
usa
cerebrospin
fluid
csf
analysi
regularli
perform
patient
neurolog
diseas
iatrogen
blood
contamin
distort
result
effect
iatrogen
blood
contamin
canin
csf
lactat
dehydrogenas
ld
creatin
kinas
ck
total
isoenzym
activ
previous
evalu
ck
exist
isoenzym
ckmm
ckmb
ckbb
ld
exist
isoenzym
serum
csf
investig
effect
blood
contamin
total
ld
ck
isoenzym
activ
could
allow
clinician
better
interpret
diagnost
prognost
valu
ld
ck
isoenzym
canin
neurolog
patient
csf
sampl
contamin
increment
amount
whole
blood
via
serial
dilut
ld
ck
total
isoenzym
activ
valu
compar
uncontamin
csf
sampl
establish
refer
interv
total
ld
ck
valu
determin
spectrophotometr
use
sieman
dimens
xpand
isoenzym
activ
determin
use
gel
electrophoresi
densitometr
scan
contamin
sampl
total
ld
ck
valu
increas
compar
uncontamin
sampl
contamin
rbcul
respect
addit
csf
isoenzym
activ
began
emul
serum
isoenzym
activ
ckbb
band
becam
promin
csf
contamin
rbcul
find
suggest
threshold
blood
contamin
artifici
distort
csf
ld
ck
total
isoenzym
analysi
therefor
valu
need
interpret
caution
iatrogen
blood
contamin
csf
object
studi
compar
clinic
outcom
dog
acut
noncompress
nucleu
pulposu
extrus
annp
presumpt
fibrocartilagin
embol
myelopathi
fcem
affect
thoracolumbar
spinal
cord
segment
medic
record
dog
present
anim
health
trust
may
april
diagnos
annp
presumpt
fcem
retrospect
review
random
list
gener
mri
studi
case
match
inclus
criteria
submit
two
boardcertifi
neurologist
ldr
one
boardcertifi
radiologist
pj
blind
clinic
data
observ
request
make
diagnosi
annp
fcem
base
previous
publish
diagnost
criteria
interobserv
agreement
evalu
kappa
statist
clinic
outcom
consensu
diagnos
compar
recoveri
motor
autonom
function
evalu
via
medic
record
telephon
questionnair
owner
clinic
reexamin
perform
possibl
base
review
mri
studi
case
diagnos
annp
presumpt
fcem
level
agreement
ldra
j
aspj
j
almost
perfect
ldrpj
j
substanti
impair
urinari
andor
fecal
contin
report
annp
group
dog
p
dog
concurr
persist
motor
deficit
four
dog
impair
urinari
andor
fecal
contin
ambulatori
present
inabl
control
urg
defec
frequent
report
deficit
faecal
contin
one
dog
becam
remain
ambulatori
without
assist
one
dog
diagnos
presumpt
fcem
present
parapleg
without
nocicept
recov
ambulatori
statu
day
euthan
dog
annp
dog
presumpt
fcem
recov
complet
normal
gait
accord
owner
includ
grade
dog
grade
dog
none
dog
plegic
present
percentag
dog
persist
motor
deficit
statist
differ
two
group
time
recoveri
motor
function
affect
limb
present
monoor
paraplegia
significantli
longer
dog
presumpt
fcem
compar
dog
annp
p
howev
two
case
variabl
present
fcem
group
dog
diagnos
presumpt
fcem
significantli
younger
p
lighter
p
dog
annp
longer
intramedullari
hyperintens
lesion
sagitt
mri
imag
p
dog
annp
frequent
report
perform
physic
activ
p
vocalis
p
time
onset
clinic
sign
frequent
receiv
antiinflammatori
drug
diagnosi
p
compar
dog
presumpt
fcem
conclus
dog
diagnos
annp
affect
thoracolumbar
spinal
cord
segment
develop
impair
urinaryfec
contin
significantli
frequent
dog
presumpt
fcem
impair
urinaryfec
contin
occur
also
dog
ambulatori
present
presenc
persist
motor
deficit
extrem
common
particularli
dog
present
nonambulatori
howev
statist
signific
differ
detect
degre
recoveri
motor
function
two
group
morpholog
abnorm
caudal
fossa
increasingli
recogn
caus
morbid
mani
brachycephal
dog
littl
inform
condit
cat
object
studi
investig
presenc
similar
morpholog
abnorm
caudal
fossa
mesaticephal
brachycephal
cat
possibl
associ
clinic
sign
final
diagnosi
felin
brain
mri
studi
two
referr
centr
review
case
without
visibl
diseas
could
alter
anatom
landmark
rais
intracrani
pressur
weight
median
plane
imag
brain
avail
spinal
cord
review
presenc
caudal
cerebellar
indent
cone
herniat
syringohydromyelia
fluid
accumul
middl
ear
area
cerebr
hemispher
cerebellum
also
measur
blind
measur
taken
two
observ
review
felin
mri
studi
meet
inclus
criteria
cerebellar
herniat
found
mesaticephal
brachycephal
cat
syringohydromyelia
identifi
mr
studi
includ
first
two
cervic
spinal
cord
segment
cat
region
spinal
cord
cat
high
signal
transvers
imag
middl
ear
detect
mesaticephal
brachycephal
cat
inform
present
complaint
result
neurolog
examin
final
diagnosi
cat
without
cerebellar
herniat
review
mesaticephal
breed
cat
show
indent
caudal
aspect
cerebellum
caudal
cerebellar
cone
similar
brachycephal
breed
cat
dimens
foramen
magnum
planum
area
cerebr
hemispher
cerebellum
measur
sagitt
mr
imag
brain
also
similar
two
group
howev
brachycephal
cat
higher
percentag
herniat
cerebellar
vermi
foramen
magnum
herniat
cerebellar
vermi
appear
associ
syringomyelia
cat
felin
hyperesthesia
syndrom
fh
first
report
describ
accentu
otherwis
normal
behavior
cat
consist
episod
tail
chase
bite
lick
lumbar
area
flank
anal
area
tail
skin
rippl
muscl
spasm
excess
unusu
vocal
wild
uncontrol
jump
run
presum
hallucin
fh
anecdot
report
associ
dermatolog
behaviour
orthopaed
neurolog
condit
treatment
phenobarbit
gabapentin
prednisolon
amitriptylin
fluoxetin
clomipramin
multivitamin
supplement
use
inconsist
respons
howev
awar
clinic
scientif
investig
felin
hyperesthesia
syndrom
retrospect
collect
data
histori
signal
diagnost
workup
treatment
three
referr
veterinari
center
inclus
criteria
histori
attack
overgroom
tail
flank
perin
area
associ
either
vocal
lumbar
hyperesthesia
manifest
rippl
thoracolumbar
skin
occur
spontan
induc
gentl
touch
inform
physic
neurolog
examin
diagnost
work
also
necessari
inclus
studi
thirteen
cat
includ
studi
median
age
present
year
year
eleven
cat
attack
overgroom
tail
two
cat
flank
perin
area
tail
mutil
report
cat
rippl
thoracolumbar
skin
cat
cat
present
unusu
vocal
episod
episod
occur
multipl
time
per
day
case
multipl
time
per
week
consist
trigger
report
result
cbc
biochemistri
avail
cat
spinal
radiograph
magnet
reson
imag
cerebrospin
fluid
analysi
electromyographi
dermatolog
assess
joint
fluid
analysi
one
cat
diagnost
work
led
diagnosi
allerg
dermat
case
immunemedi
polyarthr
one
case
definit
diagnosi
reach
remain
case
treatment
includ
corticosteroid
cat
gabapentin
clomipramin
topiram
phenobarbit
cyclosporin
major
case
receiv
combin
drug
studi
confirm
previou
anecdot
report
fh
affect
young
cat
possibl
fh
sign
secondari
inflammatori
skin
condit
definit
diagnosi
reach
case
howev
case
diagnost
work
full
behavior
dermatolog
assess
base
result
retrospect
studi
specialist
neurolog
behavior
dermatolog
formul
standard
questionnair
propos
ration
diagnost
approach
investig
treatment
constel
clinic
sign
cat
platform
futur
prospect
studi
although
pelvic
limb
paralysi
partial
circumv
use
cart
allow
greater
mobil
care
urinari
bladder
often
problemat
addit
urinari
incontin
recurr
urinari
tract
infect
possibl
mani
affect
anim
suffer
detrusor
hyperreflexia
risk
factor
chronic
elev
bladder
pressur
secondari
renal
damag
human
canin
spinal
cord
injuri
patient
describ
cytometr
quantif
bladder
dysfunct
chronic
parapleg
pet
dog
dog
kg
sustain
sever
spinal
cord
injuri
result
inabl
walk
control
urin
persist
least
three
month
postinjuri
duallumen
steril
urinari
cathet
use
cystometri
one
lumen
use
infus
steril
salin
bladder
measur
intravesicular
pressur
infus
termin
leak
appar
extern
urethr
orific
physiolog
maximum
hold
capac
mlkg
reach
mmhg
intravesicular
pressur
threshold
reach
sever
cystometr
metric
measur
studi
intravesicular
pressur
leak
bladder
hold
capac
express
percentag
physiolog
maximum
hold
capac
mlkg
bladder
complianc
determin
chang
bladder
volum
divid
chang
intravesicular
pressur
two
standard
point
use
calcul
bladder
complianc
intravesicular
pressur
bladder
volum
start
bladder
fill
zero
intravesicular
pressur
bladder
volum
cystometr
capac
immedi
start
detrusor
contract
result
urin
leakag
cystometr
data
record
dog
chronic
spinal
cord
injuri
intravesicular
pressur
leak
rang
mmhg
mmhg
mean
mmhg
median
mmhg
patient
intravesicular
pressur
reach
mmhg
threshold
two
addit
paramet
use
quantifi
detrusor
hyperreflexia
highli
variabl
within
popul
whole
bladder
complianc
mean
mlmmhg
median
mlmmhg
rang
mlmmhg
bladder
hold
capac
mean
median
rang
conclud
evid
detrusor
hyperreflexia
occur
small
proport
pet
dog
paralyz
sever
spinal
cord
injuri
character
elev
intravesicular
pressur
reduct
bladder
complianc
bladder
hold
capac
identif
specif
type
neurogen
bladder
dysfunct
permit
time
intervent
mitig
renal
damag
potenti
therapi
treat
detrusor
hyperreflexia
evalu
use
quantifi
bladder
function
paramet
deriv
cystometri
osseousassoci
cervic
spondylomyelopathi
oacsm
condit
character
static
dynam
spinal
cord
compress
dynam
compon
cervic
spondylot
myelopathi
human
hcsm
evalu
kinemat
mri
kmri
purpos
studi
evalu
kmri
dog
oacsm
use
posit
devic
allow
control
flexion
extens
cervic
vertebr
column
hypothesi
kmri
would
reveal
new
compress
lesion
identifi
standard
posit
ten
great
dane
doberman
pinscher
neurolog
examin
find
consist
cervic
myelopathi
prospect
evalu
dog
underw
standard
mri
neutral
posit
sagitt
transvers
weight
imag
use
magnet
patient
place
right
later
recumb
posit
devic
cervic
vertebr
column
first
flex
extend
sagitt
transvers
weight
imag
acquir
flexion
extens
morpholog
morphometr
assess
cervic
vertebr
column
neutral
flexion
extens
perform
morpholog
analysi
includ
modifi
spinal
cord
compress
score
previous
publish
direct
spinal
cord
compress
signal
intens
chang
within
spinal
cord
worst
site
spinal
cord
compress
morphometr
assess
includ
spinal
cord
height
intervertebr
disc
width
spinal
cord
width
spinal
cord
area
vertebr
canal
height
fischer
exact
test
use
evalu
morpholog
data
mixedeffect
linear
regress
use
analyz
morphometr
data
interobserv
intraobserv
analys
perform
given
space
constraint
portion
result
report
neutral
patient
compress
patient
compress
patient
compress
patient
compress
total
compress
flexion
patient
compress
patient
compress
patient
compress
patient
compress
patient
compress
total
compress
extens
patient
compress
patient
compress
patient
compress
patient
compress
total
compress
extens
associ
mild
compress
p
note
neutral
flexion
extens
caus
worsen
compress
compress
present
neutral
compress
extens
present
neutral
compress
dorsal
compon
presenc
dorsal
compress
extens
signific
p
flexion
associ
increas
intervertebr
disc
width
p
extens
caus
widen
intervertebr
disc
signific
morphometr
find
note
patient
synovi
cyst
identifi
neutral
note
caus
mild
spinal
cord
compress
extens
result
support
use
kmri
patient
oacsm
reveal
new
compress
site
dorsal
compress
enhanc
visual
extradur
compress
lesion
synovi
cyst
multitud
infecti
agent
differenti
list
dog
focal
multifoc
neurolog
dysfunct
number
bartonella
spp
includ
b
hensela
b
vinsonii
subsp
berkhoffii
b
clarridgeai
known
infect
dog
multipl
human
case
neurobartonellosi
recent
describ
role
organ
play
clinic
diseas
central
nervou
system
dog
wide
explor
purpos
studi
use
polymeras
chain
reaction
pcr
amplifi
bartonella
spp
dna
cerebrospin
fluid
csf
natur
expos
dog
endem
area
meet
criteria
inflammatori
central
nervou
system
cn
diseas
csf
sampl
pure
mix
breed
dog
submit
colorado
state
univers
wwwdlabcolostateedu
either
washington
state
univers
neurolog
depart
januari
septemb
colorado
state
univers
veterinari
teach
hospit
januari
septemb
csf
sampl
store
evalu
studi
dog
neurolog
examin
consist
focal
multifoc
neurolog
dysfunct
csf
pleocytosi
total
nucleat
cell
count
nucleat
red
blood
cell
includ
anim
normal
neurolog
examin
also
includ
csf
met
criteria
csf
thaw
centrifug
x
g
minut
supernat
remov
pellet
assay
previous
publish
pcr
assay
target
rrna
intergen
region
posit
amplicon
sequenc
determin
infect
bartonella
spp
total
dog
met
inclus
criteria
none
posit
bartonella
spp
dna
csf
csf
sampl
one
posit
b
hensela
dna
csf
dog
contain
red
blood
cell
bartonella
spp
intraerythrocyt
phase
specul
minim
peripher
rbc
contamin
csf
dog
system
bartonella
spp
infect
may
lead
posit
bartonella
pcr
assay
result
absenc
cn
diseas
associ
thu
posit
pcr
bartonella
spp
dna
csf
dog
must
interpret
light
number
rbc
within
sampl
well
presenc
inflamm
system
infect
failur
amplifi
bartonella
spp
dna
csf
dog
inflammatori
diseas
studi
suggest
organ
involv
organ
cn
tissu
csf
organ
present
quantiti
undetect
pcr
assay
combin
pcr
cultur
found
sensit
way
detect
bartonella
spp
sampl
dog
human
use
techniqu
consid
futur
studi
anxieti
relat
behavior
report
human
diagnos
epilepsi
one
veterinari
studi
shown
increas
frequenc
anxieti
behavior
epilept
dog
compar
medic
popul
purpos
studi
determin
presenc
sever
anxieti
relat
behavior
dog
genet
epilepsi
compar
control
patient
studi
aim
investig
associ
exist
increas
anxieti
relat
behavior
preictal
postict
phase
seizur
episod
compar
interict
period
whether
dog
refractori
epilepsi
sever
seizur
could
account
increas
anxieti
relat
behavior
side
effect
report
human
dog
multiinstitut
studi
use
questionnair
base
canin
behavior
assess
research
questionnair
cbarq
previous
valid
abil
analyz
canin
behavior
owner
dog
diagnos
genet
epilepsi
ask
complet
questionnair
seizur
sever
scale
section
cbarq
relat
separ
attach
attent
seek
obedi
train
behavior
modifi
includ
addit
paramet
detect
anxieti
base
behavior
chang
associ
differ
phase
seizur
episod
questionnair
also
distribut
primari
care
client
present
dog
well
examin
owner
dog
intervertebr
disc
diseas
ivdd
veterinarian
dog
studi
also
complet
brief
questionnair
well
identifi
verifi
diagnos
dog
particip
studi
fischer
exact
test
util
assess
differ
behavior
trait
exhibit
epilept
ivdd
primari
care
group
signific
differ
group
detect
post
hoc
test
fischer
exact
test
pairwis
comparison
perform
bonferroni
correct
appli
account
multipl
comparison
dog
epilepsi
ivdd
group
like
fearfulanxi
approach
unfamiliar
dog
dog
well
group
p
epilept
dog
increas
seizur
sever
significantli
like
show
fear
anxieti
approach
unfamiliar
dog
p
show
significantli
less
excit
taken
car
trip
p
epilept
dog
receiv
polytherapi
signific
decreas
excit
take
walk
p
taken
car
trip
compar
dog
monotherapi
p
dog
receiv
polytherapi
significantli
increas
fear
anxieti
groom
bath
household
member
p
increas
shake
shiver
trembl
left
left
p
dog
receiv
polytherapi
signific
increas
becom
agit
owner
other
show
affect
anoth
person
preictal
p
postict
p
interict
p
r
period
owner
other
show
affect
anoth
dog
anim
preictal
p
postict
p
interict
p
period
compar
dog
monotherapi
find
behavior
chang
present
throughout
differ
seizur
phase
studi
rais
question
epilepsi
affect
canin
patient
qualiti
life
background
canin
osteosarcoma
os
aggress
sarcoma
character
patholog
skelet
resorpt
pulmonari
metastas
limit
number
neg
prognost
factor
includ
bone
alkalin
phosphatas
identifi
dog
diagnos
os
howev
biolog
underpin
observ
thoroughli
investig
mediat
signal
activ
bone
repair
respons
osteoblast
migrat
prolifer
bone
alkalin
phosphatas
express
hypothesi
signal
axi
activ
canin
os
cell
pathway
util
malign
osteoblast
promot
cellular
migrat
prolifer
bone
alkalin
phosphatas
activ
anim
dog
appendicular
os
method
express
endothelin
receptor
studi
os
cell
line
spontan
tumor
sampl
biolog
activ
mediat
signal
investig
character
respons
os
cell
line
dog
os
bone
alkalin
phosphatas
concentr
correl
primari
tumor
osteoproduct
result
canin
os
cell
express
endothelin
receptor
signal
axi
function
mediat
os
migrat
prolifer
bone
alkalin
phosphatas
activ
osbear
dog
circul
bone
alkalin
phosphatas
activ
posit
correl
primari
tumor
rel
bone
miner
densiti
conclus
clinic
import
canin
os
cell
express
function
endothelin
receptor
potenti
autocrin
paracrin
protumorigen
signal
loop
elev
bone
alkalin
phosphatas
associ
osteoblast
os
lesion
might
epiphenomenon
activ
signal
excess
osteoproduct
within
local
bone
microenviron
introduct
combin
chemotherapi
hold
promis
improv
outcom
canin
malign
care
must
taken
avoid
overlap
toxic
method
dog
cytolog
histolog
diagnos
tumor
histolog
exclud
mast
cell
tumor
stage
allow
standard
openlabel
phase
dosecohort
escal
design
employ
toceranib
dose
remain
constant
mgkg
administ
oral
everi
day
doxorubicin
initi
administ
iv
everi
day
four
dose
doxorubicin
dose
escal
cohort
mtd
reach
dlt
defin
grade
advers
event
except
hematopoiet
ae
grade
ae
consid
dose
limit
grade
ae
refractori
support
care
persist
beyond
seven
day
also
consid
doselimit
result
twentyon
patient
enrol
repres
histolog
includ
hemangiosarcoma
multicentr
lymphoma
anal
sac
adenocarcinoma
epitheliotrop
lymphoma
prostat
carcinoma
dlt
neutropenia
occur
doxorubicin
mtd
combin
determin
doxorubicin
toceranib
mgkg
grade
gastrointestin
novel
ae
observ
addit
antitumor
activ
observ
sever
case
conclus
combin
doxorubicin
iv
day
toceranib
mgkg
po
eod
well
toler
efficaci
longer
term
toxic
combin
investig
phase
iiiii
trial
peopl
chang
cytokin
environ
link
develop
lymphoma
multipl
circul
cytokin
shown
relev
biomark
respons
chemotherapi
prognosi
therefor
purpos
studi
measur
serum
level
cytokin
dog
multicentr
lymphoma
compar
popul
healthi
dog
hypothes
would
signific
differ
cytokin
level
dog
lymphoma
healthi
dog
dog
b
cell
cell
lymphoma
thirti
one
dog
cytolog
histopatholog
diagnos
multicentr
lymphoma
prospect
enrol
lymphoma
group
cbc
biochemistri
perform
dog
immunophenotyp
determin
flow
cytometri
dog
separ
group
b
cell
n
cell
n
nineteen
healthi
dog
enrol
control
group
dog
similar
exclus
criteria
includ
previou
administr
chemotherapi
system
immunomodulatori
medic
includ
corticosteroid
nsaid
within
last
two
week
vaccin
within
last
four
week
ttest
chisquar
test
use
compar
match
continu
variabl
age
weight
categor
variabl
sex
respect
lymphoma
control
group
cytokin
concentr
measur
use
commerci
canin
multiplex
magnet
beadbas
luminex
assay
measur
gmcsf
tnfa
ifnc
kclike
serum
level
cytokin
compar
amongst
three
group
b
cell
lymphoma
cell
lymphoma
healthi
control
use
anova
kruskalw
test
appropri
statist
signific
set
p
signific
differ
lymphoma
healthi
control
group
regard
sex
age
weight
kclike
significantli
higher
dog
lymphoma
compar
healthi
dog
p
p
p
p
respect
kclike
significantli
higher
b
cell
lymphoma
group
healthi
group
p
p
p
respect
level
significantli
higher
cell
lymphoma
group
healthi
group
p
p
p
respect
final
significantli
higher
cell
lymphoma
group
b
cell
lymphoma
group
p
p
respect
signific
differ
serum
gmcsf
tnfa
ifnc
lymphoma
control
group
conclus
studi
found
differ
serum
cytokin
profil
dog
lymphoma
healthi
dog
also
differ
serum
cytokin
profil
dog
b
cell
tcell
lymphoma
studi
necessari
underway
investig
role
cytokin
lymphoma
pathogenesi
respons
treatment
prognosi
theoret
risk
perfor
due
rapid
cell
death
associ
chemotherapi
preval
clinic
find
associ
perfor
describ
object
studi
document
preval
time
postchemotherapi
perfor
cat
git
mass
caus
intermedi
larg
cell
lymphoma
hypothes
tumor
size
presenc
hypoproteinemia
suppur
inflamm
within
mass
time
diagnosi
would
associ
perfor
cat
diagnosi
intermedi
larg
cell
lymphoma
base
cytolog
examin
mass
lesion
git
treat
variabl
chemotherapi
identifi
search
patient
record
databas
two
referr
hospit
gastrointestin
perfor
confirm
histopatholog
use
ultrasound
analysi
abdomin
fluid
twentythre
cat
intermedi
n
larg
cell
n
lymphoma
identifi
gastrointestin
perfor
confirm
cat
perfor
occur
day
induct
associ
tumor
size
presenc
hypoproteinemia
suppur
inflamm
within
mass
time
diagnosi
subsequ
perfor
perfor
rel
common
cat
git
mass
lesion
caus
intermedi
larg
cell
lymphoma
howev
find
exploratori
studi
suggest
acut
perfor
induct
chemotherapi
common
tyrosin
kinas
inhibitor
tki
commonli
use
therapi
human
veterinari
medicin
incid
proteinuria
human
receiv
vegfrtki
report
high
veterinari
medicin
tki
masitinib
mesyl
shown
induc
proteinlos
nephropathi
subset
patient
document
report
proteinuria
use
toceranib
phosphat
scarc
purpos
studi
describ
overal
incid
proteinuria
associ
use
toceranib
phosphat
medic
record
retrospect
review
septemb
octob
canin
patient
type
malign
receiv
toceranib
phosphat
minimum
week
urinalysi
urin
protein
creatinin
ratio
upc
indic
fiftyf
case
met
inclus
criteria
median
dose
toceranib
phosphat
mgkg
rang
mgkg
given
mondaywednesday
friday
prednison
use
conjunct
toceranib
phosphat
dog
median
dose
mgkg
rang
mgkg
given
tuesdaythursdaysaturdaysunday
toceranib
phosphat
plu
prednison
group
proteinuria
develop
dog
median
day
rang
day
median
upc
rang
toceranib
phosphat
alon
group
dog
develop
proteinuria
median
day
rang
day
median
upc
rang
use
toceranib
phosphat
associ
develop
proteinuria
subset
patient
care
monitor
includ
frequent
serial
urin
proteincreatinin
ratio
recommend
present
studi
design
reach
better
understand
biolog
behavior
felin
oral
squamou
cell
carcinoma
foscc
evalu
varieti
growth
factor
pathway
known
contribut
aggress
behavior
mani
cancer
addit
evalu
novel
transcript
factor
biomark
head
neck
squamou
cell
carcinoma
hnscc
foscc
biopsi
grade
immunohistochemistri
use
quantifi
rel
express
egfr
vegfd
chisquar
test
determin
express
correl
express
receptor
growth
factor
western
blot
foscc
cell
line
employ
verifi
express
egfr
src
erk
vegfd
western
blot
foscc
cell
line
determin
phosphoryl
effect
src
inhibitor
dasatinib
activ
mtt
assay
appli
foscc
cell
line
follow
treatment
dasatinib
elisa
quantifi
vegf
product
foscc
cell
without
dasatinib
treatment
stain
intens
moder
strong
foscc
foscc
biopsi
intens
stain
highest
number
posit
cell
p
biopsi
express
vegfd
express
egfr
vari
intens
correl
increas
egfr
express
approach
signific
p
foscc
cell
line
express
pegfr
psrc
perk
vegfd
dasatinib
treatment
lower
cell
viabil
inhibit
activ
suppress
vegf
product
ligand
stimul
egfr
result
increas
activ
egfr
erk
increas
vegfvegfd
product
partial
rescu
foscc
cell
effect
dasatinib
studi
repres
first
descript
express
cat
foscc
demonstr
activ
src
pathway
foscc
cell
make
src
strateg
therapeut
target
could
use
clinic
set
expos
foscc
cell
dasatinib
inhibitori
effect
cell
prolifer
egfr
consist
decreas
product
vegf
base
result
dasatinib
may
antiprolif
antiangiogen
effect
foscc
sinc
egf
abl
partial
rescu
cell
effect
dasatinib
futur
studi
evalu
dual
target
inhibit
src
egfr
egfr
vegfr
well
combin
src
inhibit
standard
chemotherapi
agent
oral
melanoma
om
high
propens
metastas
region
lymph
node
ln
lung
surgeri
andor
radiotherapi
rt
effect
local
treatment
howev
dog
succumb
distant
metastasi
immunotherapi
repres
attract
strategi
potenti
immunogen
tumor
object
multiinstitut
retrospect
studi
examin
clinic
outcom
dog
om
treat
oncept
tm
melanoma
vaccin
surgeri
andor
rt
medic
record
dog
om
treat
oncept
tm
review
seven
veterinari
radiotherapi
facil
mani
dog
underw
concurr
surgeri
andor
rt
gray
x
weekli
fraction
dog
distant
metastasi
receiv
concurr
chemotherapi
exclud
one
hundr
twenti
six
dog
includ
receiv
oncept
tm
sixti
adequ
local
control
alc
complet
excis
irradi
microscop
diseas
fifteen
treat
microscop
set
fiftyon
treat
gross
diseas
set
underw
rt
median
time
progress
median
progressionfre
surviv
median
overal
surviv
day
respect
dog
alc
improv
clinic
outcom
follow
also
correl
favor
clinic
outcom
rostral
locat
stage
absenc
ln
metastasi
low
mitot
index
absenc
boni
lysi
absenc
gross
diseas
largest
report
seri
dog
om
treat
oncept
tm
clinic
outcom
similar
report
recent
dog
treat
surgeri
andor
rt
alon
sever
prognost
indic
confirm
prospect
random
control
studi
need
determin
clinic
benefit
oncept
tm
enhanc
doxorubicin
effect
combin
salinomycin
fiss
cell
line
lucia
borll
brittani
zumbo
kelli
r
hume
cornel
univers
ithaca
ny
usa
michigan
state
univers
mi
usa
felin
inject
site
sarcoma
fiss
aggress
neoplasia
remain
challeng
clinician
radic
surgeri
first
choic
treatment
alway
feasibl
chemotherapeut
respons
document
gener
short
durat
tumor
often
develop
resist
quickli
salinomycin
ionophor
shown
inhibit
cancer
stem
cell
increas
sensit
human
soft
tissu
sarcoma
cell
doxorubicin
chemotherapi
aim
studi
determin
salinomycin
could
use
increas
sensit
fiss
cell
line
doxorubicin
two
primari
cell
line
cultur
felin
patient
histolog
confirm
fiss
use
purpos
sinc
threshold
respons
doxorubicin
differ
rank
cell
accord
sensit
doxorubicin
use
one
sensit
line
one
resist
line
cell
viabil
assay
mtt
use
determin
respons
singl
agent
combin
therapi
three
independ
assay
perform
sampl
evalu
triplic
assay
student
ttest
employ
compar
result
individu
doxorubicin
concentr
without
salinomycin
combin
therapi
addit
um
salinomycin
result
statist
signific
p
reduct
cell
viabil
compar
singl
agent
doxorubicin
multipl
concentr
cell
line
result
highlight
potenti
chemotherapi
protocol
treatment
fiss
investig
need
pursu
defin
effect
novel
therapeut
combin
valid
result
vivo
canin
nonhodgkin
lymphoma
nhl
occur
approxim
dog
per
year
account
canin
hematopoiet
cancer
standardofcar
treatment
canin
nhl
compris
multidrug
chemotherapeut
protocol
dog
enter
complet
clinic
remiss
follow
induct
chemotherapi
median
firstremiss
durat
rang
day
resist
chemotherapi
increas
subsequ
relaps
less
patient
surviv
longer
year
diagnosi
prolong
overal
surviv
effect
therapi
requir
prevent
relaps
follow
success
induct
chemotherapi
direct
immun
system
specif
target
malign
cell
power
strategi
treatment
cancer
previous
develop
vaccin
strategi
util
autolog
b
cell
antigenpres
cell
electropor
autolog
tumor
rna
antigen
payload
stimul
antitumor
immun
dog
nhl
first
clinic
trial
show
dog
vaccin
three
time
three
week
interv
follow
success
induct
chemotherapi
tendenc
toward
prolong
remiss
time
overal
surviv
compar
histor
control
furthermor
vaccin
dog
relaps
show
statist
signific
increas
overal
surviv
follow
rescu
chemotherapi
result
coupl
immun
analysi
vaccin
patient
suggest
rna
load
b
cell
prime
antitumor
immun
respons
insuffici
maintain
remiss
furthermor
hypothes
rescu
chemotherapi
boost
vaccin
prime
tumorspecif
immun
lead
prolong
second
remiss
time
therefor
hypothes
repeat
administr
rnaload
b
cell
given
everi
month
follow
initi
prime
cours
would
maintain
antitumor
immun
prevent
relaps
investig
hypothesi
current
perform
second
phase
iii
clinic
trial
use
rnaload
b
cell
fifteen
dog
recruit
studi
elig
criteria
includ
recent
diagnosi
nhl
prior
treatment
chemotherapi
steroid
evid
circul
blast
time
diagnosi
peripher
blood
mononuclear
cell
malign
lymph
node
tissu
harvest
gener
b
cell
whole
tumor
rna
respect
dog
undergo
chopbas
chemotherapi
protocol
dog
complet
clinic
remiss
follow
induct
chemotherapi
elig
receiv
autolog
vaccin
dog
vaccin
everi
three
week
three
dose
everi
two
month
clinic
relaps
induct
mainten
antitumor
immun
determin
use
ifnc
elispot
assay
primari
endpoint
trial
time
progress
secondari
endpoint
includ
durat
antitumor
immun
overal
surviv
lymphomaspecif
surviv
date
ten
dog
recruit
b
cell
success
gener
nine
dog
briefli
pbmc
cocultur
feeder
cell
consist
irradi
cell
transfect
human
presenc
cyclosporin
gener
b
cell
cell
electropor
rna
extract
autolog
malign
lymph
node
tissu
canin
distemp
viru
hemagglutinin
antigen
cdvha
mrna
control
vaccin
time
write
dog
complet
induct
chemotherapi
receiv
initi
prime
vaccin
advers
event
occur
follow
vaccin
administr
neither
dog
yet
relaps
trial
ongo
preliminari
data
confirm
feasibl
autolog
cell
vaccin
gener
safeti
administr
elispot
analysi
baselin
vaccin
time
point
perform
elucid
whether
repeat
vaccin
effect
maintain
antitumor
immun
circul
concentr
acut
phase
protein
app
use
biomark
canin
oncolog
increas
concentr
observ
cancer
patient
decreas
concentr
link
patient
remiss
human
increas
app
concentr
link
low
vitamin
statu
sever
diseas
state
low
vitamin
statu
also
observ
human
canin
cancer
patient
therefor
possibl
increas
app
concentr
link
decreas
vitamin
statu
canin
cancer
patient
object
studi
examin
relationship
blood
vitamin
app
concentr
healthi
dog
dog
cancer
dog
lymphoma
n
osteosarcoma
n
mast
cell
tumor
n
diagnos
cytolog
andor
histolog
present
one
referr
hospit
treatment
well
clientown
healthi
control
dog
n
enrol
blood
sampl
collect
dog
prior
treatment
analyz
plasma
oh
use
radioimmunoassay
haptoglobin
hp
glycoprotein
aag
serum
amyloid
saa
use
elisa
kit
statist
analys
complet
sa
vitamin
app
concentr
compar
group
use
anova
follow
tukeykram
posthoc
analys
pearson
correl
coeffici
perform
determin
relationship
vitamin
app
concentr
within
group
meanaesd
plasma
oh
concentr
significantli
lower
dog
lymphoma
ae
nmoll
healthi
dog
ae
nmoll
p
meanaesd
plasma
hp
aag
concentr
significantli
higher
dog
lymphoma
ae
ngml
ae
ngml
respect
healthi
dog
ae
ngml
p
ae
ngml
p
respect
signific
differ
blood
saa
level
among
group
pearson
correl
coeffici
reveal
moder
invers
relationship
plasma
aag
oh
concentr
r
p
lymphoma
patient
lower
plasma
oh
higher
hp
aag
concentr
canin
lymphoma
patient
compar
healthi
dog
consist
previou
report
howev
studi
first
report
observ
within
popul
research
need
investig
whether
decreas
plasma
oh
concentr
factor
cancer
develop
consequ
cancer
determin
clinic
relev
find
continu
low
dose
chemotherapi
administr
report
antiangiogen
effect
efficaci
multipl
tumour
type
studi
aim
retrospect
assess
use
metronom
cyclophosphamid
histopatholog
confirm
solid
malign
canin
tumour
patient
record
review
multidisciplinari
referr
hospit
dog
without
histolog
confirm
diagnosi
exclud
thirtyseven
case
epitheli
mesenchym
malign
dog
treat
mg
cyclophosphamid
dailyeveri
day
identifi
includ
high
grade
soft
tissu
sarcoma
soft
tissu
sarcoma
undefin
grade
intermedi
grade
soft
tissu
sarcoma
splenic
haemangiosarcoma
incomplet
excis
low
grade
soft
tissu
sarcoma
thyroid
carcinoma
adenocarcinoma
bladder
haemangiosarcoma
splenic
fibrosarcoma
apocrin
gland
carcinoma
metastat
prostat
carcinoma
metastat
carcinoma
unknown
origin
two
lost
follow
twentytwo
least
one
attempt
surgic
excis
three
underw
radiotherapi
prior
initi
chemotherapi
three
dog
develop
haematuria
advers
effect
report
haematuria
resolv
three
dog
cessat
cyclophosphamid
dog
stabl
diseas
partialcomplet
remiss
day
cyclophosphamid
includ
two
dog
fail
previou
chemotherapi
protocol
one
receiv
radiotherapi
four
dog
resect
primari
tumour
three
remain
clinic
well
day
dog
dfi
month
still
aliv
one
year
later
dog
intermediatehigh
grade
sarcoma
n
median
surviv
time
mst
day
one
dog
lost
follow
four
still
aliv
dog
carcinoma
n
one
lost
follow
two
still
aliv
year
later
clinic
sign
one
dog
reduc
rate
progress
stabl
diseas
day
clinic
sign
diseas
two
dog
thyroid
carcinoma
still
aliv
three
year
later
contrast
report
mst
invas
thyroid
carcinoma
treat
cisplatin
day
studi
add
evid
metronom
cyclophosphamid
may
use
treatment
malign
mesenchym
epitheli
tumour
howev
import
note
even
low
dose
side
effect
may
occur
purpos
studi
solicit
compil
data
practic
veterinari
specialist
regard
use
toceranib
cat
mast
cell
neoplasia
provid
initi
assess
possibl
clinic
benefit
toxic
american
colleg
veterinari
intern
medicin
oncolog
small
anim
intern
medicin
listserv
use
solicit
data
pertain
case
toceranib
use
treatment
felin
mast
cell
neoplasia
case
includ
follow
data
receiv
signal
age
gender
breed
anatom
classif
diseas
cutan
viscer
previou
concurr
treatment
toceranib
dose
mgkg
schedul
durat
therapi
best
respons
document
advers
event
case
data
cat
cutan
n
viscer
n
mast
cell
neoplasia
receiv
clinic
benefit
cb
seen
includ
cutan
viscer
involv
cat
n
receiv
concurr
radiat
chemotherapi
though
major
n
receiv
glucocorticoid
toceranib
treatment
mean
durat
toceranib
treatment
cat
experienc
cb
week
week
cutan
viscer
case
respect
toceranib
administ
median
dose
mgkg
cat
cb
drug
given
time
per
week
treatment
gener
well
toler
cat
experienc
advers
effect
point
toceranib
treatment
major
sign
lowgrad
grade
gastrointestin
hematolog
toxic
resolv
treatment
break
andor
dose
adjust
toceranib
appear
welltoler
felin
patient
mast
cell
neoplasia
biolog
activ
drug
evid
studi
cat
howev
prospect
studi
need
fulli
elucid
role
treatment
condit
gastrointestin
common
anatom
form
lymphoma
cat
system
chemotherapi
indic
treatment
although
cat
achiev
complet
remiss
chemotherapi
relaps
occur
may
associ
multidrug
resist
mdr
cell
mechan
mdr
includ
activ
transmembran
protein
reduc
intracellular
concentr
differ
chemic
compound
alter
drug
target
main
protein
relat
mdr
phenotyp
pglycoprotein
overexpress
result
reduc
concentr
certain
drug
within
cell
link
resist
aim
studi
investig
p
glycoprotein
pgp
express
cat
tcell
lymphocyt
gastrointestin
lymphoma
immunohistochemistri
perform
sampl
use
monoclon
antibodi
mous
polyclon
rabbit
dako
mous
antipglycoprotein
clone
life
scienc
pgp
immunoreact
analys
degre
stain
intens
express
strong
express
lymphoma
consid
posit
pgp
neoplast
popul
express
protein
three
cat
strong
moder
express
compris
case
median
overal
surviv
time
month
cat
complet
partial
respons
treatment
median
observ
cat
studi
conclus
express
pgp
observ
cat
tcell
lymphocyt
gastrointestin
lymphoma
express
relat
treatment
respons
overal
surviv
time
purpos
studi
describ
initi
experi
stereotact
radiat
therapi
srt
protocol
gy
x
daili
fraction
deliv
mv
photon
via
linear
acceler
use
treatment
nonlymphomat
nasal
tumor
dog
retrospect
analysi
case
treat
august
octob
nc
state
veterinari
hospit
perform
dog
includ
biopsyconfirm
nonlymphomat
nasal
tumor
dog
treat
chemotherapi
exclud
gross
tumor
volum
gtv
contour
use
preand
postcontrast
mm
slice
thick
ct
imag
set
clinic
target
volum
ctv
expans
use
includ
ipsilater
nasal
caviti
sinus
well
cm
contralater
nasal
caviti
ptv
expans
use
ctv
ptv
thirti
gray
gy
prescrib
gtv
ptv
plan
simultan
boost
center
gtv
cone
beam
ct
index
biteblock
system
treatment
couch
degre
freedom
use
set
deliveri
case
review
inform
relat
patient
demograph
tumor
characterist
radiat
plan
dosimetri
collect
twentyf
case
includ
stage
includ
n
n
n
n
none
evid
distant
metastasi
nineteen
region
lymph
node
aspir
metastasi
present
one
tumor
type
includ
adenocarcinoma
n
chondrosarcoma
n
transit
nasal
carcinoma
n
intranas
squamou
cell
carcinoma
n
neuroesthesioblastoma
n
clinic
sign
improv
case
twelv
case
recheck
ct
scan
month
postsrt
partial
complet
tumor
respons
seen
case
minim
acut
toxic
detect
late
effect
note
date
oronas
fistula
develop
one
dog
month
postsrt
anticip
due
tumor
invas
palat
diagnosi
median
diseas
progressionfre
surviv
time
reach
dog
progressionfre
year
nine
dog
deceas
median
surviv
time
day
aliv
day
post
srt
three
fraction
srt
use
treat
nonlymphomat
nasal
tumor
dog
limit
advers
event
continu
accrual
followup
necessari
confirm
low
toxic
elucid
effect
stage
outcom
character
clinic
efficaci
osteosarcoma
osa
local
invas
highli
metastat
hypothes
standardofcar
carboplatin
chemotherapi
follow
continu
administr
toceranib
phosphat
tp
result
improv
surviv
dog
osa
compar
histor
control
receiv
tp
addit
hypothes
tp
decreas
circul
level
proangiogen
downstream
factor
surrog
marker
vegf
receptor
inhibit
ten
dog
histolog
confirm
osa
evid
thorac
metastasi
diagnosi
treat
amput
follow
dose
carboplatin
chemotherapi
iv
q
week
fourteen
day
chemotherapi
complet
tp
initi
dose
mgkg
po
q
hour
serum
sampl
vegf
bloodwork
evalu
toxic
screen
metastasi
thorac
radiograph
qualityoflif
qol
score
monitor
via
owner
survey
perform
monthli
kaplanmei
method
use
calcul
osafre
surviv
overal
surviv
os
friedman
test
use
compar
vegf
mmp
valu
baselin
pretp
end
studi
kruskalw
test
repeat
measur
use
compar
plateletcorrect
vegf
valu
baselin
pretp
end
studi
p
valu
consid
signific
three
dog
requir
dose
reduct
carboplatin
secondari
neutropenia
two
requir
drug
holiday
tp
treatment
dog
withdrawn
studi
due
toxic
seven
dog
develop
local
recurr
metastasi
first
event
one
dog
withdrawn
studi
due
owner
wish
one
euthan
due
osteoarthr
one
develop
lymphoma
evid
osa
metastasi
signific
differ
mmp
vegf
absolut
plateletcorrect
time
point
correl
valu
osafre
surviv
os
median
osafre
surviv
day
rang
os
day
rang
although
combin
carboplatin
follow
tp
welltoler
dog
appendicular
osa
surviv
time
exceed
previous
publish
data
dog
treat
amput
follow
chemotherapi
serum
vegf
level
remain
unchang
baselin
despit
continu
administr
tp
result
studi
support
ongo
tp
administr
post
amput
standardof
care
chemotherapi
dog
appendicular
osa
oncolyt
virus
virus
whose
replic
restrict
tumour
cell
lead
cytolysi
grow
number
virus
develop
oncolyt
virus
variou
strategi
util
target
tumour
cell
group
develop
biotherapeut
combin
two
emerg
cancer
treatment
modal
tumour
vaccin
oncolyt
virus
recent
determin
oncolyt
virus
express
tumour
antigen
transgen
excel
mean
boost
enhanc
tumour
vaccin
preliminari
studi
cat
first
vaccin
adenoviru
express
cancer
gene
boost
anoth
viru
maraba
also
express
cancer
gene
vaccin
protocol
elicit
strong
immun
cancer
cell
caus
ill
effect
cat
purpos
studi
determin
safeti
toxic
genet
alter
oncolyt
maraba
viru
cat
five
young
male
month
old
purposebr
cat
vaccin
intramuscularli
x
pfu
nonrepl
human
serotyp
adenovir
vaccin
vector
prime
three
week
later
cat
administ
x
pfu
maraba
viru
intraven
boost
cat
monitor
physic
exam
observ
clinic
sign
complet
blood
count
cbc
peripher
blood
saliva
urin
fece
collect
viru
isol
day
postmaraba
viru
infus
sever
advers
event
two
cat
mild
transient
pyrexia
c
hour
post
maraba
viru
infus
typic
cytokin
induct
cbc
reveal
transient
mild
neutrophilia
cat
one
day
maraba
viru
infus
refer
interv
x
l
thrombocytopenia
x
l
refer
rang
x
l
note
one
cat
day
post
maraba
viru
infus
anoth
cat
thrombocytopenia
x
l
x
l
day
respect
post
maraba
viru
infus
viral
genom
replicationcompet
virus
detect
secondari
lymphoid
tissu
ie
spleen
day
replicationcompet
viru
detect
peripher
blood
saliva
urin
fece
viral
genom
secondari
lymphoid
tissu
without
concurr
replicationcompet
viru
find
similar
mice
primat
reflect
propens
maraba
viru
taken
antigenpres
cell
deliv
system
make
ideal
vector
boost
immun
respons
lack
replicationcompet
viru
saliva
urin
fece
peripher
blood
satisfi
canadian
food
inspect
agenc
cfia
concern
regard
potenti
shed
enabl
initi
clinic
trial
util
maraba
viru
treat
cat
mammari
cancer
trial
heterolog
prime
boost
strategi
target
tumour
antigen
test
introduct
canin
hemangiosarcoma
highli
malign
tumor
associ
poor
longterm
surviv
due
develop
earli
widespread
metastat
diseas
current
littl
known
regard
biolog
canin
hemangiosarcoma
mechan
account
highli
metastat
natur
tumor
poorli
understood
human
rodent
monocyt
shown
play
key
role
metastasi
promot
tumor
cell
extravas
seed
growth
angiogenesi
well
suppress
antitumor
immun
howev
littl
investig
role
monocyt
canin
tumor
metastasi
therefor
investig
potenti
role
monocyt
infiltr
regul
tumor
metastasi
dog
method
address
question
initi
perform
immunohistochemistri
determin
degre
monocyt
infiltr
necropsi
sampl
obtain
sever
common
metastat
tumor
dog
includ
hemangiosarcoma
osteosarcoma
variou
carcinoma
result
found
compar
tumor
type
hemangiosarcoma
metastas
significantli
greater
infiltr
monocyt
next
migrat
assay
use
compar
abil
tumor
cell
line
stimul
monocyt
migrat
vitro
hemangiosarcoma
cell
line
among
strongest
stimul
monocyt
migrat
also
found
highest
produc
monocyt
chemoattract
addit
hemangiosarcoma
metastas
vivo
found
produc
larg
amount
compar
tumor
metastas
conclus
result
consist
therefor
hypothesi
overexpress
recruit
larg
number
monocyt
may
explain
part
aggress
metastat
natur
canin
hemangiosarcoma
moreov
find
suggest
immunotherapeut
intervent
design
block
monocyt
recruit
mobil
may
effect
adjuv
strategi
suppress
tumor
metastasi
dog
hemangiosarcoma
introduct
target
chemotherapi
includ
repurpos
drug
previous
consid
clinic
irrelev
due
mark
toxic
low
therapeut
index
tubulysin
one
drug
compel
antiprolif
activ
vitro
poor
toler
vivo
high
affin
folat
receptor
fr
express
previous
found
canin
transit
cell
carcinoma
tcc
serv
druggabl
target
phase
clinic
trial
folatetubulysin
conduct
dog
urinari
tract
tcc
method
pacuc
approv
elig
dog
enrol
dose
escal
cohort
studi
folatetubulysin
endocyt
west
lafayett
inclus
criteria
histolog
diagnosi
tcc
presenc
fr
tcc
cell
detect
immunohistochemistri
andor
folat
uptak
tcc
detect
nuclear
scintigraphi
inform
pet
owner
consent
initi
dose
mgkg
given
intraven
everi
two
week
intraand
intercohort
escal
mgkg
least
two
consecut
treatment
escal
continu
dose
limit
toxic
dlt
observ
maximum
toler
dose
mtd
determin
result
eleven
dog
enrol
obtain
maximum
toler
dose
mtd
total
twenti
seven
dog
enrol
investig
toxic
tumor
respons
folatetubulysin
mtd
mgkg
administ
everi
two
week
common
dlt
neutropenia
anorexia
andor
lethargi
resolut
side
effect
occur
minim
support
care
dog
treatment
delay
earli
categor
tumor
respons
includ
partial
remiss
stabl
diseas
progress
diseas
conclus
folatetubulysin
gener
well
toler
given
mtd
conjug
tubulysin
folat
allow
use
compound
otherwis
would
possibl
due
toxic
work
support
anim
cancer
foundat
endocyt
homeostasi
deterior
rapidli
age
burmes
cat
compar
nonburmes
margareth
rose
leder
jacqui
rand
nubia
lope
john
morton
nick
jonsson
univers
glasgow
glasgow
scotland
uk
univers
queensland
gatton
qld
australia
jemora
pti
ltd
geelong
vic
australia
burmes
cat
predispos
diabet
mellitu
australia
new
zealand
unit
kingdom
diseas
time
preval
breed
compar
domest
cat
mechan
predispos
burmes
cat
diabet
remain
unclear
studi
compar
hormon
biochem
variabl
associ
glucos
lipid
metabol
mixedag
lean
overweight
clinic
healthi
burmes
nonburmes
cat
burmes
cat
older
year
higher
fast
glucos
compar
nonburmes
p
mmoll
higher
year
mmoll
higher
year
age
p
year
age
mean
glucos
concentr
glucos
toler
test
higher
burmes
nonburmes
cat
p
indic
rel
glucos
intoler
lean
burmes
cat
luml
higher
fast
insulin
concentr
nonburmes
suggest
insulin
resist
p
time
minut
gtt
burmes
cat
lower
insulin
concentr
compar
nonburmes
higher
minut
p
p
consist
diminish
first
phase
increas
prolong
second
phase
insulin
releas
pattern
insulin
secret
describ
prediabet
diabet
obes
human
obes
cat
fast
triglycerid
concentr
mmoll
higher
p
fast
nefa
concentr
mmoll
higher
p
burmes
compar
nonburmes
result
demonstr
burmes
cat
rapid
deterior
bcell
function
age
impair
glucos
homeostasi
lipid
metabol
occur
concurr
cat
previou
studi
indic
serum
fructosamin
level
decreas
hyperthyroid
cat
howev
clinic
util
diabet
hyperthyroid
cat
report
hypothes
hyperthyroid
diabet
cat
result
clinic
signific
decreas
serum
fructosamin
level
compar
euthyroid
diabet
cat
data
serum
total
thyroxin
fructosamin
hyperthyroideuthyroid
diabeticnondiabet
cat
new
zealand
veterinari
patholog
colorado
state
univers
retriev
statist
analyz
serum
fructosamin
significantli
lower
hyperthyroid
diabet
euthyroid
diabet
cat
mean
ci
n
versu
mean
ci
n
differ
hyperthyroid
diabet
euthyroid
nondiabet
cat
mean
ci
n
versu
mean
ci
n
signific
neg
correl
serum
concentr
serum
fructosamin
glucos
concentr
n
p
n
p
respect
hyperthyroid
cat
diabet
significantli
p
lower
serum
glucos
euthyroid
cat
diabet
diabet
random
variabl
account
chang
serum
fructosamin
wherea
age
popul
minim
impact
serum
fructosamin
conclus
current
studi
serum
fructosamin
concentr
significantli
decreas
diabet
hyperthyroid
cat
similar
fructosamin
concentr
euthyroid
nondiabet
cat
addit
approxim
chang
serum
fructosamin
independ
diabet
futur
studi
undertaken
explor
specif
factor
impact
fructosamin
level
insulin
aspart
aspart
rapidact
insulin
analog
shown
effect
treatment
diabet
ketoacidosi
dka
administ
intermitt
subcutan
sc
inject
human
cat
rapidact
insulin
analog
yet
evalu
commonli
use
protocol
dka
involv
deliveri
regular
insulin
via
constant
intraven
infus
technic
challeng
aim
studi
determin
pharmacodynam
pd
pharmacokinet
pk
aspart
follow
sc
intramuscular
im
inject
healthi
cat
use
isoglycem
clamp
method
timeact
profil
gener
eight
healthi
cat
determin
pharmacodynam
aspart
follow
sc
im
inject
pharmacokinet
determin
measur
plasma
aspart
concentr
everi
minut
clamp
use
isoinsulin
elisa
kit
mean
ae
sem
time
onset
action
durat
action
differ
significantli
sc
ae
minut
ae
minut
im
inject
ae
minut
ae
minut
method
administr
result
accept
plasma
concentr
blood
glucos
lower
effect
subcutan
inject
result
greater
plasma
aspart
concentr
minut
greater
peak
concentr
compar
im
inject
p
p
respect
aspart
rapidli
absorb
follow
sc
im
inject
healthi
cat
effect
predict
glucos
lower
effect
insulin
aspart
may
advantag
treatment
dka
cat
obes
major
risk
factor
develop
diabet
cat
recent
retinoidrel
orphan
receptor
gamma
rorc
identifi
import
transcript
factor
develop
larg
insulinresist
adipocyt
rorc
inhibit
ligand
tetrahydroxyl
bile
acid
thba
oral
supplement
thba
reduc
adipocyt
size
improv
insulin
sensit
prevent
hyperglycemia
obes
mice
purpos
studi
investig
palat
possibl
side
effect
thba
effect
thba
supplement
adipocyt
size
insulin
sensit
healthi
cat
six
healthi
purposebr
cat
fed
mgkgday
thba
week
thba
given
small
amount
food
cat
individu
daili
ration
offer
complet
blood
count
biochem
profil
insulin
toler
test
itt
iukg
insulin
aspart
iv
perform
week
hour
fast
blood
glucos
concentr
record
rate
constant
disappear
glucos
k
itt
calcul
subcutan
fat
tissu
sampl
taken
umbil
area
mm
biopsi
punch
adipocyt
size
determin
histolog
imag
base
analysi
least
section
per
anim
data
analyz
parametr
test
p
oral
supplement
thba
well
accept
cat
side
effect
note
none
cat
display
abnorm
complet
blood
count
serum
biochem
profil
fast
blood
glucos
concentr
averag
size
white
subcutan
adipocyt
significantli
lower
week
thba
administr
wherea
k
itt
differ
reduct
adipocyt
size
respons
thba
treatment
accord
data
mice
underscor
possibl
role
rorc
signal
control
adipos
tissu
metabol
observ
signific
reduct
fast
glucos
overal
insulin
sensit
improv
find
might
explain
fact
insulin
sensit
normal
weight
subject
mainli
determin
liver
muscl
cell
function
alter
adipocyt
size
would
contribut
significantli
itt
futur
studi
obes
cat
alter
dose
regim
requir
assess
whether
thba
improv
insulin
resist
cat
addit
direct
effect
adipocyt
size
studi
overweight
cat
fed
mainten
diet
md
week
follow
weight
control
diet
wcd
lower
fat
higher
carbohydr
fiber
cat
fed
ad
libitum
initi
food
restrict
achiev
loss
bodi
weight
weekli
week
lean
cat
fed
md
addit
week
standard
meal
test
smt
use
third
diet
perform
least
day
diet
weight
loss
smt
total
glucos
insulin
glucagonlik
glucosedepend
insulinotrop
peptid
gip
concentr
measur
immedi
hour
feed
smt
area
concentr
curv
auc
compar
use
nonparametr
test
glucos
insulin
concentr
differ
smt
time
point
fast
gip
concentr
also
differ
postprandi
gip
secret
affect
degre
adipos
p
trend
toward
effect
diet
p
gip
secret
lean
cat
fed
wcd
higher
obes
fed
md
p
conclus
compar
overweight
state
gip
secret
increas
cat
respons
smt
lean
state
ongo
exposur
wcd
increas
gip
respons
smt
suggest
dietari
macronutri
content
import
determin
gip
respons
acut
also
longterm
basi
hyperthyroid
commonli
affect
geriatr
cat
aetiolog
poorli
understood
previou
studi
shown
siames
himalayan
burmes
cat
reduc
risk
develop
hyperthyroid
breed
colourpoint
coat
result
temperaturesensit
mutat
tyrosinas
gene
limit
convers
tyrosin
melanin
pigment
tyrosin
essenti
synthesi
melanin
thyroid
hormon
coat
pigment
may
impact
rel
tyrosin
avail
thyroid
hormon
product
studi
aim
identifi
potenti
associ
coat
phenotyp
develop
hyperthyroid
investig
breed
coat
colour
hair
length
risk
factor
felin
hyperthyroid
retrospect
studi
cat
age
year
refer
singl
uk
veterinari
teach
hospit
use
electron
patient
record
obtain
ownerreport
data
regard
breed
coat
colour
age
sex
clinic
data
classifi
cat
hyperthyroideuthyroid
bayesian
multivari
logist
regress
use
evalu
breed
age
sex
risk
factor
hyperthyroid
statu
cat
purebr
nonpurebr
avoid
interact
coat
length
colour
purebr
effect
coat
colourpattern
colour
dilut
base
pigment
white
mark
hair
length
assess
nonpurebr
cat
separ
analysi
variabl
p
univari
analys
evalu
multivari
model
final
variabl
signific
p
risk
factor
quantifi
odd
ratio
pvalu
cat
includ
final
analysi
hyperthyroid
euthyroid
multivari
result
show
burmes
p
persian
p
siames
p
abyssinian
p
british
shorthair
p
reduc
risk
hyperthyroid
compar
domest
shorthair
domest
longhair
p
show
increas
risk
hyperthyroid
compar
domest
shorthair
coat
colour
colour
dilut
base
pigment
white
mark
signific
effect
overal
femal
p
increas
risk
hyperthyroid
compar
male
compar
year
old
increas
risk
found
cat
age
year
p
year
p
year
p
author
knowledg
first
studi
report
increas
risk
hyperthyroid
long
hair
nonpurebr
domest
cat
consist
number
previou
studi
increas
risk
hyperthyroid
found
increas
age
femal
sex
reduc
risk
burmes
siames
persian
breed
howev
studi
also
newli
identifi
two
purebr
abyssinian
british
shorthair
reduc
risk
hyperthyroid
neither
exclus
colourpoint
coat
colour
found
associ
risk
hyperthyroid
analysi
domest
cat
howev
relianc
secondari
data
may
result
misclassif
error
coat
phenotyp
may
poor
surrog
marker
melanin
concentr
studi
requir
evalu
tyrosin
avail
potenti
factor
aetiolog
felin
hyperthyroid
investig
appar
protect
effect
certain
purebr
associ
hyperthyroid
hair
length
medic
record
search
cat
receiv
therapi
document
feed
prescript
diet
least
day
cat
exclud
prescript
diet
supplement
food
methimazol
administ
concurr
subsequ
prescript
diet
owner
contact
directli
provid
miss
dietari
inform
nine
cat
fulfil
studi
criteria
prescript
diet
fed
median
day
rang
interv
discontinu
diet
administ
day
cat
day
cat
day
cat
highest
serum
total
thyroxin
without
therapi
use
calcul
dose
median
highest
mcgdl
rang
mcgdl
refer
rang
mcgdl
median
dose
administ
mci
rang
mci
cat
initi
evalu
day
therapi
hyperthyroid
resolv
cat
median
posttherapi
total
mcgdl
rang
mcgdl
total
refer
rang
cat
mcgdl
initi
posttherapi
evalu
normal
day
later
mcgdl
respect
small
group
cat
pretreat
limit
iodin
diet
advers
affect
respons
therapi
mani
dog
misdiagnos
hypothyroid
vagu
present
sign
limit
thyroid
function
test
lead
inappropri
treatment
levothyroxin
chronic
supplement
hypothalamicpituitarythyroid
axi
hpta
suppress
may
make
difficult
accur
determin
thyroid
function
follow
withdraw
levothyroxin
sought
determin
hpta
suppress
follow
levothyroxin
administr
euthyroid
dog
time
requir
resolut
suppress
hypothes
levothyroxin
administr
would
suppress
hpta
euthyroid
dog
hpta
would
recov
within
week
dog
regardless
durat
treatment
twentyeight
healthi
euthyroid
dog
administ
levothyroxin
mean
dose
mgkg
everi
hour
either
week
group
week
group
dose
levothyroxin
adjust
weekli
target
total
thyroxin
serum
concentr
nmoll
obtain
hour
post
pill
serum
concentr
free
thyroxin
ft
equilibrium
dialysi
thyrotropin
tsh
triiodothyronin
measur
everi
week
supplement
month
levothyroxin
discontinu
mix
model
anova
follow
tukey
procedur
multipl
comparison
use
compar
thyroid
function
test
within
group
level
signific
set
mean
serum
concentr
ft
significantli
higher
tsh
significantli
lower
levothyroxin
administr
compar
baselin
group
mean
serum
concentr
ft
tsh
begin
week
levothyroxin
discontinu
significantli
differ
compar
valu
levothyroxin
administr
compar
baselin
valu
group
compar
differ
mean
ft
concentr
group
levothyroxin
supplement
suppress
hpta
occur
levothyroxin
supplement
mean
serum
ft
tsh
concentr
return
refer
interv
week
discontinu
group
appear
assess
thyroid
function
test
week
longterm
levothyroxin
supplement
may
reliabl
establish
dog
euthyroid
autoantibodi
direct
side
chain
cleavag
enzym
recent
describ
proport
dog
affect
hypoadrenocortic
consist
immunemedi
diseas
process
human
affect
addison
diseas
autoantibodi
predict
valu
detect
prior
clinic
sign
develop
shown
persist
postdiagnosi
furthermor
autoantibodi
posit
statu
postdiagnosi
associ
success
remiss
addison
diseas
follow
bcell
deplet
rituximab
suggest
activ
patholog
case
current
studi
explor
chang
serum
autoantibodi
statu
time
dog
diagnos
spontan
hypoadrenocortic
autoantibodi
measur
radioimmunoassay
initi
cohort
dog
indic
preval
thirti
two
dog
repeat
sampl
n
total
avail
analysi
two
six
sampl
avail
dog
obtain
two
day
apart
five
dog
consist
autoantibodi
posit
sampl
day
sampl
time
compris
one
male
four
femal
dog
three
crossbre
dogo
argentino
english
springer
spaniel
three
dog
initi
autoantibodi
posit
becam
neg
later
time
point
month
old
male
entir
bull
terrier
month
old
femal
neuter
beagl
femal
entir
crossbre
dog
one
dog
month
old
femal
entir
standard
poodl
initi
neg
autoantibodi
seroconvert
month
diagnosi
remain
dog
multipl
sampl
avail
consist
autoantibodi
neg
persist
associ
sex
p
studi
demonstr
persist
autoantibodi
subset
dog
affect
hypoadrenocortic
seroconvers
one
year
postdiagnosi
whilst
autoantibodi
posit
associ
sex
femal
higher
preval
sex
differ
persist
demonstr
express
ovari
may
act
addit
sourc
antigen
stimul
femal
dog
explain
later
seroconvers
observ
one
individu
howev
parallel
human
addison
diseas
antibodi
persist
dog
hypoadrenocortic
might
repres
persist
patholog
due
residu
antigen
stimul
autoimmun
inflamm
adren
gland
hypoadrenocortic
addison
diseas
occur
dog
breed
age
certain
breed
includ
nova
scotia
duck
toll
retriev
nsdtr
increas
incid
diseas
specif
nsdtr
appear
least
two
form
addison
diseas
breed
juvenil
onset
form
jadd
occur
dog
year
age
adult
onset
form
occur
dog
year
age
averag
jadd
differ
adult
onset
addison
diseas
multisystem
ill
appear
involv
autoimmun
compon
support
identif
cell
infiltr
histolog
section
jadd
affect
adren
gland
sampl
mani
case
often
affect
autoimmun
diseas
includ
immunemedi
hemolyt
anemia
thrombocytopenia
immunemedi
polyarthr
hypothyroid
identifi
genet
basi
jadd
genomewid
associ
studi
perform
use
illumina
canin
hd
snp
array
nsdtr
diagnos
addison
diseas
less
year
age
healthi
control
nsdtr
year
age
case
definit
diagnos
adrenocorticotroph
hormon
stimul
test
genomewid
associ
analysi
identifi
mb
associ
haplotyp
chromosom
whole
genom
sequenc
perform
nsdtr
associ
haplotyp
well
unaffect
nsdtr
dog
differ
breed
analysi
variant
yield
segreg
snp
associ
region
intergen
intron
code
untransl
region
gene
code
variant
missens
mutat
caus
amino
acid
chang
prolin
leucin
occur
current
uncharacter
gene
predict
damag
deleteri
base
sequenc
conserv
summari
genomewid
associ
whole
genom
sequenc
analysi
identifi
novel
gene
mutat
implic
multiorgan
autoimmun
juvenil
onset
addison
diseas
nsdtr
adrenocorticotrop
hormon
stimul
test
ast
often
use
diagnosi
canin
hyperadrenocortic
wide
rang
sensit
specif
thu
hypothes
standard
neg
feedback
hypothalamicpituitaryadrenalaxi
result
larg
variabl
post
ast
serum
cortisol
concentr
therefor
studi
aim
evalu
variabl
post
ast
serum
cortisol
healthi
dog
statist
examin
paramet
may
influenc
cortisol
respons
fourteen
healthi
harrier
hound
dog
mean
age
mean
bodi
weight
random
latin
squar
design
receiv
treatment
placebo
mg
mg
mg
mg
cortison
acet
ca
five
treatment
period
separ
washout
period
ast
perform
hour
last
dose
ca
treatment
serum
cortisol
analyz
electrochemiluminesc
immunoassay
signific
dose
depend
decreas
mean
aesem
post
ast
serum
cortisol
observ
placebo
ae
nmoll
ca
mg
ae
nmoll
ca
mg
ae
nmoll
ca
mg
ae
nmoll
ca
mg
ae
nmoll
signific
p
betweenweek
variabl
post
ast
serum
cortisol
placebo
mg
mg
ca
group
overal
variabl
post
ast
serum
cortisol
concentr
attribut
individu
dog
random
unexplain
variabl
dose
ca
age
bodi
weight
time
treatment
wide
rang
publish
specif
ast
may
relat
larg
variat
cortisol
respons
etiolog
concurr
diseas
clinic
sign
associ
hypercalcemia
cat
report
past
base
measur
total
calcium
exclud
case
idiopath
hypercalcemia
ihc
report
rel
frequenc
variou
diagnos
concurr
clinic
sign
associ
ioniz
hypercalcemia
cat
medic
record
academ
institut
treat
primari
secondari
case
search
case
treat
year
case
includ
serum
plasma
ioniz
calcium
concentr
upper
limit
refer
interv
least
twice
cat
exclud
ioniz
hypercalcemia
present
followup
examin
final
diagnosi
made
sixtynin
case
identifi
common
diagnos
ihc
chronic
kidney
diseas
urolithiasi
diagnos
calcium
oxal
neoplasia
lymphoma
primari
hyperparathyroid
diagnos
includ
hyperthyroid
hypertroph
cardiomyopathi
felin
idiopath
cystiti
diabet
mellitu
averag
age
diagnosi
hypercalcemia
ae
year
common
clinic
sign
report
ihc
group
versu
diagnos
clinic
sign
could
relat
primari
diseas
necessarili
hypercalcemia
anorexia
versu
vomit
versu
lethargi
versu
constip
versu
conclus
ioniz
hypercalcemia
cat
frequent
idiopath
associ
felin
ioniz
hypercalcemia
etiolog
clinic
sign
explor
casecontrol
studi
canin
hypoadrenocortic
potenti
lifethreaten
endocrin
disord
character
glucocorticoid
defici
without
concurr
mineralocorticoid
defici
current
standard
diagnos
hypoadrenocortic
acth
stimul
test
simpler
less
expens
test
similar
accuraci
would
desir
previou
studi
regard
diagnost
util
basal
plasma
serum
cortisol
concentr
limit
low
number
affect
dog
receiv
oper
characterist
roc
method
util
identifi
optim
cutoff
point
purpos
studi
evalu
diagnost
util
basal
cortisol
concentr
diagnosi
hypoadrenocortic
larg
number
dog
construct
roc
curv
identifi
optim
cutoff
sensit
specif
furthermor
diagnost
util
evalu
two
subpopul
dog
electrolyt
abnorm
na
k
ratio
without
electrolyt
abnorm
na
k
ratio
medic
record
dog
acth
stimul
test
perform
clinic
suspicion
hypoadrenocortic
retrospect
review
dog
receiv
treatment
hyperadrenocortic
recent
glucocorticoid
therapi
exclud
five
hundr
fourteen
dog
met
inclus
criteria
includ
dog
hypoadrenocortic
postacth
stimul
cortisol
concentr
nmol
l
roc
curv
construct
basal
cortisol
concentr
use
commerci
avail
softwar
area
roc
curv
roc
curv
nearli
ident
evalu
dog
without
electrolyt
abnorm
accuraci
optim
nmoll
provid
sensit
specif
respect
cutoff
nmoll
nmoll
sensit
specif
respect
use
previous
estim
preval
cut
point
nmoll
nmoll
result
neg
posit
predict
valu
respect
even
lower
preval
rate
posit
predict
valu
remain
high
low
cut
point
result
studi
reaffirm
high
sensit
neg
predict
valu
basal
cortisol
concentr
diagnosi
hypoadrenocortic
howev
high
specif
posit
predict
valu
low
cut
point
could
major
import
veterinari
practition
prospect
studi
need
substanti
find
congenit
hypothyroid
ch
associ
signific
morbid
mortal
pediatr
felin
thyroid
hormon
th
essenti
normal
develop
nervou
skelet
system
pauciti
inform
th
level
inabl
identifi
earli
histopatholog
chang
led
ch
underdiagnosi
literatur
th
level
kitten
spars
incongru
compris
mostli
case
report
refer
state
kitten
total
thyroxin
level
time
higher
adult
cat
level
also
make
assumpt
free
thyroxin
level
higher
adult
cat
abstract
previous
present
show
kitten
th
level
exceed
adult
cat
normal
valu
measur
assay
longer
use
normal
pediatr
th
level
must
evalu
newer
current
avail
assay
purpos
studi
determin
total
triidiothyronin
free
triidiothyronin
thyroid
stimul
hormon
tsh
level
healthi
kitten
age
week
measur
level
weekli
interv
use
current
avail
diagnost
method
normal
healthi
kitten
research
coloni
approv
facil
univers
pennsylvania
school
veterinari
medicin
use
one
half
one
millilit
whole
blood
base
bodi
weight
drawn
jugular
venipunctur
week
serum
immedi
obtain
frozen
analysi
sampl
submit
michigan
state
univers
diagnost
laboratori
anim
popul
health
th
measur
perform
serum
tsh
measur
use
canin
chemiluminesc
assay
measur
radioimmunoassay
measur
use
equilibrium
dialysi
assay
previous
valid
cat
sampl
collect
time
morn
weekli
interv
valu
report
mean
initi
adult
cat
refer
rang
acrr
nmoll
week
peak
week
nmoll
nmoll
respect
return
within
acrr
week
elev
week
nmoll
return
within
acrr
week
remain
stabl
week
remain
within
acrr
pmoll
week
show
similar
peak
week
pmoll
pmoll
respect
tsh
within
acrr
ngml
throughout
week
tsh
remain
stabl
ngml
week
decreas
within
acrr
week
peak
week
ngml
continu
decreas
ngml
week
remain
within
acrr
week
hormon
peak
week
remain
level
week
th
level
pediatr
kitten
measur
newer
assay
except
th
level
within
acrr
elev
twice
upper
limit
acrr
time
point
consist
within
acrr
week
age
peak
seen
week
peak
also
seen
week
tsh
level
use
canin
tsh
assay
valid
use
adult
cat
valu
yet
report
kitten
tsh
level
remain
within
acrr
show
similar
peak
week
pattern
like
occur
due
increas
growth
develop
week
conflict
result
report
regard
lipid
concentr
dog
diabet
mellitu
dm
studi
report
lowdens
lipoproteincholesterol
ldlc
significantli
differ
dog
without
dm
goal
studi
report
total
cholesterol
tc
total
triglycerid
tg
highdens
lipoproteincholesterol
hdlc
lowdens
lipoproteincholesterol
vldlc
ldlc
fast
dog
without
dm
twentytwo
dog
dm
nine
healthi
control
dog
normocholesterolemia
prospect
enrol
follow
minimum
eighthour
fast
plasma
lipid
fraction
measur
ultracentrifug
tc
hdlc
vldlc
ldlc
direct
sampl
analysi
tg
coupl
enzymat
reaction
spectrophotometr
end
point
roch
coba
median
lipid
concentr
dog
without
dm
compar
use
twosampl
wilcoxon
ranksum
test
pvalu
consid
signific
dog
dm
median
tc
mgdl
tg
mgdl
hdlc
mgdl
vldlc
mgdl
ldlc
mg
dl
concentr
significantli
higher
concentr
healthi
dog
mgdl
mgdl
mgdl
mgdl
mgdl
respect
p
comparison
greatest
differ
measur
ldlc
concentr
time
higher
dog
dm
compar
control
vldlc
tc
tg
concentr
time
higher
respect
dog
dm
compar
healthi
dog
smallest
differ
note
hdlc
concentr
conclud
increas
ldlc
import
compon
dyslipidemia
dog
dm
futur
studi
therapeut
focus
decreas
ldlc
dog
dm
may
warrant
object
present
studi
examin
whether
circul
concentr
leptin
adiponectin
distribut
abdomin
fat
mrna
express
leptin
adiponectin
abdomin
adipos
tissu
affect
hydrocortison
administr
six
laboratori
dog
receiv
hydrocortison
mgkg
oral
everi
hour
day
measur
serum
concentr
leptin
adiponectin
use
caninespecif
elisa
kit
quantifi
viscer
fat
use
ct
scan
analyz
mrna
express
leptin
adiponectin
abdomin
fat
use
realtim
pcr
hydrocortison
administr
result
increas
abdomin
viscer
fat
mass
day
compar
fat
mass
administr
day
addit
viscer
fat
area
level
also
increas
hydrocortison
administr
serum
leptin
concentr
began
increas
day
hydrocortison
administr
significantli
increas
day
compar
concentr
day
serum
adiponectin
concentr
day
decreas
compar
concentr
day
mrna
express
leptin
adiponectin
abdomin
fat
increas
day
compar
express
day
express
decreas
day
compar
day
identifi
correl
serum
leptin
adiponectin
concentr
viscer
fat
distribut
studi
show
hydrocortison
administr
affect
viscer
fat
distribut
serum
concentr
leptin
adiponectin
dysregul
leptin
adiponectin
express
recombin
dna
technolog
use
modifi
structur
human
insulin
yield
analog
rapidlyact
regular
insulin
longer
durat
action
nph
insulin
longact
insulin
analog
studi
cat
routin
use
manag
felin
diabet
recent
isoglycem
clamp
method
use
studi
metabol
effect
rapidact
insulin
analog
healthi
cat
gener
timeact
profil
studi
pharmacodynam
properti
insulin
formul
requir
measur
plasma
insulin
concentr
measur
provid
use
pharmacokinet
data
use
valid
timeact
profil
isoinsulin
elisa
mercodia
ab
uppsala
sweden
use
measur
concentr
insulin
analog
plasma
previou
studi
use
actual
felin
serum
sampl
wide
rang
insulin
concentr
measur
commerci
elisa
fail
detect
crossreact
felin
insulin
isoinsulin
elisa
purpos
studi
evalu
crossreact
felin
insulin
isoinsulin
elisa
use
purifi
felin
insulin
standard
five
purifi
felin
insulin
standard
known
concentr
rang
ngl
ngl
use
calibr
commerci
felin
insulin
elisa
mercodia
ab
uppsala
sweden
use
elisa
perform
duplic
accord
manufactur
recommend
mean
absorb
valu
felin
insulin
elisa
calibr
mean
absorb
valu
lowest
isoinsulin
calibr
except
first
calibr
slightli
higher
mean
absorb
slightli
higher
absorb
first
calibr
like
result
minor
technic
issu
sensit
elisa
sinc
calibr
higher
insulin
concentr
consist
absorb
lowest
isoinsulin
calibr
result
demonstr
purifi
felin
insulin
concentr
ngl
detect
isoinsulin
elisa
therefor
interfer
insulin
analog
measur
felin
plasma
alopecia
x
melissa
sanch
marcia
jeric
eric
janu
ario
pet
care
centro
veterin
ario
sao
paulo
sp
brazil
universidad
anhembi
morumbi
clinica
veterin
aria
alto
da
lapa
sao
paulo
sp
brazil
alopecia
x
skin
diseas
unknown
etiolog
character
noninflammatori
bilater
symmetr
alopecia
hyperpigment
absenc
pruritu
condit
frequent
observ
young
dog
nordic
breed
thought
relat
abnorm
adren
gland
function
trilostan
melatonin
propos
possibl
treatment
altern
studi
aim
evalu
comprehens
steroid
panel
therapeut
respons
pomeranian
dog
diagnos
alopecia
x
eighteen
pomeranian
dog
admit
veterinari
clinic
paulo
brazil
chief
complaint
symmetr
bilater
alopecia
studi
includ
male
femal
neuter
age
year
anim
subject
thorough
laboratori
screen
complet
blood
count
differenti
leukocyt
count
liver
function
enzym
urea
creatinin
triglycerid
cholesterol
blood
glucos
thyroid
panel
well
urinalysi
abdomin
ultrasonographi
exam
result
within
refer
valu
subsequ
blood
sampl
collect
quantifi
radioimmunoassay
provet
laboratori
brazil
tennesse
univers
follow
hormon
synthet
acth
stimul
singl
dose
mgkgev
aldosteron
androstenedion
cortisol
estradiol
progesteron
testosteron
eight
dog
subject
treatment
trilostan
mgkg
po
bid
seven
dog
subject
treatment
b
trilostan
mgkg
po
bid
melatonin
mgdog
po
bid
two
dog
receiv
treatment
c
melatonin
mgdog
po
bid
three
anim
lost
followup
comparison
refer
valu
establish
laboratori
neuter
nonneut
dog
anim
alopecia
x
present
higher
level
three
seven
hormon
acth
stimul
test
abnorm
elev
hormon
level
observ
prior
follow
acth
stimul
respect
dog
dog
androstenedion
dog
progesteron
also
abnorm
elev
testosteron
level
observ
dog
prior
acth
stimul
dog
follow
acth
stimul
two
dog
present
abnorm
decreas
estradiol
level
prior
follow
acth
stimul
hand
abnorm
elev
cortisol
level
observ
dog
prior
acth
stimul
elev
level
maintain
one
dog
follow
acth
administr
contrast
dog
aldosteron
level
within
refer
rang
except
one
dog
slightli
elev
aldosteron
level
prior
acth
stimul
dog
subject
treatment
four
complet
hair
regrowth
three
partial
regrowth
three
month
treatment
dog
subject
treatment
b
one
complet
hair
regrowth
four
partial
regrowth
one
show
sign
regrowth
treatment
one
two
dog
subject
treatment
c
withdrawn
due
emesi
pomeranian
dog
affect
alopecia
x
present
increas
level
androstenedion
testosteron
progesteron
prior
follow
stimul
synthet
acth
suggest
adren
gland
increas
function
sex
hormon
product
due
trilostan
steroidogenesi
blocker
found
posit
therapeut
option
alopecia
x
without
associ
melatonin
phenotyp
identif
cat
risk
develop
diabet
yet
defin
burmes
cat
report
dyslipidemia
time
like
develop
diabet
breed
identifi
plasma
metabolit
differ
healthi
senior
burmes
match
nonburmes
cat
rang
lean
obes
determin
signific
correl
exist
metabolit
measur
glucos
metabol
hormon
biochem
relat
diabet
cat
test
nonburmes
lean
bc
overweight
bc
obes
bc
burmes
lean
overweight
obes
food
withheld
hour
cephal
vein
cathet
implant
venou
blood
sampl
collect
serum
plasma
separ
frozen
glucos
toler
test
glucos
gkg
perform
biochem
screen
fast
blood
glucos
glucos
toler
test
triglycerid
hormon
leptin
adiponectin
leptin
adiponectin
ratio
insulin
glucos
insulin
ratio
enzymat
fpli
analys
perform
plasma
serum
sampl
extract
analys
use
gcm
perform
linear
model
use
identifi
statist
signific
adjust
pvalu
metabolit
associ
obes
whether
respons
affect
sex
age
pearson
correl
use
identifi
relationship
metabolit
paramet
gcm
analys
identifi
metabolit
significantli
p
differ
burmes
nonburmes
cat
burmes
cat
metabolit
involv
amino
acid
metabol
either
increas
phenylalanin
tyrosin
valin
serin
threonin
cystein
prolin
arginin
decreas
cystein
alanin
balanin
compar
nonburmes
cat
metabolit
carbohydr
metabol
decreas
glucos
fructos
lactic
acid
involv
lipid
metabol
glucos
phosphat
phosphor
acid
stearic
acid
cholesterol
metabolit
correl
known
measur
glucos
metabol
numer
amino
acid
posit
correl
insulin
triglycerid
tyrosin
phenylalanin
cystein
prolin
glutamin
arginin
posit
correl
insulin
tyrosin
phenylalanin
also
correl
triglycerid
result
agre
human
studi
futur
risk
develop
diabet
found
associ
chang
metabolit
amino
acid
metabolit
alanin
threonin
tyrosin
neg
correl
adiponectin
glucos
fructos
posit
associ
blood
glucos
follow
glucos
toler
test
howev
metabolit
consid
discrimin
impair
fast
glucos
increas
human
risk
diabet
phosphor
acid
alanin
stearic
acid
decreas
burmes
cat
metabolit
glycerolipid
metabol
glycer
glycerol
phosphat
glucos
fructos
studi
first
report
metabolit
differ
healthi
nonburmes
burmes
cat
identifi
biomark
involv
amino
acid
carbohydr
lipid
metabol
alter
burmes
cat
similar
pattern
identifi
human
risk
diabet
research
requir
determin
use
marker
metabol
dysfunct
cat
risk
develop
diabet
diabet
mellitu
dm
common
felin
endocrinopathi
pathophysiolog
similar
human
type
diabet
occur
due
combin
insulin
resist
bcell
dysfunct
sever
studi
identifi
environment
genet
suscept
factor
cat
environment
factor
obes
physic
inact
link
howev
identif
genet
factor
challeng
date
gene
shown
associ
increas
suscept
dm
overweight
domest
short
hair
dsh
cat
aim
present
studi
perform
genomewid
associ
studi
gwa
identifi
loci
associ
dm
lean
dsh
cat
illumina
infinium
iselect
dna
array
use
interrog
genom
dna
sampl
lean
diabet
dsh
cat
royal
veterinari
colleg
felin
dm
archiv
control
dsh
cat
data
analys
use
plink
whole
genom
data
analysi
toolset
signific
establish
p
x
snp
minor
allel
frequenc
call
rate
individu
genotyp
rate
exclud
analysi
total
snp
avail
analysi
exclud
cat
low
genotyp
rate
control
dsh
lean
diabet
dsh
cat
evalu
diabet
cat
mean
sd
age
male
femal
nondiabet
cat
mean
sd
age
femal
male
control
cat
significantli
older
diabet
cat
p
ttest
five
signific
snp
identifi
p
x
p
x
p
x
p
x
p
x
first
snp
locat
within
chromosom
other
locat
within
mb
region
toward
end
chromosom
snp
chromosom
locat
kb
upstream
peptidas
similar
involv
incretin
inactiv
within
identifi
region
chromosom
gene
interest
includ
associ
human
like
caus
insulin
resist
first
gwa
dm
cat
number
signific
snp
identifi
locat
proxim
gene
associ
other
could
involv
pathophysiolog
relat
dm
investig
candid
gene
warrant
disclosur
disclosur
report
snp
chip
gwa
provid
morri
anim
foundat
elev
serum
canin
pancreat
lipas
immunoreact
cpli
concentr
highli
specif
pancreat
addit
studi
dog
primari
gastrointestin
gi
diseas
suggest
neg
outcom
dog
increas
serum
cpli
concentr
gi
diseas
includ
foreign
bodi
fb
mimic
clinic
sign
pancreat
gi
fb
also
propos
risk
factor
develop
pancreat
dog
date
preval
pancreat
dog
gi
fb
unknown
primari
aim
studi
determin
preval
elev
cpli
concentr
measur
spec
cpl
dog
gi
fb
correl
spec
cpl
concentr
patient
surviv
secondari
aim
compar
spec
cpl
concentr
among
dog
base
age
fb
type
fb
locat
type
remov
procedur
serum
spec
cpl
measur
dog
prospect
enrol
endoscop
surgic
confirm
gi
fb
may
may
sampl
obtain
day
procedur
prior
anesthet
induct
dog
retrospect
group
base
age
year
n
year
n
year
n
fb
type
linear
n
discret
n
fb
locat
stomach
n
duodenum
n
jejunum
n
involv
multipl
segment
n
type
remov
procedur
endoscopi
n
surgeri
n
preval
serum
spec
cpl
upper
limit
refer
interv
suggest
cutoff
valu
pancreat
l
determin
dog
serum
spec
cpl
concentr
compar
amongst
group
use
kruskalw
mannwhitney
u
test
appropri
statist
signific
set
p
spec
identifi
dog
spec
spec
cpl
median
rang
higher
dog
year
ugl
year
age
dog
year
p
age
spec
cpl
higher
dog
linear
fb
dog
discret
fb
p
spec
cpl
higher
dog
fb
affect
multipl
gi
segment
dog
gastric
fb
p
spec
cpl
higher
dog
undergo
surgeri
dog
undergo
endoscopi
p
two
dog
euthan
cours
studi
dog
evid
septic
periton
time
euthanasia
dog
spec
cpl
concentr
elev
respect
overal
preval
spec
cpl
dog
gi
fb
rel
low
respect
spec
cpl
higher
middl
age
older
dog
dog
linear
fb
dog
need
undergo
surgeri
fb
remov
spec
note
dog
euthan
due
small
number
addit
studi
would
need
confirm
elev
spec
cpl
associ
neg
outcom
dog
gi
fb
prednison
glucocorticoid
gc
commonli
use
longterm
medic
treat
multitud
immun
mediat
inflammatori
neoplast
diseas
dog
patient
mani
diseas
may
clinic
sign
overlap
patient
pancreat
effect
longterm
gc
administr
canin
serum
spec
cpl
concentr
adequ
assess
therefor
aim
studi
determin
longterm
administr
gc
supraphysiolog
dose
affect
serum
concentr
spec
cpl
dog
varieti
differ
diseas
dog
prospect
enrol
veterinari
specialti
hospit
san
diego
februari
octob
inclus
criteria
enrol
includ
prescrib
longterm
week
administr
least
mgkgday
prednisoneequival
gc
serum
spec
cpl
concentr
measur
prior
initi
gc
therapi
dog
serv
control
second
measur
serum
spec
cpl
concentr
obtain
dog
least
week
treatment
gc
dog
dosag
chang
within
one
week
sampl
evalu
dose
gc
record
dose
administ
time
second
serum
sampl
collect
case
exclud
poor
owner
complianc
gc
administr
defin
miss
two
consecut
dose
gc
administr
medic
known
suspect
increas
serum
spec
cpl
concentr
eg
potassium
bromid
phenobarbit
gc
administr
within
month
prior
enrol
comparison
serum
spec
cpl
pre
gc
administr
week
post
gc
administr
perform
use
wilcoxon
matchedpair
sign
rank
test
statist
signific
set
p
total
dog
enrol
eight
case
exclud
due
euthanasia
n
lack
follow
second
sampl
n
gc
dose
mgkgday
time
second
sampl
collect
n
chang
gc
dose
week
second
sampl
collect
n
fifteen
case
met
inclus
criteria
case
enrol
reason
chronic
gc
administr
includ
immun
mediat
thrombocytopenia
n
immun
mediat
hemolyt
anemia
n
protein
lose
enteropathi
n
histiocyt
sarcoma
n
suspect
immun
mediat
pancytopenia
n
myelofibrosi
n
mast
cell
tumor
n
median
spec
cpl
concentr
pre
post
gc
administr
lgl
lgl
lgl
lg
l
respect
statist
signific
differ
serum
spec
cpl
concentr
baselin
post
gc
therapi
week
group
patient
p
figur
result
studi
reveal
statist
signific
differ
spec
cpl
concentr
dog
prior
administr
gc
week
administr
supraphysiolog
dose
gc
thu
administr
gc
compromis
clinician
abil
interpret
result
spec
cpl
concentr
role
cytokin
pancreat
well
character
human
medicin
howev
limit
inform
avail
role
dog
pancreat
aim
studi
describ
serum
concentr
interleukin
il
tumor
necrosi
factoralpha
tnfa
dog
increas
serum
concentr
pancreat
lipas
immunoreact
cpli
measur
spec
cpl
fortynin
surplu
serum
sampl
dog
serum
cpli
concentr
use
studi
ten
healthi
dog
serum
cpli
concentr
use
control
serum
cytokin
concentr
measur
use
previous
analyt
valid
electrochemiluminesc
immunoassay
data
analyz
use
nonparametr
statist
signific
set
p
cytokin
concentr
significantli
increas
dog
serum
cpli
concentr
compar
healthi
control
conclus
serum
tnfa
concentr
significantli
increas
dog
serum
cpli
concentr
prospect
studi
need
assess
util
cytokin
earli
diagnost
marker
prognost
marker
dog
pancreat
fishhook
foreign
bodi
common
present
certain
geograph
area
often
requir
emerg
remov
gastrointestin
tract
skin
author
institut
endoscop
retriev
consid
highli
success
contrast
previou
literatur
object
studi
describ
locat
retriev
complic
outcom
associ
fishhook
electron
medic
record
cat
dog
admit
fishhook
foreign
bodi
search
radiograph
locat
fishhook
retriev
method
document
complic
outcom
data
test
normal
mannwhitney
test
odd
ratio
construct
compar
associ
differ
variabl
one
hundr
seven
case
cat
dog
total
fishhook
includ
singl
shank
hook
compris
multipl
shank
hook
compris
case
common
locat
pharyng
oral
region
cervic
esophagu
stomach
three
hook
cutan
embed
hook
multipl
shank
time
like
associ
esophag
damag
singl
shank
hook
ci
p
endoscop
retriev
success
case
attempt
esophag
perfor
occur
endoscop
case
total
case
necessit
surgeri
surviv
studi
support
endoscop
retriev
highli
success
surviv
even
case
requir
surgeri
multipl
shank
fishhook
like
caus
esophag
damag
neither
type
hook
locat
affect
outcom
alana
redfernallen
blake
guard
jan
suchodolski
joerg
steiner
jonathan
lidburi
albert
jergen
iowa
state
univers
ame
ia
usa
texa
univers
colleg
station
tx
usa
intestin
microbiota
recent
link
develop
human
metabol
diseas
includ
diabet
mellitu
dm
due
role
energi
balanc
gut
permeabl
host
inflammatori
state
microbi
imbal
may
also
affect
bile
acid
ba
metabol
alter
profil
primari
secondari
ba
modul
signal
pathway
involv
insulin
resist
via
induct
character
intestin
microbiota
ba
dog
dm
systemat
evalu
therefor
aim
studi
investig
fecal
microbiota
ba
composit
healthi
dog
dog
dm
fecal
sampl
collect
heathi
control
dog
diabet
dog
fecal
microbiota
evalu
prior
intervent
use
quantit
polymeras
chain
reaction
qpcr
e
coli
streptococcu
turicibact
faecalibacterium
fusobacterium
blautia
fecal
concentr
primari
ie
cholic
chenodeoxychol
acid
secondari
ie
litho
deoxi
ursodeoxychol
acid
ba
measur
use
ga
chromatographi
mass
spectrometri
nonparametr
mannwhitney
u
test
use
compar
paramet
healthi
dog
dog
dm
statist
signific
set
p
result
indic
dm
dog
exhibit
imbal
fecal
microbiota
character
decreas
number
turicibact
p
faecalibacterium
p
compar
healthi
dog
perturb
ba
metabol
observ
dm
cohort
involv
increas
primari
ba
decreas
secondari
ba
p
conclud
dog
dm
signific
imbal
intestin
microbiota
also
alter
bile
acid
metabol
may
contribut
diseas
pathogenesi
morbid
studi
warrant
elucid
mechan
behind
alter
whether
primarili
due
diseas
secondari
environment
factor
includ
diet
antibiot
variat
microbiom
metabolom
along
canin
gastrointestin
tract
jb
honneff
jm
steiner
ja
lidburi
js
suchodolski
gastrointestin
laboratori
texa
univers
colleg
station
tx
usa
gastrointestin
tract
git
dog
complex
ecosystem
biolog
biochem
composit
vari
along
length
git
analysi
fecal
sampl
frequent
use
surrog
indic
gastrointestin
diseas
occur
proxim
intestin
section
canin
gastrointestin
biogeographi
microbiom
previous
describ
correspond
metabolit
profil
variou
point
along
git
healthi
dog
character
knowledg
therefor
aim
studi
perform
rrna
gene
sequenc
untarget
metabolom
sampl
multipl
site
character
metabolom
microbiom
along
git
healthi
dog
sampl
duoden
ileal
colon
rectal
content
collect
six
adult
dog
immedi
human
euthanasia
anoth
studi
microbiota
character
use
illumina
sequenc
rrna
gene
metabolom
character
untarget
mass
spectrometrybas
method
interanim
variat
statist
address
block
softwar
jmp
subsequ
wilcoxon
test
benjaminihochberg
correct
multipl
comparison
statist
signific
set
p
predomin
phyla
throughout
sampl
proteobacteria
firmicut
fusobacteria
bacteroidet
percentag
read
identifi
proteobacteria
decreas
abor
p
duodenum
ileum
colon
rectum
firmicut
increas
p
ga
chromatographi
platform
uniqu
compound
detect
assign
name
metabolit
name
metabolit
least
one
sitepair
comparison
reach
statist
signific
key
ferment
compound
sugar
amino
acid
vari
site
distribut
glucos
increas
progress
along
git
along
p
respect
nearli
amino
acid
exhibit
decreas
ileum
colon
eg
alanin
citrullin
glutamin
glycin
lysin
methionin
tryptophan
valin
p
conclus
metabolom
microbiom
vari
along
canin
git
studi
need
explor
effect
local
diseas
specif
site
determin
host
versu
microbi
origin
metabolit
possibl
enhanc
extrapol
fecal
assay
result
improv
understand
gi
diseas
abnorm
interact
gi
microbiom
immun
system
major
contribut
factor
ibd
treatment
often
includ
use
antimicrobi
like
metronidazol
use
elimin
diet
ie
hydrolyz
protein
diet
effect
intestin
microbiota
well
studi
recent
epidemiolog
studi
human
link
gut
dysbiosi
due
antibiot
risk
factor
variou
chronic
diseas
obes
diabet
asthma
better
understand
function
effect
antibiot
diet
microbiom
need
aim
studi
prospect
evalu
impact
metronidazol
administr
versu
hydrolyz
protein
diet
metabolom
healthi
dog
twentyfour
healthi
pet
dog
assign
one
group
dog
control
dog
intervent
group
dog
treat
soybas
hydrolyz
diet
purina
ha
week
administr
metronidazol
mgkg
po
h
week
dog
maintain
usual
diet
administ
dose
metronidazol
week
fece
blood
collect
day
day
microbi
commun
analyz
illumina
sequenc
rrna
gene
softwar
picrust
use
predict
function
gene
famili
serum
fecal
metabolom
assess
untarget
approach
combin
variou
mass
spectrometri
platform
assess
paramet
adjust
multipl
comparison
use
benjamin
hochberg
adjust
adjust
p
consid
signific
signific
differ
evalu
paramet
observ
control
group
also
dietari
switch
hydrolyz
diet
baselin
week
lead
signific
chang
evalu
paramet
howev
dog
dog
receiv
metronidazol
signific
chang
observ
respons
group
similar
combin
statist
analysi
microbiom
structur
divers
significantli
alter
baselin
time
complet
metronidazol
treatment
also
week
end
metronidazol
treatment
anosim
p
signific
chang
increas
e
coli
decreas
firmicut
function
gene
famili
found
significantli
abund
antibiot
administr
includ
lipopolysaccharid
biosynthesi
glutathion
metabol
recombin
repair
protein
tryptophan
metabol
fatti
acid
metabol
p
cessat
antibiot
administr
function
gene
famili
found
significantli
abund
includ
bile
secret
xylen
degrad
dioxin
degrad
signal
transduct
mechan
p
metronidazol
lead
alter
measur
fecal
metabolit
major
chang
observ
reduct
secondari
bile
acid
p
increas
oxid
stress
pathway
p
chang
tryptophanindol
pathway
p
chang
revers
day
end
antibiot
administr
evalu
bacteri
taxa
metabolit
remain
significantli
alter
week
end
administr
end
studi
conclus
metronidazol
profound
effect
fecal
microbiom
metabolom
partial
resolv
week
studi
warrant
assess
whether
dysbiosi
disrupt
metabol
pathway
due
metronidazol
may
pose
risk
factor
develop
chronic
diseas
contrast
hydrolyz
diet
notic
effect
microbiom
metabolom
healthi
dog
alter
fecal
bile
acid
metabol
dog
chronic
enteropathi
blake
guard
linda
toresson
julia
honneff
amanda
blake
yuri
lawrenc
jonathan
lidburi
joerg
steiner
jan
suchodolski
texa
univers
colleg
station
tx
usa
evidensia
specialist
anim
hospit
helsingborg
sweden
helsinki
univers
helsinki
finland
chronic
enteropathi
dog
character
multifactori
diseas
thought
involv
inappropri
ongo
activ
mucos
immun
system
addit
microbi
dysbiosi
recent
studi
human
suggest
patient
inflammatori
bowel
diseas
microbi
dysbiosi
drive
bile
acid
ba
dysmetabol
primari
ba
synthes
liver
secret
intestin
lumen
enzymat
reaction
catalyz
bacteria
lead
ba
biotransform
addit
ba
particip
gastrointestin
mucos
defens
exampl
secondari
ba
shown
antiinflammatori
potenti
decreas
synthesi
proinflammatori
cytokin
tnfa
therefor
aim
studi
investig
fecal
ba
profil
dog
chronic
enteropathi
fecal
sampl
collect
healthi
dog
n
dog
chronic
enteropathi
histolog
confirm
inflamm
n
fecal
bile
acid
analyz
ga
chromatographi
coupl
mass
spectrometri
mannwhitney
u
test
use
compar
concentr
ba
group
cholic
acid
chenodeoxychol
acid
among
primari
bile
acid
measur
deoxychol
acid
lithochol
acid
ursodeoxychol
acid
among
secondari
bile
acid
measur
statist
signific
set
p
signific
differ
fecal
concentr
primari
bile
acid
found
healthi
dog
dog
chronic
enteropathi
deoxychol
acid
significantli
decreas
dog
chronic
enteropathi
conclus
studi
reveal
decreas
fecal
secondari
bile
acid
dog
chronic
enteropathi
studi
need
investig
interplay
specif
bacteri
group
alter
bile
acid
metabol
well
relationship
intestin
inflamm
dog
chronic
enteropathi
diseas
chronic
inflamm
gastrointestin
tract
includ
idiopath
inflammatori
bowel
diseas
ibd
thought
perpetu
bacteri
dysbiosi
dysregul
mucos
immun
system
human
anim
gastrointestin
gi
absorpt
metabolit
alter
inflamm
concurr
chang
microbi
metabol
within
gi
tract
cholesterol
primari
sterol
mammal
incorpor
cell
membran
throughout
bodi
use
build
block
endogen
hormon
steroid
bile
acid
phytosterol
shown
antiinflammatori
properti
shown
decreas
diseas
sever
murin
coliti
model
therefor
aim
studi
compar
fecal
sterol
profil
dog
chronic
enteropathi
healthi
dog
fecal
sampl
collect
healthi
dog
n
dog
chronic
enteropathi
n
biopsyconfirm
inflamm
sterol
lyophil
fece
subject
trimethylsilyl
ether
derivat
analyz
ga
chromatographymass
spectrometri
gcm
oper
singl
ion
monitor
sim
mode
target
analyt
includ
cholesterol
cholestanol
bsitosterol
sitostanol
fucosterol
stigmaterol
campesterol
fecal
concentr
sterol
express
lgmg
lyophil
fece
mannwhitney
u
test
use
comparison
anim
group
statist
signific
set
p
fecal
cholesterol
cholestanol
significantli
alter
healthi
dog
dog
chronic
enteropathi
howev
phytosterol
significantli
decreas
dog
chronic
enteropathi
healthi
group
median
minmax
conclus
studi
suggest
fecal
sterol
profil
dog
chronic
enteropathi
character
decreas
phytosterol
addit
studi
requir
explor
effect
dietari
supplement
phytosterol
investig
sterol
relat
specif
bacteri
group
digest
dietari
plant
materi
patient
exocrin
pancreat
insuffici
epi
dog
syndrom
inadequ
synthesi
secret
pancreat
enzym
lead
clinic
sign
maldigest
previou
report
show
small
intestin
bacteri
dysbiosi
occur
dog
epi
revers
pancreat
enzym
therapi
howev
studi
evalu
fecal
microbiom
dog
epi
object
studi
compar
fecal
microbiom
healthi
dog
n
untreat
n
dog
epi
dog
epi
treat
enzym
replac
therapi
n
includ
studi
dog
least
year
age
clinic
sign
epi
serum
ctli
concentr
lgl
free
concurr
diseas
three
natur
void
fecal
sampl
collect
three
consecut
day
frozen
immedi
collect
pool
fecal
sampl
collect
similar
manner
healthi
dog
without
clinic
sign
gastrointestin
diseas
extract
dna
fecal
sampl
use
illumina
sequenc
bacteri
rrna
gene
analyz
use
quantit
insight
microbi
ecolog
qiim
analysi
similar
anosim
function
statist
softwar
packag
primer
primer
ltd
luton
uk
use
unweight
unifrac
distanc
matrix
determin
group
sampl
contain
significantli
differ
bacteri
commun
signific
differ
fecal
microbi
commun
healthi
dog
compar
treat
p
untreat
p
dog
epi
quantit
insight
microbi
ecolog
qiim
analysi
similar
anosim
function
statist
softwar
packag
primer
primer
ltd
luton
uk
use
unweight
unifrac
distanc
matrix
determin
group
sampl
contain
significantli
differ
bacteri
commun
signific
differ
fecal
microbi
commun
healthi
dog
compar
treat
p
untreat
p
dog
epi
alpha
divers
significantli
decreas
untreat
treat
epi
dog
compar
healthi
dog
p
famili
bifidobacteriacea
p
enterococcacea
p
lactobacillacea
p
significantli
increas
untreat
treat
dog
epi
compar
healthi
dog
contrast
lachnospiracea
p
blautia
p
significantli
decreas
dog
epi
conclus
studi
suggest
fecal
microbiom
dog
epi
treat
untreat
differ
healthi
dog
intestin
microbiota
short
chain
fatti
acid
scfa
import
varieti
metabol
disord
hypothes
obes
diet
affect
intestin
microbiota
scfa
cat
eight
cat
use
repeatedmeasur
studi
cat
fed
mainten
diet
mdiet
studi
day
switch
weightloss
diet
wldiet
day
without
calori
restrict
day
day
daili
intak
restrict
achiev
weightloss
per
week
day
feed
mdiet
resum
maintain
stabl
bodi
condit
score
bc
fecal
sampl
collect
store
analysi
sampl
collect
day
obesemdiet
obesewldiet
leanwldiet
leanmdiet
microbiota
scfa
profil
bodi
weight
bc
muscl
condit
score
bodi
fat
percentag
assess
throughout
studi
microbiota
scfa
profil
reveal
chang
associ
diet
bc
microbiota
divers
speci
rich
alter
note
acet
butyr
acid
product
significantli
differ
obes
lean
cat
diet
bc
signific
interact
statist
model
remain
scfa
posthoc
analysi
isobutyr
valer
isovaler
acid
significantli
differ
obes
lean
cat
mainten
diet
valer
isovaler
differ
mdiet
wldiet
obes
cat
microbiota
scfa
profil
alter
note
base
bodi
condit
studi
warrant
determin
impact
chang
inflamm
metabol
disord
canin
inflammatori
bowel
diseas
ibd
immunemedi
enteropathi
like
trigger
environment
immunoregulatori
factor
genet
suscept
dog
previou
studi
suggest
pivot
role
intestin
bacteria
diseas
pathogenesi
sinc
lumin
microbi
composit
markedli
alter
diagnosi
suggest
probiot
bacteria
effect
promis
agent
treatment
ibd
human
anim
howev
effect
probiot
bacteria
directli
interact
host
resid
intestin
microbiota
poorli
understood
aim
present
studi
investig
impact
multistrain
probiot
vsl
supplement
visbiom
exegi
pharma
dose
billion
bacteriakgday
fecal
intestin
mucos
microbiota
dog
ibd
nineteen
dog
diagnos
moderatetosever
ibd
cibdai
random
receiv
standard
ibd
therapi
ie
elimin
diet
prednison
without
probiot
vsl
week
dog
evalu
clinic
week
endoscop
histopatholog
week
fecal
mucos
microbiota
investig
treatment
use
rrna
base
quantit
polymeras
chain
reaction
qpcr
fluoresc
situ
hybrid
fish
respect
cohort
ibd
dog
show
reduct
gi
sign
week
therapi
compar
baselin
cibdai
score
p
use
qpcr
placebo
group
fail
show
signific
chang
bacteri
group
analyz
contrast
vsl
treat
dog
show
signific
p
increas
total
lactic
acid
bacteria
bifidobacteria
streptococci
lactobacilli
treatment
week
versu
baselin
valu
bifidobacteria
also
significantli
p
increas
week
postvsl
treatment
fish
analysi
show
vsl
alter
number
spatial
distribut
colon
mucos
bacteri
group
includ
total
bacteria
number
bifidobacteria
fecalibacteria
lactobacilli
streptococci
enterobacteriacea
p
number
mucusladen
attach
bifidobacteria
streptococci
also
significantli
p
increas
dog
receiv
vsl
conclus
probiot
therapi
ibd
dog
vsl
increas
number
fecal
mucos
probiot
genera
especi
lactic
acid
bacteria
ibd
dog
receiv
standard
therapi
placebo
show
littl
chang
composit
microbi
commun
despit
exhibit
clinic
improv
chronic
enteropathi
ce
multifactori
diseas
involv
aberr
immun
respons
commens
bacteria
dietari
antigen
although
macrophag
shown
play
import
role
human
diseas
littl
inform
avail
dog
scaveng
receptor
specif
macrophag
detect
canin
duodenum
aim
studi
determin
intestin
posit
cell
popul
alter
success
treatment
ce
calprotectin
use
addit
marker
macrophag
dog
prospect
enrol
underw
standard
diagnosi
treatment
trial
ce
duoden
biopsi
taken
longterm
resolut
clinic
sign
month
serial
histolog
section
stain
use
calprotectin
posit
stain
cell
five
villou
crypt
region
manual
count
percentag
posit
stain
cell
total
nucleat
cell
per
lm
treatment
compar
repeatedmeasur
anova
five
dog
dietaryrespons
three
steroidrespons
ce
significantli
increas
follow
treatment
villi
p
wherea
calprotectin
significantli
decreas
increas
decreas
calprotectin
also
observ
follow
treatment
crypt
although
signific
similar
chang
seen
food
steroid
respons
dog
result
suggest
macrophag
may
play
role
canin
ce
character
macrophag
warrant
understand
role
ce
term
proteinlos
enteropathi
ple
often
appli
case
chronic
enteropathi
ce
diseas
process
result
hypoalbuminemia
multipl
previou
studi
identifi
hypoalbuminemia
risk
factor
neg
outcom
dog
chronic
enteropathi
yet
determin
whether
histopatholog
differ
ce
dog
without
hypoalbuminemia
goal
retrospect
studi
compar
histopatholog
find
determin
wsava
score
system
dog
ce
without
hypoalbuminemia
electron
medic
record
colorado
state
univers
review
dog
intestin
biopsi
perform
januari
includ
dog
clinic
sign
compat
ce
least
week
durat
dog
signific
concurr
diseas
potenti
nongi
caus
hypoalbuminemia
intestin
lymphoma
complet
medic
record
could
obtain
exclud
case
suitabl
inclus
dog
place
either
ce
albumin
gmdl
ce
w
ple
albumin
gmdl
group
record
data
includ
signal
present
complaint
clinic
sign
addit
clinicopatholog
abnorm
tissu
type
avail
method
biopsi
procur
blind
pathologist
slp
ask
review
biopsi
appli
wsava
score
system
intestin
biopsi
case
one
tissu
type
avail
tissu
type
highest
total
wsava
score
use
analysi
result
summar
tabl
notabl
discrep
group
occur
categori
crypt
distens
cd
lacteal
dilat
ld
villou
stunt
vs
lamina
propria
neutrophil
lp
n
greater
proport
dog
ce
w
ple
exhibit
chang
histopatholog
villou
epitheli
injuri
vei
intraepitheli
lymphocyt
iel
also
appreci
common
dog
ce
w
ple
group
lamina
propria
lymphocyt
plasma
cell
lp
l
pc
lamina
propria
eosinophil
lp
e
observ
group
mucos
fibrosi
mf
uncommon
group
dog
ple
secondari
ce
greater
percentag
lacteal
dilat
injuri
villi
crypt
distens
lamina
propria
neutrophil
dog
ce
normal
albumin
furthermor
although
lacteal
dilat
note
ple
case
list
primari
diagnosi
case
investig
requir
determin
differ
repres
differ
underli
etiolog
alter
treatment
strategi
specif
case
perinuclear
antineutrophil
antibodi
panca
previous
shown
serum
marker
canin
ibd
like
associ
food
respons
diarrhea
frd
case
steroid
respons
diseas
srd
indirect
immunofluoresc
assay
use
previou
public
base
isol
canin
granulocyt
donor
dog
subsequ
fix
ethanol
microscop
slide
incub
patient
serum
secondari
antibodi
assay
time
consum
shown
low
interobserv
agreement
pilot
studi
therefor
sought
investig
whether
commerci
avail
human
granulocyt
indirect
immunofluoresc
assay
could
use
detect
panca
dog
evalu
preliminari
sensit
specif
assay
group
dog
frd
versu
srd
fortyfour
dog
frd
dog
srd
includ
studi
granulocyt
mosaic
biochip
slide
euroimmun
ag
contain
human
granulocyt
fix
ethanol
human
granulocyt
fix
formalin
purifi
myeloperoxidas
protein
mpo
purifi
protein
cell
use
assay
biochip
allow
detect
panca
cytoplasm
antineutrophil
antibodi
canca
well
antinuclear
antibodi
ana
slide
assay
perform
accord
manufactur
instruct
briefli
biochip
incub
dilut
serum
sampl
min
wash
incub
secondari
antidog
igg
fitclabel
antibodi
min
wash
slide
embed
medium
cover
evalu
fluoresc
light
magnif
two
independ
observ
number
panca
canca
posit
result
group
frd
dog
contrari
none
dog
srd
group
evid
panca
canca
seroreact
consequ
sensit
new
assay
predict
frd
amongst
group
dog
chronic
enteropathi
ci
specif
ci
compar
previou
studi
use
canin
granulocyt
method
sensit
specif
fisher
exact
test
reveal
statist
signific
associ
posit
panca
canca
test
frd
p
interobserv
agreement
assay
good
kappa
furthermor
anca
posit
case
possibl
identifi
either
mpo
antigen
biochip
conclus
human
granulocyt
immunofluoresc
assay
use
studi
abl
identifi
seroposit
anca
high
percentag
dog
frd
data
suggest
assay
could
use
altern
canin
assay
detect
anca
dog
citrullin
nonproteinogen
amino
acid
recent
describ
biomark
enterocyt
function
human
decreas
concentr
plasma
citrullin
report
patient
short
bowel
syndrom
crohn
diseas
viral
enter
critic
ill
patient
dog
relationship
serum
citrullin
concentr
small
intestin
dysfunct
well
character
citrullin
mainli
synthes
glutamin
enterocyt
metabol
duodenum
jejunum
therefor
intestin
injuri
lead
decreas
serum
citrullin
concentr
aim
studi
analyt
valid
gcm
method
measur
citrullin
canin
serum
assess
concentr
amino
acid
dog
chronic
enteropathi
surplu
serum
sampl
dog
use
analyt
valid
citrullin
assay
thirtyon
surplu
serum
sampl
healthi
dog
dog
chronic
enteropathi
use
evalu
possibl
alter
serum
citrullin
concentr
dog
chronic
enteropathi
valid
variabl
includ
lower
limit
detect
linear
spike
recoveri
precis
serum
citrullin
concentr
dog
chronic
enteropathi
compar
healthi
dog
mannwhitney
u
test
perform
compar
serum
citrullin
concentr
healthi
diseas
dog
statist
signific
set
p
lower
limit
detect
citrullin
serum
observedtoexpect
ratio
citrullin
dilut
parallel
n
recoveri
spike
concentr
citrullin
serum
sampl
n
mean
intraand
interassay
coeffici
variat
cv
citrullin
assay
respect
dog
chronic
enteropathi
significantli
lower
serum
citrullin
concentr
median
minimum
maximum
healthi
dog
median
minimummaximum
p
assay
evalu
shown
linear
precis
accur
reproduc
dog
chronic
enteropathi
significantli
lower
serum
citrullin
concentr
healthi
dog
studi
warrant
assess
clinic
util
serum
citrullin
biomark
enterocyt
function
dog
dog
symptom
ce
serum
cbl
ngl
refer
interv
ngl
includ
evidensia
specialist
anim
hospit
helsingborg
sweden
helsinki
univers
hospit
finland
two
swedish
veterinari
clinic
dog
random
treatment
either
daili
po
cbl
tablet
whole
studi
period
cyanocobalamin
behepan
mgtablet
dog
kg
receiv
tablet
dog
kg
tablet
dog
kg
tabletday
pe
cbl
accord
protocol
current
suggest
diagnost
laboratori
http
vetmedtamuedugilabresearchcobalamininform
dose
blockrandom
schedul
perform
extern
statistician
prior
start
studi
march
studi
approv
swedish
board
agricultur
viikki
campu
research
ethic
committe
finland
serum
cbl
followup
analyz
ae
day
ae
day
initi
supplement
use
autom
chemiluminesc
immunoassay
immulit
siemen
healthcar
diagnost
dog
breed
includ
median
age
rang
dog
symptom
ce
concurr
medic
treatment
diet
given
base
clinic
judgement
intestin
biopsi
small
larg
intestin
confirm
chronic
inflamm
avail
dog
statist
signific
differ
serum
cbl
concentr
baselin
two
group
p
mann
whitney
test
serum
cbl
increas
dog
supplement
group
receiv
po
supplement
median
serum
cbl
concentr
ngl
inclus
n
ngl
day
n
ngl
month
n
differ
baselin
day
statist
signific
p
wilcoxon
matchedpair
sign
rank
test
well
differ
day
month
wilcoxon
matchedpair
sign
rank
test
group
receiv
pe
cbl
mean
cbl
concentr
ae
ngl
inclus
n
ae
ngl
day
n
ae
ngl
n
month
differ
baselin
day
statist
signific
p
pair
ttest
well
differ
day
month
p
pair
ttest
compar
increas
serum
cbl
concentr
day
baselin
increas
significantli
higher
pe
group
po
group
mean
increas
ae
ngl
ae
ngl
respect
p
unpair
ttest
howev
month
median
rang
increas
serum
cbl
concentr
compar
baselin
group
significantli
higher
po
pe
group
ngl
ngl
respect
p
mann
whitney
test
conclud
po
pe
cbl
supplement
appear
effect
increas
serum
cbl
concentr
dog
ce
hypocobalaminemia
studi
compar
cellular
cobalamin
statu
po
pe
supplement
warrant
dog
ce
present
hokkaido
univers
veterinari
teach
hospit
juli
june
recruit
fourteen
laboratori
beagl
use
control
plasma
ete
concentr
chromium
manganes
iron
cobalt
copper
zinc
selenium
molybdenum
measur
induct
coupl
plasmamass
spectrometri
plasma
ete
concentr
ce
dog
compar
control
ce
dog
correl
plasma
ete
concentr
canin
chronic
enteropathi
activ
index
ccecai
plasma
albumin
concentr
histopatholog
score
calcul
accord
world
small
anim
veterinari
associ
wsava
criteria
twentytwo
dog
ce
enrol
studi
signific
differ
plasma
ete
concentr
ce
dog
control
except
molybdenum
plasma
molybdenum
concentr
ce
dog
median
ngml
rang
ngml
higher
control
median
ng
ml
rang
ngml
p
howev
plasma
molybdenum
concentr
nt
correl
ccecai
albumin
concentr
histopatholog
score
result
indic
might
obviou
plasma
ete
defici
dog
ce
studi
necessari
clarifi
reason
increas
plasma
molybdenum
concentr
dog
ce
preval
gastric
empti
ge
disord
cat
unknown
due
lack
clinic
applic
diagnost
test
studi
assess
agreement
ge
time
ultrasonographi
gold
standard
healthi
cat
scintigraphi
static
acquisit
perform
right
left
later
recumb
minut
follow
mci
solid
test
meal
daili
energi
requir
interv
thereaft
mean
total
count
gastric
region
interest
measur
imag
geometr
mean
decaycorrect
count
calcul
amount
gastric
radioact
express
percentag
initi
count
use
nonlinear
regress
analysi
ge
time
determin
sonograph
assess
ge
repeat
three
time
meal
nonlabel
use
time
point
mean
crosssect
area
transvers
imag
relax
antrum
obtain
express
percentag
maxim
area
area
curv
calcul
ge
time
determin
good
correl
found
scintigraphi
sonographi
ae
mean
ae
sd
ae
minut
respect
r
p
ge
time
ae
ae
minut
respect
r
p
ultrasound
evalu
antral
crosssect
area
valid
altern
scintigraphi
late
phase
ge
healthi
cat
impair
gallbladd
motil
might
respons
pathogenesi
gallbladd
mucocel
biliari
sludg
dog
improv
gallbladd
motil
possibl
exert
prevent
effect
progress
gallbladd
diseas
howev
littl
studi
treatment
enhanc
gallbladd
motil
dog
report
receptor
agonist
improv
gallbladd
empti
human
gallston
patient
mosaprid
select
receptor
agonist
practic
use
prokinet
canin
gastrointestin
diseas
induc
increas
motilin
physiolog
induc
gallbladd
motor
activ
studi
investig
effect
mosaprid
postprandi
gallbladd
motil
plasma
level
motilin
dog
without
biliari
sludg
furthermor
examin
express
receptor
use
gallbladd
tissu
normal
dog
nine
appar
healthi
beagl
own
univers
tokyo
enrol
studi
gallbladd
abnorm
group
n
biliari
sludg
group
base
assess
ultrasonographi
gallbladd
eject
fraction
ef
compar
dog
given
diet
without
simultan
singl
oral
administr
mosaprid
mgkg
ef
estim
ultrasonographi
describ
previou
studi
briefli
dog
fast
least
hour
examin
fast
gallbladd
volum
ultrasonograph
measur
given
test
diet
without
mosaprid
postprandi
gallbladd
volum
record
hour
feed
ultrasonographi
blood
collect
measur
plasma
motilin
level
experi
anim
care
compli
polici
outlin
guid
anim
use
care
univers
tokyo
express
receptor
evalu
western
blot
use
archiv
canin
gallbladd
group
n
median
ef
dog
treat
mosaprid
significantli
higher
without
treatment
rang
versu
respect
p
tendenc
also
observ
group
although
differ
signific
treatment
versu
without
treatment
p
howev
median
degre
increas
plasma
motilin
concentr
feed
significantli
differ
dog
without
mosaprid
either
group
group
n
mosaporid
pgml
rang
pgml
versu
feed
pgml
pg
ml
group
mosaporid
pgml
rang
pg
ml
versu
feed
pgml
pgml
western
blot
immunoreact
band
observ
posit
kda
use
protein
purifi
archiv
gallbladd
suggest
express
canin
gallbladd
result
suggest
mosaprid
enhanc
postprandi
gallbladd
motil
although
mechan
effect
still
clarifi
result
suggest
mosaprid
enhanc
gallbladd
motil
possibl
via
gallbladd
receptor
motilin
play
role
effect
studi
need
support
result
tritrichomona
foetu
tf
flagel
protozoan
parasit
recogn
signific
caus
diarrhea
domest
cat
preval
rate
high
drug
shown
consist
elimin
tf
infect
cat
cystein
proteas
cp
identifi
mediat
tfinduc
adhesiondepend
cytotox
intestin
epithelium
thu
cp
repres
novel
target
treatment
felin
trichomonosi
howev
cat
also
produc
cp
part
lifecrit
system
thu
parasit
cp
need
select
target
reduc
potenti
host
toxic
previou
studi
demonstr
import
specif
cp
mediat
bovin
human
trichomonad
cytopathogen
thu
aim
studi
character
presenc
felin
tf
isol
evalu
effect
target
inhibit
felin
tfinduc
adhes
depend
cytotox
presenc
differ
felin
tf
isol
evalu
indirect
immunofluoresc
flow
cytometri
use
rabbit
polyclon
antibodi
target
bovin
tf
felin
tf
treat
rabbit
igg
andor
secondari
ab
absenc
ab
bovin
tf
use
neg
posit
control
respect
effect
inhibit
activ
tf
adhesiondepend
cytopathogen
determin
use
cfselabel
felin
tf
allow
adher
monolay
porcin
intestin
epitheli
cell
ipec
cocultur
effect
inhibit
felin
tf
adhes
cytotox
evalu
immunofluoresc
quantif
assay
crystal
violet
spectrophotometr
analysi
minimum
replic
perform
cocultur
experi
data
analyz
use
systat
softwar
p
express
identifi
felin
tf
isol
test
indirect
immunofluoresc
flow
cytometri
treatment
felin
isol
ab
result
significantli
decreas
tf
adhes
cytotox
toward
monolay
compar
rabbit
iggtreat
tf
isol
studi
establish
express
felin
tf
isol
may
import
virul
factor
cytopathogen
felin
tf
result
studi
provid
strong
evidencebas
justif
investig
novel
target
prevent
andor
treatment
felin
trichomonosi
chronic
proton
pump
inhibitor
administr
associ
electrolyt
imbal
cobalamin
defici
disrupt
bone
homeostasi
serum
hypergastrinemia
rebound
acid
hypersecret
human
side
effect
could
import
clinic
implic
cat
howev
studi
explor
cat
receiv
prolong
oral
omeprazol
eg
week
durat
experi
similar
side
effect
hypothes
prolong
oral
omeprazol
administr
would
result
alter
bone
homeostasi
andor
serum
calcium
magnesium
cobalamin
andor
gastrin
concentr
healthi
cat
within
subject
pre
post
design
adult
healthi
coloni
cat
receiv
either
omeprazol
mgkg
po
h
placebo
mg
lactulos
po
h
day
analys
serum
calcium
magnesium
cobalamin
gastrin
concentr
perform
day
dual
energi
xray
absorptiometri
perform
day
treatment
day
omeprazol
treatment
intragastr
ph
capsul
place
two
cat
measur
effect
rapid
omeprazol
cessat
continu
data
analys
use
twoway
anova
test
account
effect
phase
treatment
time
measur
interact
phase
time
log
transform
serum
gastrin
bone
miner
densiti
bmd
bone
miner
content
bmc
requir
data
meet
anova
normal
assumpt
reduc
possibl
type
error
due
analysi
multipl
studi
variabl
bonferroni
correct
appli
sa
use
perform
data
analys
gener
descript
statist
signific
chang
observ
treatment
placebo
paramet
except
serum
gastrin
significantli
higher
omeprazol
treatment
comparison
placebo
p
although
chang
signific
cat
experienc
decreas
bmc
end
omeprazol
treatment
arm
evid
gastric
hyperacid
seen
cat
follow
cessat
omeprazol
conclus
result
studi
provid
evid
omeprazol
may
rel
safe
administ
cat
day
less
slow
withdraw
medic
recommend
base
hypergastrinemia
rebound
hyperacid
demonstr
pilot
trial
howev
studi
involv
cat
need
confirm
result
littl
known
behavior
food
materi
esophagu
transit
stomach
dog
aim
project
standard
contrast
video
fluoroscopi
techniqu
evalu
esophag
transit
time
dog
sit
vertic
posit
use
inform
determin
appropri
durat
individu
patient
remain
vertic
drink
feed
twelv
dog
includ
studi
six
dog
congenit
dog
idiopath
acquir
dog
secondari
myasthenia
gravi
dog
place
vertic
posit
use
adjust
sizeappropri
bailey
chair
bailey
chair
construct
thin
wood
allow
radioluc
three
differ
feed
session
dog
given
standard
amount
liquid
barium
can
food
meatbal
mix
barium
normal
diet
also
mix
barium
diet
differ
consist
meatbal
gener
slurri
fluoroscopi
perform
minut
increment
visual
transit
food
barium
time
ingest
full
clearanc
materi
esophagu
maximum
minut
liquid
barium
minut
food
materi
dog
accustom
bailey
chair
perform
contrast
video
fluoroscopi
technic
straightforward
signific
individu
variat
seen
dog
transit
time
three
ingesta
type
ingesta
consist
affect
transit
time
consist
allow
rapid
transit
time
vari
individu
mean
transit
time
liquid
min
dog
clearanc
liquid
min
mean
transit
time
meatbal
min
incomplet
clearanc
meatbal
minut
mean
transit
time
slurri
consist
min
test
dog
incomplet
clearanc
food
min
three
dog
identifi
gastroesophag
reflux
one
dog
found
concurr
swallow
disord
base
individu
imag
result
recommend
made
alter
manag
strategi
dog
chang
food
consist
chang
time
kept
upright
dog
alter
pharmacolog
therapi
fluoroscopi
perform
util
vertic
posit
modifi
bailey
chair
dog
provid
clear
inform
allow
individu
evalu
ideal
food
consist
anticip
behavior
ingest
water
overal
esophag
transit
time
ingest
food
materi
inform
permit
inform
decisionmak
regard
food
type
appear
best
individu
dog
whether
provid
drink
water
time
separ
feed
like
well
toler
long
dog
would
need
remain
vertic
posit
eat
drink
imag
also
allow
identif
concurr
disord
affect
food
toler
allow
specif
manag
strategi
major
dog
lack
simpl
wide
avail
test
assess
gastrointestin
motil
dog
make
diagnos
disord
difficult
ambulatori
lightbas
imag
easi
use
novel
gastrointestin
imag
techniqu
perform
oral
administr
fulli
autom
capsules
camera
devic
alicam
propel
natur
peristalsi
time
requir
passag
capsul
stomach
small
intestin
determin
base
correl
imag
intern
clock
aim
studi
evalu
feasibl
use
alicam
measur
gastric
transit
time
gtt
small
intestin
transit
time
stt
healthi
dog
studi
subject
clinic
healthi
dog
year
age
weigh
kg
dog
fast
hour
hour
capsul
administr
imag
download
independ
review
boardcertifi
internist
review
determin
gtt
stt
reproduc
result
compar
review
median
minmax
gtt
minut
median
minmax
stt
minut
agreement
among
review
intraclass
correl
coeffici
gtt
stt
respect
upper
limit
confid
interv
gtt
stt
healthi
dog
minut
respect
ambulatori
lightbas
imag
use
assess
gastrointestin
transit
time
healthi
dog
studi
need
determin
role
dog
gastrointestin
diseas
ambulatori
lightbas
imag
gastrointestin
imag
techniqu
perform
oral
administr
fulli
autom
camera
devic
contain
capsul
alicam
propel
natur
peristalsi
gastric
transit
time
gtt
determin
visual
capsul
passag
stomach
duodenum
correl
imag
clock
function
devic
aim
studi
use
alicam
system
compar
gtt
healthi
dog
gtt
sick
dog
clinic
sign
could
consist
gastric
hypomotil
studi
popul
consist
group
clinic
healthi
dog
group
dog
retch
regurgit
andor
vomit
dog
fast
hour
hour
capsul
administr
studi
review
boardcertifi
internist
case
gtt
determin
wilcoxin
rank
sum
test
use
compar
two
group
median
gtt
minmax
healthi
dog
minut
median
minmax
gtt
sick
dog
minut
sick
dog
capsul
remain
stomach
durat
studi
minut
record
time
repres
minimum
gtt
gtt
sick
dog
significantli
longer
healthi
dog
p
result
studi
suggest
gastric
hypomotil
occur
subset
dog
present
retch
regurgit
andor
vomit
studi
need
determin
dog
would
benefit
prokinet
therapi
purpos
studi
test
safeti
feasibl
dispos
fulli
autom
ingest
camera
system
imag
gastrointestin
tract
ambulatori
dog
five
ambulatori
lightbas
imag
ali
devic
construct
contain
within
transluc
mm
capsul
key
compon
batteri
light
sourc
autofocus
camera
intern
memori
system
microprocessor
acceleromet
synchron
camera
activ
devic
motion
five
clientown
dog
food
restrict
hour
hour
capsul
administr
capsul
administ
use
direct
pill
techniqu
normal
activ
access
water
permit
throughout
studi
recoveri
capsul
inspect
damag
imag
download
independ
review
three
boardcertifi
internist
capsul
success
administ
dog
recov
within
hour
advers
event
median
minmax
studi
durat
hour
capsul
record
median
minmax
imag
median
minmax
gastric
small
intestin
transit
time
minut
minut
respect
visual
mucosa
imag
qualiti
describ
excel
stomach
small
bowel
colon
poorli
imag
due
retain
fece
ali
safe
feasibl
dog
produc
high
qualiti
imag
throughout
major
gastrointestin
tract
visual
colon
might
feasibl
addit
prepar
noninvas
techniqu
may
expand
role
imag
dog
gastrointestin
sign
number
studi
demonstr
poor
correl
histopatholog
clinic
sever
chronic
enteropathi
dog
well
potenti
contribut
variou
immunohistochem
ihc
marker
enhanc
interpret
intestin
biopsi
although
standard
score
system
develop
felin
enteropathi
use
clinic
paramet
histopatholog
sever
similar
investig
includ
util
ihc
marker
yet
perform
cat
purpos
studi
identifi
correl
histopatholog
sever
immunohistochem
marker
clinic
score
cat
chronic
enteropathi
modifi
felin
chronic
enteropathi
activ
index
score
fceai
standard
panel
gastrointestin
serum
paramet
standard
quantif
histopatholog
quantit
fecal
score
group
immunohistochem
ihc
marker
determin
cat
present
sign
consist
chronic
enteropathi
studi
particip
clientown
popul
cat
experienc
diarrhea
andor
vomit
least
durat
evid
nongastrointestin
diseas
base
histori
physic
examin
biochem
profil
complet
blood
count
urinalysi
total
fpli
ftli
endoscopi
biopsi
histopatholog
small
intestin
part
diagnost
workup
serum
cobalamin
folat
concentr
also
determin
histopatholog
grade
ihc
quantif
perform
singl
board
certifi
pathologist
blind
addit
inform
regard
case
immunohistochemistri
perform
identifi
preval
cellular
stain
tgfb
degre
cellular
stain
measur
random
separ
area
valu
averag
give
final
immunohistochem
score
particular
marker
biochem
paramet
fceai
score
histopatholog
grade
score
test
normal
use
kolmogorovsmirnov
test
sinc
vast
major
data
normal
distribut
nonparametr
statist
use
analysi
nonlinear
regress
analysi
demonstr
signific
posit
correl
fceai
score
ihc
marker
tgfbeta
r
p
r
p
r
p
mac
r
p
histopatholog
sever
score
found
signific
neg
correl
ihc
tgfbeta
r
p
fox
r
p
signific
posit
correl
r
p
mac
studi
fail
demonstr
signific
correl
histopatholog
sever
score
either
fecal
score
modifi
fceai
score
index
dog
appear
absenc
signific
correl
histolog
sever
clinic
score
clinic
sever
index
fecal
score
cat
chronic
enteropathi
signific
correl
howev
identifi
novel
set
ihc
marker
histopatholog
clinic
sever
score
pathophysiolog
relev
clinic
util
marker
remain
determin
exocrin
pancreat
insuffici
epi
dog
character
maldigest
result
inadequ
synthesi
secret
pancreat
enzym
previou
studi
shown
dog
epi
small
intestin
dysbiosi
sid
may
requir
concurr
antibiot
therapi
addit
pancreat
enzym
replac
therapi
human
patient
short
bowel
syndrom
also
character
maldigest
sid
report
increas
fecal
lactat
concentr
therefor
aim
studi
compar
abund
lactic
acidproduc
bacteria
dand
llactat
concentr
fece
healthi
dog
n
dog
undergo
enzym
replac
therapi
epi
n
untreat
dog
epi
n
inclus
criteria
dog
epi
serum
ctli
concentr
age
year
clinic
sign
epi
concurr
diseas
healthi
dog
clinic
sign
gastrointestin
diseas
fecal
sampl
obtain
three
consecut
day
pool
dna
extract
use
isol
kit
mobio
laboratori
analysi
lactic
acid
produc
bacteria
quantit
pcr
fecal
sampl
deprotein
fecal
dand
llactat
measur
enzymat
method
rbiopharm
dllactic
acid
kit
kruskalw
test
follow
dunn
posttest
use
compar
lactat
concentr
bacteri
abund
group
statist
signific
set
p
dlactat
significantli
increas
treat
median
lactobacillu
bifidobacterium
significantli
increas
treat
p
p
respect
untreat
dog
p
p
respect
epi
compar
healthi
control
conclus
studi
suggest
fecal
dand
llactat
increas
dog
exocrin
pancreat
insuffici
regardless
enzym
replac
treatment
statu
also
lactateproduc
bacteri
group
alter
dog
epi
compar
healthi
control
dog
betahydroxybutyr
bhb
keton
bodi
synthes
liver
acetyl
coa
util
energi
sourc
glucos
suppli
limit
bhb
demonstr
play
role
oxid
stress
respons
bind
histon
deacetylas
suppress
inflammatori
diseas
antagon
cryopyrin
inflammasom
previou
untarget
metabolom
studi
human
canin
patient
idiopath
inflammatori
bowel
diseas
shown
significantli
higher
serum
concentr
bhb
diseas
patient
healthi
control
suggest
bhb
may
use
biomark
inflammatori
bowel
diseas
studi
investig
serum
bhb
concentr
healthi
dog
dog
two
type
chronic
enteropathi
food
respons
diarrhea
steroidrespons
diarrhea
serum
sampl
dog
food
respons
diarrhea
frd
n
steroid
respons
diarrhea
srd
n
group
healthi
control
dog
n
use
sampl
surplu
materi
previou
studi
dog
diagnos
food
respons
steroid
respons
diarrhea
base
respons
treatment
serum
concentr
bhb
measur
serum
sampl
use
colorimetr
assay
kit
betahydroxybutyr
colorimetr
assay
kit
cayman
chemic
kruskalw
perform
compar
serum
concentr
group
median
serum
bhb
concentr
minimummaximum
mmoll
healthi
dog
mmoll
dog
srd
mmoll
dog
frd
signific
differ
three
group
p
result
suggest
serum
concentr
bhb
significantli
increas
dog
chronic
enteropathi
compar
healthi
dog
object
studi
examin
influenc
kidney
function
indic
serum
creatinin
level
serum
acid
methylresorufin
ester
dggr
lipas
pancreat
lipas
immunoreact
pli
cat
use
electron
record
search
cat
identifi
serum
biochemistri
profil
order
ontario
veterinari
colleg
januari
april
serum
creatinin
measur
anim
health
laboratori
ahl
univers
guelph
enzymat
uv
method
randox
coba
analyz
roch
diagnost
serum
lipas
measur
ahl
dggr
colorimetr
assay
coba
analyz
case
aliquot
serum
sampl
submit
spec
fpl
idexx
laboratori
markham
laboratori
result
retriev
correspond
medic
record
review
data
obtain
record
includ
avail
hydrat
statu
bodi
condit
score
assess
attend
clinician
data
first
assess
independ
event
analyz
result
first
serum
biochemistri
profil
obtain
cat
n
median
lipas
valu
group
cat
creatinin
valu
refer
interv
n
ul
rang
ul
higher
p
median
lipas
valu
ul
rang
ul
group
cat
creatinin
valu
n
although
rang
overlap
substanti
trend
p
observ
pli
respect
group
median
rang
cat
creatinin
n
median
rang
cat
creatinin
n
signific
weak
correl
creatinin
lipas
valu
across
cat
p
n
correl
present
group
cat
creatinin
valu
n
correl
creatinin
pli
multivari
linear
regress
use
assess
influenc
creatinin
hydrat
bodi
condit
lipas
cat
inform
avail
n
none
variabl
demonstr
signific
effect
p
creatinin
hydrat
bodi
condit
respect
data
next
assess
manova
variat
time
within
individu
cat
repeat
serum
biochemistri
medic
record
data
avail
n
hydrat
demonstr
signific
effect
creatinin
p
trend
toward
effect
lipas
p
creatinin
demonstr
relationship
lipas
p
pli
repeat
cat
valu
move
direct
creatinin
case
data
indic
kidney
function
mild
effect
dggrlipas
level
cat
may
part
due
hydrat
statu
studi
may
underpow
show
effect
analys
pli
creatinin
may
underestim
decreas
kidney
function
underweight
cat
affect
result
overal
weak
associ
creatinin
lipas
creatinin
pli
suggest
elev
lipas
pli
attribut
sole
decreas
kidney
function
azotem
cat
may
magnitud
increas
lipas
pli
pancreat
disord
overwhelm
magnitud
effect
kidney
function
preval
pathogen
role
differ
speci
helicobact
dog
definit
document
date
prospect
studi
includ
privat
own
dog
preval
gastric
helicobact
speci
associ
gastric
lesion
determin
accuraci
differ
diagnost
techniqu
compar
inclus
criteria
consist
chronic
gi
clinic
sign
vomit
diarrhea
anorexia
weight
loss
exclus
nongi
diseas
discontinu
medic
least
week
biopsi
specimen
obtain
gastroduodenoscopi
helicobact
speci
remain
undetermin
patient
hp
found
anim
examin
dog
endoscop
appear
gastric
mucosa
normal
overal
common
endoscop
lesion
eros
ulcer
increas
granular
gastric
mucosa
gastriti
diagnos
histolog
dog
posit
helicobact
spp
dog
without
evid
helicobact
colon
sever
lymphocyticplasmacyt
gastriti
acut
purulentnecrot
gastriti
found
singl
hb
infect
moder
lymphocyticplasmacyt
gastriti
singl
hh
ss
infect
associ
presenc
mix
infect
includ
hh
ss
hb
lower
sever
gastric
inflamm
detect
compar
singl
helicobact
speci
infect
larg
studi
evalu
associ
individu
helicobact
speci
histolog
confirm
gastriti
dog
dog
frequent
colon
helicobact
spp
hp
may
repres
reservoir
human
infect
nonhp
helicobact
spp
combin
cytolog
rapid
ureas
test
perform
gastric
biopsi
sampl
repres
reliabl
diagnost
method
suitabl
clinic
practic
competit
inhibit
may
occur
helicobact
speci
simultan
detect
gastric
biopsi
presenc
one
helicobact
speci
may
interfer
virul
helicobact
speci
ambulatori
lightbas
imag
ali
new
imag
modal
allow
noninvas
endolumin
visual
gastrointestin
mucosa
ali
perform
oral
administr
capsul
contain
fulli
autom
camera
alicam
propel
natur
peristalsi
capsul
retriev
dog
fece
imag
download
familiar
normal
abnorm
find
essenti
accur
interpret
studi
yet
document
veterinari
patient
aim
studi
present
galleri
normal
abnorm
imag
canin
gastrointestin
tract
use
alicam
alicam
studi
dog
evalu
retrospect
boardcertifi
internist
averag
studi
consist
imag
obtain
hour
patient
evalu
includ
dog
clinic
sign
gastrointestin
diseas
asymptomat
dog
patient
rang
age
month
year
old
weight
kg
imag
repres
normal
mucosa
common
lesion
save
log
common
reason
alicam
administr
vomit
diarrhea
sign
gastrointestin
bleed
combin
sever
gastrointestin
sign
gastric
lesion
identifi
dog
gastrointestin
sign
includ
irregular
mucosa
polyp
ulcer
eros
mass
foreign
materi
small
intestin
lesion
identifi
includ
irregular
mucosa
dilat
lacteal
ulcer
eros
mass
parasit
tapeworm
hookworm
colon
lesion
includ
mass
eros
establish
characterist
normal
abnorm
find
import
step
evolut
ali
diagnost
test
proteinlos
enteropathi
ple
document
variou
cardiac
diseas
ie
congest
heart
failur
constrict
pericard
congenit
heart
diseas
typic
relat
increas
interstiti
pressur
intestin
lymphangiectasia
human
fecal
proteinas
inhibitor
fa
pi
stabl
protein
lost
gastrointestin
tract
rate
compar
albumin
therefor
serv
endogen
marker
gastrointestin
protein
loss
ple
suspect
dog
cardiac
diseas
publish
studi
avail
aim
studi
evalu
fa
pi
concentr
dog
varieti
cardiac
diseas
singl
natur
void
fecal
sampl
adult
dog
year
age
puppi
year
age
collect
dog
congenit
acquir
cardiac
diseas
two
dog
one
puppi
one
adult
serial
fecal
evalu
ie
occlus
patent
ductu
arteriosu
pda
amplatz
canin
ductal
occlud
acdo
devic
dog
studi
echocardiogram
perform
board
certifi
cardiologist
resid
supervis
board
certifi
cardiologist
fecal
sampl
frozen
upon
collect
fa
pi
concentr
measur
use
inhous
radioimmunoassay
compar
establish
refer
interv
healthi
adult
dog
fa
pi
concentr
lgg
fece
consid
abnorm
three
adult
dog
congenit
cardiac
diseas
increas
fa
pi
concentr
median
minimum
maximum
lgg
fece
also
nine
puppi
congenit
heart
dieas
increas
fa
pi
concentr
median
minimum
maximum
lgg
fece
dog
multipl
congenit
heart
defect
echocardiograph
evalu
also
sever
cardiac
diseas
vari
patient
two
pda
dog
sampl
two
time
point
avail
reduct
fa
pi
concentr
post
coil
embol
lgg
fece
puppi
lgg
fece
adult
increas
fa
pi
concentr
puppi
interpret
caution
higher
fa
pi
concentr
report
previous
puppi
specif
refer
interv
puppi
establish
limit
studi
includ
small
number
dog
lack
intestin
biopsi
rule
caus
increas
gastrointestin
protein
loss
lack
multipl
fecal
sampl
account
day
day
variabl
fa
pi
concentr
report
earlier
varieti
cardiac
diseas
lack
complet
serum
chemistri
profil
dog
howev
studi
show
fa
pi
concentr
may
increas
subset
dog
cardiac
diseas
prospect
studi
need
establish
increas
fa
pi
concentr
dog
occur
consist
congenit
heart
diseas
increas
dog
acquir
heart
diseas
increas
interstiti
pressur
elev
influenc
treatment
prognosi
clinic
use
mesenchym
stem
cell
msc
therapi
may
optim
precondit
method
would
enhanc
immunomodulatori
function
investig
effect
precondit
strategi
cytokin
product
femal
canin
adiposederiv
msc
may
optim
clinic
effect
msc
applic
speci
adiposederiv
msc
gener
healthi
adult
femal
dog
subject
condit
supernat
harvest
hour
level
cytokin
present
supernat
determin
elisa
tgfb
releas
measur
level
within
hour
period
test
cultur
condit
larg
amount
ngml
vegf
ngml
small
amount
pgml
constitut
produc
cell
hour
precondit
strategi
except
tgfb
alter
measur
cytokin
product
msc
control
level
hour
poli
c
increas
secret
ifnc
increas
decreas
vegf
secret
serumfre
decreas
vegf
secret
mix
hypox
environ
inhibit
vegf
secret
chang
cytokin
secret
evid
hour
time
point
maxim
level
hour
suggest
hour
cultur
period
suffici
induc
relev
chang
msc
cytokin
secret
initi
studi
show
specif
precondit
method
hold
promis
tailor
augment
canin
msc
immunomodulatori
properti
treat
specif
diseas
although
studi
necessari
current
go
thrombin
play
central
role
hemostasi
thrombosi
involv
vivo
hemostat
pathway
calibr
autom
thrombographi
cat
thrombin
gener
assay
may
therefor
valid
physiolog
test
hemostat
disord
dog
object
establish
refer
interv
cat
thrombin
gener
assess
effect
preanalyt
biolog
variabl
assay
healthi
dog
lag
time
lag
time
peak
ttpeak
peak
thrombin
gener
peak
endogen
thrombin
potenti
etp
measur
clinic
healthi
dog
direct
jugular
venipunctur
wingedneedl
catheterassist
saphen
venipunctur
use
collect
sampl
dog
storag
stabil
assess
month
subset
sampl
biolog
variabl
cat
assess
via
nest
anova
use
sampl
obtain
weekli
dog
consecut
week
sampl
cat
analysi
stabl
month
sampl
collect
via
wingedneedl
cathet
venipunctur
show
poor
repeat
compar
direct
venipunctur
sampl
also
poor
agreement
two
sampl
method
intraindividu
variabl
cat
variabl
low
interindividu
variabl
rang
analyt
precis
goal
met
ttpeak
peak
etp
indic
individu
rang
conclus
thrombin
gener
seem
stabl
repeat
healthi
dog
direct
venipunctur
sampl
recommend
cat
indic
individu
low
cat
variabl
suggest
limit
util
populationbas
refer
interv
assay
method
object
quantif
clinic
bleed
canin
immunemedi
thrombocytopenia
itp
need
itp
patient
variabl
bleed
tendenc
directli
relat
sever
thrombocytopenia
consist
descript
bleed
would
allow
direct
comparison
bleed
heterogen
multiinstitut
studi
applic
standard
bleed
assess
tool
would
help
stratifi
itp
patient
clinic
trial
base
bleed
sever
provid
object
comparison
patient
outcom
among
treatment
protocol
studi
aim
develop
valid
daili
canin
itp
bleed
assess
tool
dogibat
evalu
util
train
cours
improv
accur
implement
dogibat
novel
bleed
assess
tool
dogibat
develop
canin
itp
compris
nine
differ
anatom
sitespecif
bleed
grade
rang
none
sever
onlin
train
cours
develop
applic
dogibat
score
clinic
case
casebas
quiz
set
still
imag
use
assess
traine
abil
appli
dogibat
tool
addit
assess
efficaci
train
cours
veterinari
student
volunt
random
take
quiz
n
without
n
train
student
score
site
case
site
score
consid
correct
agre
investig
prespecifi
classif
frequenc
correct
score
compar
train
untrain
student
logist
regress
model
use
assess
associ
train
score
adjust
correl
respons
site
within
case
clinician
n
technician
n
take
quiz
follow
train
abl
correctli
appli
dogibat
score
respons
correctli
respons
student
receiv
train
correctli
score
compar
respons
student
receiv
train
odd
train
student
give
correct
answer
higher
untrain
student
p
anatom
site
train
import
correct
score
oral
bleed
train
without
p
similarli
score
ocular
train
without
p
cutan
bleed
train
without
p
improv
train
cours
student
clinic
experi
better
abl
appli
dogibat
correctli
fourth
year
third
year
p
studi
suggest
dogibat
simpl
score
tool
classif
bleed
sever
dog
itp
short
onlin
train
cours
shown
improv
accuraci
consist
dogibat
score
adopt
dogibat
score
system
futur
clinic
trial
canin
itp
patient
facilit
rigor
assess
treatmenteffect
base
standard
bleed
outcom
aspirin
commonli
use
effort
prevent
thrombu
format
dog
highdos
aspirin
mgkg
po
q
h
reliabl
inhibit
platelet
function
thromboxan
txa
synthesi
associ
unaccept
side
effect
includ
inhibit
prostacyclin
synthesi
counteract
effect
inhibit
txa
lower
dose
aspirin
contrast
inhibit
platelet
function
txa
synthesi
side
effect
allow
ongo
prostacyclin
synthesi
howev
lowdos
aspirin
therapi
standard
dosag
mgkg
po
q
h
reliabl
inhibit
platelet
function
phenomenon
known
aspirin
resist
aspirinassoci
platelet
dysfunct
shown
highli
dosedepend
suggest
tradit
lowdos
aspirin
may
underdos
canin
patient
studi
use
increment
increas
dosag
determin
dose
aspirin
consist
inhibit
platelet
function
txa
synthesi
without
inhibit
prostacyclin
synthesi
eight
healthi
adult
research
dog
separ
one
group
group
given
differ
oral
dose
aspirin
dose
mgkg
h
dose
b
mgkg
h
dose
c
mgkg
h
dose
mgkg
h
dose
e
mgkg
h
prior
aspirin
therapi
day
one
week
day
drug
administr
blood
urin
collect
assess
platelet
function
turbidimetr
aggregometri
closur
time
urin
b
stabl
metabolit
txa
f
stabl
metabolit
prostacyclin
synthesi
dog
consid
aspirin
respond
reduct
maxim
amplitud
aggregometri
day
closur
time
second
aggregometri
dose
ae
mean
decreas
maximum
amplitud
respect
compar
day
signific
decreas
day
dose
maximum
amplitud
decreas
indic
aspirin
respons
dog
receiv
dose
c
greater
similar
aggregometri
closur
time
day
compar
day
signific
increas
dose
day
dose
ae
mean
closur
time
second
indic
aspirin
respons
respect
compar
day
signific
decreas
day
concentr
p
p
howev
chang
depend
aspirin
dose
result
studi
suggest
aspirin
dose
mg
kg
po
h
reliabl
inhibit
platelet
function
normal
dog
base
establish
gold
standard
assay
platelet
aggregometri
addit
even
though
aspirin
dose
inhibit
prostacyclin
synthesi
degre
differ
prostacyclin
concentr
dose
mgkg
po
h
tradit
use
lower
dose
base
result
increas
standard
aspirin
lowdos
mgkg
po
h
may
minim
risk
aspirin
resist
dog
critic
need
biomark
differenti
activ
primari
immun
mediat
thrombocytopenia
pitp
secondari
caus
thrombocytopenia
concentr
correl
diseas
statu
dog
biomark
would
provid
valuabl
diagnost
tool
modul
therapi
evalu
risk
relaps
reduc
patient
exposur
potenti
harm
immunosuppress
medic
b
cell
activ
factor
baff
cytokin
within
tumor
necrosi
factor
famili
play
crucial
role
b
cell
matur
surviv
class
switch
increas
concentr
baff
mice
peopl
link
immunemedi
diseas
system
lupu
erythematosu
rheumatoid
arthriti
itp
central
hypothesi
baff
product
significantli
specif
increas
dog
untreat
pitp
purpos
pilot
studi
quantifi
compar
transcript
baff
blood
dog
untreat
pitp
dog
secondari
thrombocytopenia
healthi
control
dog
quantit
realtim
pcr
qrtpcr
use
assess
baff
mrna
express
total
rna
isol
dog
untreat
pitp
healthi
dog
dog
secondari
thrombocytopenia
pitp
defin
dog
platelet
count
cellsml
pcr
serolog
neg
babesia
ehrlichia
anaplasma
evid
neoplasia
abdomin
thorac
imag
histori
drug
administr
antibiot
corticosteroid
vaccin
chemotherapeut
secondari
thrombocytopen
control
dog
platelet
count
refer
interv
due
diagnos
pitp
healthi
dog
present
well
exam
normal
platelet
count
qrtpcr
perform
use
intronspan
primer
amplifi
base
pair
region
mrna
bactin
use
refer
gene
rel
mrna
express
baff
pitp
dog
increas
compar
healthi
control
dog
dog
secondari
thrombocytopenia
respect
p
figur
result
indic
rel
express
baff
mrna
increas
significantli
specif
dog
pitp
compar
healthi
dog
dog
caus
thrombocytopenia
similar
previou
find
peopl
thu
baff
may
use
biomark
distinguish
dog
pitp
caus
thrombocytopenia
use
primer
group
also
identifi
canin
macrophag
cell
line
express
baff
util
protein
identif
quantit
well
character
baff
mrna
splice
variant
dog
antiplatelet
drug
aspirin
asa
clopidogrel
may
use
effort
prevent
thromboembol
respons
drug
might
variabl
human
therefor
platelet
function
test
may
warrant
monitor
treatment
effect
studi
aim
evalu
effect
asa
clopidogrel
combin
therapi
healthi
laboratori
beagl
use
three
platelet
function
test
multipl
analyz
mp
platelet
function
pfa
plateletwork
pw
secondari
goal
comparison
pw
use
two
hematolog
analyz
vetscan
use
imped
advia
use
flow
cytometri
evalu
novel
innov
cartridg
pfa
evalu
clopidogrelinduc
platelet
inhibit
six
dog
given
asa
mgkgday
placebo
clopidogrel
mgkgday
placebo
combin
drug
week
drug
given
random
crossov
design
latin
squar
dog
random
one
three
treatment
three
differ
phase
dog
receiv
treatment
investig
blind
treatment
washout
period
week
occur
phase
blood
sampl
collect
day
phase
analyz
use
mp
adenosin
diphosph
adp
arachidon
acid
aa
collagen
col
agonist
pfa
coladp
colepinephrin
epi
cartridg
pw
adp
aa
col
agonist
tube
use
two
hematolog
analyz
signific
p
chang
mean
valu
pre
post
treatment
mp
area
curv
auc
unit
u
decreas
col
combin
therapi
pre
u
post
u
auc
decreas
aa
either
clopidogrel
pre
u
post
u
combin
therapi
pre
u
post
u
auc
decreas
adp
treatment
asa
pre
u
post
u
clopidogrel
pre
u
post
u
combin
pre
u
post
u
pfaclosur
time
ct
increas
cartridg
clopidogrel
pre
second
post
second
combin
therapi
pre
second
post
second
ct
increas
coladp
cartridg
clopidogrel
pre
second
post
second
combin
therapi
pre
second
post
second
ct
increas
colepi
cartridg
asa
pre
second
post
second
pw
use
analyz
aggreg
agg
aa
decreas
treatment
asa
pre
post
clopidogrel
pre
post
combin
pre
post
adp
agg
decreas
level
plasma
baff
mrna
healthi
dog
control
dog
secondari
thrombocytopenia
tp
dog
itp
ratio
baff
mrna
dog
itp
compar
secondari
thrombocytopenia
healthi
dog
respect
clopidogrel
pre
post
combin
therapi
pre
post
pw
result
advia
show
almost
perfect
agreement
kappa
although
result
reveal
chang
mean
valu
treatment
result
variabl
individu
dog
test
everi
dog
individu
valu
follow
chang
mean
valu
mp
col
combin
therapi
pfa
cartridg
clopidogrel
combin
therapi
pw
adp
clopidogrel
combin
therapi
pw
aa
treatment
three
platelet
function
test
detect
asa
clopidogrel
effect
dog
may
util
monitor
antiplatelet
therapi
cartridg
superior
coladp
cartridg
detect
clopidogrel
effect
pfa
pw
perform
either
vetscan
advia
pw
use
aa
test
detect
drug
effect
vaccin
suggest
caus
initi
develop
relaps
immunemedi
thrombocytopenia
itp
although
relationship
definit
establish
dog
studi
aim
identifi
case
canin
primari
itp
vaccin
cessat
treatment
assess
vaccin
case
show
sign
relaps
record
anim
diagnos
itp
retrospect
review
multidisciplinari
hospit
case
includ
diagnosi
presumpt
primari
itp
made
platelet
count
l
ref
dog
diagnos
secondari
itp
exclud
case
assess
underli
diseas
minimum
investig
requir
compris
full
haematolog
biochem
assess
includ
blood
film
evalu
abdomin
ultrasonographi
thorac
radiographi
infecti
diseas
pcr
test
also
perform
case
discret
clinician
involv
refer
veterinari
practic
contact
followup
inform
regard
length
treatment
ongo
vaccin
protocol
includ
date
vaccin
administ
surviv
data
requir
one
hundr
fortysix
thrombocytopen
dog
identifi
dog
surviv
discharg
sixtyeight
dog
exclud
due
detect
underli
infecti
neoplast
diseas
dog
presumpt
itp
lost
followup
dog
still
receiv
prednisolon
immunosuppress
agent
four
dog
remain
longterm
prednisolon
due
relaps
dose
taper
dog
remiss
immunosuppress
treatment
withdrawn
receiv
vaccin
diagnosi
none
dog
show
sign
relaps
followup
period
remain
dog
receiv
least
one
vaccin
minimum
one
month
discontinu
immunosuppress
treatment
one
dog
initi
relaps
earli
treatment
cours
prompt
longer
treatment
protocol
withdraw
treatment
none
dog
receiv
vaccin
immunosuppress
treatment
withdrawn
show
sign
relaps
includ
receiv
multipl
vaccin
sever
year
vaccin
administ
includ
combin
core
booster
intranas
vaccin
bordetella
bronchiseptica
one
dog
receiv
rabi
booster
travel
result
fail
show
associ
relaps
presumpt
primari
itp
dog
vaccin
although
possibl
exclud
futur
studi
assess
higher
number
dog
would
requir
assess
potenti
associ
aspirin
acetylsalicyl
acid
asa
cyclooxygenas
inhibitor
prevent
synthesi
hemostat
activ
prostaglandin
low
dose
aspirin
use
inhibit
platelet
function
ultim
thrombu
format
human
patient
appear
nonrespons
antiplatelet
effect
term
aspirin
resist
phenomenon
identifi
dog
could
contribut
factor
format
thromboemboli
risk
patient
accur
predict
aspirin
respons
prior
treatment
could
prevent
inappropri
drug
therapi
devast
thrombu
format
otherwis
manag
diseas
object
studi
determin
whether
asa
concentr
need
caus
inhibit
platelet
aggreg
measur
use
dog
blood
collect
asa
treatment
ie
vitro
could
use
predict
valu
measur
dog
administr
lowdos
oral
aspirin
ie
vivo
twenti
clientown
healthi
dog
util
studi
vitro
test
perform
two
separ
occas
least
week
apart
determin
individu
repeat
blood
incub
six
concentr
aspirin
aggreg
measur
use
multipl
electrod
imped
aggregomet
multipl
instrument
vivo
test
perform
least
week
vitro
test
dog
receiv
singl
dose
mgkg
aspirin
oral
aggreg
assess
baselin
prior
administr
minut
minut
minut
administr
addit
plasma
concentr
asa
salicyl
acid
sa
measur
time
point
use
liquid
chromatographymass
spectrometri
lcm
sa
major
asa
metabolit
may
better
indic
asa
exposur
bioavail
asa
calcul
vitro
allow
dog
separ
four
differ
respons
group
sixteen
dog
vitro
valu
umol
consist
appropri
aspirin
respons
mean
ae
sd
rang
valu
ae
umol
valu
evalu
repeat
mean
differ
found
highest
differ
independ
measur
dog
one
dog
show
consist
poor
respons
vitro
valu
umol
time
measur
two
dog
substanti
variat
vitro
valu
two
time
point
classifi
variabl
respond
one
addit
dog
show
signific
inhibit
platelet
aggreg
time
asa
concentr
umol
classifi
nonrespond
vivo
aspirin
dose
mgkg
caus
measur
inhibit
platelet
aggreg
dog
singl
dose
time
point
vivo
could
establish
base
find
inhibit
never
achiev
dose
plasma
asa
sa
concentr
avail
dog
mean
ae
sd
rang
maximum
plasma
concentr
cmax
asa
ae
umol
sa
ae
umol
two
dog
asa
concentr
detect
limit
umol
studi
suggest
individu
variat
aspirin
respons
exist
dog
assess
multipl
electrod
aggregometri
singl
low
dose
mgkg
aspirin
suffici
caus
measur
inhibit
platelet
aggreg
healthi
dog
result
asa
sa
concentr
substanti
less
vitro
lowdos
mgkg
aspirin
therapi
may
reliabl
antithrombot
therapi
singl
dose
thu
necessit
potenti
need
addit
therapi
first
hour
research
look
higher
oral
aspirin
dose
multipl
day
dose
warrant
better
establish
vivo
determin
predict
valu
vitro
determin
prior
commenc
therapi
differenti
intestin
lymphoma
inflammatori
bowel
diseas
ibd
diagnost
challeng
anemia
frequent
paraneoplast
syndrom
dog
lymphoma
eccentrocyt
also
report
canin
lymphoma
purpos
studi
assess
preval
anemia
variou
rbc
morpholog
anomali
peripher
blood
dog
diagnosi
lymphoma
ibd
determin
associ
specif
diseas
sever
lymphoma
medic
record
dog
diagnos
form
lymphoma
dog
diagnos
ibd
control
dog
present
centr
hospitali
universitair
v
et
erinair
retrospect
review
blood
smear
blindli
reassess
boardcertifi
pathologist
comparison
follow
group
healthi
dog
dog
ibd
dog
lymphoma
well
within
lymphoma
group
stage
versu
substag
versu
b
small
versu
intermediatelarg
cell
perform
follow
hematolog
paramet
hematocrit
hemoglobin
erythrocyt
count
mean
corpuscular
volum
mean
corpuscular
hemoglobin
concentr
total
number
specif
rbc
anomali
compar
group
rbc
morpholog
anomali
also
categor
underli
patholog
process
regen
anemia
oxid
stress
morpholog
chang
compar
group
preval
anemia
significantli
higher
dog
lymphoma
dog
ibd
p
healthi
dog
p
significantli
higher
stage
lymphoma
compar
stage
p
significantli
higher
total
number
rbc
morpholog
anomali
peripher
blood
dog
lymphoma
compar
dog
ibd
p
healthi
dog
p
dog
substag
b
lymphoma
also
higher
preval
total
rbc
morpholog
anomali
compar
substag
p
categor
patholog
etiolog
dog
lymphoma
significantli
higher
number
rbc
anomali
associ
regen
anemia
p
oxid
stress
p
rbc
anomali
p
compar
healthi
dog
signific
differ
compar
dog
ibd
preval
eccentrocyt
significantli
higher
dog
lymphoma
compar
ibd
p
well
healthi
dog
p
differ
note
small
intermedi
larg
cell
lymphoma
paramet
studi
conclus
observ
anemia
increas
total
number
rbc
morpholog
anomali
blood
smear
specif
presenc
eccentrocyt
could
increas
clinic
suspicion
lymphoma
compar
ibd
dog
suggest
clinic
present
canin
felin
xenotransfus
increasingli
report
veterinari
literatur
temporari
question
effect
mean
address
life
threaten
anemia
recipi
cat
studi
conduct
determin
invitro
compat
felin
red
blood
cell
rbc
canin
sera
convers
canin
rbc
felin
sera
cat
dog
salin
assess
initi
conduct
determin
preexist
autoagglutin
exist
major
minor
cross
match
perform
major
defin
felin
sera
canin
rbc
minor
defin
felin
rbc
canin
sera
cross
match
perform
via
manual
techniqu
degre
centigrad
end
assess
incompat
base
score
assess
macroscop
microscop
agglutin
andor
hemolysi
rbc
first
group
cross
match
consist
blood
type
cat
five
dog
dog
select
compris
broad
spectrum
dog
erythrocyt
antigen
dea
possibl
cat
major
minor
cross
match
five
dog
three
temperatur
total
data
point
none
cross
match
compat
incompat
expand
databas
canin
bloodtyp
second
novel
group
seven
blood
type
cat
major
minor
cross
match
ten
dog
five
dog
cohort
first
set
cross
match
data
yield
data
point
assess
compat
similar
first
data
set
none
cross
match
compat
incompat
data
suggest
inher
incompat
dog
cat
blood
regardless
compon
test
clinician
contempl
canin
felin
xenotransfus
cautiou
util
techniqu
even
presenc
life
threaten
anemia
jame
swann
julia
wu
barbara
glanemann
oliv
garden
royal
veterinari
colleg
london
uk
wherea
clinic
featur
immunemedi
hemolyt
anemia
imha
describ
extens
dog
immunolog
phenotyp
diseas
yet
fulli
character
hypothes
phenotyp
would
differ
dog
primari
imha
dog
inflammatori
diseas
immunemedi
etiolog
serum
edtaanticoagul
blood
sampl
collect
healthi
control
dog
hc
dog
primari
imha
imha
dog
inflammatori
diseas
inf
dog
consid
primari
imha
anem
hematocrit
less
fulfil
one
follow
criteria
signific
spherocytosi
fresh
blood
smear
persist
agglutin
erythrocyt
dilut
salin
titer
greater
direct
antiglobulin
test
dog
exclud
underli
caus
diseas
detect
serum
biochem
test
imag
thorax
abdomen
test
infecti
agent
dog
inf
group
diseas
consid
immunemedi
etiolog
previou
histori
autoimmun
diseas
dog
hc
group
previou
histori
autoimmun
diseas
unremark
physic
examin
owner
dog
consent
collect
use
sampl
studi
approv
institut
ethic
review
committe
lysi
red
blood
cell
peripher
blood
mononuclear
cell
pbmc
stain
fluorophoreconjug
antibodi
specif
analyz
flow
cytometri
identifi
major
lymphocyt
subset
total
rna
extract
pbmc
quantit
revers
transcriptas
polymeras
chain
reaction
use
primer
three
refer
gene
interferon
gamma
ifnc
interleukin
il
serum
concentr
five
cytokin
tnfa
measur
use
enhanc
chemiluminesc
assay
result
complet
blood
cell
count
serum
biochem
profil
record
inf
imha
case
sampl
obtain
imha
dog
addit
hc
inf
dog
group
similar
age
sex
distribut
differ
proport
regulatori
cell
helper
cell
cytotox
cell
group
p
serum
concentr
p
tnfa
p
significantli
greater
imha
dog
compar
either
group
serum
concentr
p
p
significantli
greater
imha
dog
compar
hc
differ
compar
inf
group
differ
group
serum
concentr
p
rel
express
p
ifnc
p
princip
compon
analysi
reveal
three
major
factor
underli
variabl
dataset
one
posit
correl
tnfa
blood
monocyt
count
serum
total
bilirubin
concentr
neg
correl
hematocrit
differ
imha
inf
dog
p
immunophenotyp
dog
imha
reveal
increas
concentr
proinflammatori
cytokin
compar
hc
inf
dog
character
factor
explain
variabl
paramet
suggest
develop
differ
underli
inflammatori
process
imha
inf
group
work
requir
determin
whether
chang
associ
surviv
whether
intervent
amelior
effect
tnfa
might
improv
outcom
dog
imha
leflunomid
immunomodul
agent
label
treatment
rheumatoid
arthriti
psoriat
arthriti
human
drug
inhibit
synthesi
ribonucleotid
uridin
monophosph
pyrimidin
ultim
lessen
lymphocyt
replic
effect
could
benefit
treatment
varieti
immun
mediat
diseas
dog
pharmacokinet
leflunomid
known
dog
drug
suppress
lymphocyt
prolifer
speci
howev
littl
clinic
inform
concern
use
drug
dog
avail
purpos
retrospect
studi
report
safeti
efficaci
leflunomid
treatment
natur
occur
immun
mediat
diseas
dog
medic
record
usa
veterinari
teach
hospit
retrospect
search
dog
immun
mediat
diseas
administ
leflunomid
data
extract
medic
record
includ
signal
bodyweight
underli
indic
leflunomid
dose
leflunomid
treatment
durat
concurr
medic
treatment
respons
advers
event
dog
immun
mediat
polyarthr
impa
assess
respons
treatment
basi
clinic
sign
impa
physic
examin
find
dog
immun
mediat
thrombocytopenia
imtp
assess
respons
treatment
base
platelet
count
dog
cutan
histiocytosi
ch
assess
treatment
respons
basi
gross
appear
skin
lesion
total
case
includ
mean
dose
leflunomid
ae
mgkgday
median
durat
use
leflunomid
week
advers
event
could
relat
leflunomid
administr
includ
diarrhea
lethargi
suspect
blood
dyscrasia
thrombocytopenia
increas
liver
enzym
activ
leflunomid
discontinu
due
possibl
advers
event
dog
signific
dose
differ
dog
advers
event
n
ae
mgkgday
dog
without
advers
event
n
ae
mgkgday
found
p
treatment
respons
could
evalu
dog
suspect
impa
dog
imtp
dog
ch
dog
impa
dog
imtp
dog
ch
receiv
leflunomid
without
administr
concurr
immunosuppress
drug
six
dog
imtp
receiv
leflunomid
concurr
immunosuppress
drug
dose
unchang
leflunomid
ad
treatment
dog
dog
dog
impa
dog
imtp
dog
ch
appar
posit
respons
use
leflunomid
signific
differ
p
dose
dog
respond
leflunomid
ae
mgkg
day
respond
ae
mgkgday
lower
start
dose
leflunomid
mgkgday
current
suggest
dose
leflunomid
mgkgday
recommend
base
find
studi
storag
blood
product
creat
unnatur
environ
acceler
product
degrad
pose
risk
recipi
eicosanoid
arachidon
acidderiv
bioactiv
molecul
involv
inflamm
accumul
insid
unit
pack
red
blood
cell
prbc
sinc
leukocyt
platelet
primari
sourc
eicosanoid
synthesi
within
unit
prbc
remov
cell
via
leukoreduct
may
decreas
eicosanoid
synthesi
potenti
reduc
risk
transfusionrel
complic
crossov
studi
unit
blood
collect
healthi
dog
half
unit
leukocyt
platelet
remov
via
leukoreduct
unit
prbc
creat
via
centrifug
store
day
initi
baselin
plasma
sampl
collect
process
storag
day
addit
sampl
collect
follow
storag
day
remov
refriger
hour
room
temperatur
simul
transfus
condit
concentr
ngml
arachidon
acid
aa
prostaglandin
e
pge
prostaglandin
pgd
prostaglandin
f
pgf
thromboxan
b
txb
stabl
metabolit
txa
f
stabl
metabolit
prostacyclin
leukotrien
b
ltb
quantifi
liquid
chromatographymass
spectrometri
differ
aa
pge
pgd
ltb
concentr
time
point
differ
concentr
leukoreduc
nonleukoreduc
unit
prior
storag
day
significantli
greater
concentr
txb
unit
leukoreduc
prbc
compar
nonleukoreduc
unit
leukoreduc
sampl
except
day
posttransfus
txb
concentr
decreas
compar
day
except
prestorag
sampl
differ
txb
concentr
leukoreduc
nonleukoreduc
unit
day
signific
increas
concentr
leukoreduc
nonleukoreduc
unit
differ
concentr
leukoreduc
nonleukoreduc
unit
except
day
post
transfus
sampl
leukoreduc
unit
increas
compar
nonleukoreduc
unit
prior
storag
pgf
concentr
significantli
greater
unit
leukoreduc
prbc
compar
nonleukoreduc
unit
howev
remain
time
point
pgf
concentr
decreas
compar
day
differ
leukoreduc
nonleukoreduc
unit
unit
prbc
leukoreduct
markedli
influenc
eicosanoid
concentr
gener
remov
platelet
white
cell
tend
decreas
product
eicosanoid
storag
eicosanoid
howev
effect
counteract
passag
blood
leukoreduct
filter
lead
mark
increas
eicosanoid
level
unit
prbc
prior
storag
studi
need
determin
impact
complex
effect
leukoreduct
eicosanoid
store
prbc
incid
transfus
reaction
dog
erythrocyt
antigen
dea
red
cell
membran
receptor
one
six
blood
group
describ
clinic
implic
recent
blood
type
unavail
antigen
previou
suppli
dea
antisera
exhaust
abil
creat
serious
hinder
novel
antisera
recent
discov
bring
back
abil
accur
blood
type
dea
antigen
proprietari
test
methodolog
develop
antisera
use
known
fact
dea
antigen
antisera
test
canin
previous
known
posit
dea
antigen
antisera
prove
identifi
dea
antigen
percent
posit
blind
inhous
trial
perform
well
technician
could
correctli
identifi
canin
dea
antigen
test
methodolog
codifi
standard
oper
procedur
sop
written
test
dea
antigen
move
phase
two
blind
clinic
test
two
close
canin
coloni
test
dea
antigen
one
compris
entir
unrel
greyhound
mix
canin
previous
portion
mix
canin
type
dea
antigen
sampl
set
known
posit
mix
unknown
sampl
blind
via
identif
number
canin
infecti
diseas
screen
date
vaccin
physic
examin
test
two
canin
coloni
reveal
interest
find
previous
thought
greyhound
incid
rate
dea
antigen
howev
test
close
greyhound
coloni
incid
rate
prove
zero
mix
breed
close
canin
coloni
incid
dea
antigen
prove
previous
known
dea
antigen
posit
mix
canin
correctli
identifi
laboratori
technician
phase
three
test
methodolog
clinic
sampl
sent
laboratori
type
dea
antigen
establish
incid
rate
period
two
month
laboratori
use
conveni
sampl
test
dea
antigen
close
phase
three
total
random
canin
sampl
test
total
canin
test
posit
dea
antigen
result
incid
rate
consist
previous
known
incid
rate
therefor
conclus
phase
three
determin
novel
antisera
valid
detect
dea
antigen
reintroduct
novel
antidea
reagent
complet
profil
canin
blood
type
achiev
result
better
clinic
decis
make
regard
transfus
canin
patient
therefor
better
outcom
includ
avoid
delay
transfus
reaction
dea
incompat
exist
nonregen
immunemedi
anemia
nrima
common
hematolog
disord
dog
bone
marrow
affect
dog
show
erythroid
hyperplasia
andor
erythroid
matur
arrest
recogn
immunemedi
destruct
erythroid
precursor
cell
varieti
immunosuppress
agent
use
treatment
diseas
inform
regard
therapeut
efficaci
limit
due
lack
prospect
research
aim
pilot
studi
assess
treatment
outcom
pre
design
immunosuppress
regimen
includ
corticosteroid
cyclosporin
mycophenol
mofetil
dog
nrima
refer
hokkaido
univers
teach
hospit
includ
inclus
criteria
research
minimum
histori
anemia
sever
nonregen
anemia
hct
absolut
reticulocyt
count
absenc
identifi
underli
diseas
could
induc
sever
anemia
follow
data
collect
dog
age
breed
sex
result
hematolog
analys
perform
admiss
result
bone
marrow
examin
first
treatment
regimen
includ
prednisolon
mgkgday
cyclosporin
mgkgday
week
good
respons
defin
absolut
reticulocyt
count
increas
hct
dog
respond
within
week
continu
treat
gradual
taper
dose
reevalu
month
dog
respond
first
regimen
proceed
second
regimen
includ
prednisolon
mycophenol
mofetil
mgkg
twice
day
similarli
good
respons
second
regimen
determin
explain
dog
respond
regimen
defin
poor
respons
dog
rang
year
old
median
age
year
includ
castrat
male
intact
femal
spay
femal
miniatur
dachshund
shihtzu
papillon
median
hct
absolut
reticulocyt
count
respect
bone
marrow
erythroid
seri
evalu
hyperplasia
dog
euplasia
dog
hypoplasia
dog
erythroid
matur
arrest
observ
dog
dog
underw
core
biopsi
dog
show
myelofibrosi
dog
respond
first
regimen
time
respons
day
dog
stop
receiv
first
regimen
due
anorexia
might
induc
cyclosporin
month
prognos
dog
complet
remiss
cr
hct
increas
refer
rang
partial
remiss
pr
hct
reach
refer
rang
respect
dog
respond
first
regimen
proceed
second
regimen
dog
show
respons
day
month
prognosi
pr
dog
discontinu
receiv
cyclosporin
also
proceed
second
regimen
month
prognos
cr
dog
pr
dog
dog
show
respons
treatment
myelofibrosi
research
respons
regimen
could
evalu
dog
median
respons
time
day
rang
result
may
valuabl
practition
consider
chang
immunosuppress
agent
hyebin
wang
hyeri
shin
jinyoung
chung
kunho
song
kyoungwon
seo
chungnam
nation
univers
daejeon
korea
kangwon
nation
univers
chuncheon
korea
thromboelastographi
teg
rapid
noninvas
diagnost
instrument
use
veterinari
medicin
evalu
haemostat
function
whole
blood
wb
recent
rapid
thromboelastographi
rteg
recogn
overal
evalu
coagul
abnorm
human
medicin
becom
avail
faster
convent
coagul
test
cct
although
rteg
becom
gener
use
human
medicin
studi
describ
use
rteg
veterinari
medicin
object
studi
valid
rteg
valu
nativ
citrat
wb
sampl
healthi
dog
compar
stabil
repeat
two
type
sampl
examin
whether
use
rteg
could
acceler
coagul
pathway
decreas
taken
time
comparison
kaolin
activ
teg
blood
collect
clinic
healthi
beagl
dog
teg
analysi
perform
kaolinactiv
citrat
rteg
nativ
rteg
blood
sampl
teg
activ
clot
time
act
kappa
valu
k
alpha
angl
maximum
amplitud
record
coeffici
variat
cv
nativ
rteg
citrat
rteg
teg
act
k
angl
respect
mean
time
citrat
nativ
rteg
ae
ae
second
mean
ae
sd
respect
comparison
ae
second
kaolin
activ
teg
nativ
citrat
rteg
test
taken
significantli
less
time
kaolin
activ
teg
test
p
base
result
studi
rteg
evalu
haemostat
statu
rapidli
coagul
test
expect
use
use
critic
set
veterinari
medicin
sarah
shropshir
christin
olver
michael
lappin
colorado
state
univers
fort
collin
co
usa
coagul
system
compris
mani
complex
interact
balanc
prothrombot
fibrinolyt
arm
necessari
maintain
normal
hemostat
function
thromboelastographi
teg
platelet
aggregometri
special
assay
help
evalu
viscoelast
properti
blood
clot
platelet
function
respect
interindividu
variabl
high
serial
evalu
within
individu
rather
singl
measur
may
provid
greater
sensit
detect
clinic
signific
chang
intraindividu
variabl
greater
interindividu
variabl
howev
serial
evalu
would
offer
increas
sensit
purpos
studi
compar
interindividu
intraindividu
variabl
time
teg
platelet
aggregometri
variabl
healthi
dog
tissu
factor
activ
teg
perform
six
specif
pathogen
free
spf
sex
agematch
healthi
beagl
three
differ
time
point
variabl
reaction
time
r
clot
time
k
rate
clot
format
maximum
amplitud
record
adenosin
diphosph
adp
induc
arachidon
acid
aa
induc
platelet
aggregometri
addit
platelet
count
hematocrit
fibrinogen
also
perform
concurr
aptt
ospt
antithrombin
activ
ddimer
concentr
measur
first
day
studi
oneway
random
effect
model
use
analyz
follow
variabl
r
k
area
curv
adp
auc
adp
area
curv
aa
auc
aa
varianc
compon
creat
random
effect
model
use
calcul
coeffici
variat
interindividu
variabl
cv
g
intraindividu
variabl
cv
repeat
measur
anova
perform
platelet
count
hematocrit
fibrinogen
three
time
point
p
consid
signific
intraindividu
variabl
lower
interindividu
variabl
time
auc
adp
auc
aa
howev
intraindividu
variabl
higher
interindividu
variabl
teg
variabl
r
k
statist
differ
platelet
count
hematocrit
fibrinogen
measur
time
base
result
studi
serial
measur
adp
aainduc
platelet
aggregometri
teg
variabl
may
provid
sensit
method
detect
relev
chang
monitor
patient
howev
due
high
intraindividu
variabl
teg
variabl
r
k
serial
measur
may
benefici
singl
measur
compar
popul
base
refer
interv
gallbladd
mucocel
commonli
recogn
form
gallbladd
diseas
dog
character
cystic
mucin
hyperplasia
insidi
accumul
viscou
bile
mucu
within
gallbladd
although
sever
predispos
factor
propos
underli
etiolog
gallbladd
mucocel
format
unknown
previou
studi
found
limit
associ
cholecyst
bacteri
infect
aim
studi
util
cultureindepend
fluoresc
situ
hybrid
fish
determin
presenc
bacteria
gallbladd
mucocel
without
concurr
cholecyst
electron
medic
record
colorado
state
univers
review
case
histopatholog
confirm
gallbladd
mucocel
decemb
januari
case
avail
suitabl
evalu
case
data
includ
patient
signal
clinic
sign
clinicopatholog
abnorm
ultrasonograph
find
histopatholog
bacteri
cultur
bile
liver
formalinfix
paraffinembed
gallbladd
section
mount
charg
glass
slide
evalu
fish
use
eubacteri
probe
concurr
control
probe
section
examin
epifluoresc
microscop
imag
captur
olympu
camera
dog
undergo
cholecystectomi
treatment
gallbladd
mucocel
rang
age
year
old
common
breed
mix
n
shetland
sheepdog
n
miniatur
schnauzer
n
pomeranian
n
miniatur
dachshund
n
ultrasound
perform
case
exam
conclud
appear
gallbladd
consist
mucocel
histopatholog
reveal
cystic
mucin
hyperplasia
case
associ
cholecyst
note
case
bacteria
detect
eubacteri
fish
case
bacteria
visual
multifoc
cluster
short
rod
within
mucu
n
adher
wall
n
within
parenchyma
n
gallbladd
case
singl
bacterium
observ
within
gallbladd
parenchyma
case
multifoc
bacteria
concurr
cholecyst
bacteri
cultur
mucocel
content
posit
case
yield
moder
growth
escherichia
coli
fish
analysi
case
show
diffus
colon
mucocel
content
mucosa
e
coli
fish
detect
presenc
bacteria
mucocel
evalu
fish
sensit
bacteri
cultur
posit
case
visibl
bacteria
result
reveal
bacteri
infect
common
previous
thought
support
need
studi
examin
relationship
gallbladd
mucocel
cholecyst
bacteri
infect
cholecystectomi
median
dog
die
hospit
discharg
caus
gbm
format
unknown
retrospect
studi
identifi
dog
gbm
diagnosi
hypothyroid
compar
normal
dog
whether
hypothyroid
independ
risk
factor
gbm
format
consequ
underli
metabol
syndrom
unknown
distinct
import
implic
regard
caus
gbm
format
may
establish
rational
diagnosi
treatment
hypothyroid
dog
undertook
prospect
case
control
studi
dog
newli
diagnos
gbm
format
lack
clinic
sign
hypothyroid
test
hypothesi
occult
hypothyroid
exist
high
preval
dog
caus
may
differ
classic
lymphocyt
thyroid
dog
diagnos
gbm
ultrasound
healthi
age
breed
sexmatch
dog
normal
gallbladd
ultrasound
enrol
exclus
criteria
includ
clinic
evid
prior
diagnosi
treatment
hypothyroid
drug
interf
thyroid
function
intact
reproduct
statu
emerg
diseas
test
includ
cbc
chem
panel
ua
thyroid
function
test
includ
serum
total
total
free
thyroxin
equilibrium
dialysi
ft
free
triiodothyronin
ft
thyrotropin
tsh
autoantibodi
tgaa
dog
stratifi
diseas
sever
clinic
sign
mild
clinic
diseas
moder
requir
hospit
sever
requir
intens
care
incl
emerg
surgeri
thyroid
histolog
gbm
dog
control
examin
pathologist
blind
diagnosi
parametr
data
analyz
ttest
nonparametr
data
mannwhitney
u
test
p
consid
signific
screen
dog
gbm
met
studi
inclus
criteria
rang
age
year
median
yr
breed
includ
shetland
sheepdog
cocker
spaniel
chihuahua
beagl
pure
breed
ill
sever
score
absent
mild
moder
sever
healthi
dog
screen
enrol
dog
gbm
significantli
lower
serum
median
rang
nm
median
rang
nm
ft
median
rang
pm
ft
median
rang
pm
compar
control
dog
rel
control
dog
dog
gbm
frequent
sever
low
individu
thyroid
hormon
concentr
serum
refer
rang
rr
gbm
dog
compar
control
four
gbm
dog
serum
rr
gbm
dog
compar
control
three
gbm
dog
serum
rr
gbm
dog
compar
control
serum
rr
gbm
dog
compar
control
signific
differ
mean
tsh
identifi
howev
gbm
dog
control
dog
elev
tsh
serum
tgaa
elev
control
dog
gbm
dog
inflamm
detect
thyroid
dog
gbm
undergo
autopsi
result
identifi
high
preval
occult
often
sever
decreas
individu
serum
thyroid
hormon
concentr
gbm
dog
influenc
nonthyroid
ill
must
consid
abnorm
lack
serum
tgaa
absent
histolog
inflamm
thyroid
gbm
dog
noteworthi
find
suggest
altern
mechan
abnorm
thyroid
function
dog
gbm
consid
hepat
fibrosi
import
complic
canin
chronic
hepat
author
knowledg
interobserv
agreement
associ
histolog
score
fibrosi
canin
hepat
biopsi
specimen
previous
report
therefor
aim
studi
evalu
interobserv
agreement
histolog
score
canin
hepat
fibrosi
paraffinembed
liver
specimen
dog
select
tissu
archiv
texa
univers
north
carolina
state
univers
two
contigu
section
cut
specimen
one
stain
hematoxylin
eosin
h
e
one
picrosiriu
red
pr
six
boardcertifi
veterinari
pathologist
assign
fibrosi
score
absent
mild
moder
mark
mark
section
use
score
system
adapt
ishak
score
system
use
human
interobserv
agreement
h
e
pr
stain
section
evalu
use
kappa
weightedkappa
statist
median
fibrosi
score
assign
h
e
pr
stain
section
dog
compar
use
wilcoxon
signedrank
test
multius
kappa
ci
h
e
stain
section
multius
weightedkappa
pathologist
complet
agreement
time
differ
one
score
level
time
differ
score
level
time
multius
kappa
ci
pr
stain
section
multius
weightedkappa
pathologist
complet
agreement
time
differ
one
score
level
time
differ
one
score
level
time
signific
differ
median
fibrosi
score
assign
pathologist
h
e
pr
stain
section
median
p
fair
interobserv
agreement
veterinari
pathologist
assess
canin
hepat
fibrosi
h
e
pr
stain
section
howev
frequent
partial
agreement
pathologist
score
system
may
accept
clinic
use
clear
benefit
routin
stain
pr
assess
hepat
fibrosi
demonstr
studi
matthia
schneider
andrea
stosic
stephan
bayer
small
anim
clinic
giessen
germani
surgic
treatment
intrahepat
portosystem
shunt
ipss
challeng
frequent
multipl
intervent
need
avoid
portal
hypertens
achiev
complet
closur
complic
seen
catheterassist
embol
commerci
coil
includ
coil
migrat
portal
hypertens
rapid
thrombot
occlus
incomplet
occlus
attenu
hepat
vein
mean
stentsupport
coil
embol
may
lead
develop
intrahepat
venou
collater
present
studi
postul
implant
singl
prototyp
coil
combin
immedi
unfraction
heparin
therapi
uht
effect
treatment
ipss
dog
fewer
complic
report
open
surgeri
dog
singl
ipss
without
intrahepat
venou
collater
includ
percutan
access
right
jugular
vein
use
retrograd
portal
vein
catheter
portal
vein
pressur
ipss
diamet
measur
unblock
block
balloon
cathet
wedg
cathet
mm
occlus
cathet
prototyp
coil
polyest
fiber
select
either
least
mm
larger
diamet
block
ipss
twice
diamet
unblock
ipss
implant
use
guid
cathet
coagul
time
assess
activ
coagul
time
act
baselin
uht
heparin
start
coil
implant
bolu
iukg
inject
portal
vein
follow
continu
rate
infus
iukgh
postop
uht
administ
iukg
h
subcutan
intermitt
iukg
intraven
achiev
act
second
adjust
base
sonograph
proven
developmentresolut
ascit
function
closur
judg
accord
result
oral
ammonia
toler
test
descript
statist
kaplanmei
analysi
use
prototyp
coil
implant
total
dog
common
breed
hovawart
n
golden
retriev
n
median
age
month
rang
median
bodi
weight
kg
rang
ipss
origin
right
later
n
right
medial
n
left
portal
vein
branch
n
dog
show
portal
hypertens
shunt
block
unblock
block
shunt
diamet
mm
median
n
median
n
respect
intervent
success
first
n
second
n
intervent
major
complic
develop
dog
lead
death
dog
minor
complic
common
mostli
associ
bleed
problem
one
dog
lost
followup
three
month
remain
dog
experienc
complic
associ
chang
nonprotein
restrict
diet
sever
neurolog
abnorm
lead
euthanasia
n
moder
symptom
lead
reintervent
n
mild
symptom
could
treat
success
chang
moder
protein
restrict
diet
n
dog
without
portal
hypertens
show
function
closur
month
followup
dog
portal
hypertens
cumul
proport
function
closur
reach
month
followup
conclus
stiff
size
prototyp
coil
respons
high
procedur
success
function
closur
rate
unfraction
heparin
treatment
need
optim
reduc
complic
gener
treatment
regimen
seem
promis
ryan
schultz
rebecca
smedley
john
buchweitz
kati
barn
sarah
abood
daniel
langloi
michigan
state
univers
colleg
veterinari
medicin
east
lans
mi
usa
canin
copperassoci
hepat
ccah
becom
increasingli
recogn
caus
progress
potenti
fatal
liver
diseas
dog
howev
exact
etiolog
remain
unclear
date
broad
epidemiolog
investig
quantifi
hepat
copper
concentr
time
predispos
ccah
nonpredispos
breed
conduct
purpos
studi
determin
compar
quantit
hepat
copper
concentr
breed
predispos
ccah
two
studi
period
hypothes
hepat
copper
concentr
increas
dog
time
rel
increas
greater
predispos
breed
retrospect
search
histopatholog
databas
michigan
state
univers
diagnost
center
popul
anim
health
conduct
two
studi
period
doberman
pinscher
labrador
retriev
west
highland
white
terrier
consid
predispos
ccah
dalmatian
skye
terrier
bedlington
terrier
exclud
analysi
due
rariti
case
limit
inform
predisposit
known
genet
etiolog
respect
case
archiv
liver
tissu
avail
randomli
select
review
classifi
breed
presenc
absenc
inflammatori
liver
diseas
hepat
copper
concentr
part
per
million
dri
weight
basi
measur
specimen
use
induct
coupl
plasma
mass
spectrometri
comparison
made
within
across
group
use
commerci
avail
statist
softwar
total
case
evalu
includ
dog
predispos
ccah
nonpredispos
dog
independ
breed
group
inflammatori
activ
mean
hepat
copper
concentr
recent
time
period
ppm
greater
histor
time
period
p
effect
predominantli
due
increas
ppm
time
predispos
breed
p
mean
hepat
copper
concentr
ppm
nonpredispos
breed
recent
year
greater
mean
hepat
copper
concentr
ppm
nonpredispos
breed
histor
period
trend
reach
signific
p
recent
period
mean
hepat
copper
concentr
ppm
predispos
breed
noninflammatori
liver
histolog
greater
mean
hepat
copper
concentr
ppm
nonpredispos
breed
noninflammatori
liver
histolog
p
differ
observ
histor
time
period
period
dog
hepat
higher
hepat
copper
concentr
without
hepat
differ
magnifi
recent
year
aggreg
find
confirm
hepat
copper
concentr
chang
time
etiolog
chang
unknown
suggest
chang
environment
copper
exposur
detail
investig
potenti
sourc
copper
exposur
name
drink
water
diet
need
elucid
potenti
environment
etiolog
addit
investig
also
need
determin
chang
import
breed
dog
borrelia
burgdorferi
bb
anaplasma
phagocytophilum
ap
transmit
ixod
spp
seropreval
rate
endem
area
greater
dog
genet
predisposit
infect
bernes
mountain
dog
clinic
ill
associ
bb
suggest
particularli
peopl
dog
lyme
nephriti
retriev
breed
vaccin
studi
wild
caught
scapulari
adult
place
feed
chamber
allow
feed
seven
day
usual
result
least
bb
infect
rate
recent
scapulari
infest
studi
use
previous
report
model
tick
similar
bb
carriag
rate
collect
area
previous
use
result
infect
rate
purpos
report
describ
genet
related
dog
use
studi
total
femal
male
purposebr
beagl
month
age
neg
antibodi
phagocytophilum
b
burgdorferi
e
cani
accuplex
biocd
system
antech
diagnost
infest
day
femal
male
wildcaught
scapulari
estim
bb
infect
rate
ap
infect
rate
blood
collect
dog
prior
tick
attach
week
week
tick
attach
screen
bb
ap
antibodi
describ
dog
seroconvert
assum
infect
statist
analys
perform
commerci
softwar
p
consid
statist
signific
antibodi
bb
detect
dog
week
postinfest
posit
dog
femal
p
posit
neg
dog
compar
signific
differ
age
number
tick
recov
number
fed
tick
antibodi
ap
detect
serum
dog
result
use
sourc
dog
tick
model
previou
public
bb
ap
respect
differ
infect
rate
current
histor
studi
similar
ap
significantli
lower
current
studi
bb
p
recent
common
ancestor
mrca
bbposit
dog
either
sibl
parent
dog
b
sibl
father
dog
c
mother
dog
matern
grandmoth
dog
b
father
dog
e
patern
great
grandfath
dog
b
c
mother
dog
f
matern
grandmoth
dog
e
mrca
bbneg
dog
either
sibl
parent
none
bb
posit
dog
mrca
sibl
parent
common
bb
neg
dog
find
provid
evid
genet
predisposit
b
burgdorferi
infect
exist
studi
investig
common
genotyp
allel
among
human
lyme
borreliosi
arthriti
also
consid
futur
studi
canin
lyme
borreliosi
babesia
gibsoni
commonli
identifi
pit
bulltyp
dog
particularli
involv
dogfight
dog
seiz
fight
oper
undergo
health
behavior
evalu
assess
suitabl
adopt
adopt
carri
risk
send
dog
harbor
infecti
diseas
unsuspect
owner
region
infect
endem
screen
larg
number
dog
infecti
diseas
expens
may
day
result
avail
rapid
costeffect
diagnost
test
would
make
identif
treatment
b
gibsoni
infect
dog
feasibl
rescu
organ
recent
develop
insul
isotherm
pcr
iipcr
made
mobil
pcr
realiti
purpos
studi
determin
perform
pockit
iipcr
system
diagnosi
b
gibsoni
dog
rescu
fight
organ
whole
blood
collect
pit
bulltyp
dog
rescu
feder
dogfight
investig
realtim
pcr
perform
babesia
speci
posit
sampl
underw
second
round
speciesspecif
pcr
commerci
diagnost
laboratori
idexx
laboratori
inc
residu
whole
blood
sampl
frozen
store
c
pend
subsequ
analysi
pockit
iipcr
perform
twice
sampl
kit
specif
b
gibsoni
kit
detect
b
gibsoni
babesia
cani
babesiosi
sensit
specif
test
calcul
use
commerci
test
gold
standard
posit
ppv
neg
npv
predict
valu
calcul
theoret
preval
studi
approv
uf
iacuc
total
dog
posit
b
gibsoni
gold
standard
commerci
pcr
test
identifi
posit
pockit
iipcr
b
gibsoni
kit
identifi
posit
iipcr
babesiosi
kit
sensit
specif
b
gibsoni
kit
respect
sensit
specif
babesiosi
kit
respect
ppv
b
gibsoni
kit
preval
respect
npv
b
gibsoni
kit
respect
ppv
babesiosi
kit
respect
npv
babesiosi
kit
respect
pockit
iipcr
system
quick
learn
portabl
short
run
time
approxim
hour
falseposit
result
indic
posit
result
like
repres
true
infect
test
highrisk
anim
approxim
infect
dog
would
miss
pockit
iipcr
system
howev
portabl
speed
result
obtain
may
result
infect
dog
diagnos
current
situat
test
rare
perform
dogfight
case
due
cost
logist
send
sampl
outsid
laboratori
system
may
also
use
b
gibsoni
treatment
monitor
use
hybrid
approach
exampl
follow
initi
diagnosi
either
pockit
system
commerci
laboratori
pockit
system
could
use
test
treatment
neg
result
obtain
sampl
could
submit
commerci
laboratori
confirm
treatment
efficaci
although
studi
focus
mass
screen
b
gibsoni
portabl
iipcr
platform
potenti
aid
rapid
detect
varieti
infect
field
condit
efficaci
sarolan
simparica
tm
zoeti
prevent
transmiss
borrelia
burgdorferi
anaplasma
phagocytophilum
infect
wildcaught
ixod
scapulari
dog
evalu
wellcontrol
laboratori
studi
twentyfour
purposebr
laboratori
beagl
dog
seroneg
b
burgdorferi
phagocytophilum
antibodi
alloc
randomli
one
three
oral
treatment
group
placebo
administ
day
sarolan
administ
day
day
prior
tick
infest
sarolan
administ
day
day
prior
tick
infest
sarolan
tablet
shave
andor
sand
base
dog
individu
bodyweight
provid
dosag
mgkg
day
dog
infest
approxim
femal
male
wild
caught
adult
scapulari
determin
random
sampl
infect
rate
b
burgdorferi
phagocytophilum
pcr
situ
tick
count
conduct
day
day
tick
count
remov
blood
sampl
collect
dog
day
test
presenc
b
burgdorferi
phagocytophilum
antibodi
use
snap
plu
test
quantit
assay
b
burgdorferi
antibodi
use
elisa
test
skin
biopsi
collect
day
test
presenc
b
burgdorferi
bacteri
cultur
pcr
acaricid
efficaci
calcul
base
reduct
geometr
mean
live
tick
count
sarolanertr
group
compar
placebotr
group
tick
count
geometr
mean
live
tick
count
placebotr
dog
day
respect
group
treat
sarolan
day
prior
infest
percent
reduct
mean
live
tick
count
day
group
treat
sarolan
day
prior
infest
geometr
mean
live
tick
count
sarolanertr
group
significantli
lower
placebo
group
count
day
p
success
transmiss
b
burgdorferi
eight
placebotr
dog
confirm
posit
antibodi
dog
pcr
dog
andor
cultur
result
dog
similarli
transmiss
phagocytophilum
confirm
presenc
antibodi
four
placebotr
dog
contrast
singl
oral
dose
sarolan
prevent
transmiss
b
burgdorferi
infect
tick
dog
infest
day
treatment
demonstr
neg
antibodi
pcr
cultur
result
prevent
phagocytophilum
transmiss
also
demonstr
neg
antibodi
sarolanertr
dog
advers
reaction
treatment
sarolan
blood
sampl
appar
healthi
stray
n
shelter
n
hunt
dog
n
outdoor
pet
dog
suspect
tick
born
diseas
n
test
use
real
time
pcr
serolog
assay
realtim
pcr
assay
use
amplifi
babesia
anaplasma
ehrlichia
dna
blood
sampl
experiment
snap
multianalyt
assay
snap
idexx
laboratori
inc
westbrook
main
usa
use
screen
sera
antibodi
anaplasma
ehrlichia
genu
peptid
phagocytophilum
plati
b
burgdorferi
e
cani
e
ewingii
e
chaffeensi
speciesspecif
peptid
modifi
knott
test
use
identifi
dog
dirofilaria
sp
microfilaria
presenc
total
preval
babesia
sp
infect
among
appar
healthi
dog
among
sick
pet
dog
preval
b
cani
highest
shelter
lowest
stray
dog
b
gibsoni
rare
among
shelter
stray
pet
dog
detect
among
hunt
dog
molecular
analysi
reveal
presenc
dog
activ
anaplasmosi
ehrlichiosi
borreliosi
howev
stray
shelter
dog
hunt
dog
sick
pet
dog
antibodi
phagocytophilum
one
dog
hunt
group
seroposit
plati
one
dog
e
ewingii
stray
group
two
dog
b
burgdorferi
stray
group
none
dog
seroposit
e
cani
e
chaffeensi
also
pet
hunt
stray
shelter
dog
microfilaria
blood
number
dog
expos
two
three
pathogen
highest
among
shelter
dog
respect
number
dog
expos
four
pathogen
highest
among
stray
dog
belgrad
area
b
cani
phagocytophilum
preval
vectorborn
pathogen
appar
healthi
outdoor
dog
popul
b
cani
dirofilaria
sp
import
pathogen
among
sick
pet
dog
island
st
kitt
west
indi
larg
feral
semifer
dog
popul
semifer
dog
present
uniqu
opportun
studi
sinc
mostli
outdoor
compar
well
taken
care
compar
feral
dog
care
tend
rang
minim
adequ
though
mani
owner
use
ministri
agricultur
veterinari
servic
prevent
medicin
rather
veterinari
hospit
set
histor
dog
island
endem
infect
infest
intern
ectoparasit
also
associ
number
vectorborn
diseas
due
high
preval
vector
rhipicephalu
sanguineu
unusu
see
high
preval
ehrlichia
cani
anaplasma
plati
sampl
collect
islandwid
field
studi
last
year
reveal
abund
serolog
data
sampl
test
util
researchbas
serolog
platform
idexx
laboratori
addit
canin
vectorborn
infect
data
collect
analys
period
month
veterinarian
student
rusvm
visit
parish
st
kitt
cover
divers
geograph
area
wide
divers
ecosystem
landscap
one
hundr
eleven
dog
identifi
visit
given
complet
physic
exam
blood
fece
collect
demograph
data
collect
includ
breed
age
hous
anim
household
evid
tick
flea
deworm
vaccin
administr
blood
analyz
use
researchbas
broader
canin
vectorborn
infect
serolog
platform
idexx
laboratori
test
specif
antibodi
e
ewingii
e
cani
e
chaffeensi
anaplasma
plati
phagocytophilum
borrelia
burgdorferi
test
platform
also
base
rapid
elisa
technolog
analys
use
new
snap
serolog
platform
reveal
evid
exposur
e
ewingii
e
chaffeensi
borrelia
burgdorferi
howev
expect
due
endem
natur
tick
vector
platform
identifi
plati
exposur
approxim
e
cani
exposur
detect
preval
approxim
interest
snap
test
also
identifi
dog
antibodi
phagocytophilum
previous
describ
st
kitt
due
absenc
ixod
tick
vector
use
snap
serolog
platform
robust
capac
detect
anaplasma
speci
addit
sensit
corrobor
previous
publish
preval
rate
e
cani
note
presenc
phagocytophilum
exposur
addit
studi
warrant
understand
explain
find
data
collect
studi
support
import
includ
exhaust
list
differenti
suspect
canin
vectorborn
infect
addit
aggress
consist
use
environment
topic
parasiticid
tick
control
least
cat
us
infect
felv
fiv
contagi
retrovirus
predispos
bone
marrow
suppress
cancer
chronic
inflammatori
condit
immun
dysfunct
wast
syndrom
equat
million
cat
affect
prevent
virus
risk
diseas
prematur
death
although
vaccin
play
role
prevent
cornerston
control
identif
segreg
infect
cat
recent
new
pointofcar
screen
test
becom
avail
independ
comparison
test
perform
need
purpos
studi
determin
perform
current
avail
felv
antigenfiv
antibodi
combin
test
kit
assess
felv
test
serum
edta
whole
blood
sampl
collect
anim
shelter
refer
laboratori
test
two
microtit
plate
elisa
detect
felv
antigen
felv
antigen
test
establish
gold
standard
sampl
concord
result
includ
studi
assess
fiv
test
plasma
sampl
previous
collect
natur
experiment
infect
cat
verifi
viru
cultur
uninfect
spf
cat
includ
none
cat
vaccin
fiv
snap
test
overal
best
perform
highstak
test
test
kit
select
high
sensit
specif
test
lack
sensit
infect
cat
may
escap
detect
remain
risk
infect
cat
specif
fall
uninfect
cat
may
unnecessarili
segreg
even
euthan
low
infect
preval
observ
felv
fiv
decreas
specif
largest
impact
erron
test
result
lead
decreas
posit
predict
valu
increas
falseposit
maddi
shelter
medicin
program
univers
florida
gainesvil
fl
usa
diagnosi
fiv
infect
base
detect
circul
fiv
antibodi
introduct
fiv
vaccin
creat
diagnost
dilemma
vaccin
antibodi
indistinguish
induc
infect
use
exist
serolog
assay
new
pointofcar
test
fiv
antibodi
avail
practition
purpos
studi
determin
accuraci
fiv
diagnost
test
fivvaccin
cat
whether
test
could
serv
diva
test
differenti
infect
vaccin
anim
plasma
sampl
collect
uninfect
spf
cat
vaccin
time
kill
dualsubtyp
fiv
vaccin
felovax
boehring
ingelheim
accord
manufactur
instruct
age
vaccin
rang
month
interv
vaccin
sampl
collect
rang
month
fivfre
infect
statu
cat
confirm
viru
cultur
three
fivinfect
cat
similarli
vaccin
test
plasma
sampl
test
commerci
pointofcar
assay
snap
felin
combo
felv
agfiv
ab
test
wit
felvfiv
test
anigen
rapid
fiv
abfelv
ag
test
kit
vetscan
felin
felvfiv
rapid
test
test
perform
personnel
blind
sampl
statu
test
result
independ
interpret
personnel
snap
vetscan
test
detect
fiv
antibodi
uninfect
vaccin
cat
respect
would
lead
misclassif
vaccin
cat
infect
wit
anigen
test
high
specif
indic
nearli
vaccin
cat
correctli
identifi
uninfect
test
correctli
identifi
fivinfect
cat
vaccin
fiv
accur
detect
fivinfect
cat
essenti
provid
appropri
care
segreg
uninfect
cat
sinc
euthanasia
tool
employ
control
fiv
especi
anim
shelter
previou
vaccin
histori
cat
usual
unknown
misidentif
vaccin
cat
infect
may
unwarr
fatal
consequ
base
studi
wit
felvfiv
test
anigen
fiv
ab
felv
ag
test
accur
differenti
fivinfect
fivvaccin
cat
meet
criteria
diva
test
tateno
yasuyuki
endo
masashi
takahashi
kagoshima
univers
kagoshima
japan
gammaherpesvirus
ghv
member
emerg
subfamili
herpesvivida
two
major
human
ghv
epsteinbarr
viru
ebv
kaposi
sarcomaassoci
herpesviru
kshv
clinic
import
pathogen
virus
possess
tumorigenesi
potenti
especi
immunecompromis
patient
felin
practic
often
experi
tumor
case
especi
lymphoma
felin
leukemia
viru
felv
major
caus
develop
lymphoma
past
day
howev
major
lymphoma
case
shift
felvfre
cat
mechan
tumorigenesi
spontan
develop
lymphoma
well
understood
situat
ghv
becam
candid
explain
lymphomagenesi
domest
cat
recent
studi
identifi
novel
ghv
domest
cat
feli
catu
ghv
fcaghv
epidemiolog
survey
found
fcaghv
distribut
sever
countri
includ
unit
state
australia
singapor
germani
austria
present
studi
molecular
epidemiolog
studi
conduct
investig
preval
ghv
japan
use
larg
number
sampl
previous
use
nationwid
epidemiolog
survey
two
felin
retrovirus
japan
nakamura
et
al
j
vet
med
sci
ghvderiv
dna
blood
sampl
detect
degener
nest
panghv
pcr
target
gb
gene
previous
report
nucleotid
sequenc
obtain
dna
fragment
determin
blast
analysi
carri
phylogen
analysi
also
conduct
risk
factor
relat
ghv
infect
clinic
paramet
includ
age
sex
statu
retroviru
infect
bite
wound
histori
clinic
sign
statist
analyz
use
univari
fisher
exact
test
multivari
logist
regress
model
analys
ghvderiv
dna
detect
japanes
domest
cat
blast
analysi
reveal
show
high
similar
fcaghv
isol
domest
cat
unit
state
phylogen
analysi
also
reveal
japanes
isol
form
one
cluster
fcaghv
age
year
old
odd
ratio
confidenti
interv
ci
p
felin
immunodefici
viru
fiv
infect
ci
p
found
risk
factor
univari
analysi
multivari
analysi
fiv
infect
ci
p
signific
risk
factor
studi
preval
ghv
japanes
domest
cat
survey
risk
factor
ghv
infect
determin
fcaghv
preval
japan
lower
previous
report
preval
countri
area
us
europ
unabl
determin
caus
differ
howev
japanes
isol
identifi
close
genet
relationship
domest
cat
deriv
fcaghv
find
suggest
viru
highli
conserv
anim
speci
ghv
harbor
host
specif
manner
well
herpesvirus
risk
factor
ghv
infect
japanes
cat
fiv
infect
previous
report
clarifi
fiv
enhanc
ghv
infect
andor
viremia
clinic
import
ghv
infect
felin
practic
still
unknown
investig
necessari
identifi
pathogen
ghv
domest
cat
ann
cohen
jill
richardson
ami
glaser
edward
dubovi
nyssa
reinesalz
chicago
veterinari
emerg
specialti
chicago
usa
merck
anim
health
madison
usa
cornel
univers
ithaca
usa
influenza
viru
avian
origin
first
isol
clinic
ill
dog
china
south
korea
canin
influenza
viru
associ
sever
respiratori
sign
clinic
sign
fever
reduc
bodi
weight
interstiti
pneumonia
case
report
present
four
confirm
natur
infect
clinic
case
canin
influenza
unit
state
case
present
pet
dog
histori
recent
exposur
dog
social
set
includ
dog
park
doggi
day
care
none
dog
origin
travel
typic
region
endem
viral
diseas
dog
present
differ
stage
ill
attribut
infecti
respiratori
diseas
one
dog
year
old
corgi
evalu
lethargi
anorexia
loos
stool
day
also
develop
cough
day
present
mild
increas
respiratori
rate
physic
examin
fever
mildli
increas
respiratori
sound
patient
repres
next
day
worsen
sign
cough
lethargi
hyporexia
thorac
radiograph
perform
show
sever
bilater
bronchopneumonia
base
poor
respons
support
care
owner
elect
human
euthanasia
necropsi
perform
new
york
state
veterinari
diagnost
laboratori
cornel
univers
necropsi
reveal
sever
acut
local
extens
necrohemorrhag
interstiti
pneumonia
epitheli
necrosi
anoth
dog
year
month
old
miniatur
pincher
evalu
day
histori
cough
wheez
weak
ataxia
hyporexia
one
day
clear
nasal
discharg
physic
examin
patient
weak
dehydr
serou
nasal
discharg
muffl
heart
sound
poor
peripher
femor
puls
harsh
bilater
thorac
sound
crackl
wheez
thorac
radiograph
perform
show
right
caudodors
left
cranial
bronchoalveolar
bronchopneumonia
patient
experienc
cardiopulmonari
arrest
upon
return
spontan
circul
owner
elect
human
euthanasia
necropsi
result
sever
acut
multifoc
coalesc
necrohemorrhag
pneumonia
hyalin
membran
format
epitheli
necrosi
enter
lesion
also
note
moder
diffus
chronic
lymphoplasmacyt
enter
multifoc
crypt
necrosi
anoth
dog
year
old
greater
swiss
mountain
dog
refer
hospit
due
right
cranial
middl
lung
lobe
consolid
fever
dyspnea
gag
phlegm
product
exercis
intoler
hyporexia
physic
examin
quiet
febril
degre
fahrenheit
increas
respiratori
rate
breath
per
minut
harsh
bronchovesicular
lung
sound
becam
oxygen
depend
puls
oximetri
recheck
thorac
radiograph
perform
fourth
day
hospit
show
worsen
alveolar
pattern
right
left
cranial
thorax
hospit
day
make
gradual
improv
discharg
confirm
via
pcr
cornel
univers
fourth
case
year
old
terrier
mix
breed
present
evalu
product
cough
two
day
one
day
lethargi
anorexia
weak
physic
examin
harsh
lung
sound
mild
increas
respiratori
rate
appreci
patient
vomit
larg
volum
bile
materi
examin
sever
fever
degre
fahrenheit
appreci
respiratori
rate
breath
per
minut
dehydr
thorac
radiograph
perform
show
mild
moder
bronchointerstiti
pattern
concentr
caudodors
lung
field
patient
hospit
day
eventu
taper
oxygen
sent
home
oral
antibiot
therapi
respiratori
panel
sent
idexx
refer
laboratori
patient
posit
influenza
assay
neg
pcr
posit
pcr
four
dog
diagnos
canin
influenza
pcr
three
new
york
state
veterinari
diagnost
laboratori
one
idexx
diagnost
laboratori
patient
characterist
clinic
featur
canin
influenza
viru
infect
still
consid
differenti
diagnosi
studi
conduct
dog
evalu
efficaci
inactiv
canin
influenza
viru
civ
vaccin
follow
experiment
challeng
virul
heterolog
strain
civ
isol
recent
civ
outbreak
unit
state
eleven
dog
week
age
vaccin
dose
inactiv
civ
vaccin
week
apart
dog
vaccin
placebo
two
week
second
vaccin
dog
challeng
intranas
virul
civ
monitor
daili
day
clinic
sign
includ
fever
nasal
discharg
sneez
cough
depress
dyspnea
nasal
swab
collect
evalu
viral
shed
serum
sampl
collect
variou
time
point
determin
antibodi
titer
necropsi
lung
score
consolid
follow
booster
vaccin
placebovaccin
control
dog
remain
seroneg
civ
vaccin
dog
develop
antibodi
titer
civ
gmt
rang
antibodi
titer
dog
treatment
group
increas
follow
challeng
increas
greater
vaccin
dog
gmt
rang
follow
challeng
placebovaccin
control
dog
euthan
prior
postchalleng
observ
period
due
sever
clinic
sign
includ
difficulti
breath
depress
fever
sever
cough
retch
wherea
none
vaccin
euthan
p
clinic
sign
evalu
base
weight
score
system
mean
clinic
score
placebovaccin
control
group
compar
vaccin
group
p
placebovaccin
control
group
shed
civ
viru
mean
day
compar
day
vaccin
group
p
median
lung
consolid
score
placebovaccin
control
group
compar
vaccin
group
p
result
studi
demonstr
inactiv
civ
vaccin
significantli
protect
dog
sever
clinic
diseas
lung
consolid
associ
virul
civ
infect
canin
infecti
respiratori
diseas
complex
cirdc
caus
mani
differ
virus
bacteria
june
veterinarian
around
atlanta
georgia
also
western
area
north
carolina
began
notic
unusu
increas
dog
present
clinic
sign
infecti
respiratori
diseas
nasal
pharyng
swab
dog
exhibit
clinic
sign
submit
anim
health
diagnost
center
ahdc
cornel
univers
canin
respiratori
polymeras
chain
reaction
pcr
screen
panel
util
allow
identif
follow
cirdc
pathogen
bordetella
bronchiseptica
mycoplasma
cyno
canin
adenoviru
canin
distemp
canin
influenza
parainfluenza
viru
pneumoviru
respiratori
coronaviru
june
august
merck
anim
health
diagnost
support
program
test
sampl
dog
clinic
sign
respiratori
diseas
georgia
north
carolina
dog
test
posit
canin
influenza
viru
case
identifi
georgia
case
north
carolina
none
test
dog
confirm
canin
influenza
strain
result
test
region
also
identifi
case
parainfluenza
viru
case
b
bronchiseptica
four
case
adenoviru
type
case
pneumoviru
case
respiratori
coronaviru
one
case
canin
distemp
evalu
posit
case
parainfluenza
show
receiv
parainfluenza
vaccin
inject
distemp
adenoviru
type
parvoviru
parainfluenza
viru
combin
vaccin
also
parainfluenza
posit
dog
vaccin
monoval
b
bronchiseptica
vaccin
oral
inject
intranas
seven
dog
vaccin
b
bronchiseptica
parainfluenza
combin
intranas
product
two
recent
vaccin
parainfluenza
sampl
may
vaccin
origin
inform
gather
test
program
document
spread
canin
influenza
viru
two
new
locat
us
addit
data
collect
support
role
parainfluenza
viru
major
prevent
pathogen
cirdc
rout
vaccin
consid
vaccin
protocol
anim
argu
play
import
role
nurs
home
provid
health
benefit
may
also
sourc
infect
injuri
anim
patient
todat
littl
known
involv
anim
nurs
home
practic
place
protect
pet
resid
health
specif
health
benefit
risk
object
studi
determin
frequenc
avenu
anim
util
nurs
home
environ
practic
safeguard
health
benefit
risk
residentanim
interact
anonym
onlin
questionnair
develop
deliv
conveni
sampl
nurs
home
administr
ohio
usa
novemb
march
respons
facil
approxim
regist
facil
oh
vari
size
geograph
locat
receiv
adequ
complet
allow
analysi
nearli
respond
allow
anim
facil
livein
visit
dog
frequent
anim
involv
facil
activ
follow
cat
bird
fish
rodent
highrisk
speci
reptilesamphibian
pet
zoo
farm
anim
eg
pig
goat
chicken
often
permit
facil
respect
facil
restrict
target
particular
speci
n
age
n
anim
anim
report
visit
facil
weekli
often
one
respond
report
anim
cat
mistreat
resid
staff
preced
month
known
suspect
animalassoci
infect
report
preced
month
perceiv
benefit
anim
facil
high
eg
particip
agreedstrongli
agre
resid
appear
happier
interact
anim
anim
use
calm
agit
resid
result
highlight
frequent
use
perceiv
benefit
involv
anim
nurs
home
also
common
gap
establish
polici
best
practic
import
reduc
resid
anim
health
risk
find
assist
develop
direct
guidanc
document
nurs
home
better
facilit
safe
interact
resid
anim
mani
bacteria
express
virul
via
quorum
sens
qs
pseudomona
aeruginosa
pa
qs
signal
molecul
nacylhomoserin
lacton
paahl
use
qs
blocker
quorum
quench
qq
attenu
bacteri
growth
virul
new
strategi
treatment
resist
bacteri
pathogen
azithromycin
az
express
invitro
invivo
qq
effect
use
clinic
reduc
pa
virul
hypothes
test
topic
treatment
az
attenu
format
common
paahl
nbutyryllhomoserin
lacton
bhl
ndecanoyllhomoserin
lacton
hhl
n
lhomoserinelacton
oddhl
enhanc
pa
clearanc
ear
canal
posit
effect
ear
canal
sampl
cytolog
reduc
sever
clinic
sign
relat
pa
associ
otiti
externamedia
paoem
dog
random
doubl
blind
placebo
control
studi
sampl
collect
dog
paoem
treat
topic
az
ml
az
solut
concentr
sid
placebo
ml
steril
salin
day
dog
prescrib
standard
paoem
treatment
regularli
evalu
veterinarian
purpos
studi
dog
clinic
evalu
ear
canal
sampl
taken
day
sampl
obtain
rins
ear
canal
ml
steril
salin
concentr
bhl
hhl
oddhl
ngml
determin
liquid
chromatographi
coupl
tandem
mass
spectrometri
bacteriolog
cytolog
analys
perform
clinic
sign
ear
canal
edema
pain
stenosi
erythema
grade
grade
summar
form
singl
clinic
sign
grade
data
analyz
use
linear
mix
effect
model
continu
outcom
gener
linear
mix
effect
model
binari
outcom
pvalu
consid
signific
concentr
bhl
hhl
oddhl
affect
time
p
az
p
presenc
pa
ear
canal
sampl
affect
time
p
az
p
presenc
rod
shape
bacteria
cocci
neutrophil
sampl
affect
time
p
az
p
macrophag
affect
time
az
clinic
sign
therefor
durat
diseas
influenc
time
p
azithromycin
effect
clinic
sign
durat
diseas
p
detect
paahl
studi
show
qs
act
promot
pa
virul
otiti
externamedia
paoem
dog
therefor
appropri
diseas
model
studi
effect
qq
pa
neither
hypothes
verifi
azithromycin
effect
paahl
elimin
pa
ear
canal
effect
cytolog
sampl
outcom
diseas
weak
tendenc
toward
quicker
elimin
pa
ear
canal
note
studi
felin
leukemia
viru
potenti
lifethreaten
oncogen
retroviru
transmit
horizont
close
contact
vertic
inutero
transmiss
viral
core
protein
produc
viru
infect
cell
found
cytoplasm
sever
blood
cell
well
free
serum
plasma
infect
cat
refer
laboratori
veterinari
clinic
commonli
use
form
enzymelink
immunoassay
elisa
particlebas
immunoassay
detect
presenc
protein
antigen
sampl
obtain
blood
purpos
studi
compar
perform
sever
inclin
test
felin
test
idexx
felvfiv
rapid
test
abaxi
felvfiv
test
zoeti
rapid
fivfelv
test
bionot
speed
felvfiv
test
virbac
sampl
popul
posit
neg
consist
serum
plasma
sampl
submit
idexx
worldwid
refer
laboratori
felin
retroviru
test
viru
isol
revers
transcriptas
polymeras
chain
reaction
result
avail
sampl
judg
posit
neg
base
result
felv
zoeti
microtit
plate
assay
use
refer
test
report
publish
studi
high
sensit
specif
hartmann
et
al
detect
felv
antigen
inclin
test
evalu
studi
compar
microtit
plate
assay
result
felin
test
highest
sensit
among
inclin
test
evalu
tabl
find
import
clinic
set
posit
test
result
may
mechan
identifi
infect
catsfals
neg
result
could
delay
support
care
result
transmiss
causalcontact
cat
addit
studi
need
determin
clinic
sensit
specif
test
use
sampl
cat
character
pcr
andor
viral
cultur
drexel
jiayou
liu
brendon
thatcher
tom
oconnor
ramaswami
chandrashekar
idexx
laboratori
westbrook
usa
giardiasi
one
common
intestin
parasit
infect
affect
dog
cat
infect
may
subclin
caus
sever
diarrhea
dog
becom
infect
ingest
giardia
cyst
contamin
water
fece
singl
fecal
flotat
diagnost
sensit
approxim
cyst
number
shed
intermitt
difficult
distinguish
fecal
matter
inexperienc
observ
fecal
flotat
combin
fecal
antigen
test
detect
solubl
cyst
wall
antigen
result
diagnost
sensit
approxim
new
giardia
antigen
assay
avail
veterinari
use
comparison
studi
part
lack
present
studi
compar
perform
three
inclin
test
giardia
test
vetscan
canin
giardia
rapid
test
abaxi
anigen
rapid
cpvccvgiardia
antigen
test
bionot
canin
fecal
sampl
use
submit
idexx
refer
laboratori
ova
parasit
test
centrifug
flotat
test
sampl
store
sampl
evalu
solubl
cyst
wall
antigen
use
thermo
scientifictm
prospecttm
giardia
micropl
assay
posit
sampl
defin
test
posit
refer
method
neg
sampl
defin
test
neg
refer
method
total
posit
sampl
neg
sampl
identifi
test
three
inclin
test
six
sampl
exclud
sensitivityspecif
analysi
fail
produc
posit
control
line
vetscan
test
despit
produc
valid
result
two
inclin
test
result
compar
consensu
refer
method
result
calcul
sensit
specif
use
criteria
snap
giardia
test
numer
greater
sensit
specif
test
studi
use
anoth
antigen
test
definit
true
posit
true
neg
result
sinc
sampl
fresh
fecal
test
use
differ
test
method
like
immunofluoresc
antibodi
assay
anaplasma
phagocytophilum
aph
borrelia
burgdorferi
bb
pathogen
bacteria
vector
ixod
spp
known
infect
cat
associ
bb
infect
felin
clinic
syndrom
unclear
studi
demonstr
aph
infect
associ
fever
sever
lethargi
thrombocytopenia
cat
present
studi
aim
evalu
seropreval
antibodi
aph
bb
larg
popul
domest
cat
across
unit
state
better
understand
risk
exposur
agent
total
sampl
submit
septemb
februari
complet
blood
count
cbc
inclus
test
profil
obtain
idexx
refer
laboratori
locat
ixod
sppendem
area
sampl
origin
state
california
illinoi
massachusett
contribut
studi
popul
popul
median
age
year
rang
month
year
similar
represent
male
femal
sampl
screen
aphspecif
bbspecif
peptid
immunoassay
result
evalu
base
variou
test
demograph
paramet
overal
felin
sera
test
studi
popul
contain
antibodi
aph
antibodi
bb
addit
cat
test
antibodi
aph
bb
observ
dog
human
antibodi
preval
rate
among
domest
cat
vari
geographi
highest
posit
rate
aph
bb
observ
connecticut
n
main
n
respect
lowest
seropreval
aph
bb
observ
nevada
aph
bb
n
result
corrobor
find
previou
studi
indic
cat
infect
aph
bb
suggest
tick
prevent
import
consider
cat
well
dog
geneviev
clark
roberta
cahil
brendon
thatcher
peter
f
smith
thoma
p
oconnor
ramaswami
chandrashekar
melissa
j
beall
jess
buch
idexx
laboratori
inc
westbrook
main
usa
felin
leukemia
viru
felv
globallydistribut
oncogen
retroviru
caus
fatal
diseas
cat
immunoassay
detect
felv
antigen
readili
use
aid
diagnosi
felv
commerciallyavail
two
decad
singlesampl
rapid
test
format
prefer
inclin
use
microtit
plate
format
enzymelink
immunosorb
assay
elisa
methodolog
commonli
employ
refer
laboratori
set
facilit
batch
test
howev
current
commerciallyavail
microtit
plate
format
elisa
felv
well
suit
purpos
reli
manual
wash
step
dropwis
addit
reagent
reagent
bottl
visual
interpret
result
purpos
studi
valid
microtit
plate
format
elisa
design
specif
maintain
perform
enhanc
throughput
refer
laboratori
set
felv
microtit
plate
format
elisa
method
valid
studi
facilit
high
throughput
oper
combin
parallel
fluid
transfer
process
autom
data
acquisit
result
interpret
assay
method
base
sequenti
orthogon
screen
confirmatori
protocol
screen
protocol
util
two
distinct
antifelv
mous
monoclon
antibodi
produc
colorimetr
respons
sampl
contain
felv
antigen
confirmatori
protocol
requir
neutral
posit
sampl
separ
set
control
assay
use
antifelv
polyclon
antibodi
block
bind
mous
monoclon
antibodi
felv
antigen
therebi
inhibit
color
gener
confirmatori
step
offer
increas
assur
specif
enabl
discrimin
infect
true
posit
fals
posit
associ
sever
factor
includ
antimous
heterophil
antibodi
patient
sampl
precis
screen
assay
determin
use
sampl
neg
low
posit
high
posit
intraassay
coeffici
variat
cv
rang
interassay
cv
rang
confirmatori
assay
low
posit
high
posit
sampl
use
demonstr
intraassay
cv
rang
interassay
cv
interfer
observ
either
protocol
bilirubin
hemoglobin
lipid
concentr
mgdl
mgdl
od
nm
respect
analyt
sensit
felv
antigen
establish
ngml
inactiv
whole
felv
ngml
purifi
recombin
felv
discrimin
analyt
specif
demonstr
base
absenc
crossreact
relat
retroviru
antigen
murin
leukemia
viru
felin
overal
assay
exhibit
diagnost
accuraci
patient
sampl
n
neg
n
posit
felv
statu
defin
combin
basi
pcr
felv
realpcr
idexx
laboratori
inc
independ
elisa
virachek
felv
zoeti
inc
result
studi
valid
new
microtit
plate
format
elisa
highli
specif
precis
accur
method
detect
felv
antigen
felin
patient
sampl
appropri
highthroughput
applic
refer
laboratori
set
small
anim
veterinari
medicin
two
common
pathogen
spirochet
genera
borrelia
spp
leptospira
spp
antibodi
develop
organ
cours
infect
dog
thought
genu
specif
studi
evalu
crossreact
antibodi
individu
borrelia
spp
leptospira
spp
peptid
part
lack
purpos
studi
determin
leptospira
spp
antibodi
induc
administr
one
four
commerci
vaccin
would
crossreact
b
burgdorferi
antigen
use
commerci
avail
assay
staff
student
own
dog
recruit
veterinari
teach
hospit
b
burgdorferi
nonendem
area
inclus
criteria
stipul
dog
appar
healthi
weigh
least
kg
administ
leptospira
spp
vaccin
within
past
year
dog
random
administ
one
four
commerci
avail
leptospira
spp
vaccin
contain
serovar
canicola
gryppotyphosa
icterohemorrhagia
pomona
blood
collect
prior
vaccin
administr
week
week
week
leptospira
spp
microagglutin
titer
mat
determin
use
commerci
avail
servic
confirm
maxim
leptospira
spp
titer
occur
week
aliquot
sera
ship
antech
diagnost
analysi
b
burgdorferi
antibodi
ospa
ospc
ospf
accuplex
biocd
system
week
sera
dog
mat
titer
least
leptospira
spp
serovar
mat
titer
greater
detect
serovar
gryppotyphosa
serovar
pomona
dog
none
sampl
contain
antibodi
b
burgdorferi
ospa
ospc
ospf
peptid
use
commerci
avail
assay
conclus
b
burgdorferi
peptid
use
accuplex
biocd
system
recogn
antibodi
induc
commerci
avail
leptospira
spp
vaccin
administ
studi
howev
later
flow
devic
manufactur
laboratori
provid
b
burgdorferi
serolog
assay
specif
sourc
peptid
may
vari
antigen
use
result
studi
may
laboratori
anaplasma
phagocytophilum
ap
transmit
ixod
spp
caus
granulocyt
anaplasmosi
mani
speci
includ
dog
cat
hors
peopl
endem
area
antibodi
ap
detect
serum
dog
healthi
dog
ap
pcr
posit
effect
prednisolon
administr
dog
infect
ap
scapulari
infest
determin
total
six
young
laboratoryrear
beagl
infect
ap
vector
born
agent
evidenc
detect
ap
dna
blood
pcr
assay
fastpanel
antech
diagnost
ap
antibodi
serum
accuplex
biocd
system
antech
diagnost
infest
wildcaught
scapulari
select
studi
week
scapulari
infest
dog
place
two
group
contain
one
ap
pcr
posit
ap
antibodi
posit
dog
two
ap
pcr
neg
ap
antibodi
posit
dog
group
administ
doxycyclin
mgkg
po
twice
daili
week
sampl
collect
morn
week
dog
administ
prednisolon
mgkg
po
daili
week
dog
evalu
daili
clinic
abnorm
cbc
ap
pcr
ap
antibodi
assay
week
sera
dog
assay
ap
antibodi
week
clinic
abnorm
detect
cours
studi
cbc
abnorm
note
anemia
thrombocytosi
neutropenia
one
group
dog
one
group
dog
week
prior
prednisolon
administr
week
one
dog
posit
ap
dna
blood
group
week
week
one
group
dog
neg
ap
antibodi
sampl
collect
week
two
group
dog
neg
ap
antibodi
week
contrast
dog
group
ap
antibodi
posit
week
dog
anemia
thrombocytosi
neutropenia
day
prednisolon
initi
clinic
normal
ap
pcr
neg
normal
cbc
evalu
suggest
result
spuriou
one
dog
group
posit
ap
dna
week
also
posit
week
prior
prednisolon
administr
none
sampl
assess
cbc
ap
pcr
assay
initi
prednisolon
administr
show
evid
activ
ap
infect
suggest
protocol
unlik
advers
affect
dog
chronic
ap
infect
field
whether
immun
suppress
protocol
would
activ
chronic
ap
infect
remain
proven
dog
becam
ap
seroneg
week
administ
doxycyclin
suggest
treatment
may
aid
elimin
chronic
ap
infect
even
prednisolon
administr
object
studi
determin
proport
felin
caliciviru
fcv
field
isol
would
neutral
vitro
sera
cat
routin
vaccin
product
contain
two
calicivirus
serum
cat
hyperinocul
felin
calicivirus
fcv
shown
cross
neutral
greater
proport
fcv
field
isol
unit
state
compar
serum
cat
hyperinocul
fcv
isol
week
age
kitten
administ
experiment
vaccin
contain
modifiedl
panleukopenia
modifiedl
felin
herpesviru
nonadjuv
inactiv
caliciviru
strain
serum
collect
kitten
day
second
dose
vaccin
pool
day
abil
pool
sera
neutral
total
fcv
strain
collect
cat
usa
determin
specif
fcv
serum
neutral
titer
fcv
defin
serum
dilut
caus
inhibit
viru
replic
use
day
postvaccin
pool
sera
fcv
isol
neutral
use
day
postvaccin
pool
sera
fcv
isol
neutral
placebo
serum
pool
undetect
antibodi
titer
fcv
field
strain
screen
crossneutr
usa
field
strain
fcv
use
pool
sera
kitten
administ
dose
inactiv
nonadjuv
vaccin
contain
strain
result
suggest
cat
vaccin
product
contain
one
fcv
isol
like
broad
heterolog
protect
expos
field
strain
fcv
giardia
spp
cryptosporidium
spp
protozoan
colon
reproduc
intestin
mani
domest
anim
includ
dog
cat
outcom
rang
subclin
infect
sever
diarrhea
cryptosporidium
spp
infect
rate
dog
cat
larg
unknown
sensit
diagnost
procedur
previous
avail
polymeras
chain
reaction
pcr
assay
avail
amplifi
giardia
spp
cryptosporidium
spp
dna
fece
purpos
studi
report
fecal
pcr
assay
result
giardia
cryptosporidium
sampl
set
dog
cat
usa
fecal
sampl
submit
commerci
laboratori
diagnost
evalu
pcr
panel
assay
ampli
dna
select
group
infecti
agent
includ
giardia
spp
dog
cat
cryptosporidium
spp
dog
cat
cryptosporidium
feli
cat
analyz
descript
univari
multivari
logist
regress
analys
conduct
assess
associ
amongst
age
sex
region
season
probabl
test
posit
either
giardia
spp
cryptosporidium
spp
pet
dog
cat
giardia
spp
cryptosporidium
spp
fecal
pcr
assay
result
avail
dog
cat
cryptosporidium
spp
dna
amplifi
fece
giardia
spp
dna
posit
dog
giardia
spp
dna
posit
cat
giardia
spp
dna
posit
cat
posit
cryptosporidium
feli
dna
logist
regress
model
result
show
age
young
region
associ
presenc
giardia
spp
dna
cryptosporidium
spp
dna
fece
dog
cat
addit
presenc
giardia
spp
dna
fece
dog
vari
season
result
indic
giardia
spp
dna
cryptosporidium
spp
dna
cryptosporidium
feli
dna
commonli
amplifi
fece
dog
cat
coinfect
common
posit
rate
vari
age
season
region
either
agent
suspect
highli
young
anim
addit
studi
requir
evalu
associ
posit
test
result
clinic
find
determin
likelihood
dog
cat
carri
zoonot
giardia
spp
cryptosporidium
spp
tickborn
diseas
includ
lyme
diseas
ehrlichiosi
anaplasmosi
becom
increasingli
preval
tick
distribut
expand
climat
chang
wildlif
migrat
increas
reloc
companion
anim
granulocyt
anaplasmosi
caus
oblig
intracellular
bacterium
anaplasma
phagocytophilum
transmit
ixod
spp
tick
dog
human
suscept
infect
dog
common
sign
infect
lethargi
anorexia
lame
fever
nonspecif
differenti
diagnosi
support
evid
morula
dna
especi
acut
case
detect
specif
antibodi
use
ifa
elisabas
test
relat
distinct
bacterium
plati
also
infect
dog
caus
infecti
cyclic
thrombocytopenia
present
studi
compar
perform
two
inclin
rapid
test
snap
plu
test
idexx
vetscan
canin
anaplasma
test
abaxi
random
canin
sampl
sourc
endem
region
phagocytophilum
character
phagocytophilum
immunoflouresc
assay
ifa
perform
commerci
refer
laboratori
platysspecif
sampl
sourc
dog
live
southwest
platysendem
region
sampl
character
use
platysspecif
peptid
elisa
character
sampl
blind
random
test
two
inclin
rapid
test
result
shown
tabl
notabl
vetscan
test
fail
detect
medium
high
titer
phagocytophilum
sampl
clientown
cat
moscow
russia
expos
flea
tick
develop
fever
hemolyt
anemia
thrombocytopenia
gingiv
clinic
problem
note
cat
countri
howev
limit
data
avail
concern
preval
rate
infecti
agent
common
eastern
western
europ
overal
object
studi
determin
estim
preval
select
felin
infecti
diseas
agent
conveni
sampl
popul
cat
moscow
russia
remnant
blood
edta
serum
client
own
cat
moscow
evalu
reason
independ
studi
collect
permiss
store
evalu
use
previous
valid
assay
sera
assay
toxoplasma
gondii
igg
toxo
bartonella
spp
igg
bart
felv
antigen
ag
fiv
antibodi
ab
total
dna
extract
blood
sampl
dna
anaplasma
spp
bartonella
spp
ehrlichia
spp
haemoplasma
amplifi
previous
valid
pcr
assay
mycoplasma
hemof
mhf
amplicon
confirm
sequenc
none
cat
posit
dna
anaplasma
spp
ehrlichia
spp
mani
cat
show
evid
exposur
current
infect
one
agent
bartonella
spp
antibodi
common
serum
candidatu
hemominutum
mhm
dna
common
blood
toxoplasma
gondii
igg
bartonella
spp
igg
titer
rang
cat
sampl
evalu
assay
singl
dual
tripl
quadrupl
infect
document
sampl
respect
use
subset
sampl
cat
evid
infect
exposur
one
select
agent
result
sampl
popul
suggest
cat
moscow
expos
intermedi
host
undercook
meat
gondii
flea
bartonella
spp
hemoplasma
come
direct
contact
infect
cat
hemoplasma
felv
fiv
infecti
agent
appropri
clinic
differenti
list
process
food
fed
ectoparasit
control
maintain
felinefelin
contact
avoid
possibl
coxiella
burnetii
rickettsi
pathogen
seriou
zoonot
implic
q
fever
transmit
direct
contact
vector
numer
tick
speci
cat
infect
c
burnetii
implic
human
infect
australia
unit
state
minim
inform
exist
concern
rout
felin
infect
recent
c
burnetii
dna
isol
ctenocephalid
feli
collect
wildlif
cypru
flea
commonli
infest
cat
purpos
studi
evalu
select
group
flea
cat
australia
unit
state
presenc
c
burnetii
dna
use
previous
optim
pcr
assay
dna
sampl
util
studi
extract
flea
infest
cat
previous
publish
bartonella
spp
hemoplasma
rickettsia
feli
studi
maintain
present
studi
flea
collect
cat
eastern
australia
southern
unit
state
alabama
florida
pool
group
compris
maximum
flea
dna
extract
previous
report
convent
pcr
assay
util
primer
pair
target
insert
sequenc
transposas
element
c
burnetii
genom
use
posit
amplicon
detect
genet
sequenc
would
perform
confirm
presenc
pathogen
studi
flea
speciat
dna
extract
howev
previou
studi
countri
suggest
c
feli
like
detect
sensit
assay
shown
ng
total
c
burnetii
genom
dna
per
pcr
reaction
util
primer
set
posit
neg
control
perform
expect
none
pool
flea
extract
posit
c
burnetii
dna
coxiella
burnetii
dna
recov
flea
collect
cat
eastern
australia
southern
unit
state
result
suggest
flea
infest
domest
cat
region
import
vector
c
burnetii
unlik
play
role
transmiss
organ
human
q
fever
canin
infect
dirofilaria
immiti
parasit
agent
respons
caus
heartworm
diseas
easili
safe
prevent
via
period
administr
one
number
prevent
agent
mani
veterinarian
oregon
routin
recommend
use
heartworm
prophylact
therefor
dog
commonli
prevent
confus
regard
use
heartworm
prevent
oregon
understand
given
pauciti
incid
data
region
decis
veterinarian
client
whether
start
prevent
often
made
base
costbenefit
analysi
cost
known
purpos
studi
evalu
risk
develop
heartworm
infect
amongst
unprotect
dog
northwestern
oregon
inform
enabl
veterinarian
client
make
inform
decis
regard
heartworm
prevent
march
august
owner
dog
surrend
oregon
human
societi
fill
short
questionnair
relat
dog
histori
questionnair
use
determin
elig
dog
studi
criteria
inclus
studi
includ
dog
possess
surrend
parti
sinc
month
age
younger
least
month
age
histori
travel
outsid
state
oregon
never
administ
heartworm
prevent
dog
meet
four
criteria
exclud
studi
addit
inform
gather
record
includ
breed
age
sex
spayneut
statu
locat
zip
code
averag
number
hour
dog
spent
outdoor
dog
meet
studi
criteria
blood
drawn
test
presenc
immiti
use
commerci
avail
elisa
test
idexx
snap
plu
total
dog
surrend
oregon
human
societi
period
met
inclus
criteria
includ
studi
none
dog
test
posit
dirofilaria
immiti
test
dog
spent
median
year
previou
owner
rang
month
year
combin
total
year
exposur
use
likelihoodbas
method
maximum
likelihood
estim
mle
risk
ci
per
year
find
studi
suggest
likelihood
unprotect
northwestern
oregon
dog
develop
heartworm
infect
current
low
heartworm
transmiss
predict
model
base
climat
data
knightlok
shown
climat
condit
area
support
heartworm
transmiss
data
compil
companion
anim
parasit
council
capcvetorg
confirm
dirofilaria
immiti
diagnos
within
state
oregon
although
posit
case
heartworm
us
state
oregon
import
consid
data
reflect
point
time
popul
oregon
continu
grow
heartworm
infect
dog
invari
arriv
chang
climat
pattern
also
influenc
transmiss
diseas
continu
monitor
vigil
recommend
last
sever
year
clinic
ill
number
peopl
baja
california
sur
exico
suspect
associ
rickettsi
diseas
agent
rickettsia
rickettsii
rickettsia
feli
andor
ehrlichia
speci
object
studi
determin
preval
select
vector
vectorborn
diseas
agent
carri
companion
dog
region
plan
commun
outreach
steril
vaccin
clinic
local
dog
consent
owner
sampl
ectoparasit
collect
infest
dog
preserv
alcohol
identif
blood
sampl
collect
edta
nonaddit
tube
retain
test
sera
assay
antigen
dirofilaria
immiti
antibodi
ehrlichia
canis
ewingii
anaplasma
phagocytophiluma
plati
borrelia
burgdorferi
use
commerci
kit
idexx
laboratori
sera
also
assay
antibodi
rickettsia
speci
indirect
fluoresc
antibodi
ifa
test
r
rickettsia
antigen
sourc
total
dna
extract
blood
evalu
convent
polymeras
chain
reaction
pcr
assay
amplifi
dna
anaplasma
speci
babesia
speci
bartonella
speci
ehrlichia
speci
rickettsia
speci
hemotrop
mycoplasma
speci
hemoplasma
posit
amplicon
sequenc
ascertain
speci
sampl
dog
avail
ectoparasit
rhipicephalu
sanguineu
dog
ctenocephalid
feli
dog
pulex
irritanssimulan
four
dog
identifi
dirofilaria
immiti
antigen
one
dog
antibodi
phagocytophiluma
plati
dog
e
canis
ewingii
dog
detect
serum
dog
two
sampl
probabl
antibodi
r
rickettsii
ifa
test
confirm
evalu
dna
dog
complet
date
e
cani
dna
amplifi
eight
dog
plati
dna
six
dog
babesia
cani
voge
dna
three
dog
mycoplasma
haemocani
dna
three
dog
coinfect
confirm
four
dog
consist
immitis
cani
one
dog
e
canisa
plati
one
dog
e
canism
haemocani
one
dog
e
canisa
plati
haemocani
one
dog
vectorborn
agent
detect
date
like
reflect
common
exposur
r
sanguineu
tick
vector
pcrconfirm
agent
inform
gain
complet
pcr
assay
analysi
blood
flea
tick
canin
group
set
locat
event
dog
temporarili
come
togeth
share
environ
eg
show
sport
event
dog
park
pose
increas
risk
infecti
diseas
transmiss
despit
increas
risk
guidelin
exist
provid
recommend
reduc
diseas
risk
set
panel
canin
infecti
diseas
expert
review
current
literatur
draft
set
evidencebas
recommend
prevent
infecti
diseas
dog
group
set
august
survey
attende
akc
canin
health
foundat
parent
organ
confer
complet
determin
agreement
perceiv
barrier
recommend
selfadminist
survey
provid
confer
attende
consist
seri
likerttyp
openend
question
onlin
paper
format
seek
feedback
recommend
survey
complet
individu
respons
review
summar
openend
comment
categor
theme
respond
selfidentifi
particip
judg
breeder
varieti
local
nation
intern
canin
group
event
respond
agre
three
panel
recommend
yet
major
respond
state
recommend
would
difficult
difficult
implement
set
primarili
dog
show
common
survey
result
theme
relat
difficulti
implement
includ
administr
concern
cost
human
resourcesmanpow
enforc
issu
ethic
concern
privaci
concern
strong
need
offici
outreach
promot
awar
educ
relat
canin
infecti
diseas
survey
respons
identifi
need
refin
recommend
aid
comprehens
clariti
especi
around
ectoand
endoparasit
control
educ
promot
cultur
chang
relat
diseas
risk
prevent
order
rais
awar
canin
infecti
diseas
group
set
amoungst
event
particip
attende
organ
onlin
freeli
avail
canin
infecti
diseas
risk
calcul
tool
develop
mycoplasma
speci
one
common
infecti
caus
conjunct
cat
mycoplasma
feli
commonli
implic
primari
pathogen
mycoplasma
speci
also
detect
clinic
ill
cat
find
previou
studi
use
convent
pcr
cpcr
investig
role
mycoplasma
speci
causat
felin
conjunct
mix
mycoplasma
carri
appar
normal
cat
therefor
purpos
studi
determin
increas
sever
conjunct
cat
correl
higher
mycoplasma
speci
copi
number
use
qpcr
total
conjunctiv
swab
collect
shelter
cat
conjunct
confirm
contain
mycoplasma
speci
dna
use
cpcr
select
studi
sever
conjunct
time
sampl
acquir
determin
use
grade
scheme
sampl
evalu
use
previous
valid
qpcr
determin
mycoplasma
copi
number
statist
method
consist
use
spearman
rho
test
determin
sever
conjunct
correl
qpcr
mycoplasma
speci
copi
number
result
reveal
sever
conjunct
significantli
correl
qpcr
mycoplasma
copi
number
spearman
correl
coeffici
p
howev
strength
correl
mild
moder
base
result
studi
futur
investig
impact
mycoplasma
speci
feli
correl
qpcr
sever
conjunct
cat
perform
colostrum
provid
puppi
passiv
immun
transfer
dog
immunoglobulin
g
igg
acquir
via
transplacent
transfer
inadequ
colostrum
intak
first
day
life
depriv
puppi
immunoglobulin
also
mani
hormon
growth
factor
nutrient
henc
increas
risk
neonat
morbid
mortal
supplement
first
hour
life
canin
serum
plasma
increas
blood
igg
concentr
colostrum
depriv
puppi
well
improv
growth
entir
neonat
period
week
studi
aim
evalu
effect
exogen
specif
antibodi
administr
via
egg
yolk
intestin
barrier
closur
growth
prewean
puppi
specif
antibodi
canin
parvoviru
type
e
coli
obtain
egg
hen
vaccin
separ
one
mention
agent
egg
yolk
flashdri
test
presenc
e
colispecif
antibodi
hyperimmun
solut
prepar
mix
egg
powder
commerci
milk
replac
babydog
milk
royal
canin
aimargu
franc
g
egg
powder
antibodi
g
egg
powder
e
coli
antibodi
ml
reconstitut
milk
total
puppi
differ
breed
enrol
one
breed
kennel
includ
studi
depend
expect
adult
bodi
weight
puppi
classifi
small
breed
dog
adult
weight
kg
larg
breed
dog
l
kg
within
litter
take
account
birth
weight
puppi
assign
supplement
control
group
puppi
supplement
group
receiv
oral
g
bw
hyperimmun
solut
within
first
hour
birth
puppi
control
group
receiv
dose
g
time
birth
h
milk
replac
puppi
weigh
birth
day
life
linear
mix
model
mix
procedur
sa
institut
inc
cari
nc
usa
litter
model
random
effect
perform
determin
variabl
affect
birth
weight
weight
gain
neonat
period
breed
size
small
larg
age
day
supplement
supplement
control
group
interact
mention
fix
effect
also
test
l
repres
includ
puppi
among
l
supplement
respect
weight
birth
significantli
higher
l
compar
median
g
interquartil
rang
g
versu
g
g
p
birth
weight
found
differ
supplement
control
puppi
whatev
breed
size
p
g
p
differ
evidenc
supplement
control
p
studi
larg
breed
puppi
supplement
birth
hyperimmun
egg
yolk
greater
weight
gain
entir
neonat
period
retard
growth
earli
stage
life
increas
risk
morbid
mortal
puppi
thu
could
hypothes
better
growth
supplement
puppi
reflect
better
health
nevertheless
studi
need
order
confirm
find
breed
kennel
larg
number
individu
poffenbarg
et
al
canin
health
product
contain
antibodi
canin
parvoviru
type
declin
cerebr
glucos
metabol
common
featur
age
peopl
anim
includ
rat
dog
monkey
close
associ
agedepend
cognit
declin
confirm
previou
studi
dietari
medium
chain
triglycerid
mct
enhanc
cognit
function
dog
provid
brain
altern
energi
sourc
studi
investig
effect
dietari
mct
voluntari
activ
dog
cat
cat
studi
sixteen
middleag
senior
cat
fed
mainten
energi
requir
mer
control
diet
one
week
switch
mctcontain
diet
day
daili
activ
monitor
feed
trial
activ
monitor
dog
studi
twenti
senior
dog
fed
mer
control
diet
day
assign
one
mctcontain
diet
dog
per
diet
day
dog
switch
altern
mct
diet
day
daili
activ
record
activ
monitor
feed
trial
cat
mctcontain
diet
significantli
increas
daytim
excess
weight
gain
associ
metabol
hormon
chang
predispos
cat
insulin
resist
disord
adipokin
leptin
import
regul
energi
metabol
circul
leptin
concentr
correl
fat
mass
cat
speci
cat
leptin
associ
insulin
resist
independ
bodyweight
although
dietari
factor
energi
densiti
fat
content
feed
pattern
increas
risk
obes
limit
inform
dietari
factor
feed
fast
macronutri
content
influenc
leptin
concentr
cat
aim
studi
compar
leptin
concentr
lean
healthi
cat
fed
diet
high
protein
fat
carbohydr
assess
associ
leptin
concentr
insulin
glucos
nefa
concentr
determin
effect
feed
pattern
baselin
postprandi
leptin
concentr
control
trial
conduct
clinic
healthi
cat
n
mean
bodi
weight
kg
cat
ideal
bodi
condit
score
scale
cat
fed
washout
diet
commerci
felin
diet
five
week
fed
one
three
test
diet
high
one
protein
fat
carbohydr
five
week
diet
dri
extrud
formul
test
diet
provid
approxim
energi
test
macronutri
energi
two
test
macronutri
leptin
concentr
measur
two
feed
pattern
mealfeed
test
daili
feed
ad
libitumfeed
test
conduct
week
commenc
test
diet
mealfeed
test
cat
ate
hour
ad
libitum
intak
singl
meal
hour
blood
sampl
ml
collect
hour
meal
feed
test
hour
ad
libitum
test
distribut
leptin
variabl
ad
libitum
mealfeed
test
similar
across
dietari
group
consumpt
washout
diet
week
mean
baselin
concentr
averag
minut
valu
mean
concentr
hour
mean
peak
leptin
concentr
meal
feed
test
vari
significantli
diet
overal
p
baselin
mean
peak
leptin
concentr
high
fat
diet
significantli
higher
high
protein
diet
baselin
mean
high
carbohydr
diet
similar
pattern
observ
ad
libitum
feed
test
highest
leptin
concentr
cat
consum
high
fat
diet
gener
leptin
concentr
consum
high
carbohydr
diet
significantli
differ
high
protein
diet
differ
leptin
concentr
high
carbohydr
diet
higher
compar
high
protein
signific
effect
diet
time
peak
leptin
concentr
mealfeed
test
overal
p
median
time
peak
leptin
concentr
hour
diet
mealfeed
test
cat
significantli
exceed
baselin
leptin
concentr
high
protein
high
fat
diet
high
carbohydr
diet
gener
leptin
concentr
decreas
significantli
approxim
hr
eat
meal
feed
test
remain
rel
constant
ad
libitum
feed
data
diet
combin
leptin
significantli
posit
correl
insulin
concentr
ad
libitum
feed
p
baselin
hour
meal
feed
test
p
respect
correl
leptin
either
glucos
nefa
across
diet
glucos
insulin
nefa
account
declin
leptin
soon
feed
meal
feed
test
conclus
independ
feed
pattern
leptin
concentr
tend
highest
lean
cat
consum
diet
energi
fat
compar
diet
high
protein
carbohydr
leptin
concentr
vari
minim
hour
ad
libitum
feed
wherea
leptin
decreas
approxim
hour
feed
follow
fast
decreas
account
chang
insulin
glucos
nefa
concentr
investig
need
understand
interact
hormon
associ
satieti
dietari
factor
weight
gain
cat
promot
water
intak
recommend
manag
dog
lower
urinari
tract
diseas
increas
dietari
salt
use
purpos
veterinari
therapeut
diet
object
studi
evalu
potenti
advers
effect
dietari
salt
sodium
chlorid
blood
pressur
cardiac
function
dog
follow
two
week
baselin
period
dog
fed
control
diet
contain
g
kcal
twenti
healthi
dog
year
old
alloc
two
group
fed
diet
differ
total
sodium
chlorid
content
control
con
g
sodium
kcal
high
sodium
diet
hna
g
kcal
dog
fed
respect
diet
month
period
indirect
systol
blood
pressur
record
monthli
overal
health
cardiac
function
evalu
echocardiographi
perform
board
veterinari
cardiologist
plasma
btype
natriuret
peptid
bnp
serum
biochemistri
urinalys
assess
month
test
bodi
composit
analyz
dual
energi
xray
absorptiometri
dexa
month
treatment
effect
analyz
use
ttest
gener
linear
mix
model
overal
dietari
sodium
level
signific
effect
blood
pressur
cardiac
function
plasma
bnp
serum
biochem
profil
urinalys
dietari
effect
diet
time
interact
bone
miner
content
bodi
composit
conclus
consumpt
diet
contain
g
kcal
advers
effect
blood
pressur
cardiac
function
healthi
adult
dog
period
determin
lactat
glucos
threshold
dog
submit
increment
exercis
test
iet
scarc
studi
aim
determin
lactat
glucos
threshold
investig
acidbas
respons
untrain
dog
submit
increment
exercis
test
fourteen
beagl
dog
year
old
healthi
untrain
use
determin
lactat
glucos
threshold
submit
iet
use
treadmil
slop
increas
speed
ms
everi
minut
test
conclud
dog
present
fatigu
signal
blood
sampl
collect
second
effort
step
though
venou
cathet
place
jugular
vein
sampl
use
determin
acidbas
alter
collect
moment
iet
immedi
five
minut
fatigu
data
submit
shapirowilk
test
pearson
use
correl
run
veloc
correspond
lactat
glucos
threshold
analysi
moment
assess
perform
use
repeat
measur
oneway
anova
p
found
high
correl
lactat
glucos
threshold
veloc
r
p
ph
pco
hco
strong
ion
differ
sid
found
moment
effect
p
basal
valu
ph
increas
p
fatigu
ae
ae
respect
pco
present
reduct
p
fatigu
minut
fatigu
ae
ae
comparison
basal
valu
ae
hco
decreas
fatigu
minut
iet
ae
ae
compar
basal
ae
valu
sid
show
decreas
fatigu
compar
valu
exercis
ae
e
ae
respect
run
veloc
correspond
lactat
glucos
threshold
show
accord
alreadi
shown
hors
human
besid
result
show
respiratori
alkalosi
metabol
acidosi
consid
chang
due
hyperventil
strenuou
anaerob
activ
decreas
pco
concentr
lead
increas
ph
increas
relat
hco
pco
sid
show
metabol
acidosi
possibl
lactat
valu
increas
result
studi
suggest
glucos
threshold
use
marker
aerob
capac
dog
use
human
hors
besid
maximum
exercis
dog
caus
acid
basic
alter
fed
food
similar
palat
cat
choos
dog
calori
protein
denni
jewel
jodi
vondran
melissa
vanchina
jean
hall
hill
pet
nutrit
inc
topeka
ks
usa
oregon
state
univers
corval
usa
dog
cat
specif
tast
prefer
influenc
macronutri
composit
physic
characterist
food
well
presenc
absenc
specif
tast
impart
compound
palat
enhanc
studi
investig
relationship
food
choic
macronutri
composit
choic
subsequ
plasma
amino
acid
concentr
experiment
food
dog
cat
individu
prepar
similar
palat
manipul
factor
independ
macronutri
food
similar
palat
prefer
respect
popul
whole
investig
intak
choic
use
dog
vari
bodi
fat
composit
mean
kg
sd
kg
rang
kg
cat
mean
bodi
fat
composit
kg
sd
kg
rang
kg
subsequ
effect
food
choic
serum
amino
acid
also
determin
four
complet
balanc
food
avail
dog
cat
time
four
vari
macronutri
content
food
high
protein
calori
protein
dog
cat
food
high
fat
calori
fat
dog
cat
food
high
carbohydr
calori
carbohydr
dog
cat
food
blend
macronutri
dog
averag
chose
consum
calori
protein
sd
rang
wherea
cat
chose
calori
protein
sd
rang
bodi
composit
influenc
choic
calori
protein
dog
posit
relationship
bodi
fat
percent
calori
consum
protein
r
p
relationship
lean
bodi
mass
percent
calori
consum
protein
r
p
overal
dog
high
bodi
fat
show
highest
prefer
dietari
calori
protein
cat
bodi
fat
lean
bodi
mass
neg
associ
calori
consum
protein
p
p
respect
posit
associ
interact
p
overal
cat
high
bodi
fat
high
lean
bodi
mass
show
highest
prefer
dietari
calori
protein
dog
higher
circul
amino
acid
concentr
threonin
methionin
isoleucin
valin
p
compar
cat
later
higher
circul
amino
acid
concentr
isoleucin
valin
tyrosin
phenylalanin
histidin
p
dog
cat
effect
protein
intak
circul
essenti
amino
acid
concentr
increas
intak
calori
protein
associ
increas
plasma
ornithin
dog
citrullin
dog
cat
concentr
p
summari
given
opportun
choos
food
similar
palat
cat
chose
consum
dog
calori
protein
although
speci
differ
circul
amino
acid
concentr
indic
metabol
shift
associ
protein
intak
chang
circul
essenti
amino
acid
concentr
purpos
doubl
mask
control
multicent
clinic
trial
determin
impact
food
ingredi
design
skin
coat
health
benefit
immun
modul
effect
clinic
sign
season
atop
dermat
versu
control
food
dog
histori
season
dermat
without
current
clinic
sign
consist
atopi
cadesi
pruriti
score
recruit
spring
gener
practic
unit
state
dog
current
food
design
advers
food
reaction
exclud
elig
dog
randomli
assign
test
control
group
evalu
veterinarian
week
consist
accept
standard
care
treatment
withheld
therefor
prescrib
medic
dose
inform
collect
oclacitinib
uniformli
avail
practic
disallow
veterinarian
grade
skin
lesion
use
modifi
cadesi
absent
sever
erythema
alopecia
excori
lichenif
bodi
site
max
score
pruriti
score
absent
sever
fortyfour
adult
dog
test
control
enrol
complet
studi
cours
studi
dog
report
dermatolog
clinic
sign
wherea
develop
posit
cadesi
andor
pruriti
score
cadesi
pruriti
score
rose
significantli
subsequ
time
point
gener
low
mean
ae
sem
cadesi
score
week
ae
ae
ae
ae
respect
mean
ae
sem
pruriti
score
ae
week
highest
week
ae
incid
locat
type
clinic
sign
manifest
differ
group
medic
dispens
dog
posit
cadesi
andor
pruriti
score
dog
control
versu
test
medic
dispens
categor
topic
contain
glucocorticoid
system
antihistamin
andor
system
administ
glucocorticoid
event
histori
analysi
reveal
time
prescrib
topic
medic
highli
similar
group
test
ae
versu
control
ae
day
less
antihistamin
test
ae
versu
control
ae
day
system
glucocorticoid
test
ae
versu
control
ae
day
studi
first
describ
recurr
rate
season
atopi
dog
gener
practic
part
grade
multicent
clinic
trial
onset
clinic
sign
result
medic
intervent
major
dog
statist
power
studi
like
influenc
gener
low
cadesi
pruriti
score
combin
medic
intervent
addit
interv
medic
intervent
like
influenc
studi
schedul
promot
frequent
evalu
case
manag
data
suggest
dog
season
atopi
benefit
frequent
evalu
data
also
suggest
alter
manag
dog
fed
test
food
medic
use
lower
interv
prior
onset
system
antihistamin
andor
glucocorticoid
longer
food
design
skin
coat
health
benefit
immun
modul
effect
part
proactiv
atopi
manag
program
may
result
less
medic
need
retrospect
felin
studi
shown
sdma
sensit
scr
earli
ckd
detect
object
compar
sdma
scr
detect
earli
ckd
prospect
longitudin
studi
older
dog
sdma
tradit
serum
urin
clinicopatholog
test
measur
biannual
four
year
dog
initi
median
age
year
persist
increas
upc
scr
sdma
decreas
usg
trigger
renal
ultrasound
us
gfr
plasma
iohexol
clearanc
evalu
necropsi
perform
whenev
possibl
dog
die
euthan
ckd
document
dog
us
abnorm
n
decreas
gfr
reduct
n
persist
renal
proteinuria
upc
n
renal
histolog
n
dog
multipl
abnorm
dog
increas
sdma
without
hypersthenuria
concurr
subsequ
ckd
diagnosi
one
dog
singl
endpoint
increas
sdma
persistentmultipl
sdma
increas
convers
dog
increas
scr
mgdl
point
dog
concurrentprior
sdma
increas
dog
decreas
gfr
scr
sdma
increas
dog
respect
persist
increas
sdma
without
hypersthenuria
without
ckd
increas
sdma
without
hypersthenuria
sensit
specif
ckd
wherea
increas
scr
without
hypersthenuria
sensit
specif
p
sdma
sensit
biomark
earli
canin
ckd
cross
idexx
laboratori
westbrook
usa
purpos
studi
determin
correl
sdma
cystatin
c
creatinin
felin
assess
util
marker
togeth
diagnos
chronic
kidney
diseas
ckd
fiftysix
felin
serum
sampl
sourc
sampl
submit
idexx
refer
laboratori
gener
chemistri
test
cystatin
c
sdma
creatinin
assay
use
beckman
clinic
chemistri
analyz
three
method
calibr
appropri
day
assay
qc
perform
prior
analysi
felin
serum
sampl
fiftysix
felin
serum
sampl
assay
duplic
three
analyt
day
sdma
valid
cat
valu
indic
ckd
like
present
studi
sdma
correl
well
serum
creatinin
one
sampl
felin
creatinin
cutoff
mgdl
also
sdma
cutoff
elev
creatinin
sampl
one
sampl
near
cutoff
sdma
creatinin
sampl
normal
creatinin
valu
distribut
normal
sdma
valu
sampl
normal
creatinin
valu
elev
sdma
valu
sampl
normal
creatinin
valu
consist
previou
data
show
sdma
elev
earlier
creatinin
case
ckd
howev
cystatin
c
effect
differenti
felin
normal
abnorm
creatinin
level
sampl
felin
sampl
abnorm
creatinin
level
show
normal
cystatin
c
use
previous
publish
cystatin
c
cutoff
mgdl
determin
cat
cat
normal
creatinin
level
half
cystatin
c
result
discrep
sampl
abnorm
cystatin
c
level
studi
altern
cutoff
valu
could
determin
cystatin
c
assay
would
significantli
increas
diagnost
valu
sdma
previous
shown
correl
well
gfr
elev
prior
creatinin
anim
make
excel
marker
ckd
felin
howev
highthroughput
immunoturbidometr
cystatin
c
assay
differenti
anim
elev
creatinin
recommend
aid
diagnos
ckd
felin
human
cat
chronic
kidney
diseas
ckd
fibroblast
growth
associ
diseas
progress
develop
renal
secondari
hyperparathyroid
rhpt
human
elev
often
preced
hyperphosphatemia
rhpt
object
studi
measur
plasma
concentr
healthi
dog
dog
ckd
determin
associ
serum
creatinin
phosphoru
parathyroid
hormon
pth
concentr
thirtyfour
dog
ckd
healthi
dog
includ
dog
ckd
stage
accord
intern
renal
interest
societi
iri
guidelin
human
elisa
valid
canin
sampl
show
linear
intraand
interassay
coeffici
variat
valu
present
median
rang
plasma
concentr
healthi
dog
dog
iri
stage
ckd
pgml
respect
p
plasma
concentr
posit
correl
creatinin
r
p
phosphoru
r
p
pth
r
p
concentr
studi
dog
nineteen
ckd
dog
concentr
upper
rang
normal
dog
base
healthi
dog
phosphoru
concentr
ckd
dog
elev
phosphoru
concentr
eight
ckd
dog
hyperparathyroid
find
suggest
concentr
rise
canin
ckd
tradit
marker
rhpt
consequ
concentr
consid
earli
indic
diseas
progress
rhpt
potenti
target
therapeut
intervent
erythropoiesisstimul
agent
current
recommend
veterinari
patient
anemia
secondari
chronic
kidney
diseas
ckd
darbepoetin
alfa
darbepoetin
replac
epoetin
due
threefold
longer
halflif
allow
less
frequent
dose
also
darbepoetin
perceiv
less
like
elicit
format
antierythropoietin
antibodi
result
pure
red
cell
aplasia
prca
previou
studi
examin
efficaci
darbepoetin
cat
ckd
cat
respond
advers
event
observ
cat
includ
two
possibl
prca
retrospect
studi
evalu
respons
darbepoetin
therapi
protocol
administr
potenti
advers
event
dog
ckd
thirtyfour
dog
iri
stage
ckd
met
inclus
criteria
medic
record
review
data
record
includ
cbc
serum
biochemistri
panel
reticulocyt
count
serum
iron
paramet
systol
blood
pressur
pack
red
blood
cell
prbc
transfus
iron
supplement
darbepoetin
dose
frequenc
administr
comorbid
advers
event
surviv
start
hct
rang
mean
start
dose
darbepoetin
rang
mcgkg
median
mcgkg
initi
dose
frequenc
everi
day
dog
nine
dog
receiv
prbc
transfus
dog
receiv
iron
supplement
form
prbc
transfus
intramuscular
iron
dextran
oral
supplement
combin
thereof
start
darbepoetin
therapi
sixteen
dog
receiv
ongo
iron
supplement
throughout
treatment
surviv
follow
initi
darbepoetin
therapi
rang
day
median
day
estim
dose
darbepoetin
administ
cours
treatment
rang
dose
administ
per
dog
median
dose
per
dog
dog
consid
respond
achiev
hct
cours
treatment
twentynin
dog
respond
time
respons
rang
day
median
day
associ
start
hct
dose
frequenc
administr
darbepoetin
initi
iron
supplement
respond
nonrespond
dog
receiv
prbc
transfus
onset
treatment
like
nonrespond
p
twentytwo
dog
transit
extend
dose
interv
follow
respons
dog
subsequ
requir
dose
interv
shorten
maintain
target
hct
dog
sustain
respons
dose
interv
greater
everi
day
potenti
advers
event
document
dog
includ
increas
systol
blood
pressur
requir
treatment
n
seizur
n
vomit
n
diarrhea
n
hypersensit
reaction
iron
inject
n
possibl
prca
develop
potenti
advers
event
result
discontinu
darbepoetin
respect
possibl
prca
case
advers
event
like
attribut
underli
diseas
darbepoetin
effect
treatment
anemia
secondari
ckd
dose
interv
day
effect
maintain
respons
therapi
studi
need
defin
effect
dose
prca
possibl
advers
event
dog
vitamin
dbind
protein
vdbp
main
carrier
vitamin
metabolit
circul
freeli
filtrat
glomerulu
complex
uptaken
megalincubilin
receptor
proxim
tubul
presenc
vdbp
urin
may
indic
proxim
tubular
dysfunctioninjuri
well
interstiti
tubular
fibrosi
also
still
remain
proven
whether
loss
vdbp
urin
may
lead
vitamin
defici
contribut
progress
chronic
kidney
diseas
ckd
dog
hypothesi
aim
studi
investig
whether
vdbp
could
previous
detect
urin
dog
ckd
regardless
urinarytoprotein
ratio
upc
valu
earli
specif
marker
proxim
tubular
injuri
forti
dog
accord
iri
stage
ckd
stage
n
stage
n
stage
n
stage
n
enrol
variou
breed
age
proteinuricassoci
diseas
nine
clinic
healthi
dog
differ
breed
age
compos
control
group
dog
ckd
classifi
accord
iri
guidelin
base
upc
nonproteinur
upc
borderlin
proteinur
upc
proteinur
upc
western
blot
perform
investig
vdbp
canin
urin
antivitamin
bind
protein
antibodi
urinari
vdbp
detect
control
dog
upc
ae
meanaesem
min
max
ckd
dog
urinari
vdbp
observ
sinc
earli
stage
ckd
stage
upc
ae
ae
mean
aesem
min
max
respect
stage
ckd
dog
urinari
vdbp
detect
dog
dog
upc
nonproteinur
rang
dog
borderlin
rang
one
proteinur
stage
ckd
dog
vdbp
urin
notic
ckd
dog
upc
one
dog
borderlin
upc
dog
slightli
proteinur
upc
ckd
dog
stage
upc
ae
vdbp
urin
immunodetect
dog
dog
upc
left
dog
proteinur
ckd
dog
stage
proteinur
upc
ae
show
vdbp
urin
conclus
immunodetect
vdbp
urin
notic
earli
stage
ckd
dog
mainli
stage
associ
upc
non
borderlin
proteinur
rang
reinforc
urinari
vdbp
could
potenti
earli
marker
kidney
injuri
well
detect
specif
segment
proxim
nephron
affect
progress
interstiti
nephriti
primari
caus
felin
chronic
kidney
diseas
consid
lead
caus
death
adult
cat
crandel
ree
felin
kidney
crfk
cell
line
commonli
use
grow
felin
herpesviru
caliciviru
panleukopenia
viru
use
fvrcp
vaccin
product
previou
studi
shown
cat
administ
fvrcp
vaccin
parenter
develop
antibodi
crfk
lysat
alpha
enolas
glycolyt
pathway
enzym
mammalian
cell
antibodi
bind
felin
renal
cell
lysat
addit
three
six
cat
hyperinocul
inject
crfk
lysat
two
year
renal
biopsi
collect
two
week
last
booster
primari
object
studi
determin
whether
could
induc
week
repeatedli
administ
market
lead
parenter
fvrcp
vaccin
potenti
use
short
term
model
studi
biomark
associ
cat
total
six
three
male
three
femal
oneyearold
purpos
bred
cat
includ
iacuc
approv
studi
cat
previous
maintain
unvaccin
control
studi
five
month
age
none
cat
clinic
sign
enrol
current
studi
week
blood
serum
urin
collect
biomark
assay
wedg
kidney
biopsi
histopatholog
evalu
alphaenolas
immunohistochemistri
obtain
sampl
collect
week
week
cat
administ
commerci
avail
fvrcp
vaccin
shown
previous
induc
anticrfk
antienolas
antibodi
sampl
collect
biomark
assay
sampl
collect
week
similarli
size
renal
biopsi
made
avoid
previou
biopsi
site
haematoxylin
eosin
stain
section
provid
two
boardcertifi
pathologist
mask
time
biopsi
anticrfk
antienolas
antibodi
level
serum
determin
elisa
cat
develop
progress
increas
antienolas
anticrfk
serum
antibodi
histolog
evid
interstiti
nephriti
detect
light
microscopi
tissu
biopsi
signific
biochem
urinalysi
chang
studi
detect
cat
adopt
privat
home
long
term
monitor
anticrfk
antienolas
antibodi
induc
model
biochem
histopatholog
abnorm
detect
result
select
biomark
enolas
immunohistochem
stain
use
evalu
potenti
model
carolin
aldridg
ellen
n
behrend
jo
smith
elizabeth
g
well
holli
p
lee
auburn
univers
auburn
al
usa
univers
georgia
athen
ga
usa
accuraci
bayer
multistix
visual
read
determin
glucos
concentr
canin
urin
behrend
et
al
j
vet
int
med
correl
visual
autom
assess
investig
furthermor
urin
glucos
creatinin
ratio
ugcr
may
use
method
quantifi
glucosuria
similar
urin
protein
creatinin
ratio
assess
purpos
studi
compar
autom
read
visual
read
ugcr
quantif
glucosuria
canin
urin
urin
sampl
submit
auburn
univers
clinic
patholog
laboratori
urinalysi
natur
glucosur
n
includ
multistix
bayer
use
accord
manufactur
instruct
read
visual
singl
train
investig
visual
read
clinitek
analyz
bayer
autom
read
urin
glucos
urin
creatinin
concentr
measur
use
hitachi
chemistri
analyz
boehring
mannheim
corp
glucos
measur
consid
true
concentr
gold
standard
spearman
rank
order
correl
use
evalu
relationship
glucos
concentr
autom
read
glucos
concentr
visual
read
autom
visual
read
autom
read
ugcr
visual
read
ugcr
signific
set
p
correl
classifi
excel
r
good
r
fair
r
poor
r
refer
interv
correl
color
test
strip
devis
base
packag
insert
mgdl
mgdl
mgdl
mgdl
mgdl
signific
correl
detect
autom
visual
read
glucos
concentr
p
correl
autom
read
good
r
fair
visual
read
r
overal
underestim
overestim
glucos
concentr
autom
read
respect
visual
read
respect
signific
correl
detect
autom
visual
read
ugcr
p
howev
correl
autom
read
classifi
good
r
visual
read
fair
r
furthermor
autom
visual
read
signific
p
good
correl
r
result
indic
despit
good
correl
autom
visual
read
bayer
multistix
autom
read
may
better
interestingli
autom
read
tend
underestim
glucos
concentr
visual
read
overestim
common
ugcr
valid
way
assess
urinari
glucos
excret
howev
offer
advantag
measur
glucos
concentr
urin
acut
pancreat
ap
acut
kidney
injuri
aki
common
comorbid
dog
human
human
patient
presenc
ap
aki
neg
prognost
factor
howev
similar
relationship
evalu
dog
consid
hemodialysi
manag
aki
dog
prognost
inform
could
import
therapeut
decis
canin
pancreasspecif
lipas
spec
use
commonli
support
diagnosi
ap
dog
purpos
studi
investig
elev
spec
outcom
dog
aki
treat
hemodialysi
medic
record
evalu
retrospect
august
june
identifi
dog
present
uc
davi
vmth
receiv
intermitt
hemodialysi
manag
aki
also
spec
spec
cpl
tm
idexx
laboratori
measur
cours
therapi
outcom
assess
day
admiss
dog
classifi
diedeuthan
aliv
surviv
dog
stratifi
non
dialysisdepend
dialysisdepend
elev
spec
defin
mcgl
median
valu
spec
compar
mannwhitney
u
test
outcom
categori
categor
data
compar
fisher
exact
test
pvalu
consid
signific
data
present
median
rang
fortythre
clientown
dog
includ
median
initi
serum
creatinin
iscr
mgdl
median
age
present
year
eighteen
male
neuter
femal
spay
intact
male
intact
femal
dog
day
dog
aliv
iscr
mgdl
die
euthan
iscr
mgdl
nine
dog
still
dialysi
depend
day
iscr
mgdl
non
dialysisdepend
iscr
mcgl
p
proport
dog
aliv
day
spec
mcgl
treatment
cours
differ
aliv
dog
spec
mcgl
versu
p
addit
proport
non
dialysisdepend
dog
spec
mcgl
treatment
cours
differ
non
dialysisdepend
dog
spec
mcg
l
versu
p
result
suggest
presenc
pancreat
assess
spec
mcgl
affect
surviv
outcom
day
howev
pancreat
may
common
comorbid
dog
sever
dialysisdepend
aki
may
influenc
renal
recoveri
bacteri
urinari
tract
infect
uti
common
dog
howev
preval
subclin
bacteriuria
sbu
healthi
dog
recent
demonstr
substanti
lower
follow
standard
creat
human
infecti
diseas
specialist
initi
put
toward
identifi
character
sbu
dog
although
consid
risk
factor
uti
preval
uti
sbu
dog
chronic
kidney
diseas
ckd
known
object
studi
retrospect
evalu
preval
posit
urin
cultur
dog
ckd
categor
patient
sbu
clinic
uti
pyelonephr
medic
record
review
retrospect
dog
diagnosi
ckd
urin
cultur
submit
diagnosi
ckd
base
intern
renal
interest
societi
iri
guidelin
patient
exclud
anoth
reason
develop
uti
name
endocrin
diseas
hyperadrenocortic
diabet
mellitu
urolithiasi
urinari
incontin
urinari
bladder
neoplasia
nidu
infect
ureter
stent
subcutan
ureter
bypass
receiv
system
immunosuppress
base
previous
report
definit
patient
place
one
follow
three
categori
base
review
medial
record
sbu
pyelonephr
uti
frequenc
neg
cultur
sbu
pyelonephr
uti
compar
across
iri
stage
use
fisher
exact
analysi
p
consid
signific
comparison
two
hundr
eightytwo
cultur
submit
patient
studi
time
period
fortyseven
cultur
perform
patient
exclud
due
presenc
ureter
stent
patient
chemotherapi
patient
diabet
mellitu
patient
transit
cell
carcinoma
patient
urinari
incontin
cystic
calculi
patient
total
cultur
submit
patient
includ
final
analysi
intact
male
castrat
male
intact
femal
spay
femal
posit
urin
cultur
cultur
obtain
patient
dog
posit
cultur
frequent
determin
diagnosi
sbu
cultur
follow
pyelonephr
cultur
uti
cultur
statist
signific
observ
relationship
iri
stage
diagnosi
p
number
posit
cultur
regardless
patient
diagnosi
statist
signific
iri
stage
p
escherichia
coli
frequent
observ
isol
cultur
popul
dog
ckd
preval
dog
posit
urin
cultur
frequent
observ
diagnosi
associ
posit
cultur
sbu
increas
iri
stage
ckd
found
associ
higher
frequenc
particular
diagnosi
e
coli
commonli
observ
isol
despit
rigor
criteria
defin
sbu
pyelonephr
uti
current
studi
possibl
patient
incorrectli
categor
prospect
research
need
determin
antibiot
therapi
indic
dog
ckd
sbu
addit
renal
biomark
may
allow
better
character
patient
sbu
occult
pyelonephr
improv
antibiot
stewardship
aim
studi
report
combin
experi
two
institut
place
subcutan
ureter
bypass
system
sub
compar
data
histor
data
cat
ureter
stent
ureter
obstruct
hypothes
includ
patient
sub
would
better
day
month
postop
creatinin
histor
ureter
stent
patient
sub
patient
would
experi
improv
periop
postop
recurr
urinari
tract
infect
rate
ureter
stent
cat
clinic
sign
relat
implant
would
similar
better
sub
system
versu
ureter
stent
adult
cat
enrol
retrospect
subsequ
alter
sub
placement
procedur
cat
manag
per
clinician
prefer
preoper
flush
sub
system
perform
everi
month
major
patient
record
cat
purdu
munich
univers
review
median
age
year
purdu
year
munich
spay
femal
castrat
male
cat
domest
shorthair
cat
domest
longhair
cat
three
breed
cat
preexist
iri
stage
ii
ckd
lethargi
vomit
inappet
common
clinic
sign
patient
median
renal
pelvic
diamet
affect
kidney
cm
institut
median
creatinin
immedi
postop
mgdl
mg
dl
purdu
mgdl
munich
major
periop
complic
uncommon
one
cat
cardiac
arrest
anoth
transfus
depend
postop
complic
includ
cat
fluid
overload
pleural
effus
cat
requir
blood
transfus
perior
postop
period
median
creatinin
mgdl
month
mgdl
month
patient
repeat
surgeri
median
time
repeat
surgeri
day
caus
repeat
surgeri
sub
port
obstruct
encrust
sub
tube
total
mortal
median
diseas
free
interv
day
year
surviv
cat
activ
urin
sediment
cultur
prior
sub
placement
postop
follow
urinari
tract
infect
occur
patient
urinari
tract
infect
within
day
surgeri
two
patient
recurr
multidrug
resist
e
coli
infect
one
cultur
biofilm
anoth
patient
develop
encrust
month
postprocedur
mandel
acid
edta
antibiot
infus
sub
fail
resolv
uti
cat
compar
sub
outcom
ureter
stent
month
postprocedur
creatinin
better
sub
group
mgdl
report
stent
mgdl
one
year
surviv
similar
stent
cat
sub
cat
longterm
infect
rate
similar
around
one
sub
patient
experienc
dysuria
beyond
postop
period
wherea
common
cat
stent
studi
suggest
sub
system
carri
similar
potenti
complic
reobstruct
encrust
infect
ureter
stent
recurr
resist
infect
potenti
biofilm
signific
concern
sub
patient
protocol
treatment
resist
uti
util
local
instil
indwel
bladder
treatment
develop
prospect
fashion
work
case
could
explor
risk
factor
uti
obstruct
cat
frequent
screen
bacteri
urinari
tract
infect
uti
absenc
clinic
sign
lower
urinari
tract
diseas
lutd
manag
condit
chronic
kidney
diseas
diabet
mellitu
purpos
studi
determin
preval
occult
uti
cat
describ
result
contemporan
urinalysi
ua
hypothes
posit
quantifi
urin
cultur
quc
could
predict
find
microscop
sediment
examin
mse
bacturia
pyuria
white
blood
cellshpf
hematuria
red
blood
cellshpf
electron
search
identifi
quc
perform
cat
univers
teach
hospit
result
includ
studi
sign
lutd
quc
perform
follow
previou
uti
quc
classifi
posit
growth
cfuml
report
posit
five
control
randomli
select
sampl
neg
quc
medic
record
group
review
sampl
posit
infect
singl
organ
n
four
contain
multipl
organ
e
coli
common
speci
isol
follow
enterococcu
speci
isol
posit
specimen
like
femal
cat
n
versu
male
n
p
patient
age
bodi
weight
associ
increas
risk
occult
uti
median
urin
specif
graviti
similar
posit
group
control
preval
proteinuria
dipstick
test
also
similar
v
occult
uti
strongli
associ
bacteriuria
v
odd
ratio
ci
p
pyuria
v
odd
ratio
ci
p
microscop
hematuria
posit
specimen
significantli
like
abnorm
sediment
exam
odd
ratio
ci
p
occult
uti
appear
uncommon
cat
usual
predict
basi
abnorm
mse
bacturia
pyuria
base
studi
littl
indic
perform
quc
cat
clinic
sign
lutd
unremark
mse
asid
associ
sever
inflammatori
diseas
calgranulin
complex
shown
express
epitheli
cell
malign
transform
human
report
upregul
patient
prostat
carcinoma
pca
transit
cell
carcinoma
tcc
respect
result
express
calgranulin
tccpca
human
ambigu
pilot
data
group
suggest
urin
canin
ratio
ucalr
may
potenti
marker
tccpca
dog
evalu
urinari
ucalr
dog
need
determin
specif
diagnosi
tcc
pca
thu
studi
investig
urinari
ucalr
dog
tccpca
urinari
tract
diseas
malign
urin
sampl
dog
tccpca
n
treatment
n
dog
nonneoplast
diseas
urinari
tract
n
neoplasm
n
dog
urinari
tract
infect
uti
n
group
healthi
control
dog
n
use
urinari
canin
measur
sampl
use
inhous
radioimmunoassay
ucalr
calcul
paramet
test
among
differ
group
dog
use
nonparametr
multipletwogroup
comparison
sensit
specif
determin
optim
cutoff
valu
posit
ppv
neg
predict
valu
npv
calcul
signific
set
p
dog
tccpca
significantli
higher
urinari
concentr
group
dog
p
except
dog
uti
wherea
ucalr
significantli
higher
tccpca
dog
compar
uti
p
tccpca
patient
uti
dog
best
distinguish
ucalr
sensit
specif
urin
canin
concentr
normal
urin
specif
graviti
usg
highest
sensit
specif
diagnos
tccpca
dog
group
dog
specif
increas
uti
exclud
use
urin
concentr
normal
usg
screen
dog
year
age
tccpca
estim
preval
yield
ppv
npv
result
studi
show
urin
ucalr
util
diagnosi
tccpca
dog
high
sensit
npv
urin
also
suggest
may
good
screen
test
tccpca
dog
studi
warrant
valid
find
larger
cohort
dog
evalu
sourc
express
canin
tccpca
caney
liberti
sieberg
jessica
quimbi
colorado
state
univers
fort
collin
co
usa
vet
profession
roslin
midlothian
uk
chronic
kidney
diseas
ckd
common
elderli
cat
purpos
studi
describ
subcutan
fluid
sq
administr
practic
owner
ckd
cat
help
owner
success
give
sq
fluid
cat
anonym
webbas
survey
advertis
via
list
serv
websit
social
media
owner
cat
ckd
particip
cat
year
older
cat
iri
stage
ii
iii
iv
unknown
owner
said
discuss
give
fluid
veterinarian
respond
state
gave
sq
fluid
tri
could
owner
given
addit
educ
resourc
said
process
okeasi
learn
experienc
said
still
somewhathighli
stress
said
somewhathighli
stress
cat
improv
toler
use
food
posit
reinforc
state
improv
toler
warm
fluid
felt
warm
fluid
increas
toler
felt
length
time
took
administ
fluid
affect
toler
said
needl
size
affect
toler
owner
check
hydrat
statu
daili
twice
daili
owner
know
said
skippedad
fluid
base
hydrat
assess
major
owner
success
administ
fluid
addit
educ
materi
could
provid
variabl
needl
size
warm
fluid
length
time
administr
may
improv
toler
felin
lower
urinari
tract
disord
often
reli
subject
caregiv
quantif
clinic
sign
establish
diagnosi
monitor
therapeut
outcom
object
studi
investig
use
video
record
system
vr
reliabl
assess
quantifi
urin
behavior
cat
litter
box
urin
behavior
quantifi
healthi
cat
cat
abnorm
urin
pattern
use
vr
day
compar
daili
caregiv
observ
video
record
analyz
use
behavior
analysi
softwar
program
mean
number
urin
per
day
detect
vr
ae
significantli
greater
compar
caregiv
observ
ae
p
five
cat
never
observ
caregiv
litter
box
mean
number
urin
per
day
detect
vr
significantli
higher
abnorm
cat
ae
compar
healthi
cat
ae
p
appar
differ
frequenc
healthi
abnorm
cat
report
caregiv
ae
ae
respect
differ
mean
urin
time
normal
abnorm
cat
determin
vr
caregiv
mean
coverup
time
determin
vr
significantli
longer
normal
cat
ae
secondsurin
compar
abnorm
cat
ae
secondsurin
p
differ
coverup
time
detect
caregiv
observ
conclus
consider
dispar
caregiv
video
observ
caregiv
commonli
underestim
urin
frequenc
vr
appear
facilit
object
assess
urin
behavior
could
valu
futur
clinic
studi
felin
urinari
disord
boag
craig
breheni
adam
gow
royal
dick
school
veterinari
studi
edinburgh
uk
standard
oper
procedur
sop
establish
inclin
laboratori
test
world
health
organis
guidelin
pack
cell
volum
independ
evid
base
guidelin
exist
dipstick
urinalysi
howev
manufactur
instruct
state
dip
stick
urin
veterinari
medicin
occasion
urin
sampl
small
volum
obtain
impract
drip
urin
stick
pipett
syring
perform
also
advantag
conserv
sampl
addit
test
hypothesi
studi
method
drip
drip
would
effect
test
result
siemen
multistix
strip
use
standardis
method
strip
analysi
siemen
clinitek
statu
analys
use
read
strip
control
time
read
result
user
variabl
interpret
colourimetr
chang
three
individu
test
aliquot
urin
dog
rang
diseas
process
dip
drip
method
result
compar
variabl
drip
dip
use
wilcoxonsign
rank
test
across
nine
variabl
assess
sg
signific
differ
method
found
one
variabl
bilirubin
p
differ
account
one
dog
test
neg
bilirubin
three
user
use
dip
method
trace
valu
three
user
use
drip
methodolog
signific
differ
found
variabl
studi
demonstr
signific
differ
dip
drip
bilirubin
caus
one
dog
level
variabl
three
user
differ
author
opinion
clinic
insignific
studi
therefor
support
use
either
dip
drip
approach
urinalysi
studi
requir
fulli
assess
role
individu
variat
perform
test
includ
level
experi
jean
hall
dale
fritsch
maha
yerramilli
edward
obar
murthi
yerramilli
denni
jewel
oregon
state
univers
corval
usa
hill
pet
nutrit
inc
topeka
ks
usa
idexx
laboratori
inc
westbrook
usa
prospect
clinic
trial
perform
clientown
dog
iri
stage
chronic
kidney
diseas
ckd
measur
eas
transit
commerci
renal
protect
food
assess
effect
food
renal
biomark
qualiti
life
attribut
dog
iri
stage
ckd
n
transit
week
variou
groceri
brand
food
modifi
protein
low
phosphoru
antioxid
enrich
test
food
prescript
hill
pet
nutrit
inc
month
owner
complet
questionnair
assess
pet
accept
test
food
dog
qualiti
life
renal
biomark
includ
serum
creatinin
cr
blood
urea
nitrogen
bun
symmetr
dimethylarginin
sdma
urinalysi
paramet
includ
urin
specif
graviti
usg
urin
protein
creatinin
ratio
upc
measur
dog
initi
enrol
transit
test
food
pet
moder
extrem
like
test
food
time
ate
food
time
moder
extrem
enthusiast
eat
time
dog
consum
test
food
show
decreas
serum
cr
bun
concentr
across
time
p
decreas
serum
sdma
concentr
usg
across
time
p
serum
renal
biomark
cr
bun
sdma
decreas
p
baselin
month
remain
decreas
baselin
month
dog
complet
studi
n
studi
show
dog
iri
stage
ckd
readili
transit
commerci
renal
food
decreas
serum
biomark
concentr
suggest
improv
kidney
function
addit
owner
report
improv
consortium
overal
health
qualiti
life
attribut
p
hair
coat
qualiti
attribut
p
decreas
glomerular
filtrat
rate
chronic
kidney
diseas
ckd
reduc
renal
phosphoru
excret
lead
increas
total
bodi
phosphoru
retent
eventu
hyperphosphatemia
addit
promot
parathyroid
hormon
synthesi
hyperphosphatemia
stimul
synthesi
fibroblast
growth
factor
phosphaturichypophosphatem
hormon
report
serum
healthi
dog
dog
ckd
goal
studi
measur
serum
concentr
healthi
dog
dog
ckd
determin
associ
serum
phosphoru
concentr
sever
renal
diseas
base
iri
stage
ckd
hypothes
serum
increas
dog
ckd
concentr
proport
ckd
sever
earli
marker
alter
phosphoru
metabol
total
dog
variou
breed
age
ckd
n
iri
stage
n
iri
stage
fed
renal
diet
healthi
dog
differ
breed
age
fed
mainten
diet
includ
dog
ckd
follow
month
death
humanspecif
elisa
valid
studi
show
linear
intra
interassay
coeffici
variat
respect
serum
concentr
higher
ckd
dog
stage
present
ae
pgml
meanaesem
compar
healthi
dog
ae
pgml
signific
differ
detect
healthi
versu
ckd
dog
stage
p
oneway
anova
stage
versu
stage
p
present
dog
stage
ckd
normophosphatem
ae
mgdl
serum
ae
dog
show
increas
concentr
pgml
correl
phosphoru
concentr
admiss
follow
r
p
stage
ckd
dog
present
normophosphatem
mgdl
hyperphosphatem
mgdl
n
increas
serum
concentr
ae
pgml
pgml
remain
elev
increas
follow
pgml
normophosphatem
dog
stage
ckd
n
develop
hyperphosphatemia
mgdl
month
follow
serum
phosphoru
posit
correl
dog
r
p
studi
period
dog
stage
die
conclus
serum
could
use
earli
marker
phosphoru
dysregul
dog
ckd
increas
concentr
found
normophosphatem
ckd
dog
stage
mark
elev
serum
level
found
advanc
renal
diseas
iri
stage
like
increas
concentr
contribut
disturb
calcium
phosphoru
homeostasi
alter
vitamin
metabol
parathyroid
gland
function
studi
target
control
serum
phosphor
concentr
dog
ckd
warrant
idiopath
cystiti
ic
common
lower
urinari
tract
disord
cat
resembl
pain
bladder
syndromeinterstiti
cystiti
human
disord
etiolog
unknown
specif
therapi
avail
diagnosi
base
clinic
sign
exclus
disord
due
lack
characterist
patholog
find
welldefin
phenotyp
object
biomark
cytokin
serv
noninvas
biomark
defin
presenc
sever
progress
diseas
respons
treatment
object
pilot
studi
determin
concentr
select
cytokin
serum
healthi
cat
cat
ic
thirteen
serum
sampl
healthi
cat
cat
ic
evalu
multiplex
analysi
cytokin
sfa
tnfa
scf
rant
pdgfbb
kc
ifnc
gmcsf
perform
multipl
antigen
luminex
beadbas
assay
accord
manufactur
recommend
result
analyz
normal
data
dagostinopearson
test
group
compar
use
mannwhitney
test
significantli
increas
mean
concentr
ae
versu
ae
pgml
p
ae
versu
ae
pgml
p
ae
versu
ae
pgml
p
detect
serum
cat
ic
compar
unaffect
cat
studi
necessari
evalu
diagnost
prognost
util
serum
cytokin
biomark
cat
ic
common
radiopaqu
cystolith
cat
compos
struvit
calcium
oxal
miner
struvit
cystolith
shown
dissolv
dietari
manag
wherea
calcium
oxal
cystolith
must
remov
surgic
commerci
avail
diet
pro
veterinari
diet
ur
formul
dissolut
struvit
cystolith
lessen
recurr
struvit
oxal
cystolith
purpos
studi
describ
clinic
laboratori
find
cat
radiopaqu
cystolith
fed
commerci
avail
diet
studi
announc
northern
colorado
anim
shelter
list
serv
cat
clinic
sign
lower
urinari
tract
diseas
cystolith
confirm
via
radiograph
enrol
iacuc
approv
studi
qualifi
cat
transfer
maintain
research
studi
site
assur
test
diet
fed
complet
blood
cell
count
serum
biochemistri
profil
abdomin
ultrasound
urinalysi
aerob
bacteri
cultur
antimicrobi
sensit
perform
entri
exit
studi
cat
hous
gang
room
fed
studi
diet
ad
libitum
assess
abdomin
radiograph
weekli
cat
cystolith
resolv
base
two
sequenti
weekli
radiograph
confirmatori
ultrasound
examin
consid
diet
success
cat
chang
cystolith
size
four
week
underw
cystotomi
stone
remov
aerob
cultur
antimicrobi
suscept
test
analysi
univers
minnesota
urolith
center
cat
adopt
privat
home
possibl
studi
diet
continu
abdomin
radiograph
obtain
evalu
recurr
date
five
cat
age
four
eight
year
age
complet
studi
cat
accept
studi
diet
weight
loss
note
cours
studi
cat
serum
biochem
data
normal
cat
urin
cultur
neg
cat
exit
studi
total
cystolith
dissolut
achiev
week
three
cat
two
cat
still
radiograph
evid
cystolith
week
one
cat
persist
cystolith
singl
ammonium
urat
cystolith
struvit
nidu
normal
pre
postbil
acid
cat
multipl
calcium
oxal
cystolith
cultur
neg
cat
recheck
radiograph
two
month
two
cat
stone
resolut
diet
cat
calcium
oxal
cystolith
three
month
postcystotomi
show
evid
cystolith
recurr
larger
case
number
need
preliminari
result
suggest
feed
purina
veterinari
diet
ur
success
dissolv
cystolith
like
struvit
may
lessen
risk
recurr
struvit
calcium
oxal
cystolith
purpos
crossov
design
studi
determin
differ
resuscit
fluid
therapi
protocol
would
increas
ntermin
probnp
nt
probnp
level
healthi
dog
protocol
includ
balanc
isoton
replac
crystalloid
solut
normosol
r
administ
mlkgh
one
hour
hyperton
salin
bolu
administ
mlkg
minut
hydroxyethyl
starch
fluid
bolu
voluven
administ
mlkg
minut
serum
ntprobnp
concentr
measur
healthi
purpos
bred
dog
prior
fluid
administr
hour
receiv
one
three
fluid
therapi
protocol
dog
randomli
assign
receiv
differ
fluid
protocol
week
week
allow
washout
period
treatment
protocol
serum
ntprobnp
concentr
significantli
elev
baselin
dog
receiv
mlkghr
crystalloid
solut
compar
dog
receiv
hyperton
salin
hydroxyethyl
starch
bolus
none
fluid
therapi
protocol
caus
elev
serum
ntprobnp
previous
report
cutoff
concentr
use
discrimin
dog
congest
heart
failur
dog
primari
respiratori
diseas
resuscit
fluid
therapi
increas
serum
ntprobnp
concentr
impact
abil
use
serum
ntprobnp
concentr
discrimin
cardiac
failur
respiratori
diseas
healthi
dog
distress
fear
anxieti
exposur
loud
nois
eg
storm
firework
behavior
welfar
concern
dog
affect
dog
lifetim
object
confirm
subsed
dose
dexmedetomidin
adrenoceptor
agonist
allevi
acut
anxieti
fear
associ
nois
dog
random
doubleblind
placebocontrol
parallelgroup
studi
conduct
site
european
countri
new
year
eve
dog
histori
anxieti
fear
due
firework
receiv
lgm
dexmedetomidin
oromucos
gel
dog
placebo
dog
owner
appli
first
dose
onset
distress
associ
firework
dose
could
repeat
time
everi
hour
owner
assess
treatment
effect
dog
behavior
also
report
oral
mucos
color
observ
function
alert
advers
event
eas
use
excel
good
treatment
effect
seen
dexmedetomidinetr
dog
placebotr
dog
overal
treatment
effect
superior
dexmedetomidin
p
dog
dexmedetomidin
display
less
pant
trembl
hide
transient
pale
mucou
membran
observ
frequent
dexmedetomidin
mucos
irrit
report
dog
remain
function
advers
event
concern
observ
owner
consid
product
easi
quit
easi
use
studi
confirm
oromucos
dexmedetomidin
subsed
dose
allevi
acut
anxieti
fear
associ
nois
dog
toniti
case
katherin
scotti
jame
barr
micah
bishop
michael
kato
matthew
mellema
medora
pashmakova
texa
colleg
station
tx
usa
anim
specialti
hospit
florida
napl
fl
usa
uc
davi
davi
ca
usa
septic
periton
sp
cat
carri
signific
mortal
etiolog
may
indetermin
aim
studi
identifi
etiolog
prognost
factor
cat
sp
medic
record
cat
hospit
sp
texa
univers
univers
california
davi
review
septic
periton
diagnos
intracellular
bacteria
cytolog
posit
bacteri
cultur
data
check
normal
compar
use
unpair
ttest
mannwhitney
test
fisher
exact
test
odd
ratio
use
compar
variabl
alpha
set
seventynin
cat
identifi
met
inclus
criteria
sourc
sp
undetermin
cat
gastrointestin
perfor
caus
sp
cat
thirti
cat
surgic
manag
medic
manag
surviv
discharg
popul
associ
leukocytosi
leukopenia
anemia
hypoalbuminemia
hyperlactatemia
ioniz
hypocalcemia
band
neutrophilia
surviv
cat
increas
creatinin
time
like
die
ci
p
hypotherm
cat
like
die
ci
p
febril
cat
time
like
live
ci
p
origin
sp
undetermin
half
cat
studi
surviv
agreement
previou
report
azotemia
hypothermia
may
reflect
persist
shock
speci
close
monitor
septic
cat
rectal
temperatur
commonli
use
clinic
evalu
canin
patient
singleus
lubric
protect
thermomet
sheath
larg
use
human
medicin
practic
routin
report
veterinari
medicin
therefor
aim
studi
compar
rectal
temperatur
measur
thermomet
without
protect
sheath
larg
canin
popul
three
hundr
eighti
two
dog
includ
studi
rectal
temperatur
assess
standard
manner
two
person
fj
mp
two
ident
digit
rectal
thermomet
thermomet
valid
accuraci
repeat
withinday
variabl
high
precis
thermomet
thermomet
valid
perform
without
protect
sheath
rectal
temperatur
measur
consecut
dog
without
protect
sheath
random
order
differ
temperatur
measur
two
method
analyz
gener
linear
model
order
temperatur
measur
age
bodi
condit
score
underweight
normal
overweight
format
stratifi
mini
medium
larg
conscienc
level
consciou
sedat
anesthet
explanatori
variabl
result
present
mean
ae
sd
accuraci
studi
thermomet
excel
averag
temperatur
differ
ae
ae
rang
without
sheath
respect
field
studi
differ
temperatur
measur
without
sheath
within
rang
measur
moreov
differ
dog
respect
except
bodi
condit
score
none
explanatori
variabl
studi
significantli
associ
differ
measur
suggest
differ
import
overweight
dog
normal
dog
averag
differ
respect
p
studi
show
thermomet
protect
sheath
use
reliabl
measur
rectal
temperatur
dog
clinic
set
therefor
strongli
advis
use
hygien
protect
measur
daili
clinic
practic
even
overweight
dog
differ
two
method
clinic
non
signific
microrna
identifi
sensit
noninvas
diagnost
marker
earli
detect
human
malign
date
studi
microrna
express
serum
domest
anim
known
analysi
microrna
present
matur
erythrocyt
felin
erythrocyt
known
sensit
oxid
damag
interest
potenti
use
model
studi
system
oxid
stress
identif
specif
microrna
dysregul
condit
may
sensit
biomark
oxid
stress
pilot
studi
aim
identifi
microrna
express
matur
felin
erythrocyt
specif
involv
isol
purifi
popul
matur
erythrocyt
cat
blood
extract
high
qualiti
microrna
purifi
popul
matur
erythrocyt
sequenc
microrna
popul
form
librari
facilit
studi
success
purifi
matur
felin
erythrocyt
whole
blood
combin
centrifug
leukoreduct
special
filter
remov
major
reticulocyt
white
blood
cell
platelet
howev
final
purif
step
util
magnet
bead
coat
antibodi
subsequ
use
ensur
pure
matur
popul
erythrocyt
immunedeplet
step
antibodi
initi
test
reactiv
felin
biotinyl
use
within
column
antibodi
use
studi
antitransferrin
receptor
remov
reticulocyt
integrin
remov
leukocyt
antibeta
integrin
remov
platelet
assess
matur
red
blood
cell
prepar
puriti
perform
autom
flow
cytometrybas
hematolog
analyz
identifi
presenc
leukocyt
platelet
reticulocyt
isol
total
rna
perform
modifi
trizol
phase
separ
method
concentr
qualiti
rna
assess
prior
librari
construct
small
rna
librari
construct
cluster
gener
sequenc
follow
qualiti
trim
map
read
feli
catu
genom
studi
success
isol
matur
felin
erythrocyt
whole
blood
sampl
extract
qualiti
microrna
isol
erythrocyt
develop
librari
microrna
present
cell
normal
popul
cat
work
establish
comparison
microrna
profil
normal
popul
cat
risk
evid
oxid
damag
help
identifi
new
potenti
inform
biomark
system
redox
statu
complic
associ
oxid
stress
cat
studi
aim
determin
effect
sedat
anesthesia
complet
blood
count
cbc
serum
chemistri
result
dog
undergo
routin
health
well
care
ten
healthi
adult
dog
select
base
physic
exam
need
undergo
anesthesia
routin
dental
prophylaxi
blood
collect
venipunctur
seri
timepoint
receiv
premed
b
prior
induct
anesthesia
c
minut
induct
anesthesia
minut
induct
anesthesia
e
minut
induct
anesthesia
premed
combin
acepromazin
mgkg
butorphanol
mgkg
given
singl
subcutan
inject
minut
prior
induct
propofol
propofol
calcul
mgkg
administ
intraven
effect
anesthesia
maintain
inhal
isofluran
ga
via
endotrach
intub
gener
linear
mix
model
conduct
compar
paramet
variou
time
point
account
correl
data
dog
particip
multipl
time
point
pvalu
less
consid
statist
signific
compar
blood
result
prior
premed
statist
signific
chang
observ
averag
hematocrit
hemoglobin
mean
cell
volum
red
blood
cell
albumin
cholesterol
protein
valu
premed
alon
induct
propofol
variat
addit
observ
white
blood
cell
count
alkalin
phosphatas
calcium
globulin
potassium
triglycerid
whole
blood
dna
concentr
minut
mainten
isofluran
ga
mean
cell
hemoglobin
concentr
monocyt
phosphoru
bilirubin
valu
addit
affect
studi
highlight
signific
effect
sedat
anesthesia
blood
analys
subsequ
interpret
clinic
relev
aim
retrospect
studi
determin
often
result
ultrasoundguid
splenic
fineneedl
aspir
impact
case
manag
adult
dog
splenic
nodul
heterogen
splenic
parenchyma
medic
record
adult
dog
ultrasoundguid
splenic
fineneedl
aspir
perform
oregon
state
univers
veterinari
teach
hospit
june
juli
retrospect
review
dog
includ
splenic
nodul
heterogen
splenic
parenchyma
incident
found
ultrasonograph
examin
patient
splenic
fineneedl
aspir
perform
day
ultrasonograph
examin
includ
dog
includ
diseas
associ
splenic
abnorm
known
present
ultrasound
one
hundr
twenti
six
adult
clientown
dog
met
inclus
criteria
fineneedl
aspir
chang
clinic
manag
dog
includ
patient
diagnos
malign
neoplasia
suppur
inflamm
lymphoma
n
sarcoma
n
malign
histiocytosi
n
suppur
inflamm
n
epitheli
neoplasm
n
melanoma
n
hemangiosarcoma
n
carcinoma
n
spindl
cell
tumor
n
remain
dog
fineneedl
aspir
spleen
chang
manag
case
includ
patient
extramedullari
hematopoiesi
n
lymphoid
reactivityhyperplasia
n
normal
spleen
n
hyperplast
nodul
n
nondiagnost
sampl
n
splenic
fineneedl
aspir
minim
invas
diagnost
modal
provid
inform
chang
case
manag
adult
dog
splenic
nodul
heterogen
splenic
parenchyma
consid
popul
patient
hour
fast
cat
receiv
mg
mgkg
itraconazol
capsul
solut
compound
capsul
compound
suspens
random
crossov
washout
capsul
administ
small
meal
wherea
solut
plasma
collect
predetermin
interv
analysi
use
high
pressur
liquid
chromatographi
compartment
noncompartment
pharmacokinet
analys
perform
use
softwar
certara
proprietari
compound
formul
data
respect
capsul
peak
concentr
c
max
halflif
cv
hour
cv
respect
valu
solut
cv
hour
cv
respect
absorpt
solut
time
greater
capsul
base
auc
ratio
c
max
time
higher
solut
compound
formul
absorb
inconsist
commonli
result
undetect
concentr
complet
pharmacokinet
result
obtain
cat
compound
capsul
suspens
group
respect
rel
absorpt
compound
itraconazol
capsul
suspens
long
halflif
itraconazol
cat
allow
daili
oral
dose
due
much
higher
absorpt
solut
versu
capsul
oral
solut
dose
substanti
reduc
compound
itraconazol
use
cat
poor
oral
absorpt
dog
david
griffin
carolyn
warner
nutramax
laboratori
veterinari
scienc
inc
lancast
sc
usa
sadenosylmethionin
use
support
liver
function
companion
anim
human
also
use
human
mental
joint
health
previou
studi
shown
administ
food
substanti
decreas
bioavabl
tabl
blind
crossov
studi
new
denamarin
nutramax
laboratori
veterinari
scienc
inc
chewabl
tablet
contain
novel
formul
salt
administ
beagl
dog
assess
bioavail
rel
administr
food
six
beagl
dose
overnight
fast
mg
ion
mean
mgkg
one
formul
supplement
follow
formul
day
later
administ
food
plasma
valu
dose
hour
determin
use
hplcesimsm
assay
supplement
plasma
level
increas
substanti
baselin
valu
ngml
return
baselin
hour
mean
valu
c
max
max
auc
compar
formul
statist
signific
differ
tabl
data
indic
novel
salt
may
use
dog
equival
bioavail
administ
food
may
increas
owner
complianc
tabl
effect
food
consumpt
tosyl
absorpt
posaconazol
activ
avail
azol
antifung
drug
absorpt
pharmacokinet
avail
guid
dose
regimen
cat
purpos
studi
determin
pharmacokinet
oral
suspens
iv
formul
posaconazol
cat
determin
feasibl
oral
administr
treatment
fungal
infect
hour
fast
healthi
cat
receiv
mgkg
posaconasol
oral
suspens
food
four
cat
also
receiv
mgkg
iv
posaconazol
washout
period
plasma
collect
predetermin
interv
analysi
use
high
pressur
liquid
chromatographi
hplc
concentr
data
analyz
use
twocompart
pharmacokinet
analysi
iv
data
onecompart
analysi
firstord
input
oral
data
use
softwar
certara
iv
dose
volum
distribut
v
ss
lkg
mean
std
deviat
termin
halflif
hour
clearanc
mlkghr
oral
dose
peak
concentr
c
max
termin
hour
bioavail
oral
administr
advers
effect
observ
either
rout
administr
despit
low
oral
absorpt
data
allow
simul
oral
dosag
regimen
could
explor
clinic
studi
two
regimen
consid
maintain
target
trough
concentr
mgkg
po
load
dose
follow
mgkg
q
hour
mgkg
po
load
dose
follow
mgkg
q
hour
mycophenol
acid
mpa
activ
moieti
prodrug
mycophenol
mofetil
mmf
select
noncompetit
inhibitor
dehydrogenas
mpa
attract
immunosuppress
option
veterinari
medicin
due
rapid
onset
commerci
avail
multipl
formul
although
mpa
use
routin
human
canin
pauciti
literatur
support
mpa
use
felin
patient
like
cat
limit
abil
glucuronid
certain
medic
goal
studi
evalu
pharmacokinet
pharmacodynam
safeti
mpa
healthi
cat
pharmacokinet
mpa
evalu
follow
intraven
infus
mgkg
n
mgkg
n
mmf
intraven
roch
lab
inc
surprisingli
plasma
concentr
mpa
cat
dose
remark
low
compar
plasma
level
consist
immunosuppress
level
human
therefor
evalu
pk
mpa
use
mgkg
mmf
administ
twice
hs
apart
n
follow
infus
cat
metabol
mmf
mpa
maximum
observ
mpa
plasma
concentr
rang
first
dose
ml
follow
second
dose
evalu
concentr
time
profil
mpa
plasma
reveal
addit
peak
mpa
could
correspond
enterohepat
recycl
mpa
mycophenol
acid
elimin
liver
biotransform
unexpectedli
concentr
mpa
plasma
decay
quickli
termin
hs
cat
suggest
fast
rate
biotransform
explain
higher
dose
mmf
metabolit
mpa
phenol
glucuronid
quantifi
cat
acyl
glucuronid
detect
cat
contrast
metabolit
mpa
phenol
glucosid
quantifi
plasma
cat
suggest
glucosid
mpa
key
rout
mpa
elimin
cat
administr
mmf
show
rapid
effect
immun
cell
second
dose
mmf
reduct
peripher
blood
mononuclear
cell
pbmc
pbmc
recov
baselin
hs
stop
infus
mmf
indic
repeat
administr
mmf
requir
maintain
constant
suppress
immun
cell
cat
importantli
neither
serum
biochemistri
chang
signific
advers
event
associ
administr
mmf
cat
studi
first
step
toward
improv
treatment
variou
autoimmun
diseas
cat
result
studi
suggest
infus
mmf
mgkg
hs
apart
provid
safe
rapid
immunosuppress
effect
cat
futur
studi
evalu
pharmacokinet
effect
mpa
target
lymphocyt
subpopul
cell
follow
multiday
intraven
oral
dose
mmf
prepar
choic
reflect
current
prescrib
practic
routin
util
concentr
sampl
acquir
prescript
two
nation
veterinari
compound
pharmaci
three
time
point
span
period
two
differ
storag
condit
evalu
sampl
four
time
point
order
date
day
mo
recoveri
perform
solidphas
extract
concentr
strength
measur
via
highperform
liquid
chromatographi
overal
accuraci
rang
pharmaci
rang
pharmaci
b
initi
day
sampl
within
unit
state
pharmacopeia
guidelin
defin
accept
rang
compar
label
strength
precis
pharmaci
pharmaci
b
storag
condit
affect
stabil
test
aqueou
suspens
averag
decreas
mo
concentr
pharmaci
sampl
pharmaci
b
compound
mo
suspens
deviat
label
strength
could
lead
potenti
overdosag
sever
neurolog
toxic
predispos
breed
bioavail
clinic
efficaci
compound
mo
suspens
still
remain
unknown
use
product
discourag
time
dolasetron
receptor
antagonist
antiemet
typic
dose
mgkg
iv
sq
daili
pharmacokinet
pk
pharmacodynam
pd
studi
cat
previous
perform
purpos
studi
evalu
paramet
purposebr
cat
five
purposebr
cat
unremark
complet
blood
count
serum
biochemistri
urinalys
util
pk
studi
cat
receiv
mgkg
subcutan
sq
intraven
iv
dolasetron
crossov
manner
serum
sampl
obtain
via
jugular
cathet
hour
administr
dolasetron
dolasetron
activ
metabolit
hydrodolasetron
measur
use
liquid
chromatographytandem
mass
spectrometri
noncompartment
pharmacokinet
analysi
perform
pd
studi
subcutan
dolasetron
mgkg
mgkg
placebo
administ
minut
prior
intramuscular
administr
mgkg
xylazin
random
crossov
manner
number
emet
event
lip
lick
time
onset
vomit
visual
nausea
score
score
blind
observ
pk
dolasetron
quickli
metabol
hydrodolasetron
two
cat
administr
rout
measur
concentr
beyond
hour
limit
assess
dolasetron
pk
paramet
signific
differ
exposur
activ
metabolit
two
rout
administr
pharmacokinet
paramet
summar
pd
dolasetron
placebo
administ
prior
xylazin
signific
differ
mean
number
emet
event
lip
lick
time
onset
vomit
visual
nausea
score
compar
placebo
mgkg
dolasetron
maintain
serum
concentr
hour
adequ
control
xylazineinduc
vomit
given
sq
even
mgkg
addit
dose
studi
need
determin
higher
dose
effect
subcutan
previous
demonstr
poor
oral
bioavail
short
elimin
halflif
requir
frequent
dose
everi
hour
impract
dose
dosesday
home
often
resign
inhospit
administr
ondansetron
candid
transderm
medic
small
size
dalton
moder
lipophil
log
purpos
studi
assess
pharmacokinet
transderm
ondansetron
administr
healthi
purposebr
cat
five
purposebr
cat
unremark
cbc
biochemistri
urinalysi
util
mg
transderm
ondansetron
lipoderm
gel
appli
intern
ear
pinna
total
volum
ml
blood
sampl
collect
via
jugular
cathet
hour
period
follow
administr
minut
minut
hour
serum
separ
frozen
prior
analysi
ondansetron
measur
via
liquid
chromatographi
coupl
tandem
mass
spectrometri
analysi
reveal
appreci
drug
present
serum
transderm
administr
mg
ondansetron
indic
accept
method
drug
deliveri
despit
characterist
drug
impli
would
adequ
pass
skin
barrier
studi
highlight
import
assess
potenti
medic
transderm
administr
kimberli
hooi
alic
defarg
andrea
sanchez
stephani
nykamp
anthoni
abramsogg
scott
wees
dorothe
bienzl
ontario
veterinari
colleg
univers
guelph
guelph
canada
purpos
studi
compar
bronchoscop
bronchoalveolar
lavag
bbal
nonbronchoscop
bronchoalveolar
lavag
nbbal
clinic
healthi
cat
two
bronchoalveolar
lavag
bal
perform
week
apart
twelv
cat
free
respiratori
diseas
bal
perform
random
order
gener
anesthesia
wedg
mm
fiberopt
bronchoscop
bbal
red
rubber
cathet
nbbal
ten
ml
aliquot
salin
infus
left
right
caudal
lung
field
aspir
ml
syring
proport
fluid
retriev
depth
wedg
anesthet
complic
record
total
nucleat
cell
count
differenti
cell
count
semiquantit
evalu
cytolog
qualiti
perform
balf
sampl
result
compar
use
anova
wilcoxon
signedrank
test
proport
balf
retriev
depth
wedg
significantli
greater
bbal
nbbal
differenti
cell
count
cytolog
qualiti
differ
significantli
techniqu
result
median
rang
complic
includ
transient
hemoglobin
desatur
bal
prolong
anesthet
recoveri
time
bal
howev
anesthet
recoveri
score
differ
significantli
techniqu
result
suggest
nbbal
procedur
provid
balf
sampl
equival
qualiti
bbal
procedur
cat
clinic
free
respiratori
diseas
character
felin
respiratori
microbiom
aida
vientosplott
aaron
ericsson
han
rindt
megan
grobman
amber
graham
kaitlin
bishop
leah
cohn
carol
reinero
univers
missouri
colleg
veterinari
medicin
compar
intern
medicin
laboratori
columbia
mo
usa
univers
missouri
metagenom
center
columbia
mo
usa
although
lower
airway
consid
steril
cultur
sequenc
rrna
amplicon
reveal
divers
bacteri
speci
human
lung
use
healthi
research
cat
stabl
environ
hypothes
rrna
amplicon
sequenc
dna
bronchoalveolar
lavag
bal
oropharyng
fecal
swab
blood
would
reveal
distinct
microbiom
site
six
healthi
research
cat
year
old
bal
oropharyng
fecal
sampl
collect
day
week
blood
week
extract
dna
underw
pcr
rrna
gene
sequenc
number
readssampl
rich
rel
abund
repres
oper
taxonom
unit
otu
determin
principl
compon
analysi
pca
describ
related
sampl
fecal
oropharyng
swab
yield
meanaesd
ae
ae
readssampl
respect
bal
blood
yield
lower
coverag
ae
ae
readssampl
respect
oropharyng
fecal
swab
significantli
richer
bal
mean
number
otu
respect
p
signific
differ
p
rich
time
point
fusobacterium
sp
campylobact
sp
bacteroid
sp
predomin
fecal
taxa
pseudomona
sp
abund
oropharynx
day
pasteurellacea
porphyromona
sp
abund
week
bal
pseudomona
sp
bradyrhizobiacea
sphingobacteriacea
predomin
day
week
abund
pseudomona
sp
declin
week
bradyrhizobiacea
sphingobacteriacea
predomin
taxa
blood
pca
reveal
distinct
microbiom
site
howev
blood
mark
composit
similar
bal
sampl
cluster
time
individu
oropharyng
swab
subject
greater
variat
sampl
healthi
cat
rich
distinct
airway
microbiom
dynam
bacteri
popul
like
depend
age
environ
data
necessari
determin
distinct
felin
microbiom
upper
lower
airway
fece
blood
establish
evolv
data
relev
comparison
healthi
cat
cat
respiratori
diseas
object
studi
determin
pharmacokinet
pulmonari
disposit
minocyclin
adult
hors
multipl
intragastr
dose
minocyclin
mgkg
administ
via
intragastr
rout
healthi
adult
hors
everi
hour
total
dose
minocyclin
concentr
measur
plasma
pulmonari
epitheli
line
fluid
pelf
bronchoalveolar
lavag
bal
cell
via
liquid
chromatographi
mass
spectrometri
multipl
time
point
h
time
period
pharmacokinet
variabl
determin
last
dose
use
noncompartment
approach
comparison
minocyclin
concentr
sampl
site
done
use
friedman
repeat
measur
anova
signific
set
p
last
dose
mean
sd
maximum
plasma
concentr
cmax
minocyclin
termin
halflif
hour
median
percentil
time
peak
concentr
tmax
hr
cmax
tmax
minocyclin
pelf
hr
respect
cmax
tmax
bal
cell
hr
respect
peak
trough
minocyclin
concentr
pelf
significantli
higher
plasma
wherea
concentr
bal
cell
significantli
lower
oral
administ
minocyclin
distribut
pelf
bal
cell
hors
knowledg
specif
minimum
inhibitori
concentr
requir
predict
efficaci
minocyclin
treatment
bacteri
pneumonia
adult
hors
cobalt
substanc
abus
human
anim
perform
strenuou
athlet
competit
administ
pharmacolog
dose
associ
induct
erythropoietin
releas
increas
hematopoiesi
thought
confer
competit
advantag
cobalt
chlorid
cocl
reportedli
given
racehors
enhanc
perform
recent
allow
limit
cobalt
set
sever
race
jurisdict
postrac
illicit
substanc
test
blood
urin
preliminari
singledos
pharmacokinet
data
publish
cocl
hors
inform
regard
effect
repeat
dose
substanc
reportedli
use
illicitli
perform
hors
unavail
even
fewer
data
publish
describ
pharmacodynam
effect
cocl
administr
hors
particularli
high
dose
purpos
pilot
studi
describ
physiolog
biochem
effect
weekli
intraven
dose
cocl
standardbr
hors
report
describ
hemodynam
effect
cocl
dose
escal
studi
five
standardbr
mare
yearsold
kg
randomli
assign
receiv
one
dose
cocl
mgkg
intraven
bolu
infus
minut
weekli
week
prior
dose
anim
instrument
pulmonari
arteri
right
atrial
cathet
transvers
facial
arteri
cathet
two
extern
jugular
venou
cathet
indwel
urinari
cathet
electrocardiographi
lead
physic
examin
paramet
blood
pressur
systol
arteri
pressur
sap
diastol
arteri
pressur
dap
mean
arteri
pressur
map
cardiac
output
qualit
ecg
assess
evalu
everi
minut
hour
immedi
administr
first
fifth
weekli
dose
cocl
mare
subject
anxiou
nostril
flare
muscular
tremorfascicul
paw
strain
minut
follow
cocl
infus
persist
minut
mare
receiv
higher
dose
mgkg
mare
receiv
mgkg
dose
develop
tachycardia
immedi
dose
hr
bpm
observ
mare
receiv
mgkg
hr
paroxysm
ventricular
tachycardia
note
first
minut
postadministr
mare
receiv
mgkg
dose
elev
sap
dap
map
note
follow
drug
administr
dose
profound
hypertens
observ
mgkg
sapdap
map
mmhg
mare
becam
hypertens
minut
follow
cocl
administr
mare
receiv
mgkg
develop
conspicu
oral
mucou
membran
congest
persist
minut
postdos
subsequ
resolv
dose
cardiovascular
paramet
return
baselin
hour
postadministr
result
preliminari
studi
document
signific
repeat
hemodynam
alter
associ
intraven
cocl
administr
hors
degre
hypertens
observ
follow
infus
rais
human
human
safeti
concern
dose
mgkg
use
studi
object
evalu
effect
patient
age
aminoglycosid
pharmacokinet
youngadult
year
versu
geriatr
year
healthi
hors
receiv
singl
mg
kg
intraven
inject
gentamicin
henri
heparin
plasma
sampl
obtain
design
timepoint
follow
drug
administr
frozen
assay
valid
immunoassay
gentamicin
plasma
concentr
versu
time
plot
analyz
use
twocompart
model
commerci
softwar
data
compar
agegroup
use
independ
sampl
ttest
p
consid
signific
baselin
physic
examin
hematolog
paramet
significantli
differ
young
median
age
rang
year
age
year
hors
asid
lower
mean
bodyweight
geriatr
group
ae
versu
ae
kg
similarli
pharmacokinet
paramet
statist
differ
age
group
mean
aesd
p
peak
plasma
concentr
c
pk
end
distribut
phase
ae
young
ae
age
hors
p
gentamicin
trough
level
reach
common
mic
equin
pathogen
ae
ae
hour
respect
p
consid
expect
postantibiot
effect
hour
dose
adjust
like
requir
meet
therapeut
need
studi
group
innat
immun
respons
bacteri
lipopolysaccharid
lp
mediat
tolllik
receptor
contribut
substanti
morbid
number
import
equin
diseas
syndrom
includ
gastrointestin
diseas
neonat
sepsi
contribut
chronic
proinflammatori
state
microrna
mirna
small
noncod
rna
molecul
nucleotid
length
function
posttranscript
regul
gene
express
mirna
recent
found
central
role
modul
signal
cascad
speci
alter
express
implic
pathogenesi
inflammatori
diseas
limit
inform
avail
mirna
express
hors
publish
data
express
equin
inflammatori
cell
object
studi
use
next
gener
sequenc
character
basal
mirna
transcriptom
isol
equin
peripher
blood
mononuclear
cell
test
hypothesi
lp
would
induc
differenti
express
mirna
peripher
blood
mononuclear
cell
isol
four
healthi
adult
hors
cell
cultur
lp
ngml
control
hour
tumor
necrosi
factor
alpha
tnfa
measur
cultur
supernat
elisa
rna
extract
cell
mirna
transcriptom
sequenc
use
illumina
hiseq
analyz
size
select
high
qualiti
sequenc
data
map
equin
genom
annot
use
mirna
databas
mirbas
differenti
express
analyz
gener
linear
model
use
benjaminihochberg
procedur
control
fals
discoveri
rate
matur
mirna
detect
present
sampl
basal
express
highli
consist
hors
abund
mirna
baselin
sampl
g
mirna
associ
cell
cycl
regul
innat
adapt
immun
speci
tnfa
express
significantli
higher
supernat
lpstreat
cell
control
hour
p
respect
correct
multipl
comparison
significantli
upregul
lp
p
fold
chang
versu
control
mirna
show
statist
signific
express
chang
time
includ
induc
lp
speci
nonsignific
upregul
lp
express
significantli
correl
supernat
tnfa
r
basal
express
character
data
provid
foundat
futur
research
role
specif
mirna
equin
inflammatori
respons
princip
lpsinduc
mirna
hors
human
mice
mirna
document
role
signal
regul
includ
enhanc
tnfa
translat
suppress
intermedi
signal
transduct
protein
thu
like
influenc
magnitud
natur
acut
inflammatori
respons
lp
hors
could
target
immun
modulatori
intervent
may
also
prove
use
marker
tlr
activ
research
necessari
valid
express
chang
wider
sampl
set
investig
target
function
mirna
hors
establish
role
natur
occur
diseas
airway
neutrophilia
characterist
find
sever
equin
asthma
heav
common
incur
condit
hors
howev
polymorphonuclear
neutrophil
pmn
contribut
diseas
remain
poorli
understood
lowdens
granulocyt
ldg
subpopul
pmn
suggest
strong
proinflammatori
properti
promot
recruit
pmn
autocrin
manner
thu
amplifi
inflammatori
respons
therefor
hypothes
ldg
increas
blood
heavesaffect
hors
compar
healthi
subject
studi
hors
heav
diseas
exacerb
remiss
healthi
anim
ldg
normaldens
neutrophil
isol
peripher
blood
use
ficol
quantif
morpholog
character
ldg
perform
blindli
use
optic
microscop
ldg
character
flow
cytometri
use
antimyeloperoxidas
mpo
antibodi
number
ldg
significantli
elev
hors
heav
exacerb
remiss
compar
healthi
hors
p
p
respect
signific
differ
found
diseas
exacerb
remiss
p
ldg
display
significantli
greater
percentag
normal
segment
hyposeg
nuclei
heavesaffect
control
hors
p
p
respect
mpo
mean
fluoresc
intens
ldg
significantli
lower
heav
exacerb
compar
control
hors
p
pmn
count
bal
ldg
level
blood
hors
heav
correl
p
diseas
exacerb
remiss
studi
describ
first
time
associ
increas
subpopul
pmn
name
ldg
inflammatori
diseas
hors
ldg
appear
mostli
constitut
matur
cell
healthi
heavesaffect
hors
signific
find
remain
ascertain
equin
protozo
myeloenceph
epm
arguabl
common
costli
equin
neurolog
diseas
unit
state
nation
seropreval
hors
develop
diseas
lifetim
epm
affect
hors
decreas
immun
respons
cellmedi
immun
respons
appear
protect
develop
epm
infect
neurona
mous
model
therefor
addit
specif
antiprotozo
medic
levamisol
propos
adjunct
therapi
upregul
immun
respons
epm
affect
hors
studi
perform
speci
address
whether
levamisol
alter
immun
function
vitro
vivo
limit
studi
equid
hypothes
hypothes
levamisol
upregul
cell
mediat
macrophag
dendrit
cell
thelper
immun
respons
vitro
first
aim
determin
optim
condit
effect
levamisol
cellular
prolifer
equin
pbmc
harvest
ten
hors
seroneg
neurona
cell
cultur
alon
follow
mitogen
concanavalin
cona
phorbol
ionomycin
pmai
combin
mitogen
levamisol
sever
condit
cellular
prolifer
assess
use
colorimetr
bromodeoxyuridin
elisa
assay
roch
life
scienc
second
aim
determin
abil
levamisol
optim
condit
upregul
respons
vitro
base
activ
function
pbmc
hors
cultur
follow
stimul
cona
levamisol
without
cona
determin
prolifer
specif
subset
cell
label
fluoresc
dye
celltrac
violet
thermofish
scientif
prolifer
subset
determin
base
dye
dilut
use
flow
cytometri
facsaria
flow
cytomet
determin
abil
levamisol
upregul
alter
immun
respons
immun
subset
identifi
use
fluoresc
label
antibodi
activ
assess
macrophag
dc
use
mhc
class
ii
express
induct
treg
base
express
specif
immun
phenotyp
determin
base
intracellular
cytokin
express
specif
subset
ifngamma
versu
versu
treg
signific
differ
respons
determin
use
mix
model
anova
signific
set
p
studi
result
indic
cell
cultur
levamisol
alon
alter
pbmc
prolifer
compar
respons
unstimul
cell
cell
cultur
either
cona
pmai
result
statist
signific
p
increas
prolifer
compar
unstimul
cell
cell
cultur
cona
levamisol
result
signific
p
decreas
prolifer
compar
cell
cultur
cona
alon
flow
cytometri
data
analysi
result
assess
levamisol
direct
immun
phenotyp
current
pend
data
demonstr
condit
levamisol
downregul
cona
stimul
pbmc
prolifer
base
vitro
result
studi
determin
effect
levamisol
modul
equin
immun
system
vivo
warrant
atrial
fibril
af
common
patholog
arrhythmia
diagnos
hors
due
advers
effect
encount
treat
quinidin
sulphat
want
improv
medic
treatment
af
studi
aim
evalu
effect
antiarrhythm
compound
dofetilid
ranolazin
equin
heart
furthermor
hypothes
use
combin
two
antiarrhythm
compound
distinct
mechan
would
allow
us
use
lower
dose
compound
therebi
minim
risk
advers
effect
three
hors
includ
safeti
studi
test
administr
intraven
dofetilid
bwt
ranolazin
mgkg
bwt
combin
two
use
similar
dose
hors
monitor
clinic
advers
reaction
holter
monitor
ecg
record
well
blood
pressur
measur
obtain
throughout
studi
follow
safeti
studi
nine
hors
includ
electrophysiolog
studi
test
effect
dofetilid
ranolazin
electr
induc
af
place
two
intraatri
electrod
abl
record
atrial
electrogram
perform
atrial
pace
measur
atrial
effect
refractori
period
aerp
induct
af
hors
went
four
procedur
dofetilid
ranolazin
respect
combin
two
drug
use
lower
dosag
control
procedur
salin
administ
day
wash
period
treatment
hors
toler
drug
combin
well
without
develop
clinic
sign
discomfort
pain
neither
drug
result
alter
blood
pressur
plasma
level
cardiac
troponin
creatinin
kinas
fraction
mb
increas
due
intraatri
pace
treatment
given
ranolazin
alon
combin
therapi
termin
af
faster
control
procedur
p
combin
therapi
result
decreas
af
durat
p
af
vulner
p
neither
treatment
alter
aerp
significantli
dofetilid
significantli
increas
qt
c
interv
multipl
time
point
howev
case
lower
dose
dofetilid
administ
combin
procedur
studi
dofetilid
ranolazin
safe
administ
healthi
hors
none
compound
electrophysiolog
procedur
caus
myocardi
damag
hors
dofetilid
given
high
dose
qtinterv
prolong
indic
alter
ventricular
repolar
ranolazin
show
antiarrhythm
effect
acut
induc
af
hors
combin
dofetilid
ranolazin
antiarrhythm
effect
obtain
low
dose
would
ineffect
administ
separ
find
lead
us
believ
combin
therapi
may
futur
treatment
regim
equin
af
aim
studi
describ
occurr
cardiac
arrhythmia
young
standardbr
hors
recent
enter
train
determin
whether
cardiac
arrhythmia
consist
present
sever
train
session
evalu
perform
predict
base
type
frequenc
observ
arrhythmia
fiftyon
standardbr
hors
age
year
f
g
examin
multipl
train
session
three
month
period
rest
exercis
electrocardiogram
holter
monitor
well
exercis
speed
gp
record
descript
statist
use
analyz
data
total
train
session
record
thirti
hors
complet
train
session
hors
complet
train
session
hors
complet
one
train
session
singl
multipl
arrhythmia
observ
session
total
hors
secondari
avblock
rest
observ
session
ventricular
prematur
contract
vpc
record
supraventricular
prematur
contract
svpc
sinu
arrhythmia
sa
session
thirteen
hors
drop
train
first
train
session
arrhythmia
vpc
svpc
sa
three
hors
drop
train
two
session
arrhythmia
vpc
sa
hors
arrhythmia
consist
record
sever
train
session
hors
drop
train
vpc
per
session
mean
ae
cardiac
arrhythmia
commonli
observ
young
standardbr
hors
recent
enter
train
hors
cardiac
arrhythmia
observ
multipl
train
session
signific
abnorm
may
less
like
continu
train
reach
first
trial
ecg
invalu
diagnost
tool
human
cardiolog
condit
left
ventricular
hypertrophi
lvh
bundl
branch
block
diagnos
base
ecg
guidelin
ecg
hors
exist
guidelin
imit
human
electrod
placement
limb
lead
record
extrem
precordi
lead
thorax
howev
differ
orient
equin
heart
alter
einthoven
triangl
wilson
central
termin
wct
therebi
chang
basi
record
aim
studi
evalu
differ
electrod
placement
base
physiolog
idea
human
einthoven
triangl
wct
may
provid
better
inform
equin
atria
ventricl
compar
standard
extrem
lead
develop
new
method
ecg
record
perform
place
limb
electrod
right
left
scapula
midlin
caudal
xiphoid
process
place
wct
middl
heart
einthoven
triangl
nearli
perpendicular
main
cardiac
depolar
vector
place
precordi
lead
superfici
pector
muscl
ventral
part
left
right
tricep
muscl
intercost
space
level
shoulder
joint
left
side
level
elbow
joint
side
inform
heart
chamber
would
record
standardbr
hors
mare
geld
stallion
mean
age
year
rang
ecg
record
use
exist
method
new
modifi
method
hors
echocardiograph
examin
perform
measur
atrial
left
atrium
area
laa
left
atrium
diamet
lad
ventricular
size
includ
calcul
lv
mass
wave
lead
measur
data
blind
analys
compar
variou
lead
ecg
two
method
show
signific
increas
p
wave
amplitud
durat
new
modifi
method
p
signific
correl
p
wave
durat
laa
lad
found
new
modifi
method
p
r
p
r
respect
amplitud
r
wave
ad
signific
correl
lv
mass
found
new
modifi
method
p
r
exist
method
p
r
also
signific
correl
mean
qr
durat
lv
mass
found
new
modifi
method
p
r
exist
method
p
r
studi
show
new
method
better
correl
left
atrial
size
lv
mass
suggest
correct
einthoven
triangl
wct
give
better
result
obtain
ecg
hors
report
frequenc
neoplasia
hors
low
like
underreport
due
difficulti
establish
definit
diagnosi
clinic
sign
may
vagu
neoplasia
often
identifi
postmortem
examin
delay
diagnosi
may
lead
increas
morbid
wherea
definit
diagnos
termin
case
provid
object
evid
elect
human
euthanasia
humor
hypercalcemia
malign
common
paraneoplast
syndrom
speci
could
util
aid
identif
equin
neoplasia
object
studi
identifi
preval
hypercalcemia
among
hors
neoplasia
compar
calcium
albumin
relationship
valu
hors
neoplasia
system
ill
hors
without
neoplasia
healthi
anim
electron
medic
record
search
perform
identifi
hors
month
age
serum
total
calcium
albumin
measur
elig
case
group
diagnosi
neoplasia
n
sick
nonneoplasia
n
healthi
orthoped
n
sick
nonneoplasia
group
subdivid
base
bodi
system
affect
diseas
addit
comparison
exclus
criteria
includ
lack
definit
diagnosi
diagnosi
renal
diseas
rhabdomyolysi
preliminari
data
identifi
higher
calcium
lower
albumin
neoplasia
group
compar
sick
nonneoplasia
group
calcium
albumin
ratio
higher
neoplasia
group
healthyorthoped
group
lower
sick
nonneoplasia
group
data
suggest
hypercalcemia
may
support
diagnosi
neoplasia
equin
patient
calcif
tunica
media
main
pulmonari
arteri
observ
larg
proport
young
racehors
human
medial
calcif
import
caus
increas
arteri
stiff
implic
pathogenesi
cerebr
renal
microvascular
diseas
puls
wave
veloc
pwv
marker
arteri
stiff
studi
aim
develop
techniqu
determin
puls
wave
veloc
main
pulmonari
arteri
hors
conveni
sampl
adult
hors
histori
respiratori
cardiovascular
diseas
use
hors
sedat
cathet
placement
continu
monitor
electrocardiographi
procedur
pulmonari
arteri
pa
trunk
cannul
via
right
heart
catheter
cathet
introduc
sheath
x
cm
introduc
placement
guid
echocardiographi
custommad
dual
pressur
sensor
cathet
psc
x
cm
insert
introduc
sheath
one
main
branch
pa
posit
psc
one
main
branch
pa
confirm
thorac
radiographi
cathet
withdrawn
cm
step
pressur
measur
record
locat
time
delay
puls
wave
two
sensor
use
calcul
pwv
histolog
pa
trunk
main
branch
perform
investig
presenc
medial
lesion
calcif
psc
placement
success
achiev
hors
without
signific
complic
asid
transient
arrhythmia
cathet
commonli
locat
left
pa
time
pressur
measur
level
sedat
variabl
hors
mean
aesd
pwv
ae
ms
proxim
pa
trunk
ae
ms
distal
cm
main
pa
branch
mean
aesd
mean
arteri
pressur
proxim
pa
trunk
ae
mmhg
ae
mmhg
distal
cm
main
pa
branch
mean
aesd
puls
pressur
proxim
pa
trunk
ae
mmhg
ae
mmhg
distal
cm
main
pa
branch
five
nine
hors
present
moder
sever
lesion
calcif
tunica
media
pa
trunk
andor
main
branch
studi
demonstr
feasibl
techniqu
determin
papwv
stand
hors
techniqu
develop
may
allow
investig
effect
calcif
larg
pulmonari
arteri
develop
pulmonari
microvascular
disord
hors
purpos
studi
describ
normal
valu
chang
competit
season
marker
autonom
tone
compet
event
ev
endur
en
hors
conjunct
previous
report
variabl
monitor
train
compar
noncompetit
breedmatch
control
evc
enc
ev
evc
en
start
project
heart
rate
variabl
hrv
noninvas
blood
pressur
nibp
splenic
volum
preand
postexercis
hematocrit
cortisol
standard
exercis
test
set
muscl
enzym
activ
measur
preseason
midseason
peakend
competit
season
hrv
lower
p
ev
evc
time
postexercis
cortisol
lower
signific
differ
en
versu
enc
hrv
postexercis
cortisol
chang
season
group
ev
higher
fit
marker
set
compar
evc
differ
en
enc
nibp
splenic
volum
hematocrit
preexercis
cortisol
muscl
enzym
activ
weight
significantli
differ
group
chang
season
conclus
compet
event
hors
show
higher
sympathet
tone
lower
postexercis
cortisol
control
nibp
splenic
volum
rest
postexercis
hematocrit
detect
chang
autonom
tone
popul
studi
marker
autonom
tone
chang
significantli
throughout
season
group
detect
chang
compet
endur
hors
compar
control
pituitari
par
intermedia
dysfunct
ppid
equin
metabol
syndrom
em
describ
common
endocrinolog
disord
hors
larg
studi
exist
describ
epidemiolog
characterist
hors
endocrin
diseas
purpos
studi
obtain
inform
includ
age
breed
sex
clinic
sign
acthinsulinglucos
statu
initi
diagnosi
potenti
endocrin
case
new
case
determin
epidemiolog
characterist
hors
hyperinsulinemia
hors
age
breed
sex
continent
us
elig
studi
enrol
long
document
exhibit
one
follow
clinic
sign
gener
region
hypertrichosi
muscl
wast
abnorm
fat
distribut
lethargi
lamin
unknown
etiolog
polyuria
polydipsia
suscept
infect
abnorm
sweat
andor
inappropri
lactat
normal
hors
exclud
studi
initi
visit
demograph
data
signal
physic
examin
conduct
clinic
sign
document
blood
drawn
basal
acth
fast
insulin
glucos
blood
sampl
process
ship
overnight
anim
health
diagnost
center
cornel
univers
ithaca
ny
analysi
associ
hyperinsulinemia
base
fast
insulin
result
clinic
sign
glucos
statist
evalu
individu
use
pearson
chisquar
test
odd
ratio
signific
predictor
hyperinsulinemia
comput
use
correspond
confid
interv
appli
multipl
logist
regress
analysi
fourhundr
eighteen
ninehundr
eighti
two
hors
complet
epidemiolog
inform
includ
final
data
analysi
hors
hi
hors
stratifi
group
base
acth
insulin
laboratori
result
ppid
hi
ppid
hi
ppid
hi
hors
ppid
hi
ppid
hi
ppid
hi
hors
evalu
hors
year
age
ppid
hi
hors
year
age
ppid
hi
hors
year
age
ppid
hi
hors
year
age
ppid
hi
hors
year
age
hi
hors
year
age
hi
hors
year
age
hi
hors
year
age
hi
onehundr
nineti
seven
hors
ppid
hi
analysi
ppidhi
ppidhi
hors
evalu
base
data
clinic
sign
ppidhi
hors
hi
significantli
p
greater
among
hors
cresti
neck
lamin
present
although
statist
signific
p
hi
greater
hors
clinic
sign
abnorm
sweat
pot
bellyweight
gain
base
clinic
sign
data
odd
hi
hors
cresti
neck
twice
hors
without
clinic
sign
similarli
hors
lamin
odd
ratio
hi
twice
hors
without
clinic
sign
enrol
hors
diagnos
hyperinsulinemia
base
combin
data
clinic
sign
interpret
glucos
level
fast
statu
cresti
neck
lamin
high
glucos
signific
predictor
hi
specif
hors
high
glucos
level
seen
almost
four
time
odd
hi
compar
normal
glucos
level
therefor
evalu
hors
suspect
endocrin
diseas
minimum
acth
insulin
glucos
evalu
long
term
studi
need
conduct
larg
popul
hors
evalu
endocrinopathi
hors
pituitari
par
intermedia
dysfunct
ppid
previous
diagnos
manag
older
hors
diseas
advanc
clinic
sign
howev
earli
ppid
clinic
sign
typic
subtl
clinic
sign
earli
ppid
includ
decreas
athlet
perform
chang
attitudelethargi
delay
hair
coat
shed
subtl
region
hypertrichosi
loss
epaxi
muscl
mass
toplin
region
adipos
lamin
one
major
limit
diagnost
test
ppid
sensit
avail
diagnost
assay
thyrotropinreleas
hormon
trh
stimul
test
shown
increas
sensit
detect
hors
earli
ppid
compar
rest
acth
studi
exist
concern
endocrinolog
test
followup
monitor
clinic
progress
diagnost
assay
result
follow
treatment
hors
earli
ppid
purpos
studi
identifi
case
earli
ppid
base
clinic
sign
laboratori
test
determin
improv
acth
level
use
rest
acth
trh
stimul
test
clinic
sign
time
sixteen
hors
enrol
januari
least
one
clinic
sign
earli
ppid
list
diagnost
confirm
trh
stimul
test
measur
acth
pretrh
min
follow
mg
iv
trh
administr
fast
insulin
glucos
also
determin
pretreat
followup
visit
hors
administ
pergolid
mesyl
oral
start
dosag
mcgkg
daili
dosag
adjust
effect
requir
exceed
mcgkg
daili
per
manufactur
label
recommend
histori
physic
examin
trh
stimul
test
evalu
conduct
month
februari
june
follow
initi
treatment
administr
compar
chang
baselin
acth
level
time
evalu
use
descript
statist
statist
signific
chang
acth
level
evalu
use
confid
interv
initi
examin
common
clinic
sign
initi
diagnosi
region
hypertrichosi
delay
shed
muscl
wast
baselin
arithmet
mean
hors
pgml
pgml
respect
follow
sixmonth
treatment
rest
hors
less
normal
refer
rang
pgml
wherea
hors
less
recommend
refer
rang
pgml
june
decreas
baselin
wherea
decreas
baselin
hors
region
hypertrichosi
delay
shed
consid
improv
resolv
wherea
bodi
condit
muscl
wast
slightli
improv
four
advers
event
relat
treatment
report
consid
resolv
within
hour
hors
improv
clinic
sign
follow
treatment
signific
chang
baselin
observ
insulin
glucos
paramet
follow
month
treatment
hors
decreas
normal
rang
compar
decreas
recommend
refer
rang
although
hors
respond
clinic
hors
remain
posit
even
though
decreas
refer
rang
option
hold
treatment
dosag
level
justifi
base
clinic
sign
improv
long
term
studi
larg
number
hors
conduct
hors
earli
ppid
octreotid
somatostatin
analog
suppress
insulin
secret
hypothes
octreotid
respons
test
ort
could
develop
detect
insulin
dysregul
id
twelv
morgan
hors
includ
insulin
statu
assess
oral
sugar
test
ost
ort
perform
fast
hors
overnight
administ
octreotid
iv
dosag
lgkg
blood
collect
minut
h
mean
aucg
differ
significantli
normal
n
id
n
group
mean
glucos
concentr
minut
significantli
p
higher
id
group
compar
ttest
mean
auci
significantli
higher
p
id
group
compar
normal
group
mean
plasma
insulin
concentr
differ
significantli
group
minut
signific
time
effect
p
detect
trend
toward
higher
insulin
concentr
time
group
time
p
result
show
insulin
concentr
decreas
within
minut
octreotid
administr
hyperglycemia
develop
result
effect
octreotid
wane
insulin
concentr
increas
preinject
baselin
insulin
secret
regain
glycem
control
magnitud
increas
insulin
concentr
reflect
insulin
sensit
evidenc
higher
auci
valu
detect
hors
id
group
oral
sugar
test
ost
use
assess
insulin
statu
hors
studi
undertaken
test
hypothesi
test
result
close
correl
blood
insulin
respons
graze
pastur
grass
correl
among
insulin
incretin
hormon
concentr
also
assess
better
understand
mechan
hyperinsulinemia
hors
eight
morgan
hors
univers
massachusett
herd
fast
overnight
subject
ost
minut
immedi
follow
turnout
pastur
grass
blood
sampl
collect
minut
plasma
activ
total
glucagonlik
respect
glucosedepend
insulinotrop
polypeptid
gip
concentr
measur
along
glucos
insulin
concentr
peak
concentr
area
curv
valu
compar
ost
minut
pastur
challeng
minut
peak
insulin
concentr
r
p
area
insulin
curv
valu
r
p
posit
correl
ost
pastur
challeng
area
curv
minut
area
gip
curv
correl
one
anoth
r
p
correl
area
insulin
curv
activ
concentr
pend
hypothesi
support
conclud
ost
use
predict
insulin
respons
graze
pastur
grass
sepsi
continu
caus
high
mortal
human
equin
neonat
hypothalamicpituitaryadren
axi
activ
sepsi
increas
cortisol
concentr
howev
secret
cortisol
insuffici
sever
diseas
number
sick
foal
group
other
shown
rel
adren
insuffici
rai
character
poor
cortisol
respons
adrenocorticotropin
acth
associ
mortal
sever
diseas
foal
studi
investig
rai
equin
patient
focus
cortisol
adrenocort
steroid
overlook
hypothes
high
dose
acth
stimul
test
stimul
releas
multipl
adrenocort
steroid
howev
rai
septic
foal
character
weak
glucocorticoid
mineralocorticoid
respons
normal
androgen
pregnan
respons
compar
healthi
foal
sick
foal
normal
adrenocort
function
also
propos
steroid
respons
acth
associ
sever
diseas
foal
day
age
n
categor
group
septic
n
sick
nonsept
sn
n
healthi
n
baselin
blood
sampl
collect
admiss
time
foal
receiv
acth
iv
addit
sampl
collect
minut
postacth
hormon
concentr
determin
immunoassay
delta
hormon
defin
percent
concentr
chang
time
minut
delta
septic
sn
foal
higher
pregnenolon
progesteron
estradiol
compar
healthi
foal
time
point
p
cortisol
aldosteron
androstenedion
concentr
higher
septic
sn
healthi
foal
time
minut
p
delta
lower
septic
compar
healthi
foal
cortisol
aldosteron
p
septic
foal
higher
dehydroepiandrosteron
dhea
delta
healthi
foal
p
studi
show
impair
respons
acth
septic
foal
involv
multipl
adrenocort
steroid
increas
dhea
respons
acth
stimul
might
good
indic
rai
septic
foal
neonat
maladjust
syndrom
nm
common
ill
newborn
foal
neuroact
steroid
pregnan
androgen
particip
neurolog
develop
imbal
implic
human
disord
recent
pathogenesi
nm
oxytocin
regul
uterin
contract
lactat
social
function
oxytocin
modul
neurosteroid
action
neurosteroid
pregnan
stimul
oxytocin
releas
grow
anim
oxytocin
releas
may
alter
human
patient
varieti
neurolog
disord
howev
role
oxytocin
patholog
newborn
foal
includ
sepsi
nm
investig
hypothes
foal
nm
sepsi
higher
oxytocin
neurosteroid
concentr
compar
healthi
foal
also
propos
concentr
neuroact
steroid
oxytocin
associ
outcom
blood
sampl
collect
admiss
foal
nm
foal
neonat
diseas
healthi
foal
day
age
blood
concentr
steroid
oxytocin
determin
immunoassay
oxytocin
concentr
higher
foal
nm
compar
healthi
foal
lower
foal
disord
includ
sepsi
compar
healthi
nm
foal
p
sick
foal
nm
diseas
increas
cortisol
aldosteron
progesteron
pregnenolon
concentr
compar
healthi
foal
p
differ
steroid
concentr
foal
nm
diseas
progesteron
concentr
higher
sick
nonsurviv
foal
compar
survivor
p
androstenedion
dehydepiandrosteron
concentr
differ
group
foal
due
neuron
modulatori
action
studi
suggest
oxytocin
concentr
may
involv
pathogenesi
nm
disord
equin
neonat
hyperprogesteronemia
associ
nm
sepsi
poor
prognosi
surviv
hospit
foal
equin
metabol
syndrom
em
cluster
clinic
sign
includ
insulin
resist
dyslipidemia
common
caus
lamin
pain
lifethreaten
diseas
hors
hoof
larg
acrossbre
studi
metabol
variat
hors
lab
demonstr
em
phenotyp
variabl
metabol
trait
influenc
genet
environment
factor
demonstr
certain
featur
em
phenotyp
differ
breed
object
project
identifi
genom
region
contribut
em
perform
genomewid
associ
studi
gwa
cohort
welsh
poni
phenotyp
metabol
trait
individu
genotyp
one
two
snp
array
snp
softwar
program
beagl
use
gener
uniform
set
maker
across
platform
million
snp
gwa
perform
use
mix
linear
regress
model
includ
random
polygen
term
determin
genom
relationship
matrix
calcul
select
trait
associ
snp
random
herd
effect
fix
covari
sex
age
signific
loci
identifi
sever
em
trait
specif
exampl
includ
loci
p
p
fast
adiponectin
triglycerid
level
respect
fast
insulin
level
signific
loci
identifi
p
p
candid
gene
region
includ
gene
associ
obes
human
gene
associ
height
insulin
resist
futur
direct
includ
haplotyp
analysi
interrog
region
whole
genom
sequenc
hyperphosphatemia
hypocalcemia
increas
parathyroid
hormon
pth
reduc
vitamin
metabolit
concentr
recent
document
critic
ill
foal
group
howev
inform
fibroblast
growth
klotho
two
factor
regul
vitamin
activ
pth
secret
associ
calcium
phosphoru
pth
vitamin
concentr
healthi
hospit
foal
lack
releas
osteocyt
respons
increas
oh
pth
phosphoru
concentr
suppress
renal
activ
pth
synthesi
klotho
secret
kidney
act
coreceptor
goal
studi
determin
relev
klotho
calcium
phosphoru
pth
vitamin
regul
includ
associ
clinic
laboratori
find
diseas
sever
outcom
hospit
foal
hypothes
elev
reduc
klotho
concentr
frequent
associ
calcium
phosphoru
dysregul
pth
vitamin
metabolit
oh
oh
concentr
sever
ill
mortal
critic
ill
foal
one
hundr
newborn
foal
day
old
divid
hospit
n
septic
sick
nonsept
sn
healthi
n
group
includ
blood
sampl
collect
admiss
serum
klotho
pth
vitamin
metabolit
measur
immunoassay
data
analyz
nonparametr
method
logist
regress
serum
concentr
significantli
higher
klotho
oh
oh
concentr
significantli
lower
septic
sn
compar
healthi
foal
p
septic
foal
higher
phosphoru
pth
low
calcium
concentr
sn
healthi
foal
p
hospit
septic
foal
serum
concentr
associ
phosphoru
pth
p
calcium
vitamin
metabolit
concentr
p
septic
foal
serum
klotho
concentr
posit
associ
oh
concentr
rs
p
hospit
foal
highest
lowest
klotho
concentr
like
die
ci
respect
high
low
klotho
concentr
presenc
elev
phosphoru
pth
concentr
suggest
resist
may
involv
pathogenesi
miner
endocrin
disord
critic
ill
foal
alphatocopherol
atp
defici
hors
lead
nutrit
myodegener
neuraxon
dystrophi
vitamin
e
defici
myopathi
motor
neuron
diseas
depend
tempor
occurr
individu
suscept
absenc
adequ
grass
pastur
atp
supplement
becom
increasingli
import
due
better
bioavail
natur
isoform
atp
rrratp
increasingli
use
rrratp
avail
two
formul
waterdispers
liquid
acet
powder
rapid
increas
serum
atp
occur
expens
liquid
rrratp
rrratp
acet
often
use
longterm
supplement
howev
due
higher
cost
liquid
rrrat
object
eightweek
studi
compar
serum
cerebrospin
fluid
csf
atp
concentr
three
group
hors
serum
atp
concentr
group
atp
n
iu
daili
rrratp
acet
n
iu
daili
rrratp
liquid
transit
iu
daili
acet
n
transit
liquid
rrratp
week
transit
week
rrratp
acet
week
hors
appear
healthi
fed
diet
hay
cube
dri
lot
serum
sampl
obtain
weekli
atlantooccipit
csf
fluid
obtain
eightweek
supplement
period
glm
anova
post
hoc
bonferroni
pair
wise
comparison
p
perform
begin
week
serum
atp
significantli
higher
liquid
acet
rrratp
transit
group
acet
supplement
group
serum
atp
increas
gradual
rrratp
acet
group
significantli
higher
supplement
group
csf
atp
increas
significantli
pre
post
supplement
liquid
acet
rrratp
group
conclus
hors
defici
atp
fastest
highest
increas
serum
atp
obtain
use
waterdispers
rrratp
regimen
rrratp
waterdispers
product
taper
rrratp
acet
provid
effect
mean
rapidli
sustain
increas
atp
serum
csf
eightweek
period
equin
metabol
syndrom
character
region
adipos
insulin
resist
predisposit
lamin
activ
inflamm
region
adipos
hors
character
subcutan
fat
deposit
nuchal
ligament
behind
shoulder
tail
head
increas
neck
circumfer
associ
insulin
resist
human
mice
viscer
fat
associ
insulin
resist
develop
diabet
metabol
activ
fat
depot
contrast
candid
gene
express
studi
hors
suggest
nuchal
fat
may
metabol
activ
viscer
fat
collect
sampl
six
adipos
tissu
depot
within
hors
nuchal
shoulder
tail
head
subcutan
sq
viscer
oment
retroperiton
intern
six
hors
vari
age
breed
sex
quantifi
differ
gene
express
variou
depot
averag
pairedend
rna
sequenc
read
per
sampl
gener
illumina
hiseq
platform
limmavoom
linear
model
identifi
gene
differenti
express
sq
intern
adipos
tissu
depot
interestingli
sever
pathway
includ
ppar
pten
associ
metabol
activ
beigebrown
fat
highli
express
sq
compar
intern
fat
depot
p
marker
beig
fat
whose
subcutan
express
level
also
posit
correl
central
obes
human
overexpress
sq
p
p
gene
express
brown
adipos
tissu
also
overexpress
subcutan
tissu
sever
differ
sq
gene
express
driven
differ
nuchal
fat
multipl
clinic
applic
acidif
equin
urin
includ
prevent
reoccurr
urolithiasi
studi
evalu
efficaci
commerci
anion
supplement
urinari
acidif
without
alter
system
ph
eight
hors
administ
achiev
dcad
meqkg
meqkg
fed
control
diet
day
random
crossov
trial
urin
plasma
ph
plasma
strong
ion
differ
plasma
anion
gap
fraction
excret
calcium
measur
compar
treatment
group
mean
urin
ph
across
collect
period
significantli
greater
control
hors
compar
either
treatment
group
differ
treatment
group
blood
ph
anion
gap
affect
treatment
blood
ph
decreas
anion
gap
increas
time
mean
bicarbon
concentr
lower
meqkg
group
control
group
differ
meq
meqkg
treatment
strong
ion
differ
meq
treatment
lower
control
group
mean
fraction
excret
calcium
time
point
differ
treatment
group
effect
time
treatment
treatment
group
increas
fraction
excret
calcium
rel
control
group
trial
day
studi
show
soychlor
supplement
decreas
equin
urinari
ph
system
ph
affect
increas
fraction
excret
calcium
occur
abrupt
chang
diet
shown
caus
gastrointestin
upset
hors
particular
sudden
larg
increas
concentr
intak
lead
hindgut
disrupt
due
acidosi
variou
dietari
addit
studi
determin
respons
may
amelior
blunt
exert
prebiot
effect
object
studi
test
hypothesi
supplement
proprietari
yeast
ferment
product
would
amelior
disrupt
effect
sudden
increas
concentr
intak
cecum
nine
cecallycannul
quarter
hors
year
mare
geld
approxim
kg
divid
control
n
treatment
n
group
base
gender
bodi
weight
acclim
diet
hous
control
diet
consist
bwd
prairi
grass
hay
divid
feed
bwd
protein
commerciallyavail
concentr
omolen
purina
anim
nutrit
topdress
kg
bw
alfalfa
pellet
placebo
feed
treatment
diet
ident
concentr
topdress
kg
bw
pellet
proprietari
yeast
ferment
product
cecal
fluid
sampl
collect
h
feed
h
h
h
h
h
h
h
h
addit
day
establish
baselin
level
morn
meal
consist
bw
concentr
challeng
follow
bw
hay
cecal
sampl
collect
previou
day
cecal
fluid
ph
measur
sampl
time
collect
lactat
later
assess
use
colorimetr
analysi
complet
random
splitsplitplot
design
use
test
effect
yeast
ferment
product
analysi
varianc
done
mix
model
sa
sa
institut
inc
cari
nc
usa
least
squar
mean
compar
use
fisher
least
signific
differ
p
advers
clinic
effect
note
follow
dietari
challeng
mean
cecal
ph
decreas
h
h
p
respect
mean
cecal
lactat
increas
h
h
h
p
respect
challeng
compar
baselin
regardless
treatment
treatment
group
hors
increas
mean
cecal
ph
h
p
decreas
mean
cecal
lactat
h
p
compar
control
group
signific
differ
control
treatment
hors
mean
cecal
ph
lactat
sampl
time
sudden
increas
concentr
intak
bw
bw
induc
signific
transient
decreas
cecal
ph
increas
cecal
lactat
inconsist
blunt
consumpt
proprietari
yeast
ferment
product
effect
supplement
alfalox
forag
equin
gastric
ulcer
score
gastric
juic
ph
frank
andrew
pilar
camacholuna
kelsey
bailey
isabel
nesen
michael
keowen
frank
garza
number
boolean
following
degre
chinchi
liu
equin
health
studi
program
louisiana
state
univers
school
veterinari
medicin
baton
roug
la
usa
ecol
national
v
et
erinair
toulous
franc
data
use
compar
nutrit
qualiti
two
period
data
analyz
statist
use
anova
repeat
measur
signific
differ
found
main
model
posthoc
least
squar
mean
test
perform
determin
signific
differ
p
alfalox
forag
topdress
grain
readili
eaten
hors
result
advers
effect
period
data
pool
alfalox
forag
treatment
day
effect
gastric
ulcer
score
gastric
juic
ph
studi
period
howev
overal
period
effect
treatment
bc
higher
gastric
ulcer
score
lower
afltreat
hors
first
period
studi
treatment
day
effect
seen
forag
analysi
show
lower
digest
energi
first
period
studi
signific
effect
seen
studi
includ
ometreat
significantli
decreas
gastric
ulcer
score
increas
gastric
juic
ph
alftreat
control
hors
gastric
ulcer
heal
hors
day
treatment
addit
gastric
ulcer
score
significantli
increas
week
ome
treatment
feeddepriv
regardless
treatment
alfalox
forag
effect
gastric
ulcer
score
ome
treatment
feeddepriv
compar
untreat
control
howev
forag
lower
digest
energi
higher
fiber
content
foragef
hors
better
bc
fewer
ulcer
thu
alfalox
forag
might
provid
gastric
support
forag
margin
nutrit
valu
point
quantiti
alfalox
forag
fed
may
adequ
affect
gastric
ulcer
score
gastric
juic
ph
hors
studi
nutrit
benefit
might
result
neonat
diarrhea
import
diseas
complex
foal
diarrhea
associ
signific
chang
composit
structur
microbiota
adult
hors
chang
associ
diarrhea
neonat
foal
unknown
object
investig
chang
equin
neonat
microbiota
associ
age
occurr
diarrhea
field
trial
fecal
sampl
collect
foal
week
age
assess
via
metagenom
sequenc
foal
monitor
occurr
diarrhea
record
wilcoxon
steelmandwass
test
use
assess
differ
age
group
foal
diarrhea
healthi
foal
within
age
group
age
signific
effect
rel
abund
bacteri
taxa
phylum
order
class
level
signific
increas
rich
time
p
foal
develop
diarrhea
structur
microbiota
significantli
differ
week
compar
week
p
week
p
diarrhea
signific
effect
rel
abund
order
class
foal
diarrhea
reduc
bacteri
rich
four
week
age
p
diarrhea
signific
effect
beta
divers
age
group
p
composit
rich
equin
neonat
microbiota
chang
rapidli
birth
similar
adult
foal
diarrhea
chang
composit
rich
microbiota
studi
need
assess
whether
chang
caus
effect
diarrhea
flow
cytometri
realtim
pcr
statist
analysi
perform
use
sigma
systat
inc
richmond
ca
signific
determin
level
p
nonnorm
distribut
data
log
transform
prior
statist
analysi
variabl
measur
cellmedi
immun
etc
mix
model
two
way
anova
repeat
measur
use
measur
humor
immun
respons
eiv
compon
vaccin
result
show
overal
signific
p
increas
chang
hi
antibodi
titer
vaccin
poni
compar
nonvaccin
salin
control
increas
eivspecif
igga
iggb
antibodi
titer
vaccin
group
poni
compar
salin
control
chang
iggt
respons
vaccin
poni
measur
cmi
respons
flow
cytometri
show
signific
increas
eivspecif
interferongamma
produc
per
cell
vaccin
poni
compar
salin
control
measur
eiv
specif
cmi
respons
realtim
pcr
show
signific
increas
eivspecif
interferon
gamma
granzym
b
gene
express
vaccin
poni
compar
control
signific
differ
gene
express
perforin
compar
vaccin
poni
control
overal
combin
kill
vaccin
induc
signific
humor
cellmedi
respons
anim
state
wnv
infect
caus
sever
acut
ill
devast
clinic
sign
ill
affect
gait
behaviour
abnorm
often
time
result
high
case
fatal
rate
thu
wnv
vaccin
recommend
core
vaccin
essenti
standard
care
hors
north
america
recommend
aaep
mani
commerci
avail
vaccin
sold
singl
pathogen
vaccin
howev
nowaday
sever
avail
multipathogen
combin
vaccin
littl
data
exist
character
immun
respons
wnv
antigen
follow
combin
vaccin
hypothes
multipathogen
combin
vaccin
elicit
signific
cellmedi
humor
immun
respons
poni
total
influenza
yearl
poni
randomli
assign
receiv
one
two
treatment
group
group
n
vetera
ewt
eiv
wnv
bivi
vaccin
group
n
control
receiv
salin
vaccin
vaccin
poni
receiv
primari
vaccin
day
follow
booster
vaccin
day
peripher
blood
collect
poni
prior
vaccin
day
everi
week
follow
week
period
serum
peripher
blood
mononuclear
cell
isol
measur
wnvspecif
antibodi
cellmedi
immun
respons
follow
assay
elisa
interferongamma
intracellular
stain
flow
cytometri
realtim
pcr
statist
analysi
perform
use
sigma
systat
inc
richmond
ca
signific
determin
level
p
nonnorm
distribut
data
log
transform
prior
statist
analysi
variabl
measur
cellmedi
immun
etc
mix
model
two
way
anova
repeat
measur
use
measur
humor
immun
respons
wnv
compon
vaccin
result
show
signific
p
increas
wnv
igg
titer
vaccin
poni
compar
nonvaccin
salin
control
measur
cmi
respons
flow
cytometri
show
signific
p
increas
percentag
wnvspecif
interferongamma
produc
cell
vaccin
poni
compar
salin
control
measur
wnvspecif
cmi
respons
rtpcr
show
signific
p
increas
wnvspecif
interferon
gamma
gene
express
vaccin
poni
compar
control
signific
p
differ
gene
express
grzb
compar
vaccin
poni
control
overal
combin
kill
vaccin
induc
signific
wnvspecif
humor
cellmedi
immun
respons
anim
infect
control
crucial
oper
veterinari
hospit
protect
patient
hospit
protect
personnel
veterinari
field
increas
risk
occup
exposur
zoonot
diseas
studi
veterinari
teach
hospit
vth
survey
report
signific
health
problem
due
zoonot
infect
among
hospit
personnel
cryptosporidium
parvum
infect
account
infect
object
studi
character
current
infect
control
practic
place
prevent
zoonot
diseas
infect
specif
infect
c
parvum
vth
vth
locat
north
america
n
oper
least
one
year
elig
particip
studi
phone
survey
biosecur
expert
conduct
juli
octob
address
polici
hygien
surveil
patient
contact
educ
awar
enter
infecti
diseas
control
among
particip
vth
n
greater
half
report
signific
outbreak
diseas
among
hospit
patient
previou
year
commonli
due
salmonella
enterica
equin
addit
report
signific
health
problem
personnel
previou
year
like
result
zoonot
infect
cryptosporidium
identifi
common
agent
major
vth
survey
committe
oversaw
biosecur
program
activ
well
written
biosecur
polici
document
howev
half
conduct
mandatori
train
biosecur
infecti
diseas
control
program
result
studi
help
improv
strategi
prevent
healthcareassoci
infect
includ
zoonot
diseas
among
patient
veterinari
personnel
allow
target
educ
tool
promot
safeti
cultur
veterinari
medicin
alexandra
bianco
georg
moor
sandra
taylor
purdu
univers
west
lafayett
usa
nonsteroid
antiinflammatori
drug
nsaid
play
integr
role
equin
medicin
due
combin
analges
antiinflammatori
properti
despit
widespread
use
limit
nsaid
avail
demonstr
variabl
advers
effect
safeti
sever
nsaid
proven
adequ
analges
undergon
rigor
evalu
antiinflammatori
efficaci
ketorolac
tromethamin
kt
nonselect
cyclooxygenas
inhibitor
use
human
patient
sinc
pharmacokinet
properti
kt
recent
determin
hors
previous
determin
sever
speci
howev
two
previou
studi
examin
kt
antiinflammatori
properti
anim
vivo
publish
studi
evalu
vitro
antiinflammatori
effect
kt
veterinari
speci
purpos
studi
evalu
antiinflammatori
effect
kt
compar
flunixin
meglumin
use
vitro
model
lpsstimul
equin
monocyt
equin
monocyt
isol
whole
blood
singl
hors
incub
either
kt
flunixin
meglumin
six
concentr
rang
hour
initi
incub
e
coli
lp
ad
well
concentr
shown
consist
activ
monocyt
well
incub
co
hour
sampl
collect
time
point
store
analysi
equinespecif
elisa
use
measur
eicosanoid
pge
txb
well
cytokin
tnf
preliminari
result
demonstr
flunixin
meglumin
suppress
pge
product
hour
concentr
ml
hour
concentr
flunixin
meglumin
suppress
txb
product
hour
concentr
hour
concentr
ketorolac
tromethamin
suppress
pge
product
hour
concentr
hour
concentr
ketorolac
tromethamin
also
suppress
txb
product
hour
concentr
suppress
product
hour
concentr
peak
eicosanoid
concentr
nontreat
sampl
occur
hour
pge
hour
txb
vitro
result
directli
correl
vivo
efficaci
result
thu
far
indic
drug
effect
suppress
eicosanoid
product
lp
stimul
effect
time
drug
concentr
base
result
studi
therapeut
dose
kt
would
effect
suppress
eicosanoid
product
case
endotoxemia
research
need
correl
vitro
result
vivo
efficaci
hyperthermia
foal
treat
erythromycin
eri
clarithromycin
azithromycin
associ
reduct
sweat
unknown
mechan
aim
studi
evalu
effect
sweat
chloramphenicol
chl
like
macrolid
bind
subunit
bacteri
ribosom
gamithromycin
gam
macrolid
subclass
azalid
yet
licens
treatment
foal
experiment
period
foal
month
old
treat
eri
mgkg
po
time
daili
day
gam
mgkg
im
chl
mgkg
po
time
daili
day
accord
mask
duplic
fulli
counterbalanc
design
quantit
intraderm
terbutalin
sweat
test
perform
success
day
treatment
baselin
day
treatment
began
data
analyz
repeat
measur
anova
post
hoc
pairwis
analys
signific
test
signific
p
suppress
sweat
eri
chl
gam
compar
sweat
baselin
valu
foal
given
eri
significantli
lower
test
day
except
day
sweat
respons
foal
given
eri
significantli
lower
given
gam
chl
day
everi
terbutalin
concentr
except
lgml
contrast
differ
chl
gam
result
show
abil
bind
bacteri
ribosom
confer
potenti
induc
anhidrosi
unlik
macrolid
eri
clarithromycin
azithromycin
gam
suppress
sweat
respons
led
increas
awar
pathogen
caus
coliti
adult
hors
object
studi
determin
whether
ecov
enterocol
distinct
clinic
andor
clinicopatholog
signatur
distinguish
enter
salmonellosi
unknown
caus
fever
neutropenia
data
collect
medic
record
north
carolina
state
univers
hors
year
old
divid
group
base
diagnosi
ecov
fecal
pcr
enter
salmonellosi
fecal
cultur
pcr
unknown
diagnosi
rule
ecov
salmonella
neg
salmonella
cultur
neg
ecov
salmonella
pcr
clinic
featur
diagnost
test
result
outcom
compar
group
statist
signific
determin
use
mannwhitney
u
test
p
data
obtain
hors
ecov
hors
salmonella
hors
without
diagnosi
ecov
case
significantli
fewer
neutrophil
median
rang
ul
compar
diagnos
differ
neutrophil
count
compar
salmonella
unknown
diagnosi
differ
temperatur
lymphocyt
platelet
count
fibrinogen
biochem
paramet
group
result
suggest
diseas
ecov
salmonella
share
clinic
featur
includ
togeth
differenti
list
fever
neutropenia
investig
warrant
determin
whether
unknown
pathogen
caus
fever
leukopenia
group
without
diagnosi
cell
glial
cell
astrocyt
perform
epm
case
sn
adjac
sntissu
formalin
fix
tissu
ffpe
block
eleven
normal
control
hors
use
section
locat
match
lesion
section
section
compar
signific
differ
anova
p
number
cell
microgliamacrophag
cell
sn
tissu
significantli
increas
compar
adjac
section
section
normal
hors
although
present
extrem
limit
number
cell
per
site
macrophag
stain
cell
statist
higher
cell
count
affect
hors
compar
normal
hors
cell
numer
differenti
cell
attempt
use
ihc
sever
marker
none
work
ffpe
section
rel
express
investig
quantit
pcr
signific
chang
cell
marker
express
fold
log
control
fold
chang
lesion
group
normal
group
conclus
presenc
sn
present
within
inflammatori
nodul
presenc
parasit
burden
associ
presenc
cell
marker
compar
cell
base
presenc
inflammatori
marker
presenc
sn
detect
outsid
aggreg
either
resid
infiltr
inflammatori
cell
object
studi
establish
refer
rang
normal
pleural
thick
measur
healthi
adult
hors
compar
measur
hors
year
age
young
year
age
old
pleural
thick
assess
part
complet
thorac
ultrasonograph
examin
normal
measur
previous
report
hypothes
measur
pleural
thick
would
mm
clinic
healthi
adult
hors
young
old
examin
curvilinear
mhz
probe
eight
thorac
locat
four
per
side
cranioventr
intercost
space
ic
midthorac
cm
dorsal
point
shoulder
po
ic
caudoventr
ic
po
caudodors
ic
measur
perform
post
hoc
two
observ
three
record
imag
site
differ
among
locat
evalu
kruskalw
differ
age
group
evalu
mann
whitney
u
interobserv
reliabl
evalu
use
intraclass
correl
icc
signific
set
p
pleural
thick
median
rang
mm
hors
mm
young
hors
mm
old
hors
signific
differ
among
locat
age
group
note
mild
pleural
irregular
subject
common
older
hors
icc
signific
measur
locat
older
hors
significantli
greater
pleural
thick
measur
measur
reproduc
measur
normal
variat
caus
investig
respiratori
diseas
bal
frequent
employ
evalu
lower
airway
inflamm
hors
rao
hors
bronchial
collaps
often
limit
retriev
balf
nbutylscopolammonium
bromid
parasympatholyg
agent
safe
produc
short
term
bronchodil
revers
airway
obstruct
raoaffect
hors
base
upon
hypothesi
syring
aspir
would
improv
balf
retriev
perform
bal
left
right
lung
sedat
summer
pastur
associ
raoaffect
hors
use
flexibl
endoscop
salin
cc
instil
via
polyurethan
tube
insert
biopsi
port
use
cc
syring
aspir
use
gentl
manual
suction
ss
cc
syring
mechan
suction
ms
use
pressur
regul
suction
pump
pressur
mm
h
retriev
balf
without
airway
collaps
bilater
bal
perform
twice
hors
without
mgkg
iv
crossov
fashion
day
washout
period
effect
suction
type
administr
volum
yield
cellularl
cell
viabil
determin
bal
perform
use
ss
demonstr
higher
volum
yield
lower
rbc
lower
nucleat
cell
count
tendenc
improv
viabil
ms
differ
yield
nucleat
cell
count
red
blood
cell
count
identifi
except
hors
demonstr
profound
collaps
use
modifi
bal
techniqu
includ
manual
syring
suction
administr
may
provid
advantag
hors
signific
airway
hyperreact
limit
airway
collaps
enhanc
diagnost
util
balf
obtain
inflammatori
airway
diseas
iad
common
caus
respiratori
problem
poor
perform
hors
recent
suggest
iad
recurr
airway
obstruct
rao
could
two
form
inflammatori
process
recent
evid
tend
establish
close
parallel
equin
diseas
asthma
human
fungi
shown
contribut
inflammatori
respons
lung
rao
hors
form
asthma
human
role
fungi
iad
yet
assess
knowledg
author
purpos
prospect
observ
clinic
studi
evalu
preval
fungal
isol
respiratori
sampl
hors
diagnos
iad
describ
clinic
sign
associ
presenc
fungi
respiratori
sampl
hors
diagnos
iad
assess
risk
factor
associ
iad
posit
fungal
cultur
prolifer
studi
perform
popul
work
sport
race
leisur
hors
base
franc
belgium
netherland
total
case
hors
refer
special
ambulatori
intern
medicin
practic
europ
assess
june
decemb
hors
refer
either
respiratori
problem
loss
perform
case
environment
evalu
clinic
examin
airway
endoscopi
tracheal
wash
tw
bronchoalveolar
lavag
bal
perform
tw
bal
underw
cytolog
evalu
tw
submit
bacteriolog
mycolog
diagnosi
iad
establish
base
bal
fluid
cytolog
accord
acvim
consensu
statement
definit
cytolog
examin
presenc
fungal
element
spore
conidiophor
hypha
record
well
sign
activ
prolifer
popul
studi
diagnosi
iad
establish
case
posit
fungal
cultur
obtain
iad
case
iadcas
commonli
isol
fungu
aspergillu
sp
penicillium
rhizomucor
relationship
could
establish
posit
mycolog
cytolog
evid
fungal
element
activ
prolifer
fungi
airway
howev
hors
fungal
element
tw
cytolog
chanc
iad
hors
fungi
ci
p
twenti
iad
hors
sign
fungal
prolifer
tw
andor
bal
mycolog
remain
neg
case
distinct
respiratori
clinic
sign
cough
breathless
nasal
discharg
show
low
sensit
high
specif
iad
diagnosi
concomit
bacteri
infect
increas
risk
fungal
isol
degre
inflamm
inflammatori
cell
bal
higher
hors
hous
indoor
bed
straw
versu
shave
mannwhitney
test
versu
p
fed
dri
hay
versu
steam
hay
versu
p
preval
fungal
contamin
iad
case
high
europ
hors
inhal
aerosol
fungal
particl
significantli
higher
risk
develop
iad
type
bed
forag
well
environment
condit
repres
signific
risk
factor
iad
fungal
contamin
equin
airway
identif
prolifer
fungi
airway
sign
fungal
infect
warrant
investig
current
studi
mycolog
cultur
seem
lack
sensit
detect
fungi
respiratori
sampl
hors
rao
exhibit
exacerb
acut
airway
obstruct
caus
respiratori
distress
result
bronchospasm
mucu
accumul
airway
inflamm
emerg
therapeut
option
control
revers
airway
bronchoconstrict
equin
airway
includ
parasympatholyt
agent
inhibit
gastrointestin
motil
agonist
well
system
corticosteroid
requir
hour
full
effect
metaanalysi
emerg
intervent
asthmat
adult
found
adjunct
infus
magnesium
sulfat
mgso
improv
lung
function
reduc
hospit
admiss
studi
examin
util
effect
intraven
mgso
novel
inexpens
easili
administ
bronchodilatori
agent
hors
natur
occur
pastureassoci
form
rao
sparao
six
sparaoaffect
hors
exhibit
natur
occur
diseas
exacerb
csre
dppl
max
cm
h
treat
three
doubl
dosag
mgso
rapid
iv
infus
use
three
way
crossov
design
hors
instrument
continu
ecg
blood
ga
monitor
tidal
volum
tv
pulmonari
resist
r
l
dynam
complianc
c
dyn
maximum
chang
pleural
pressur
dppl
max
monitor
minut
interv
use
convent
pulmonari
mechan
mix
model
fit
percent
chang
baselin
valu
outcom
use
proc
mix
sa
sa
institut
cari
nc
signific
decreas
dppl
max
r
l
signific
increas
c
dyn
identifi
dosag
accompani
increas
p
decreas
p
co
substanti
improv
ventil
conclud
intraven
infus
mgso
immedi
bronchodilatori
effect
hors
make
therapi
valuabl
adjunct
hors
sign
respiratori
distress
refer
bronchoconstrict
etyp
prostaglandin
pge
play
divers
role
throughout
bodi
includ
regul
gastrointestin
gi
homeostasi
modul
inflamm
treat
inflamm
antiinflammatori
medic
includ
nonsteroid
antiinflammatori
drug
nsaid
design
inhibit
prostaglandin
product
unfortun
potenti
advers
effect
nsaid
use
hors
includ
gastric
ulcer
right
dorsal
coliti
prevent
treat
nsaidassoci
gi
injuri
equin
practition
commonli
administ
pge
analog
misoprostol
addit
serv
gastroprotect
misoprostol
shown
antiinflammatori
effect
cell
model
potenti
increas
intracellular
cyclic
amp
camp
elev
camp
known
dampen
leukocyt
effector
function
damag
host
tissu
includ
cellular
adhes
tissu
infiltr
cytokin
superoxid
product
effect
misoprostol
equin
leukocyt
effector
function
undetermin
thu
purpos
studi
determin
effect
misoprostol
equin
leukocyt
proinflammatori
cytokin
superoxid
product
vitro
equin
leukocyt
isol
whole
blood
stimul
lipopolysaccharid
lp
presenc
absenc
misoprostol
misoprostol
concentr
lm
significantli
inhibit
tumor
necrosi
factora
mrna
product
measur
qpcr
misoprostol
also
elicit
concentrationdepend
decreas
neutrophil
superoxid
product
respons
granulocytemonocyt
colonystimul
factor
prime
lp
stimul
measur
luminolenhanc
chemiluminesc
data
conclud
misoprostol
produc
antiinflammatori
effect
equin
leukocyt
vitro
pave
way
vivo
studi
investig
misoprostol
antiinflammatori
treatment
hors
sian
durwardakhurst
nichol
schulz
elain
norton
raymond
geor
jame
mickelson
molli
mccue
univers
minnesota
mn
usa
mmassey
univers
palmerston
north
new
zealand
equin
metabol
syndrom
em
character
abnorm
insulin
regul
increas
adipos
lamin
larg
acrossbre
studi
individu
morphometr
biochem
metabol
trait
lab
demonstr
phenotyp
variabl
due
individu
factor
includ
age
breed
sex
genet
phenotyp
variabl
result
share
environ
despit
variabl
em
phenotyp
relat
share
environ
variabl
explain
diet
amount
intens
exercis
season
suggest
environment
factor
play
role
em
develop
recent
work
identifi
associ
endocrin
disrupt
chemic
edc
human
metabol
syndrom
endocrin
abnorm
preliminari
data
demonstr
hors
farm
within
mile
edc
dispos
site
epa
superfund
site
like
lamin
p
higher
post
oral
sugar
challeng
insulin
concentr
ost
in
p
suggest
edc
exposur
em
risk
factor
object
studi
determin
plasma
edc
concentr
correl
metabol
measur
plasma
edc
concentr
measur
use
caluxdr
bioassay
morgan
welsh
poni
farm
gram
fat
extract
plasma
sex
femal
neg
correl
edc
concentr
edc
concentr
posit
associ
ost
in
p
result
suggest
unexplain
environment
varianc
identifi
individu
em
due
exposur
edc
veterinarian
identifi
equin
metabol
syndrom
em
common
caus
lamin
within
equin
practic
oral
sugar
test
ost
use
clinic
identifi
risk
hors
although
rigor
compar
gold
standard
frequent
sampl
intraven
glucos
toler
test
fsigtt
larg
number
hors
across
differ
breed
eightynin
horsesponi
five
differ
breed
quarter
hors
qh
arabian
morgan
welsh
poni
thoroughbr
ost
mlkg
karo
syrup
fsigtt
perform
least
hour
apart
optim
time
sampl
determin
repeat
measur
anova
roc
curv
use
identifi
optim
threshold
insulin
valu
insulin
resist
ir
equid
insulin
sensit
si
spearman
correl
util
examin
possibl
correl
ost
outcom
measur
area
curv
insulin
auci
peak
insulin
concentr
si
acut
insulin
respons
glucos
airg
latter
two
determin
minim
model
analysi
fsigtt
ir
hors
ost
insulin
glucos
concentr
minut
significantli
higher
insulin
sensit
hors
cohort
singl
time
point
insulin
concentr
indic
insulin
resist
moder
correl
rho
si
strong
correl
airg
evid
auci
peak
insulin
concentr
weak
correl
exist
glucos
concentr
si
airg
qh
significantli
lower
ost
auci
breed
except
morgan
differ
current
recommend
literatur
advis
measur
insulin
concentr
singl
blood
sampl
minut
postkaro
syrup
administr
use
iuml
threshold
practition
awar
breed
may
play
role
insulin
concentr
achiev
ost
valu
overnight
fast
hay
fed
hors
consid
support
insulin
dysregul
although
well
recogn
in
increas
bodi
condit
fat
mass
recent
evid
suggest
may
also
age
breed
differ
regard
basal
insulin
concentr
howev
littl
data
exist
draft
breed
consequ
test
hypothesi
in
differ
variou
breed
draft
hors
independ
age
bodi
condit
age
obtain
ownerstrain
bodi
condit
score
bc
assess
basal
rest
fast
in
measur
draft
hors
particip
intern
competit
includ
belgian
clydesdal
percheron
in
measur
use
radioimmunoassay
valid
equin
serum
averag
intraand
interassay
cv
low
high
equin
control
sera
respect
none
hors
examin
histori
current
evid
lamin
age
bc
in
normal
distribut
thu
median
valu
confid
interv
determin
tabl
data
analyz
use
anova
rank
chi
squar
analysi
spearman
rank
order
correl
median
age
differ
hors
sampl
breed
although
clydesdal
breed
lower
bc
compar
belgian
breed
differ
median
in
breed
proport
hors
elev
in
signific
albeit
weak
posit
correl
age
in
r
p
bc
in
r
p
age
bc
r
p
howev
greatest
interest
onethird
nearli
half
vari
breed
hors
test
elev
in
support
insulin
dysregul
despit
hors
train
competit
without
evid
lamin
conclus
conveni
sampl
studi
draft
hors
provid
support
in
may
vari
light
breed
draft
breed
breed
need
consid
interpret
in
result
among
differ
caus
colic
intestin
obstruct
identifi
major
caus
hospit
death
hors
around
world
small
colon
occur
mainli
due
fecaloma
enterolith
ischem
process
decreas
oxygen
tension
insid
cell
occur
reduc
gener
adenosin
triphosph
atp
result
cellular
homeostasi
disord
calcium
accumul
insid
cell
produc
signific
increas
phospholipas
activ
directli
damag
cell
membran
increas
product
arachidon
acid
lysophosphatidylcholin
platelet
aggreg
factor
platelet
aggreg
factor
potent
inflammatori
mediat
import
effect
vascular
permeabl
neutrophil
activ
neutrophil
adhes
endothelium
may
also
caus
damag
endotheli
cell
thu
amplifi
reaction
occur
due
releas
reactiv
oxygen
speci
ro
proteoglycan
enzym
matrix
metalloproteinas
mmp
elastas
lysosom
cell
degener
therefor
aim
studi
evalu
neutrophil
migrat
matrix
activ
hors
experiment
intralumin
obstruct
purpos
eight
healthi
adult
mixedbre
hors
subject
small
colon
distens
use
surgic
implant
latex
ball
lumen
ethic
approv
cebeaprotocol
blood
periton
fluid
sampl
obtain
intestin
distens
hour
distens
ball
deflat
remov
hour
decompress
twelv
hour
ball
remov
also
collect
periton
fluid
sampl
neutrophil
count
data
submit
friedman
test
follow
posthoc
dunn
multipl
comparison
test
model
induc
alter
neutrophil
migrat
periton
fluid
concentr
significantli
higher
compar
ae
ae
ae
ae
also
alter
plasma
proenzym
form
periton
fluid
significantli
increas
compar
mean
ae
standard
error
arbitrari
unit
plasma
ae
know
multipl
proteinas
present
granul
neutrophil
conclud
increas
proenzym
form
small
colon
decompress
may
associ
neutrophil
migrat
clydesdal
percheron
p
valu
age
bc
b
b
nonglandular
ng
gastric
ulcer
part
equin
gastric
ulcer
syndrom
egu
common
perform
hors
current
fdaapprov
pharmaceut
agent
omeprazol
effect
treatment
expens
alter
gastric
juic
ph
recent
interest
natur
feed
supplement
improv
stomach
health
use
hors
compet
drugfre
competit
purpos
studi
evalu
effect
feed
supplement
contain
porcin
collagen
hydrolys
gastric
ulcer
score
gastric
juic
ph
stallconfin
hors
treat
omeprazol
undergo
intermitt
feed
ten
thoroughbr
use
twoperiod
crossov
studi
supplement
chl
collagen
hydrolys
gram
mix
sweet
feed
omelen
purina
anim
nutrit
llc
gray
summit
mo
sweet
feed
control
group
twice
daili
two
period
day
treatment
group
administ
omeprazol
ome
mgkg
po
qd
gastrogard
merial
limit
duluth
ga
day
hors
underw
altern
feeddepriv
period
induc
worsen
ulcer
gastroscopi
perform
hors
day
treatment
gastric
juic
aspir
ph
measur
scope
nonglandular
gastric
ulcer
number
ngn
sever
ng
score
assign
examin
pi
fma
mask
treatment
data
analyz
use
anova
repeat
measur
signific
differ
found
main
model
posthoc
tukey
test
use
determin
signific
differ
p
chlsupplement
powder
form
mix
grain
readili
consum
hors
advers
effect
seen
mean
ngn
ng
gastric
ulcer
score
lower
gastroscopi
examin
signific
treatment
effect
seen
day
studi
addit
gastric
ulcer
score
significantli
lower
group
day
compar
day
due
omeprazol
treatment
day
two
week
omeprazol
discontinu
ulcer
reoccur
group
hors
day
gastric
ulcer
score
significantli
increas
due
intermitt
feed
treatment
effect
observ
gastric
juic
ph
valu
low
variabl
throughout
trial
period
except
day
ph
significantli
higher
chlsupplement
treat
group
compar
control
group
omeprazol
treatment
effect
increas
gastric
juic
ph
significantli
decreas
gastric
ulcer
score
addit
collagen
hydrolys
supplement
significantli
increas
gastric
juic
ph
hors
omeprazol
treatment
conclus
collagen
hydrolys
amelior
sever
gastric
ulcer
stallconfin
hors
undergo
feed
stress
day
feed
equin
coronaviru
ecov
consid
emerg
enter
viru
report
morbid
rate
rang
fatal
rate
rang
adult
hors
object
studi
assess
safeti
humor
respons
viral
shed
commerci
avail
modifiedl
bovin
coronaviru
bcov
vaccin
given
healthi
adult
hors
twelv
confirm
healthi
adult
hors
vaccin
twice
week
apart
either
oral
intranas
intrarect
two
healthi
unvaccin
hors
serv
sentinel
control
follow
vaccin
administr
hors
monitor
daili
physic
abnorm
onset
durat
bcov
shed
determin
quantit
pcr
qpcr
nasal
secret
fece
whole
blood
collect
everi
week
determin
bcovspecif
antibodi
except
transient
selflimit
chang
fecal
charact
observ
vaccin
control
hors
addit
abnorm
clinic
find
found
studi
hors
follow
first
second
vaccin
administr
two
one
hors
respect
test
qpcrposit
bcov
nasal
secret
post
intranas
vaccin
vaccin
hors
test
qpcr
posit
bcov
fece
follow
vaccin
administr
one
two
hors
shed
bcov
seroconvert
bcov
first
vaccin
administr
addit
vaccin
hors
oral
intrarect
seroconvert
bcov
second
vaccin
administr
conclus
result
show
modifiedl
bcov
safe
administ
hors
via
variou
rout
caus
minim
shed
detect
antibodi
bcov
vaccin
recent
report
indic
percentag
overweight
hors
may
rang
anywher
obes
key
compon
equin
metabol
syndrom
em
typic
defin
criteria
set
acvim
consensu
statement
region
neck
crest
rump
etc
gener
obes
hyperinsulinemia
insulin
resist
histori
predisposit
toward
lamin
obes
human
dietinduc
obes
mice
shown
reduc
immun
respons
vaccin
howev
immun
respons
em
hors
vaccin
unknown
therefor
object
studi
determin
effect
em
immun
respons
routin
vaccin
hypothes
similar
speci
em
hors
would
reduc
respons
routin
influenza
vaccin
compar
nonem
age
match
control
establish
hors
preexist
herd
use
studi
classifi
em
avcim
consensu
statement
criteria
nonem
age
match
control
within
group
serv
salin
control
remain
hors
serv
vaccin
lowdos
dexamethason
suppress
test
trh
stimul
test
perform
hors
prior
start
studi
insur
hors
test
posit
pituitari
par
intermedia
dysfunct
ppid
venou
blood
drawn
weekli
consecut
week
vaccin
salin
administ
intramuscularli
week
hors
vaccin
inactiv
influenza
vaccin
fluvac
zoeti
blood
sampl
use
determin
humor
cell
mediat
immun
respons
humor
immun
respons
measur
hemagglutin
assay
total
ig
antibodi
respons
elisa
igga
iggb
iggt
antibodi
isotyp
respons
cell
mediat
immun
measur
determin
via
pbmc
isol
eivstimul
subsequ
flow
cytometri
rtpcr
analysi
cytokin
protein
gene
express
respect
humor
immun
data
log
transform
analyz
use
repeat
measur
design
protect
lsd
adjust
age
analys
complet
use
proc
mix
sa
sa
institut
inc
cari
nc
usa
result
express
least
squar
mean
ae
standard
error
mean
data
consid
statist
signific
p
overal
hors
respond
vaccin
signific
increas
p
hi
titer
follow
initi
vaccin
compar
salin
control
signific
increas
p
igga
iggb
iggt
eiv
specif
antibodi
respons
vaccin
also
observ
em
significantli
affect
p
humor
immun
respons
measur
hi
titer
igg
isotyp
influenza
vaccin
howev
work
need
explor
possibl
differ
cmi
respons
possibl
obes
compar
insulin
resist
play
larger
role
modul
immun
process
consid
em
hors
insulin
resist
significantli
greater
region
obes
cresti
neck
score
compar
nonem
control
moder
gener
obes
bodi
condit
score
may
suffici
impact
immun
respons
vaccin
pituitari
par
intermedia
dysfunct
ppid
endocrinopathi
affect
age
equid
popul
ppid
character
variou
clinic
manifest
hallmark
hypertrichosi
addit
ppid
hors
exhibit
immunosuppress
make
suscept
opportunist
infect
lab
establish
age
hors
exhibit
immunosenesc
inflammag
lowgrad
chronic
inflamm
occur
system
age
determin
whether
agerel
chang
cellmedi
immun
respons
may
affect
presenc
ppid
peripher
blood
mononuclear
cell
pbmc
prolifer
cytokin
product
compar
agematch
ppid
nonppid
hors
ppid
statu
determin
use
thyrotropin
releas
hormon
trh
stimul
test
sixteen
age
hors
yr
includ
n
ppid
hors
mean
ae
yr
n
nonppid
hors
mean
ae
yr
mix
breed
sex
sampl
determin
immun
function
heparin
blood
collect
asept
pbmc
isol
stimul
phorbol
pma
stain
intracellularli
proinflammatori
cytokin
interferonc
ifnc
tumor
necrosi
factora
tnfa
flow
cytometri
perform
determin
percent
lymphocyt
produc
ifnc
tnfa
realtim
polymeras
chain
reaction
rtpcr
use
determin
pbmc
gene
express
cytokin
interleukin
il
ifnc
tnfa
pbmc
prolifer
also
determin
use
carboxyfluorescein
succinimidyl
ester
cfse
stain
stimul
variou
amount
concanavalin
con
trh
stimul
test
perform
adrenocorticotropin
hormon
acth
level
measur
plasma
minut
post
intraven
administr
trh
mgml
salinehors
data
analyz
use
statist
softwar
program
sigmaplot
version
analyz
flow
cytometri
rtpcr
data
differ
ppid
nonppid
hors
ttest
perform
analyz
lymphocyt
prolifer
data
variou
concentr
con
stimul
twoway
analysi
varianc
repeat
measur
perform
signific
differ
ppid
nonppid
hors
found
immun
measur
examin
includ
flow
cytometri
rtpcr
prolifer
data
p
result
indic
immunosuppress
associ
ppid
appear
due
differ
pbmc
prolifer
cytokin
product
compar
age
ppid
hors
age
nonppid
hors
thu
research
warrant
understand
immunolog
mechan
respons
immunosuppress
suscept
opportunist
infect
ppid
hors
fals
posit
result
may
occur
test
hors
antibodi
corynebacterium
pseudotuberculosi
synergist
hemolysi
inhibit
shi
small
rumin
elisa
test
base
exotoxin
cell
wall
antigen
greater
accuraci
shi
diagnosi
caseou
lymphaden
purpos
studi
compar
detect
c
pseudotuberculosi
antibodi
equin
serum
shi
small
rumin
elisa
test
use
exotoxin
cell
wall
antigen
sera
poni
experiment
infect
c
pseudotuberculosi
analyz
test
correl
agreement
calcul
pearson
kappa
coeffici
respect
receiv
oper
characterist
analysi
use
obtain
optim
cutoff
valu
calcul
elisa
score
patient
optic
densityneg
control
optic
densiti
x
antigen
reactiv
sera
evalu
immunoblot
shi
titer
consid
posit
result
optim
elisa
score
cutoff
determin
posit
statu
sensit
specif
respect
shi
correl
test
strong
r
ci
p
agreement
determin
posit
statu
poor
ci
correl
agreement
strong
poni
weak
immunoblot
show
band
time
intens
infect
compar
preinfect
sera
correspond
exotoxin
antigen
nonspecif
reactiv
cell
wall
antigen
use
elisa
test
hors
recommend
develop
elisa
test
specif
antigen
c
pseudotuberculosi
biovar
equi
need
macrolideinduc
anhidrosi
concern
foal
treat
rhodococcu
equi
pneumonia
sweat
hors
caus
activ
receptor
sweat
gland
interest
evalu
respons
iv
epinephrin
foal
given
erythromycin
four
ponycross
foal
treat
day
prior
epinephrin
infus
either
erythromycin
mgkg
oral
time
daili
control
prepar
accord
random
mask
design
epinephrin
given
cri
minut
lgkgminut
follow
data
collect
interv
minut
onset
infus
sweat
absorb
absorb
pad
heart
respiratori
rate
system
arteri
bp
pupil
size
pcv
plasma
protein
blood
glucos
concentr
cardiac
rhythm
monitor
continu
ecg
univari
repeat
measur
anova
use
analyz
data
friedman
test
use
data
set
fail
assumpt
anova
post
hoc
pairwis
analys
perform
anova
indic
signific
p
effect
foal
given
either
treatment
signific
p
effect
epinephrin
heart
rate
pupil
size
pcv
blood
glucos
sweat
arteri
bp
also
increas
significantli
controlbut
erythromycintr
foal
signific
treatment
x
time
interact
found
sweat
pairwis
comparison
signific
everi
point
time
result
suggest
erythromycin
caus
gener
suppress
aand
badrenerg
respons
anhidrosi
may
tissuespecif
receptor
postreceptor
effect
erythromycin
macrolid
vectorborn
diseas
impact
health
welfar
hors
worldwid
recogn
vectorborn
diseas
among
hors
includ
anaplasmosi
anaplasma
phagocytophilum
lyme
diseas
borrelia
burgdorferi
potomac
hors
fever
neorickettsia
risticii
piroplasmosi
babesia
cabal
theleria
equi
addit
bartonella
ehrlichia
rickettsia
hemotrop
mycoplasma
speci
detect
hors
clinic
diseas
spectrum
rang
nonclin
fatal
goal
studi
investig
serolog
molecular
pcr
test
detect
vectorborn
diseas
vbd
pathogen
hors
appli
broad
diagnost
panel
gain
definit
pictur
vectorborn
equin
pathogen
includ
novel
speci
coinfect
three
popul
hors
use
test
serolog
molecular
diagnost
test
group
n
edtawhol
blood
wb
serum
set
clinic
healthi
hors
pastur
north
carolina
clinic
suspicion
vbd
group
ii
n
wb
set
hors
submit
diagnost
test
vbddl
presum
clinician
suspect
vectorborn
diseas
group
iii
n
wb
hors
erida
nicaragua
high
degre
tick
exposur
serolog
pcr
test
perform
retrospect
dna
extract
wb
qpcr
assay
perform
test
sampl
infect
bacteri
speci
within
follow
genera
anaplasma
babesia
bartonella
ehrlichia
mycoplasma
neorickettsia
rickettsia
theilera
sampl
posit
result
infecti
agent
speciat
speciesspecif
qpcr
assay
sampl
andor
dna
sequenc
pcr
amplicon
seroreact
babesia
bartonella
neorickettsia
rickettsia
antigen
determin
use
ifa
seroreact
ehrlichia
speci
anaplasma
speci
b
burgdorferi
antigen
determin
use
commerci
avail
snap
plu
elisa
researchbas
snap
elisa
combin
use
serolog
molecular
assay
studi
gave
evid
infect
pcr
exposur
seroreact
anaplasma
babesia
bartonella
borrelia
ehrlichia
spp
theileria
rickettsia
spp
none
sampl
contain
dna
mycoplasma
spp
two
sampl
posit
infect
rickettsia
feli
constitut
first
report
instanc
equin
infect
r
feli
detect
pcr
novel
equin
ehrlichia
speci
report
hors
nicaragua
detect
addit
nicaraguan
hors
sampl
studi
pcr
ifa
elisa
studi
highlight
widerang
exposur
infect
vectorborn
pathogen
hors
selenium
defici
associ
death
fifteen
adult
hors
andrew
allen
debra
sellon
fairfield
bain
daniel
nelson
washington
state
univers
pullman
wa
usa
nutrit
myopathi
due
selenium
se
defici
typic
present
young
rapidli
grow
calv
lamb
kid
foal
report
myodegener
secondari
selenium
defici
adult
hors
less
frequent
investig
herd
nutrit
myopathi
gener
skelet
muscl
degener
signific
death
loss
adult
hors
two
american
paint
hors
farm
present
diagnost
laboratori
post
mortem
evalu
signific
necropsi
histopatholog
find
includ
myonecrosi
cardiac
skelet
muscl
widespread
subcutan
edema
pleural
effus
ulcer
glossiti
farm
investig
perform
discov
hors
includ
two
present
hors
die
farm
similar
clinic
sign
last
year
complet
blood
count
serum
chemistri
panel
perform
remain
hors
physic
examin
perform
entir
herd
four
hors
elev
creatinin
kinas
activ
ck
aspart
aminotransferas
ast
level
herd
overal
low
bodi
condit
score
hors
elev
heart
rate
one
hors
pit
ventral
edema
hors
extrem
low
blood
selenium
level
box
elder
tree
found
farm
gastric
content
dead
hors
feed
supplement
found
free
ionophor
farm
echocardiograph
studi
perform
month
post
initi
investig
three
sever
affect
hors
find
appear
within
normal
limit
second
investig
two
dead
hors
reveal
similar
scenario
herd
wide
myodegener
secondari
selenium
defici
although
unusu
selenium
defici
consid
rule
adult
hors
show
sign
ventral
edema
weak
abrupt
death
process
concentr
feed
contain
high
concentr
sugar
case
nonstructur
carbohydr
nsc
exceed
feed
commonli
fed
stallconfin
hors
especi
competit
grain
high
nsc
overwhelm
glucos
receptor
proxim
small
intestin
increas
deliveri
sugar
hindgut
lead
ferment
colon
acidosi
feed
supplement
might
enhanc
glucos
absorpt
small
intestin
would
provid
energi
substrat
exercis
decreas
deliveri
sugar
hindgut
purpos
studi
determin
effect
feed
supplement
alf
alfalox
forag
tripl
crown
nutrit
inc
wayzata
mn
contain
chop
alfalfa
hay
mannanoligosaccharid
omega
fatti
acid
lcarnitin
topdress
grain
plasma
glucos
concentr
serum
insulin
activ
hors
grain
feed
eight
healthi
thoroughbr
geld
mare
age
yr
use
cross
studi
hors
fed
alf
lb
kg
twice
daili
top
dress
sweet
feed
grain
kg
omelen
purina
anim
nutrit
llc
grey
summit
mo
control
grain
alon
day
part
anoth
studi
day
withdraw
feed
overnight
blood
sampl
drawn
morn
grain
feed
without
alf
hour
alf
topdress
grain
treat
grain
alon
control
fed
plasma
serum
separ
within
minut
collect
sampl
frozen
shipment
diagnost
center
popul
anim
health
dcpah
michigan
state
univers
east
lans
mi
plasma
glucos
serum
insulin
analyz
use
autom
chemistri
analyz
data
analyz
statist
use
anova
proc
mix
sa
cari
nc
repeat
measur
signific
differ
p
found
main
model
posthoc
ttest
perform
determin
signific
differ
alfalox
forag
topdress
grain
readili
eaten
hors
result
advers
effect
period
data
pool
day
fast
mean
sem
serum
insulin
activ
significantli
increas
pmoll
pmoll
control
alftreat
hors
respect
pmoll
pmoll
respect
hour
feed
sweet
feed
addit
day
mean
serum
insulin
activ
significantli
increas
mean
sem
serum
insulin
concentr
pmoll
pmoll
control
alftreat
hors
respect
pmoll
pmoll
respect
two
hour
feed
sweet
feed
mean
serum
insulin
activ
significantli
higher
alftreat
hors
compar
control
hors
hour
feed
sweet
feed
mean
plasma
glucos
concentr
significantli
increas
hour
feed
forag
topdress
grain
result
higher
blood
insulin
valu
significantli
increas
blood
glucos
concentr
hour
feed
sweet
feed
alfalox
forag
result
increas
absorpt
sugar
small
intestin
effici
util
glucos
energi
like
decreas
amount
sugar
deliv
larg
colon
endotheli
progenitor
cell
epc
contribut
neovascular
vascular
repair
vivo
attract
clinic
use
ischem
diseas
epc
track
essenti
determin
engraft
administr
semiconductor
quantum
dot
qd
promis
cell
label
due
eas
uptak
mani
cell
line
continu
presenc
mani
cell
gener
purpos
studi
evalu
function
growth
equin
epc
qd
label
equin
epc
incub
qd
nm
intens
label
assess
fluoresc
microscopi
cell
prolifer
epc
label
qd
optimum
time
concentr
assess
compar
number
cell
doubl
per
day
ncd
popul
doubl
time
pdt
label
unlabel
cell
epc
function
assess
compar
uptak
acetyl
lowdens
lipoprotein
dioacldl
vitro
tubul
format
label
unlabel
cell
equin
epc
readili
label
qd
show
maximum
fluoresc
use
nm
qd
incub
time
ncd
pdt
unchang
qd
label
p
p
uptak
dioacldl
epc
affect
presenc
qd
label
label
cell
unlabel
cell
tubul
format
matrigel
affect
presenc
qd
label
equin
epc
effect
label
qd
qd
concentr
nm
affect
cell
growth
function
use
qd
label
equin
epc
may
help
track
engraft
epc
clinic
applic
coagulas
neg
staphylococci
cn
preval
pathogen
isol
intramammari
infect
goat
differ
speci
identifi
goat
milk
unlik
cow
relationship
cn
infect
somat
cell
count
milk
loss
goat
less
clear
conflict
result
studi
cn
mastiti
goat
may
explain
variat
studi
regard
distribut
cn
speci
vari
pathogen
speci
presenc
confound
factor
affect
outcom
measur
variat
studi
regard
speciat
method
phenotyp
speciat
use
studi
howev
genotyp
consid
reliabl
phenotyp
identif
cn
speci
goat
object
studi
estim
preval
speciesspecif
cn
intramammari
infect
larg
dairi
goat
herd
missouri
composit
milk
sampl
asept
collect
lactat
goat
aerob
bacteriolog
cultur
perform
cultur
yield
cfuml
cn
consid
posit
isol
milk
sampl
yield
singl
coloni
morpholog
identifi
cn
use
prepar
lysat
pcr
amplif
speci
identif
base
pcr
amplif
sequenc
either
rpob
tuf
gene
rrna
sequenc
compar
genbank
databas
use
ncbi
nucleotideblast
algorithm
rpob
speci
identif
assign
ident
separ
differ
speci
tuf
speci
identif
assign
ident
separ
differ
speci
speci
identif
assign
ident
separ
differ
speci
pcr
amplif
sequenc
rpob
tuf
perform
sequenti
identif
assign
instanc
tuf
perform
isol
rpob
either
yield
unsuccess
amplif
criterion
identif
sequenc
analysi
met
follow
tuf
amplif
sequenc
analysi
fail
milk
sampl
cultur
yield
growth
cn
singl
coloni
morpholog
isol
success
speciat
identifi
rpob
tuf
remain
isol
unabl
speciat
base
criteria
list
overal
differ
speci
identifi
tabl
among
isol
could
assign
identif
met
criterion
ident
insuffici
separ
speci
warneri
pasteuri
rpob
tuf
sequenc
typeabl
cn
isol
goat
milk
studi
use
gene
sequenc
typeabl
rpob
gene
sequenc
alon
lower
expect
may
result
underrepresent
isol
caprin
origin
refer
databas
unsuccess
pcr
amplif
proport
isol
could
reflect
imperfect
match
primer
target
sequenc
rel
preval
differ
speci
similar
previou
studi
use
genotyp
phenotyp
object
studi
evalu
impact
implement
antimicrobialus
algorithm
antimicrobi
ab
treatment
mortal
rate
diarrheic
calv
three
commerci
dairi
farm
enrol
farm
record
obtain
collect
data
incid
diarrhea
ab
treatment
mortal
rate
preced
month
antimicrobialus
algorithm
farm
personnel
base
presenc
three
clinic
sign
diarrhea
fever
decreas
milk
intak
develop
direct
ab
therapi
diarrheic
calv
dayold
farm
data
collect
record
system
month
respect
treatment
record
calv
avail
preintervent
period
incid
diarrhea
ab
administ
diarrheic
calv
mortal
rate
attribut
diarrhea
respect
algorithm
implement
data
avail
calv
diarrhea
develop
calv
three
farm
treatment
rate
significantli
lower
p
impact
mortal
respect
p
use
simpl
practic
antimicrobialus
algorithm
provid
signific
reduct
use
antimicrobi
decreas
treatment
cost
improv
antimicrobi
stewardship
neg
impact
calf
health
bovin
coronaviru
bocv
endem
pathogen
associ
enter
diseas
especi
calv
studi
conduct
assess
preval
bcov
healthi
diarrheic
calv
determin
whether
presenc
bcov
fece
associ
age
health
statu
calf
prospect
casecontrol
studi
fecal
sampl
diarrheic
calv
three
differ
commerci
dairi
farm
test
bcov
use
pcr
assay
studi
case
one
agematch
control
calf
farm
enrol
categor
variabl
analyz
use
x
univari
logist
regress
analys
multivari
analysi
use
mix
effect
logist
regress
model
farm
random
effect
perform
determin
signific
associ
test
posit
bcov
fece
age
presenc
diarrhea
age
calf
categor
use
cutoff
day
age
healthi
diarrheic
calv
ae
ae
day
respect
p
signific
differ
preval
bcov
healthi
diarrheic
calv
p
multivari
logist
regress
reveal
calv
posit
bcov
like
older
day
age
ci
p
diarrhea
ci
p
studi
determin
bcov
detect
healthi
diarrheic
calv
howev
likelihood
bcov
higher
diarrheic
calv
futur
studi
investig
whether
bcov
strain
detect
healthi
diarrheic
calv
genet
differ
warrant
alivecor
heart
monitor
smartphonebas
electrocardiogram
ecg
record
devic
promis
new
diagnost
tool
veterinari
medicin
devic
valid
canin
felin
equin
speci
clinic
util
domest
goat
yet
evalu
eight
healthi
adult
dairi
breed
eight
healthi
adult
meat
breed
goat
simultan
alivecor
standard
base
apex
ecg
perform
stand
posit
alivecor
ecg
record
use
two
differ
devic
posit
left
cardiac
apex
brisket
region
paper
speed
mmsec
amplitud
mmmv
ecg
evalu
unpair
independ
datablind
veterinari
cardiologist
averag
heart
rate
determin
use
second
ecg
record
rhythm
diagnosi
record
trace
ecg
given
qualiti
score
find
review
determin
alivecor
devic
compar
base
apex
ecg
rate
rhythm
diagnosi
via
pair
ttest
differ
qualiti
score
read
goat
assess
via
mannwhitney
utest
qualiti
score
differ
assess
mannwhitney
utest
breed
locat
alivecor
ecg
rhythm
agreement
assess
compar
blind
rhythm
diagnos
made
cardiologist
signific
differ
found
heart
rate
collect
via
alivecor
standard
base
apex
ecg
p
qualiti
score
significantli
higher
alivecor
trace
compar
standard
base
apex
trace
p
signific
differ
alivecor
qualiti
score
note
meat
dairi
breed
p
signific
differ
note
qualiti
score
alivecor
read
taken
left
cardiac
apex
sternal
region
p
normal
sinu
rhythm
present
goat
could
diagnos
via
alivecor
trace
case
base
studi
alivecor
ecg
clinic
use
heart
rate
determin
diagnosi
normal
sinu
rhythm
goat
interestingli
alivecor
ecg
higher
qualiti
score
compar
standard
base
apex
ecg
left
displac
abomasum
lda
uncommon
condit
beef
cattl
compar
dairi
cattl
rare
describ
suck
beef
calv
true
preval
lda
beef
calv
unknown
difficult
gaug
base
report
case
remain
pauciti
inform
regard
diagnosi
treatment
lda
beef
calv
four
beef
calv
two
mix
breed
beef
one
beefmast
one
angu
two
week
three
month
age
treat
lda
novemb
march
four
calv
histori
decreas
appetit
leftsid
abdomin
distent
two
recent
treat
necrot
laryng
one
calf
treat
suspect
clostridi
abomas
highpitch
ping
splash
auscult
percuss
succuss
left
abdomen
ultrasonographi
confirm
abomasum
displac
rumen
left
bodi
wall
four
calv
blood
ga
analysi
reveal
hypokalem
hypochlorem
metabol
alkalosi
three
calv
four
calv
initi
treat
roll
correct
left
abomas
displac
facilit
correct
metabol
abnorm
follow
roll
abomasum
redisplac
three
calv
within
one
hour
day
one
calf
becam
acut
colicki
result
mesenter
volvulu
right
paramedian
abomasopexi
preform
case
three
four
calv
grew
well
remain
herd
six
month
later
one
calf
euthan
day
surgeri
due
complic
associ
necrot
laryng
base
find
lda
like
common
beef
calv
mani
veterinarian
recogn
consid
differenti
calv
present
abdomin
distent
concurr
laryng
dysfunct
previous
describ
beef
calv
lda
may
contribut
factor
pathogenesi
disord
ultrasonographi
wide
avail
chutesid
diagnost
techniqu
rapidli
confirm
diagnosi
beef
calv
roll
use
adjunct
measur
allow
temporari
improv
case
sever
metabol
alter
may
associ
catastroph
intestin
complic
calv
report
adult
cow
therefor
surgic
correct
recommend
right
paramedian
abomasopexi
sedat
local
block
feasibl
method
correct
lda
beef
calv
adequ
absorpt
bovin
colostrum
correl
improv
neonat
health
appar
effici
absorpt
aea
immunoglobulin
measur
use
mathemat
equat
base
serum
colostr
igg
concentr
level
well
volum
colostrum
fed
bodi
weight
calf
commonli
measur
research
project
littl
inform
avail
normal
aea
across
larg
group
healthi
calv
multipl
farm
purpos
studi
observ
contribut
factor
volum
feed
birthweight
time
feed
alter
aea
establish
normal
rang
aea
healthi
calv
one
hundr
two
holstein
heifer
calv
differ
dairi
north
carolina
colorado
sampl
normal
calv
aliquot
colostrum
fed
heifer
save
heifer
receiv
either
liter
liter
colostrum
within
hour
birth
blood
sampl
collect
hour
birth
birthweight
measur
use
weight
tape
farm
radial
immunodiffus
assay
perform
obtain
igg
concentr
colostrum
serum
sampl
data
aea
calcul
aea
rang
mean
ae
median
aea
calv
fell
signific
correl
p
r
birthweight
aea
volum
fed
aea
p
r
correl
time
feed
aea
total
igg
mass
fed
aea
aea
vari
wide
calv
even
feed
standard
appear
opportun
improv
serum
igg
concentr
calv
feed
increas
volum
colostrum
studi
unabl
satur
absorpt
process
wide
rang
aea
valu
obtain
may
opportun
improv
aea
genet
select
object
studi
determin
disposit
chlortetracyclin
ctc
pregnant
ewe
unborn
fetus
follow
oral
administr
mgheadday
last
trimest
gestat
five
pregnant
sheep
administ
mg
ctc
divid
dose
day
day
fetu
surgic
implant
venou
line
sampl
placenta
amniot
fluid
harvest
fetal
plasma
sampl
hour
last
dose
ctc
subsequ
ewe
sacrif
sampl
amniot
fluid
placenta
fetal
kidney
fetal
liver
fetal
stomach
content
collect
observ
ctc
concentr
limit
quantif
fetal
tissu
except
liver
kidney
two
fetus
fetal
liver
concentr
rang
ngml
fetal
kidney
concentr
rang
ngml
hour
last
dose
ctc
although
studi
indic
ctc
cross
placent
barrier
base
accumul
fetal
kidney
liver
concentr
achiev
far
minimum
inhibitori
concentr
mic
report
literatur
isol
abort
outbreak
limit
quantif
amniot
fluid
fetal
stomach
content
placenta
studi
demonstr
concentr
ctc
prevent
abort
campylobact
spp
find
suggest
either
dosag
use
studi
high
enough
pharmacodynam
paramet
relat
prevent
dose
pathogen
mic
yet
determin
increas
keton
bodi
concentr
blood
use
monitor
goat
last
month
pregnanc
diagnos
anim
subclin
andor
clinic
case
pregnanc
toxemia
pt
sinc
clinic
case
pt
highli
fatal
earli
diagnost
tool
predict
mortal
farm
would
use
produc
save
money
anim
lower
chanc
surviv
initi
aggress
therapi
depend
valu
anim
fetus
object
studi
determin
increas
keton
bodi
concentr
associ
mortal
goat
herd
histori
pregnanc
toxemia
prospect
cohort
studi
perform
lactat
goat
commerci
herd
qu
ebec
canada
goat
follow
weekli
last
week
pregnanc
parturit
farm
visit
pregnant
goat
sampl
group
kid
blood
sampl
jugular
vessel
collect
analyz
directli
farm
use
electron
onfarm
test
quantif
blood
bhydroxybutyr
acid
bhba
concentr
precis
xtra
abbott
diabet
care
saintlaur
canada
produc
evalu
goat
presenc
pt
base
degre
scale
absenc
low
moder
strong
suspicion
pt
use
standard
definit
number
fetus
mortal
difficulti
kid
presenc
treatment
anorexia
lethargi
isol
rest
herd
evalu
first
week
follow
parturit
pregnanc
toxemia
diagnosi
goat
preval
mortal
prepartum
first
week
lactat
period
case
mortal
prepartum
period
associ
pt
case
mortal
first
week
lactat
associ
pt
critic
cutpoint
predict
mortal
last
month
pregnanc
first
week
lactat
determin
base
highest
sum
sensit
specif
everi
week
blood
concentr
mmoll
week
kid
sensit
se
specif
sp
se
sp
se
sp
kid
mmoll
week
kid
se
sp
first
week
lactat
se
sp
select
optim
cutpoint
studi
presenc
treatment
last
month
pregnanc
associ
increas
mortal
dairi
goat
p
conclus
even
hyperketonemia
associ
low
moder
sensit
week
week
test
show
good
specif
rel
low
preval
mortal
reason
hyperketonemia
appear
cheap
test
assess
risk
mortal
last
month
pregnanc
howev
other
paramet
evalu
access
prognosi
goat
pt
object
measur
ph
abomas
outflow
fluid
indic
abomas
ph
adult
cattl
administr
h
receptor
agonist
famotidin
singl
dose
mgkg
iv
three
dose
mgkg
iv
everi
eight
hour
mimic
clinic
applic
secondli
describ
pharmacokinet
behavior
intraven
famotidin
adult
cattl
prospect
random
twoway
crossov
studi
design
implement
use
healthi
adult
angu
steer
previous
fit
duoden
cannula
locat
orad
bile
pancreat
duct
steer
fed
alfalfa
hay
adlib
whole
corn
soybean
hull
meal
pellet
lbshead
hour
apart
day
steer
administ
either
mgkg
famotidin
equal
volum
salin
via
jugular
cathet
whole
blood
abomas
outflow
sampl
obtain
interv
period
day
steer
administ
either
mgkg
famotidin
salin
iv
time
hour
washout
period
opposit
treatment
administ
studi
repeat
whole
blood
abomas
outflow
sampl
obtain
interv
period
abomas
outflow
fluid
test
ph
use
commerci
bench
top
ph
meter
within
minut
sampl
fluid
ph
analys
use
mix
model
sa
treatment
sampl
hour
treatment
hour
fix
effect
steer
treatment
period
random
effect
least
squar
mean
separ
use
least
signific
differ
serum
separ
store
pharmacokinet
analysi
serum
famotidin
analysi
perform
use
tandem
liquid
chromatographi
mass
spectrometri
pharmacokinet
analysi
perform
use
commerci
softwar
treatment
sampl
hour
interact
affect
abomas
outflow
ph
singl
dose
multipl
dose
famotidin
p
singl
dose
intraven
famotidin
result
signific
increas
abomas
outflow
ph
compar
control
group
hour
administr
p
administ
everi
hour
abomas
outflow
ph
famotidin
treat
group
greater
control
group
hour
first
dose
p
hour
second
dose
hour
third
dose
p
pharmacokinet
analysi
demonstr
famotidin
termin
halflif
median
rang
hour
volum
distribut
lkg
clearanc
mlminkg
conclus
h
antagonist
famotidin
increas
gastric
ph
reduc
acid
product
pariet
cell
studi
show
singl
intraven
dose
famotidin
administ
mgkg
effect
increas
abomas
outflow
ph
adult
cattl
hour
compar
salin
control
administ
everi
hour
mimic
clinic
therapeut
recommend
abomas
outflow
ph
significantli
higher
hour
administr
first
dose
howev
effect
seem
decreas
subsequ
dose
result
studi
indic
famotidin
administ
mgkg
iv
effect
rais
abomas
ph
may
effect
treatment
abomas
ulcer
adult
cattl
howev
efficaci
treatment
may
decreas
time
may
requir
frequent
dose
sustain
elev
abomas
ph
studi
object
evalu
effect
patient
age
aminoglycosid
pharmacokinet
youngadult
year
age
year
healthi
alpaca
receiv
singl
mgkg
intraven
inject
gentamicin
henri
heparin
plasma
sampl
obtain
design
timepoint
follow
drug
administr
frozen
assay
valid
immunoassay
gentamicin
plasma
concentr
versu
time
plot
analyz
use
twocompart
model
commerci
softwar
data
compar
agegroup
use
independ
sampl
ttest
p
consid
signific
baselin
physic
hematolog
paramet
significantli
differ
young
median
age
rang
year
age
year
alpaca
asid
lower
mean
heart
rate
older
anim
ae
versu
ae
beat
minut
laboratori
result
differ
pre
posttreat
compar
pharmacokinet
paramet
display
mean
aesd
p
peak
gentamicin
concentr
end
distribut
phase
ae
versu
ae
p
mean
timepoint
gentamicin
trough
level
reach
common
mic
largeanim
pathogen
significantli
lower
youngadult
versu
older
anim
ae
versu
ae
hour
p
data
indic
reduc
renal
drug
clearanc
age
alpaca
recumb
dairi
cow
analysi
cerebrospin
fluid
csf
ancillari
test
frequent
use
referr
center
interpret
csf
analysi
result
cattl
challeng
part
report
interv
speci
differ
previou
retrospect
studi
demonstr
recumb
cow
csf
total
nucleat
cell
count
tncc
protein
concentr
gl
spinal
cord
lesion
post
mortem
examin
howev
csf
result
threshold
valu
exclud
presenc
lesion
object
studi
determin
shortterm
longterm
prognosi
recumb
adult
dairi
cow
underw
plasma
concentr
aucarea
curv
elimin
halflif
vssvolum
distribut
steadi
state
clclearanc
csf
analysi
previous
mention
threshold
valu
tncc
protein
concentr
use
hypothes
recumb
cow
csf
valu
higher
predetermin
threshold
valu
would
less
favor
shortterm
longterm
prognosi
dairi
cattl
year
age
recumb
csf
analysi
includ
studi
n
case
csf
analysi
perform
board
certifi
pathologist
csf
analysi
contain
tncc
protein
concentr
includ
studi
success
shortterm
prognosi
base
return
farm
success
longterm
prognosi
base
complet
least
one
lactat
use
canadian
dairi
network
databas
statist
analysi
perform
use
chisquar
test
compar
number
cow
group
age
patient
rang
year
median
year
two
hundr
eight
cow
holstein
ayrshir
jersey
durat
hospit
rang
day
median
day
cow
inform
avail
day
milk
rang
day
median
day
cow
dri
case
studi
cow
csf
valu
tncc
protein
concentr
threshold
valu
cow
csf
valu
predetermin
threshold
valu
result
show
tncc
andor
protein
concentr
gl
associ
wors
shortterm
prognosi
recumb
dairi
cattl
inde
cow
csf
valu
predetermin
threshold
valu
discharg
hospit
compar
surviv
rate
recumb
adult
dairi
cow
present
referr
center
surviv
rate
n
shortterm
surviv
rate
cow
tncc
valu
threshold
p
protein
concentr
threshold
p
csf
paramet
threshold
p
howev
cow
discharg
hospit
n
longterm
prognosi
compar
amongst
group
cow
csf
valu
threshold
cow
one
csf
valu
threshold
complet
least
one
lactat
return
farm
p
base
studi
conclud
shortterm
prognosi
recumb
adult
dairi
cattl
csf
tncc
andor
protein
concentr
gl
lower
cow
csf
valu
threshold
howev
cattl
csf
valu
threshold
surviv
longterm
prognosi
seem
accept
suggest
cow
may
spinal
cord
lesion
revers
